<SEC-DOCUMENT>0001628280-22-011751.txt : 20220502
<SEC-HEADER>0001628280-22-011751.hdr.sgml : 20220502
<ACCEPTANCE-DATETIME>20220502164218
ACCESSION NUMBER:		0001628280-22-011751
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220502
DATE AS OF CHANGE:		20220502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDIFAST INC
		CENTRAL INDEX KEY:			0000910329
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS [2090]
		IRS NUMBER:				133714405
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31573
		FILM NUMBER:		22882672

	BUSINESS ADDRESS:	
		STREET 1:		11445 CRONHILL DRIVE
		CITY:			OWINGS MILLS
		STATE:			MD
		ZIP:			21117
		BUSINESS PHONE:		7327640619

	MAIL ADDRESS:	
		STREET 1:		11445 CRONHILL DRIVE
		CITY:			OWINGS MILLS
		STATE:			MD
		ZIP:			21117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHRITE INC
		DATE OF NAME CHANGE:	19951120

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XX
		DATE OF NAME CHANGE:	19950619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	00
		DATE OF NAME CHANGE:	19950619
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>med-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:232fca58-02a7-458a-8362-c56d4dfdb306,g:546ed23b-bace-40f2-b1e1-3b5a5060da68,d:35e36ffd713d4c4192dc577fa494572d--><html xmlns:med="http://www.medifast1.com/20220331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>med-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80L2ZyYWc6NDljYjg2MWYwZmNhNDllYmEzZjg2ZjNiMTkyMmEyM2MvdGFibGU6MWZjODNkNzI2NTM3NDk2ZWFmZDlhNTcwODMyNTNkY2UvdGFibGVyYW5nZToxZmM4M2Q3MjY1Mzc0OTZlYWZkOWE1NzA4MzI1M2RjZV8yNi0xLTEtMS00ODg_640388b1-19bd-420f-8499-ca50d432d6aa">0000910329</ix:nonNumeric><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80L2ZyYWc6NDljYjg2MWYwZmNhNDllYmEzZjg2ZjNiMTkyMmEyM2MvdGFibGU6MWZjODNkNzI2NTM3NDk2ZWFmZDlhNTcwODMyNTNkY2UvdGFibGVyYW5nZToxZmM4M2Q3MjY1Mzc0OTZlYWZkOWE1NzA4MzI1M2RjZV8yNy0xLTEtMS00ODg_a2c931e0-59af-4f69-bb27-a7545a2387fc">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80L2ZyYWc6NDljYjg2MWYwZmNhNDllYmEzZjg2ZjNiMTkyMmEyM2MvdGFibGU6MWZjODNkNzI2NTM3NDk2ZWFmZDlhNTcwODMyNTNkY2UvdGFibGVyYW5nZToxZmM4M2Q3MjY1Mzc0OTZlYWZkOWE1NzA4MzI1M2RjZV8yOC0xLTEtMS00ODg_0f686f11-115a-4fc3-87a4-f5ea427a97e4">2022</ix:nonNumeric><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80L2ZyYWc6NDljYjg2MWYwZmNhNDllYmEzZjg2ZjNiMTkyMmEyM2MvdGFibGU6MWZjODNkNzI2NTM3NDk2ZWFmZDlhNTcwODMyNTNkY2UvdGFibGVyYW5nZToxZmM4M2Q3MjY1Mzc0OTZlYWZkOWE1NzA4MzI1M2RjZV8yOS0xLTEtMS00ODg_0f6c1937-8114-4a21-9977-09e04abe61df">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80L2ZyYWc6NDljYjg2MWYwZmNhNDllYmEzZjg2ZjNiMTkyMmEyM2MvdGFibGU6MWZjODNkNzI2NTM3NDk2ZWFmZDlhNTcwODMyNTNkY2UvdGFibGVyYW5nZToxZmM4M2Q3MjY1Mzc0OTZlYWZkOWE1NzA4MzI1M2RjZV8zMC0xLTEtMS00ODg_d862e4b4-0758-456b-8749-8e8ec9e25cf6">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="med-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e537e172aa24299ab41085f17256d35_I20220425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3de035571620420bb741ec985a844201_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i82c8748a0dca4006b1fc0390e3411793_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92fe6c57a504e2dbbad3803d0be8e31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a9e8a7828aa4da5bce1881ad3c595da_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27de280f347a42329dd3679897047b8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec04f01121844a2a66d23c8da8a89bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib222e481175248a4bef2b9ea56746606_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06713cb95b949a49641dbf1aa583e7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5fd06983c614bf0a83447b06a1785d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa03549ad0aa4903a08e29e78ed12366_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d670baf3e44e3eb7b81105877274fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie692dfbd3ece4eac8ee8cdea802b204e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea0b38550ff4a6db4e7c2f402dd7f1d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i497f48ef092c4f08a729248571d78cb2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f07595224e43ba81c8686f0fa8a13a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4629aa81a2fc409b96bd6ec6da4b9822_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibefafab12e4a4838bfdac00e2c56ea5f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39886d8f6ad44174b5479a2615523738_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2a9b2a18a7b4e56ab717cb5e1d08b9d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1f4b37e28c44289b679e4cf804f107_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab9310916204a50b1fb226d4d9ed1ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2724646ee9f747a9b9f3dc65301854ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if88269ad30744ca48e26fa63c42b1e63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1426349a333471bb4ed8e3f0ea276ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb60d524f67d49a7a0c81ec19020ec38_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf7bc84211b14477af22b912ebaf38e6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie967876d049142cfbde149fe84c69778_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if25fc543e5b44b6490ed11b7fda2ada2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide80a5cd921c4800b5bfab2a45d02323_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf170ac1a1024a05892c136030ccc3d3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia47fc4a92db64d20830468f635bbde08_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e02779182f94724b5916bd946bfe720_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d2306fe85c8431f9cf6ad772507e0c7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79e50c2945b94470bc8362df60bf8e6d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a53f9a4936845ba8bdfa229ddc8998c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d0f3fdadff47b4afb4b4e30c9150cd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2bb291e995d4d86b1e75f18f4e74ee5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c217599ebec4b3589ddacf77b65907d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2b6de404d154f3f8c233c0224e3b3e7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if341a78362b04aefa35a1524227f0dcc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b3ce0080ee84b2f978c642e022afcc3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b9de190e3684b94a74889bd8f6df7f4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic66942bf9f2549b198eead688af58b58_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie622384d50f24bd79471044dac2a7bff_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9500da6417d34000ac404737b417d8bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a78198c05df4b5a8deb5385b586ffe7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec6e288c739f42379b23b2ef8e67c86d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da58c43207b48f6a1b9e434f1ac7154_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i725856e7f4ec432cacc3baf8010f0fe5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d54eafa8284f25ac3bd19cff7f6312_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">med:OptionsAndRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i709a3e52837649cbbf38c0e95f31cc71_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">med:OptionsAndRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7869becf472402087fb85cd424874b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d3b43d4638447b812e122f37bd7ad9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c4d1405e900437a8c01cb40906f7245_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie07a6fa52afa4a8a8e828f7b91d96c7b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6500946c2204f099dd45b758d12ef35_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4d70137b9f4805a994076e0d6ab3c9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd3cc3169134d66a71696dd84d37aa2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a672405cc1c46b1ab2da765c6d7a422_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1830bc344d452b941276a1a72aeebc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd9ad4c02af44a4c8285da667d06c96c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40d4dcdbd49490291af588086ec5521_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">med:OperatingLeaseArrangementForRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c29fd8c68674ff7803a9bee93d6d42a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">med:OperatingLeaseArrangementForRealEstateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1c011b39e09482b9d155a886f684109_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">med:OperatingLeaseArrangementForEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie77f1726dab04431a3971d0a6973047b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">med:OperatingLeaseArrangementForEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6f1737eb3fa34225b424226bad5f803d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8f508f43e54111833213da6455af89_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6407fc628f864d3fa3ae6e4aac9245af_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">med:GovernmentAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa9fb09240445bf98fca5702ebfec16_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">med:GovernmentAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8513597370b84626bfb13b09cf0983ee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i653038e869054618added697946df31b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a5e80f0c594a478bfaeab9d9c75376_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief468fba41754dcfb701ff282f1d7886_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i974db996e18c46f18311cfb1651cd09d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i235c14ce303349c8b5bd8fb87f69b715_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife377ae99f2f433eb0a7cf0a05c6b0dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">med:GovernmentAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79de0bb84114512b113cea98756e693_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">med:GovernmentAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc62a0c317534ee789386d9dc17785ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ce626a32c3a44f081b4594e23a21964_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de4c2e8202f4fccbc696b8231685861_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib61ff22c30ce4b0caf4653ce9e1255e2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia68ebc6c33294b0189b4af137724ab7b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic11da4d8ef7f495db6691f1262fb8e0c_I20210413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if64b680e548d49b194bcae4857dedc09_I20210413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icef01955e8974f7697be299053de3a2f_I20210413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">med:UncommittedIncrementalFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fb986de689d4becaae458587ee9b2fd_D20210413-20210413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-13</xbrli:startDate><xbrli:endDate>2021-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i450c071fc9504d04b9fc30de60ec4480_D20210413-20210413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-13</xbrli:startDate><xbrli:endDate>2021-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c2bfdfda3ad4daa9fd8c347153a8690_D20210413-20210413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-13</xbrli:startDate><xbrli:endDate>2021-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f88c0342b14d22baf0e44c2b6dbf25_D20210413-20210413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-13</xbrli:startDate><xbrli:endDate>2021-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ac0c800edb46e5a7552707f96539fb_I20210413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d6fd02196e4a488975ef3607163df9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i35e36ffd713d4c4192dc577fa494572d_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="margin-top:21.6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzM2_db1edae4-0542-4531-8b4d-d3a4edfc646a">10-Q</ix:nonNumeric></span></div><div style="margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzMy_2e7034d1-a947-41f3-a847-06fbd0adb9e8">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended  <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF82MDQ3MzEzOTU1MTU0_268b4bb8-9bfa-432a-8449-abce7b0cfee8">March 31, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzI4_9e961826-445e-4354-b481-eb81c6e0fc7c">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from________ to ________.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzI1_86795076-931c-4fe3-aea6-30ed6c10dd3e">001-31573</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzI2_297c6fa4-b2f1-4cd8-9b20-3c0ca1cd70f2">Medifast, Inc.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6ODgxMWVjNmY1MWJlNDdkZWE3YTAxMGUwM2Q3NWVkNDgvdGFibGVyYW5nZTo4ODExZWM2ZjUxYmU0N2RlYTdhMDEwZTAzZDc1ZWQ0OF8wLTAtMS0xLTQ4OA_a1abcf96-7ace-4657-aefa-2a51708c0b4e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6ODgxMWVjNmY1MWJlNDdkZWE3YTAxMGUwM2Q3NWVkNDgvdGFibGVyYW5nZTo4ODExZWM2ZjUxYmU0N2RlYTdhMDEwZTAzZDc1ZWQ0OF8wLTItMS0xLTQ4OA_41998647-6d89-4846-9ab7-bc462d9d3192">13-3714405</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzMz_69e446b8-7abc-4dc7-a272-b8a3374743dd">100 International Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzI5_afd6a4b2-55be-4d67-9528-2333f0e914a7">Baltimore</ix:nonNumeric>, <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzI3_b11cafff-0aba-4dce-944d-bcd7c2d56a85">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzM3_248e95c7-639f-4194-a9a8-3cea56aec107">21202</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Telephone Number: (<ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzM4_7e0f08c6-28bd-4be3-94f9-6109ae6e70e5">410</ix:nonNumeric>) <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzM5_c39b8354-31c2-4334-a37c-a270f1a93235">581-8042</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices, Zip Code and Telephone Number, Including Area Code)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 3.28pt;text-align:center;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 3.28pt;text-align:center;text-indent:-7.2pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6YTNmN2M4MGYzOWM5NDk3MmJkMzFjZDQ4MTkxYmU4NDkvdGFibGVyYW5nZTphM2Y3YzgwZjM5Yzk0OTcyYmQzMWNkNDgxOTFiZTg0OV8xLTAtMS0xLTI4MDg1_1fcdd646-eb94-4da9-ab84-41396fb71014">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6YTNmN2M4MGYzOWM5NDk3MmJkMzFjZDQ4MTkxYmU4NDkvdGFibGVyYW5nZTphM2Y3YzgwZjM5Yzk0OTcyYmQzMWNkNDgxOTFiZTg0OV8xLTItMS0xLTI4MDg1_9d3582bf-a26d-4504-91f3-3dbb9a798006">MED</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6YTNmN2M4MGYzOWM5NDk3MmJkMzFjZDQ4MTkxYmU4NDkvdGFibGVyYW5nZTphM2Y3YzgwZjM5Yzk0OTcyYmQzMWNkNDgxOTFiZTg0OV8xLTQtMS0xLTI4MDg1_ef5b6693-68c7-4777-960f-73508e32c5cd">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzMw_e6138fe8-a92a-4595-97f1-66b97042e4e8">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzMx_67c49a8d-e770-423a-b172-be529c1ef021">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6NmE5MzJlZTU2NzQyNDY5N2ExM2IzZTIyNmIzMTU1N2IvdGFibGVyYW5nZTo2YTkzMmVlNTY3NDI0Njk3YTEzYjNlMjI2YjMxNTU3Yl8wLTAtMS0xLTIwNzI1_dc89fef2-f40e-4030-a68a-9eea58a38aab">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6NmE5MzJlZTU2NzQyNDY5N2ExM2IzZTIyNmIzMTU1N2IvdGFibGVyYW5nZTo2YTkzMmVlNTY3NDI0Njk3YTEzYjNlMjI2YjMxNTU3Yl8xLTMtMS0xLTIyMzE2_cff34600-08e3-4760-9691-8faed833e125">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6NmE5MzJlZTU2NzQyNDY5N2ExM2IzZTIyNmIzMTU1N2IvdGFibGVyYW5nZTo2YTkzMmVlNTY3NDI0Njk3YTEzYjNlMjI2YjMxNTU3Yl8yLTEtMS0xLTIyMzE2_1b2bef68-9784-4509-969a-4405707a1f40">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzM0_0839d407-e636-480e-a4da-6f3de18ca644">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of the registrant&#8217;s common stock outstanding at April&#160;25, 2022 was <ix:nonFraction unitRef="shares" contextRef="i6e537e172aa24299ab41085f17256d35_I20220425" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8xNjQ5MjY3NDQ0MTE1_c0ae6415-d4c0-493d-a927-3e8eb13c66fa">11,513,656</ix:nonFraction>.</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></div></div><div id="i35e36ffd713d4c4192dc577fa494572d_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medifast, Inc. and Subsidiaries</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_10">Part 1 &#8211; Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_13">Item 1 &#8211; Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_16">Condensed Consolidated Statements of Income (unaudited) for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_16">Three Months Ended March 31, 2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_16"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_16">2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_16">2</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_19">Condensed Consolidated Statements of Comprehensive Income (unaudited) for the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_19">3</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_22">Condensed Consolidated Balance Sheets (unaudited) as of March 31, 2022 and December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_22">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_22">4</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_25">Condensed Consolidated Statements of Cash Flows (unaudited) for the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_25">5</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_28">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (unaudited) for the Three Months Ended March 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_28">6</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_31">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_31">7</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_58">Item 2 &#8211; Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_58">13</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_79">Item 3 &#8211; Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_79">18</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_82">Item 4 &#8211; Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_82">18</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_85">Part II &#8211; Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_88">Item 1 &#8211; Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_88">19</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_91">Item 1A &#8211; Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_91">19</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_94">Item 2 &#8211; Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_94">19</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_97">Item 6 &#8211; Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i35e36ffd713d4c4192dc577fa494572d_97">20</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><div id="i35e36ffd713d4c4192dc577fa494572d_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%"> </span></div><div id="i35e36ffd713d4c4192dc577fa494572d_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:115%"> </span></div><div id="i35e36ffd713d4c4192dc577fa494572d_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(U.S. dollars in thousands, except per share amounts &amp; dividend data)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:54.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.242%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.318%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMy0xLTEtMS00ODg_344b7bf5-b4a6-41c0-8876-144620ff52e6">417,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMy0zLTEtMS00ODg_3afd07db-41d6-4e72-8f28-343437dae382">340,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNC0xLTEtMS00ODg_ade938a3-610e-4eb4-bc8c-b0870d1613ba">115,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNC0zLTEtMS00ODg_f7183791-6646-4bb1-952b-abd13191a2a5">92,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNS0xLTEtMS00ODg_e0ef6118-d359-439c-8c83-31f172ccca04">302,286</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNS0zLTEtMS00ODg_d6237054-9aa7-4b6a-bef3-119ddca32aca">248,547</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNy0xLTEtMS00ODg_fba5e72b-6cdf-4e39-9b3b-b06fb91a6170">247,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNy0zLTEtMS00ODg_70636431-db68-49ab-b577-ee3356eff502">195,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfOS0xLTEtMS00ODg_c108dd20-4131-47fd-9965-986531e8ca5b">55,087</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfOS0zLTEtMS00ODg_787be65f-206e-4720-94f9-22b420d9b630">52,799</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other (expense) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest (expense) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTItMS0xLTEtNDg4_100b9294-e10d-40b9-a22a-07439c60e2d9">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTItMy0xLTEtNDg4_9bee5753-d2b8-4300-a1ac-4b4edd84d9ae">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other (expense) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTMtMS0xLTEtNDg4_8890fa79-19c9-42da-b3da-cd30e9826dd2">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTMtMy0xLTEtNDg4_e101696d-88c0-46d0-afc1-318d23a7b8d8">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTQtMS0xLTEtNDg4_e9e4b45e-62f3-4cd3-a369-63c9396b9716">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTQtMy0xLTEtNDg4_5eb02821-57af-4c54-b0ae-aadfcce6bd80">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Income from operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTYtMS0xLTEtNDg4_096cc62f-3775-441a-9983-9e364b59e785">54,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTYtMy0xLTEtNDg4_22092e3d-3e92-45e2-a465-5e66a5657077">52,841</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTgtMS0xLTEtNDg4_4040120e-bd11-4fac-85a1-5301e0d19ecf">13,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTgtMy0xLTEtNDg4_54502c86-4b6a-4196-8207-1650837fb431">11,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjAtMS0xLTEtNDg4_f7cc0f58-46b8-4539-841c-2b0f73fc0492">41,781</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjAtMy0xLTEtNDg4_b394e038-c3a5-49ac-8ec2-69fc4f8a5bd9">41,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="INF" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjItMS0xLTEtNDg4_d67fb4d4-36c7-4341-911d-96860e609b5b">3.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="INF" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjItMy0xLTEtNDg4_e68fa3c1-acd0-4bd6-8d63-7abaa9503819">3.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="INF" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjQtMS0xLTEtNDg4_6249ef22-9187-453f-aba6-6e96f68afbb5">3.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="INF" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjQtMy0xLTEtNDg4_fd3c7ab4-49d8-4cb4-a45b-403107e82305">3.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted average shares outstanding </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjctMS0xLTEtNDg4_66ac087a-1851-4504-9580-3db9de666195">11,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjctMy0xLTEtNDg4_039ed7b9-ff95-42c5-812b-af1b8c3aeaed">11,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjgtMS0xLTEtNDg4_5903fdaf-944f-4734-a6a2-2e7b4f8d457f">11,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjgtMy0xLTEtNDg4_b0804eaf-33d0-4560-b1aa-a45587fdd4a3">11,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash dividends declared per share</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMzAtMS0xLTEtNDg4_612787bf-4e7a-4409-9cf8-6200152df65d">1.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMzAtMy0xLTEtNDg4_7c2af0a6-53af-4967-bc35-68529533ed15">1.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="i35e36ffd713d4c4192dc577fa494572d_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(U.S. dollars in thousands)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:55.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.123%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfMy0xLTEtMS00ODg_7ae051ac-2885-49e7-8f13-83d848f0bb54">41,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfMy0zLTEtMS00ODg_8514ef19-9b49-4ea2-87e7-0422355ee362">41,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other comprehensive income, net of tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfNS0xLTEtMS00ODg_9fa2870e-46a2-4994-b863-9d5ffb279d03">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfNS0zLTEtMS00ODg_01d477a4-be07-4cab-b4bc-d86837d455a9">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized losses on investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfNi0xLTEtMS00ODg_9685e839-be41-44f3-ac90-22b187885668">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfNi0zLTEtMS00ODg_bb348928-d750-45e5-b9c8-3643dfda796c">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfOC0xLTEtMS00ODg_efb54e78-087c-48c1-8e8f-3733f32bd4d5">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfOC0zLTEtMS00ODg_12334ae1-a0e7-4ebe-8157-1d8f4044d8d9">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfMTAtMS0xLTEtNDg4_66db0b74-a3be-4565-bc87-da7afa03994b">41,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfMTAtMy0xLTEtNDg4_bd5b2aad-8119-47c7-a8e8-f41fafff3d0c">41,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="i35e36ffd713d4c4192dc577fa494572d_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(U.S. dollars in thousands, except par value)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:58.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNC0xLTEtMS00ODg_5bcdaf3b-4561-4317-adc0-9559f6ec89e0">118,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNC0zLTEtMS00ODg_9ad75895-fcc4-41d2-8fe2-58b4df528345">104,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNS0xLTEtMS00ODg_63bce763-b8d3-4dbc-a230-124bede4269e">188,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNS0zLTEtMS00ODg_b236e9d7-11f4-4b9e-bcb2-16ed3fd84b86">180,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNi0xLTEtMS00ODg_95366ff2-1a83-49f8-9fb5-76e93c8ac240">4,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNi0zLTEtMS00ODg_bc2e05e7-a92c-4c4b-9ca8-334e9296aa6f">5,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income taxes, prepaid</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNy0xLTEtMS0yMDczNw_fdc1fcba-6f4d-4f6f-8dad-2749eca4cfc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:PrepaidTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNy0zLTEtMS0xNzcxMA_4a6114ea-a2e1-408c-afc4-d941233c76ec">945</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNy0xLTEtMS00ODg_0f90b59f-6cef-46ad-afbd-4931fb7000f1">13,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNy0zLTEtMS00ODg_8c61d1d4-739c-45b4-aebf-9129412abe03">16,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfOC0xLTEtMS00ODg_a4d43e37-4261-46a1-80eb-af22ff572fee">324,259</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfOC0zLTEtMS00ODg_2a234fd5-01f9-4585-ae9b-bd4cd91f5eaf">306,866</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment - net of accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTAtMS0xLTEtNDg4_b050d9c1-cad7-4c7f-adb6-d89a4206a4d3">57,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTAtMy0xLTEtNDg4_fd947738-937b-446a-9c4e-14d877066c37">56,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTEtMS0xLTEtNDg4_cafc16e5-1d3f-43de-969d-54f11da3a712">22,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTEtMy0xLTEtNDg4_5b42aaa7-4500-41d1-baf4-311b5ecbfb25">24,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTItMS0xLTEtNDg4_346574b7-0aa4-4380-b1d1-ab8f85f36979">12,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTItMy0xLTEtNDg4_a3882975-e2f1-4b13-8495-3575b922a7e3">6,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTMtMS0xLTEtNDg4_3a6bb291-37f4-4281-9a26-513d4c7a5de1">4,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTMtMy0xLTEtNDg4_65616f5e-1046-4474-b580-c437ba5d7bf1">4,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTYtMS0xLTEtNDg4_03a13e62-d10b-4543-bbc9-4d61ffb2d946">421,435</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTYtMy0xLTEtNDg4_56cadadf-127d-41cf-aae9-e1c8d934b4d9">398,326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjAtMS0xLTEtNDg4_cdb43eaf-ba64-42f7-b1cb-e2aed2f350b3">174,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjAtMy0xLTEtNDg4_a0cedf41-367d-4f22-8fc9-f3dc5553dda3">163,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;Current lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjEtMS0xLTEtNDg4_647ed1d9-9178-4931-9ed6-41a24a1acffe">6,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjEtMy0xLTEtNDg4_c049fbbd-abdc-4725-ac50-5a9bc5bb40fe">6,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjItMS0xLTEtNDg4_2f8f9f69-155b-4288-b9f3-15de05974993">181,032</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjItMy0xLTEtNDg4_31d60c74-9f26-4eda-941a-d3b697a815de">169,832</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;Lease obligations, net of current lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjQtMS0xLTEtNDg4_4b39eb0c-5c43-4703-bbe7-0ed7d1441813">24,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjQtMy0xLTEtNDg4_012bd12e-c660-4ee6-9691-4296cc475123">26,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjUtMS0xLTEtNDg4_802bc970-5775-4c39-905c-e5fccaa9d43a">205,411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjUtMy0xLTEtNDg4_74c33ab7-1c02-4c3a-9852-0281d66ffd93">195,852</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:-1.19pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjgtMC0xLTEtNDg4L3RleHRyZWdpb246YjY1ZWQzNTA2OGUyNDUwYjk5NWFhOTNlODlhYjgzYjZfODc5NjA5MzAyMjI5Nw_3fd3682d-c4b5-4ade-9474-18a333cc8579"><ix:nonFraction unitRef="usdPerShare" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjgtMC0xLTEtNDg4L3RleHRyZWdpb246YjY1ZWQzNTA2OGUyNDUwYjk5NWFhOTNlODlhYjgzYjZfODc5NjA5MzAyMjI5Nw_a7cadb76-16d0-4513-9b8a-09495da0bdb7">0.001</ix:nonFraction></ix:nonFraction> per share: <ix:nonFraction unitRef="shares" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjgtMC0xLTEtNDg4L3RleHRyZWdpb246YjY1ZWQzNTA2OGUyNDUwYjk5NWFhOTNlODlhYjgzYjZfODc5NjA5MzAyMjMwNg_725d07ce-47cd-4745-be24-84eab321f91f"><ix:nonFraction unitRef="shares" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjgtMC0xLTEtNDg4L3RleHRyZWdpb246YjY1ZWQzNTA2OGUyNDUwYjk5NWFhOTNlODlhYjgzYjZfODc5NjA5MzAyMjMwNg_d3e55c11-8792-4f51-b718-81bac2bbafe6">20,000</ix:nonFraction></ix:nonFraction> shares authorized;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjktMC0xLTEtNDg4L3RleHRyZWdpb246MWJiZDMwZTgxMGUwNDE1Zjk3NGIyZDE2ODNiZmEzM2ZfODc5NjA5MzAyMjI3Ng_4fb589f9-68a3-4c68-90ea-93fa553347a4">11,553</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjktMC0xLTEtNDg4L3RleHRyZWdpb246MWJiZDMwZTgxMGUwNDE1Zjk3NGIyZDE2ODNiZmEzM2ZfODc5NjA5MzAyMjI4NQ_9897552a-bd92-4857-95cb-dc2497b3af1c">11,594</ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjktMC0xLTEtNDg4L3RleHRyZWdpb246MWJiZDMwZTgxMGUwNDE1Zjk3NGIyZDE2ODNiZmEzM2ZfODc5NjA5MzAyMjMxMA_3eb03341-669f-4319-8799-b777aa9141d7">11,552</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjktMC0xLTEtNDg4L3RleHRyZWdpb246MWJiZDMwZTgxMGUwNDE1Zjk3NGIyZDE2ODNiZmEzM2ZfODc5NjA5MzAyMjMwNQ_7b1a755a-3b4f-4838-aa67-95dbe3d5383e">11,593</ix:nonFraction> outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">at March&#160;31, 2022  and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzAtMS0xLTEtNDg4_77bdd7c9-3252-4f72-9c6c-8419b559fa79">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzAtMy0xLTEtNDg4_6d7df3fc-4141-45fd-9e03-aad4bcdbe00e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzEtMS0xLTEtNDg4_baf4298d-40af-4be2-b619-d507c1d21224">12,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzEtMy0xLTEtNDg4_fae4a467-8dfe-4d7c-b863-f09f7182fec9">12,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzItMS0xLTEtNDg4_b7fabd1c-abac-4408-aaf2-8696dea565eb">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzItMy0xLTEtNDg4_fdf38dbb-bd64-4788-b04e-f54f0bc2681c">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Retained earnings </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzMtMS0xLTEtNDg4_97412d59-049a-4d8e-aa1c-f3953e66099e">203,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzMtMy0xLTEtNDg4_f0b4f4a0-09d8-42f6-8063-a70194bb7fdb">190,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzUtMS0xLTEtNDg4_f367f032-d4f3-4a87-a29e-86d2ca891d57">216,024</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzUtMy0xLTEtNDg4_17ee29b0-56fb-427f-8c48-651e334f2211">202,474</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzctMS0xLTEtNDg4_97f4d09b-a352-4f44-b193-6ff2a15c401a">421,435</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzctMy0xLTEtNDg4_52939c0a-3a3e-4e5c-b4ec-9d01365af23f">398,326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="i35e36ffd713d4c4192dc577fa494572d_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(U.S. dollar in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:57.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.286%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNC0xLTEtMS00ODg_b912d8bc-2ee3-4e6b-81bb-03a178566b34">41,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNC0zLTEtMS00ODg_739485ea-9108-4c87-8032-c429eeb9512d">41,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Adjustments to reconcile net income to cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 17.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNi0xLTEtMS00ODg_89d14652-4d12-4fd7-a81d-2549857beba0">2,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNi0zLTEtMS00ODg_2e1a640d-4933-4e8e-973a-4d5e43ccff38">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 17.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="med:OperatingLeaseExpenseNonCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNy0xLTEtMS0yMTc5Nw_0005c318-69f5-4789-87e4-3182157f3163">1,619</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="med:OperatingLeaseExpenseNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNy0zLTEtMS0yNDA2NQ_94423c80-5dac-4546-976c-49f5bdefecd7">889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 17.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNy0xLTEtMS00ODg_1f40749b-586c-4ab6-ae85-26f649f45438">2,275</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNy0zLTEtMS00ODg_47346595-f354-449a-810c-9ef9a65cd461">2,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 17.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Amortization of premium on investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="med:AmortizationOfPremiumOnInvestmentSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfOC0xLTEtMS00ODg_2e214302-75d4-4da1-8c88-2d6185991a0b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="med:AmortizationOfPremiumOnInvestmentSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfOC0zLTEtMS00ODg_67339b3f-b824-4a0f-b562-a756217e8d82">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 17.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTEtMS0xLTEtNDg4_33fec060-f1fc-437c-8e80-4e8b59233641">8,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTEtMy0xLTEtNDg4_030cf1e7-cd8a-4a89-8d3d-422ef5180615">8,842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income taxes, prepaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTItMS0xLTEtNDg4_9beaa105-969e-455a-ae0b-42dca3180e87">945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTItMy0xLTEtNDg4_386d4122-9cd8-4b67-959f-719572b43a69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTMtMS0xLTEtNDg4_c51de5bc-7697-4538-9966-47130858fc97">3,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTMtMy0xLTEtNDg4_2f71fda4-f038-443c-816a-af30fec709e1">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTQtMS0xLTEtNDg4_41b87597-d330-42f8-8e13-e30b901544fe">6,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTQtMy0xLTEtNDg4_975eb954-12f4-47a0-aeee-754dc03d7e3d">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable and accrued expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTUtMS0xLTEtNDg4_f5192eab-b681-4c41-b921-b5d27cbd1cb2">7,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTUtMy0xLTEtNDg4_a4fefa44-d319-4753-b678-6f16fc3f8f30">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net cash flow provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTYtMS0xLTEtNDg4_4d6a1059-10a2-4736-bc7f-79356068f857">43,673</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTYtMy0xLTEtNDg4_e51b3257-5e10-432d-b7f8-3e0e530b3093">65,326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Sale and maturities of investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTktMS0xLTEtNDg4_4cd48fc5-82f8-4da7-920f-831db1a8c62e">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTktMy0xLTEtNDg4_4127217a-ad3b-4b37-a087-78f22d2662df">3,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjAtMS0xLTEtNDg4_fe9aa438-5787-42c4-99e9-c662a709f537">3,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjAtMy0xLTEtNDg4_bb3dee5b-f929-4d25-8d2c-808a4b91287d">4,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net cash flow used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjEtMS0xLTEtNDg4_57d39338-2668-4aca-ad19-368142189561">1,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjEtMy0xLTEtNDg4_7e8455a3-0ea9-4c6d-94e9-9a123b066af1">878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Options exercised by executives and directors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjQtMS0xLTEtNDg4_7e5a6742-ae0b-4f38-8c75-936890cfae3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjQtMy0xLTEtNDg4_2644f32a-d4ec-4b87-98de-021a223c4b62">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net shares repurchased for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfOtherEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjUtMS0xLTEtNDg4_9c7332d2-6e21-4c2b-8152-bb4dfc02a24b">1,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfOtherEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjUtMy0xLTEtNDg4_56a924ab-591f-41ed-b451-52c294f08214">1,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash dividends paid to stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjYtMS0xLTEtNDg4_720dccb1-1859-495e-b08a-2befededf572">16,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjYtMy0xLTEtNDg4_b4d64719-1393-4811-857e-5195328c1e5b">13,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjctMS0xLTEtNDg4_30babda1-91de-49c8-ac26-0910f302a006">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjctMy0xLTEtNDg4_7d7b6133-04aa-422e-b15e-67d6eb585e0b">7,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net cash flow used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjgtMS0xLTEtNDg4_40739665-4111-44ad-a802-e5a306a85e16">28,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjgtMy0xLTEtNDg4_fde27235-9eb4-4cb5-8c6b-b43dd19ce313">22,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzAtMS0xLTEtNDg4_63577b4d-3d1e-4759-9e76-311760527757">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzAtMy0xLTEtNDg4_0b5676f3-1ac5-488e-ab9c-d9040144a22d">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzItMS0xLTEtNDg4_c438e240-6852-467a-b120-6822d9744ea0">13,820</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzItMy0xLTEtNDg4_e1f5ded0-4e1d-4299-9f9e-7a96b667908a">42,308</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents - beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzMtMS0xLTEtNDg4_78c1e1a8-6fc0-42e6-9df7-28c0520c6180">104,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92fe6c57a504e2dbbad3803d0be8e31_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzMtMy0xLTEtNDg4_81dd79f3-81a4-46df-b366-3d25bec43e9d">163,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents - end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzQtMS0xLTEtNDg4_296c4e69-a6f9-4051-8dcc-557ace3be4cf">118,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9e8a7828aa4da5bce1881ad3c595da_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzQtMy0xLTEtNDg4_efadf8f8-fdab-48ba-8b78-e79f43b29392">206,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzctMS0xLTEtNDg4_8d742a74-38fc-4eff-9e79-c90e6153952e">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzctMy0xLTEtNDg4_18d0306a-4a3c-45e1-8feb-0d5f764beaa8">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Dividends declared included in accounts payable</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzgtMS0xLTEtNDg4_8eda104c-70d5-4d2b-b022-6b5a66d87c14">19,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:DividendsCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzgtMy0xLTEtNDg4_aec4eb8a-9582-4825-8421-c6728d5581e3">17,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i35e36ffd713d4c4192dc577fa494572d_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (UNAUDITED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(U.S. dollars in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:30.030%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of<br/>Shares Issued</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Common Stock</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Additional Paid-In <br/>Capital</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated Other <br/>Comprehensive Income</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Retained <br/>Earnings</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Treasury Stock</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27de280f347a42329dd3679897047b8e_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy0xLTEtMS00ODg_965a7176-93ed-44c5-93d3-f1b2edb7f35e">11,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27de280f347a42329dd3679897047b8e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy0zLTEtMS00ODg_bf856fa6-fd62-4663-b1e2-8bd7586efca8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec04f01121844a2a66d23c8da8a89bc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy01LTEtMS00ODg_c52c19ff-a356-4739-9ef7-6420097d9d62">12,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib222e481175248a4bef2b9ea56746606_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy03LTEtMS00ODg_9341a118-274d-44ae-85d3-0b161bc3b2db">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06713cb95b949a49641dbf1aa583e7e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy05LTEtMS00ODg_3e862ec8-20b8-40b9-ab5f-36254d0c8b77">190,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5fd06983c614bf0a83447b06a1785d5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy0xMS0xLTEtNDg4_acebc2c0-96e4-4196-a9a5-616b25d9a86a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy0xMy0xLTEtNDg4_d53c8e93-73e0-4aad-ade8-78d969be0e05">202,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa03549ad0aa4903a08e29e78ed12366_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNC05LTEtMS00ODg_bbe07c6b-4ee0-41c0-8e3c-429c1293a706">41,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNC0xMy0xLTEtNDg4_cf0c25ff-9aae-47b7-a6a2-10fc7874b6e7">41,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5d670baf3e44e3eb7b81105877274fb_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNS0xLTEtMS00ODg_92c6666c-bb11-4817-b01d-20ccf3a82aad">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie692dfbd3ece4eac8ee8cdea802b204e_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNS01LTEtMS00ODg_3d4924c0-d880-4c86-8450-579ae1f5cc68">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNS0xMy0xLTEtNDg4_34670cd9-e78b-479a-b570-c1f39ec09084">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net shares repurchased for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib5d670baf3e44e3eb7b81105877274fb_D20220101-20220331" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNi0xLTEtMS00ODg_44438c89-3a1a-4b50-9fb7-34c620a2107a">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie692dfbd3ece4eac8ee8cdea802b204e_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNi01LTEtMS00ODg_bb05c756-a29a-4d1f-8f72-65968c5f225a">1,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNi0xMy0xLTEtNDg4_a01d81a6-51b6-4fc8-890d-9c88c7d86c9e">1,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Treasury stock from stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ea0b38550ff4a6db4e7c2f402dd7f1d_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNy0xMS0xLTEtNDg4_88cb6120-eb23-4678-b9a6-8679ba1e3eaf">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNy0xMy0xLTEtNDg4_7a594ec6-934d-4e64-8e69-2c2a88528d7b">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Treasury stock retired from stock repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib5d670baf3e44e3eb7b81105877274fb_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockSharesRetired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOC0xLTEtMS00ODg_f798f281-3a7e-49b4-9d9b-167ae6be0233">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa03549ad0aa4903a08e29e78ed12366_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOC05LTEtMS00ODg_abd80191-37f2-4a46-87bd-37735bb842d6">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ea0b38550ff4a6db4e7c2f402dd7f1d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOC0xMS0xLTEtNDg4_bff9f551-e232-419f-94e6-5f08711bf0ef">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOC0xMy0xLTEtNDg4_3d1aa150-00dd-4b69-b938-ecd8d597adb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i497f48ef092c4f08a729248571d78cb2_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOS03LTEtMS00ODg_9aa23059-e56e-4fc7-a275-f00b611779f7">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOS0xMy0xLTEtNDg4_e2ca21d1-852a-482f-8cf5-54e6d76530d6">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash dividends declared to stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa03549ad0aa4903a08e29e78ed12366_D20220101-20220331" decimals="-3" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTAtOS0xLTEtNDg4_6582e932-763b-4f36-82bd-36d0d7c9b976">19,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTAtMTMtMS0xLTQ4OA_5d32c72b-c97d-455b-a827-a8ee36fe955a">19,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52f07595224e43ba81c8686f0fa8a13a_I20220331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItMS0xLTEtNDg4_8b776187-1820-49fc-a5d0-d3c09305ed43">11,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f07595224e43ba81c8686f0fa8a13a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItMy0xLTEtNDg4_4b3fe7ef-1a1d-44b8-b880-1bf0c0b1a035">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4629aa81a2fc409b96bd6ec6da4b9822_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItNS0xLTEtNDg4_25df164d-d78e-4bdb-ab4f-48751fff69fc">12,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibefafab12e4a4838bfdac00e2c56ea5f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItNy0xLTEtNDg4_ff8741fd-e15a-4bba-bdfd-655bb40630e2">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39886d8f6ad44174b5479a2615523738_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItOS0xLTEtNDg4_0b96e1a7-06d7-4e12-a429-92178ab4fa7a">203,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2a9b2a18a7b4e56ab717cb5e1d08b9d_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItMTEtMS0xLTQ4OA_ba6998c1-2142-4328-91eb-6658f3ee7d3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItMTMtMS0xLTQ4OA_e609e587-0cad-4c7d-b645-e055a60a0a59">216,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Number of <br/>Shares Issued</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Common Stock</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Additional Paid-In <br/>Capital</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated Other<br/>Comprehensive Income</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Retained <br/>Earnings</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Treasury Stock</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f1f4b37e28c44289b679e4cf804f107_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy0xLTEtMS00ODg_32dd5146-157b-465c-a1bf-359175ce0f99">11,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1f4b37e28c44289b679e4cf804f107_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy0zLTEtMS00ODg_156d8c11-8ebd-44f8-9304-b334ef18aa91">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ab9310916204a50b1fb226d4d9ed1ba_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy01LTEtMS00ODg_1081cf24-7ceb-47e9-b03b-5f0fbce71821">7,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2724646ee9f747a9b9f3dc65301854ec_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy03LTEtMS00ODg_9246d596-f29a-48a6-820a-69ab8027d90f">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if88269ad30744ca48e26fa63c42b1e63_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy05LTEtMS00ODg_933e3704-55db-46d1-b318-49e85d614c67">154,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1426349a333471bb4ed8e3f0ea276ef_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy0xMS0xLTEtNDg4_a0f93db2-6974-4701-b9cb-e8b124a52e09">5,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92fe6c57a504e2dbbad3803d0be8e31_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy0xMy0xLTEtNDg4_834cc743-e97b-4eb5-9e43-926481364295">157,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb60d524f67d49a7a0c81ec19020ec38_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTItOS0xLTEtNDg4_288a8b01-1dc3-468a-a253-8de94f0bdead">41,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTItMTMtMS0xLTQ4OA_af8623dd-e243-4eb5-ba33-390145486374">41,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf7bc84211b14477af22b912ebaf38e6_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTMtMS0xLTEtNDg4_c12a94db-fad3-48a9-bb5f-9bafacd43628">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie967876d049142cfbde149fe84c69778_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTMtNS0xLTEtNDg4_e4d32566-dfcf-4746-bf63-3eaf5b4ceca7">2,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTMtMTMtMS0xLTQ4OA_9e0d3d38-bc67-4f5a-9248-83aa11e5ac58">2,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Options exercised by executives and directors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf7bc84211b14477af22b912ebaf38e6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTQtMS0xLTEtNDg4_347a568b-e5bc-49aa-bc83-eb4adbcad401">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie967876d049142cfbde149fe84c69778_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTQtNS0xLTEtNDg4_a8d58c95-d5dc-48b3-9371-8eb9bf22db8f">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTQtMTMtMS0xLTQ4OA_488d4431-6cf2-4404-ad43-4deb79d31134">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net shares repurchased for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibf7bc84211b14477af22b912ebaf38e6_D20210101-20210331" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTUtMS0xLTEtNDg4_69433408-e574-4b48-93e1-791c916e8a14">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie967876d049142cfbde149fe84c69778_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTUtNS0xLTEtNDg4_caad9f57-11cd-4e72-a0c4-d6ed97a49726">1,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTUtMTMtMS0xLTQ4OA_96a7f88a-a3c0-4ca2-bac3-ebe2cf8ffedb">1,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Treasury stock from stock repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if25fc543e5b44b6490ed11b7fda2ada2_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTYtMTEtMS0xLTE3NDAx_68094ad1-17b7-49ab-910d-ffbbe66fb8ef">7,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTYtMTMtMS0xLTE3NDAx_fc960f50-3fe4-40a1-8f9d-03981c7f006d">7,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide80a5cd921c4800b5bfab2a45d02323_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTYtNy0xLTEtNDg4_90ba7023-cd29-45bd-ad3b-f52ea7ea12a0">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTYtMTMtMS0xLTQ4OA_bdef63d9-d486-4339-8bd9-4ee05fe4afdd">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash dividends declared to stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb60d524f67d49a7a0c81ec19020ec38_D20210101-20210331" decimals="-3" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTgtOS0xLTEtNDg4_5050a0c4-3890-4cfb-8f1c-6c409269b8c0">16,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTgtMTMtMS0xLTQ4OA_5ba5f0f8-aae3-4b7b-a961-1f84679f7be4">16,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf170ac1a1024a05892c136030ccc3d3_I20210331" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtMS0xLTEtNDg4_1bd2e7da-9b11-4e21-827f-838b61787f4e">11,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf170ac1a1024a05892c136030ccc3d3_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtMy0xLTEtNDg4_313dcf7b-46ff-4c00-b972-6127481991bd">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia47fc4a92db64d20830468f635bbde08_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtNS0xLTEtNDg4_9267b03d-6e34-4b02-bf8c-73f434b26a48">8,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e02779182f94724b5916bd946bfe720_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtNy0xLTEtNDg4_00db51d1-44e3-4fa4-b8df-7b7141753769">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2306fe85c8431f9cf6ad772507e0c7_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtOS0xLTEtNDg4_e9e5caa3-1d64-4333-8614-4096174c41e2">178,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e50c2945b94470bc8362df60bf8e6d_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtMTEtMS0xLTQ4OA_10e53be5-6ab3-4058-a614-252162d36433">12,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9e8a7828aa4da5bce1881ad3c595da_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtMTMtMS0xLTQ4OA_ef7df276-e326-467e-bbe3-d7e7bfa04720">174,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="i35e36ffd713d4c4192dc577fa494572d_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_34"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgwOA_ea6eb08c-6318-44e6-a5d5-1e5e9d6cb4d1" continuedAt="i5b26c1b981914cd0b0c1c271e1dd62aa" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i5b26c1b981914cd0b0c1c271e1dd62aa" continuedAt="i85fc327439b34944a0c0f15661b292ba"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgwOQ_831848a6-2f38-4961-9304-aa30057c76e5" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (&#8220;Medifast,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from the audited consolidated financial statements at that date included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 (&#8220;2021 Form 10-K&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2022 are not necessarily indicative of results that may be expected for the fiscal year ending December&#160;31, 2022. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the 2021 audited consolidated financial statements and notes thereto, which are included in the 2021 Form 10-K.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgxMA_73ee7742-1d07-4aed-bf6a-a92c52a77cbc" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Presentation of Financial Statements -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.</span></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgxMQ_8c1d6ae7-db89-4717-8a47-c8fb156fb6b0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the condensed consolidated financial statements had a material impact on the presentation.</span></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgxMg_d78f6123-fb38-4dbd-9014-f0896131e44a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgxMw_caf51a6e-0cca-4c5b-b7c5-1659164a6446" continuedAt="i3fd7d73d112648c4888b9bedef2eea48" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Adopted in 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:nonNumeric></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i85fc327439b34944a0c0f15661b292ba" continuedAt="i71be0854783149368bbd9b3d005c22c8"><ix:continuation id="i3fd7d73d112648c4888b9bedef2eea48" continuedAt="i4e947f2e279941ad8e6d351ce935084d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i71be0854783149368bbd9b3d005c22c8"><ix:continuation id="i4e947f2e279941ad8e6d351ce935084d">, which provides optional guidance for a limited time to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying accounting principles under GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met and to other derivative instruments if there is a change to the interest rates used for discounting, margining or contract price alignment. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. We adopted Topic 848 beginning in the first quarter of fiscal 2022 without any material impact on the Company's financial position and results of operations.</ix:continuation></ix:continuation>  </span></div><div id="i35e36ffd713d4c4192dc577fa494572d_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RleHRyZWdpb246N2QwMWYxY2IxMmQ3NDMxYTk5NDE1ZmRhNjIwYTM4OWVfNjAy_124ae758-94d8-4b5b-b390-6b9c79b5f138" continuedAt="i222d21a1292f4cb4917571e7d7b85cb3" escape="true">INVENTORIES</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i222d21a1292f4cb4917571e7d7b85cb3" continuedAt="i50605d8a3d4d4f83a12a54549a5fcd1f">Inventories consist principally of raw materials, non-food finished goods and packaged meal replacements held in the Company&#8217;s warehouses and outsourced distribution centers. Inventories are stated at the lower of cost or net realizable value, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><ix:continuation id="i50605d8a3d4d4f83a12a54549a5fcd1f"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventories for unsalable or obsolete inventories.</span></div><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RleHRyZWdpb246N2QwMWYxY2IxMmQ3NDMxYTk5NDE1ZmRhNjIwYTM4OWVfNjAz_9cef8361-8bb4-4278-89df-c99300213983" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:56.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfMi0xLTEtMS00ODg_36398977-5e9f-481c-bcf1-cf482c293188">15,340</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfMi0zLTEtMS00ODg_272f1397-545b-4423-8388-f13890edde15">15,196</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Packaging</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfMy0xLTEtMS00ODg_6df5cec3-4205-4965-a5e5-a960f823dd87">3,640</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfMy0zLTEtMS00ODg_f09ebc78-81f1-4409-bdbb-0b029e33ee75">3,641</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-food finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="med:InventoryNonFoodFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNC0xLTEtMS00ODg_b83a1b49-7f12-4ce1-9425-aff6ec8ffe03">13,316</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="med:InventoryNonFoodFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNC0zLTEtMS00ODg_a45eb039-1857-4403-93dd-f97336959d91">15,991</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNS0xLTEtMS00ODg_9b56926b-56ca-4e21-bed9-ee50955ccc22">161,698</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNS0zLTEtMS00ODg_9afccdf4-d578-4608-b4a4-236a67f5e620">152,687</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Reserve for obsolete inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNi0xLTEtMS00ODg_7818aa36-5afe-4f81-843c-783b6449fe1c">5,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNi0zLTEtMS00ODg_e5e0cbe2-2d26-40c8-a0a1-05cf746e47f7">7,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNy0xLTEtMS00ODg_7d6c526c-4d49-4d9d-adbb-20682b3b64da">188,972</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNy0zLTEtMS00ODg_e32d7afa-de6a-4bcb-87a3-64178f13e3bd">180,043</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i35e36ffd713d4c4192dc577fa494572d_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RleHRyZWdpb246ZjdhM2MwMWU1OTg4NDJiZDhkMzlkZWE0ZTI5OGEwYjFfMTEyMw_3119b9e6-ac74-4e22-be11-5f036815a280" continuedAt="i973df5e930b24a36b5b010b1b761167b" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i973df5e930b24a36b5b010b1b761167b" continuedAt="i293ce7807daf43bc8a60e6ff7e4b1012"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) computations are calculated utilizing the weighted average number of shares of the Company&#8217;s common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of the Company&#8217;s common stock outstanding adjusted for the effect of dilutive common stock equivalents.</span></div><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RleHRyZWdpb246ZjdhM2MwMWU1OTg4NDJiZDhkMzlkZWE0ZTI5OGEwYjFfMTEyNA_2b98b2ed-8601-4abf-963f-a741fe503d3c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:55.887%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.421%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.398%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfNC0xLTEtMS00ODg_f7cc0f58-46b8-4539-841c-2b0f73fc0492">41,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfNC0zLTEtMS00ODg_b394e038-c3a5-49ac-8ec2-69fc4f8a5bd9">41,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfNy0xLTEtMS00ODg_66ac087a-1851-4504-9580-3db9de666195">11,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfNy0zLTEtMS00ODg_039ed7b9-ff95-42c5-812b-af1b8c3aeaed">11,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Effect of dilutive common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfOC0xLTEtMS00ODg_040447d5-3a06-41a3-9616-e046b513a7b2">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfOC0zLTEtMS00ODg_55d08ec3-2989-4d86-b4e7-d26c21cc8fbb">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfOS0xLTEtMS00ODg_5903fdaf-944f-4734-a6a2-2e7b4f8d457f">11,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfOS0zLTEtMS00ODg_b0804eaf-33d0-4560-b1aa-a45587fdd4a3">11,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="INF" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfMTEtMS0xLTEtNDg4_c6b995f7-e541-4c09-8650-8c93d747804e">3.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="INF" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfMTEtMy0xLTEtNDg4_9e2359a0-bec9-472a-8503-e96129673f99">3.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="INF" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfMTMtMS0xLTEtNDg4_ce581a74-121f-467e-af33-f0ad4ffb7437">3.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="INF" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfMTMtMy0xLTEtNDg4_c4f3d095-87e2-4c60-9988-d23385e0962e">3.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i293ce7807daf43bc8a60e6ff7e4b1012">The calculation of diluted EPS excluded <ix:nonFraction unitRef="shares" contextRef="i4a53f9a4936845ba8bdfa229ddc8998c_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RleHRyZWdpb246ZjdhM2MwMWU1OTg4NDJiZDhkMzlkZWE0ZTI5OGEwYjFfODc5NjA5MzAyMzc1NQ_44e183b6-c333-4133-9cb7-07bc418f332b">44</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id3d0f3fdadff47b4afb4b4e30c9150cd_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RleHRyZWdpb246ZjdhM2MwMWU1OTg4NDJiZDhkMzlkZWE0ZTI5OGEwYjFfODc5NjA5MzAyMzc0OQ_b09a286c-fda2-40ce-b0d7-2f2e00cbbab1">267</ix:nonFraction> antidilutive restricted stock awards for the three months ended March 31, 2022 and 2021, respectively.</ix:continuation> </span></div><div id="i35e36ffd713d4c4192dc577fa494572d_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDY1MQ_37e0fd90-4748-4b04-883d-d652af0b819d" continuedAt="i8821bd3a079d45b7bd48d4496208603e" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i8821bd3a079d45b7bd48d4496208603e" continuedAt="ieb8335db713c47fdb08042847545992c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified and incentive stock options to employees and non-employee directors. The fair value of these options are estimated on the date of grant using the Black-Scholes option pricing model, which requires estimates of the expected term of the option, the risk-free interest rate, the expected volatility of the price of the Company&#8217;s common stock, and dividend yield. Options outstanding as of March&#160;31, 2022 generally vest over a period of <ix:nonNumeric contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg4MQ_b31e7ab3-db6f-4ff3-8557-3beb82e66631">three years</ix:nonNumeric> and expire <ix:nonNumeric contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg4Ng_8a4e1635-f887-4dce-aaaf-5179d238551a">ten years</ix:nonNumeric> from the date of grant. The exercise price of these options ranges from $<ix:nonFraction unitRef="usdPerShare" contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg5MQ_70b7d88d-4a20-418d-90b5-748f84fd3394">26.52</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg5NQ_f61982d4-1613-439b-baec-f75ee55e1d35">66.68</ix:nonFraction>. Due to the Company&#8217;s lack of option exercise history on the date of grant, the expected term is calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each option. The risk free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant that most closely corresponds to the expected term of the option. The expected volatility is based on the historical volatility of the Company&#8217;s common stock over the period of time equivalent to the expected </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><ix:continuation id="ieb8335db713c47fdb08042847545992c" continuedAt="ib3e8bb2493384a2292c5fbca39573250"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term for each award. The dividend yield is computed as the annualized dividend rate at the grant date divided by the strike price of the stock option. For the three months ended March 31, 2022 and 2021, the Company did <ix:nonFraction unitRef="shares" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDM5ODA0NjUyNDQ1Nw_83fa08fd-b902-47a4-9b0b-01363256cd06"><ix:nonFraction unitRef="shares" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDM5ODA0NjUyNDQ1Nw_ff1f768f-bcf1-4c03-a406-e7eb9a1a5381">no</ix:nonFraction></ix:nonFraction>t grant stock options. </span></div><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDY0OA_e1e78f13-341a-448a-863b-10d4efc24b25" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of our stock option activity (in thousands, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:29.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2bb291e995d4d86b1e75f18f4e74ee5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNC0xLTEtMS00ODg_ce48a462-f571-4e53-a542-d2a33650d2af">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie2bb291e995d4d86b1e75f18f4e74ee5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNC0zLTEtMS00ODg_ede6d234-c3ef-42ae-bf9b-7d182da2b2ad">54.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c217599ebec4b3589ddacf77b65907d_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNC01LTEtMS00ODg_0e38bfcf-9545-4752-bb6c-952388ce105d">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c217599ebec4b3589ddacf77b65907d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNC03LTEtMS00ODg_309eeb60-a3da-4361-953a-45e2f5f9e047">48.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2b6de404d154f3f8c233c0224e3b3e7_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNS0xLTEtMS00ODg_0df8c33e-0b6c-4234-873d-63df8282d20d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie2b6de404d154f3f8c233c0224e3b3e7_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNS0zLTEtMS00ODg_b6dde6fc-e2b8-4877-8c52-486d119f5ecd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if341a78362b04aefa35a1524227f0dcc_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNS01LTEtMS00ODg_f6172879-bac6-428f-a66f-f773e1461f16">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if341a78362b04aefa35a1524227f0dcc_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNS03LTEtMS00ODg_ed0829c8-8488-411e-bbee-9c60d17c9da3">42.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b3ce0080ee84b2f978c642e022afcc3_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNy0xLTEtMS00ODg_cecd9722-86c5-438d-9ae9-f24c7582e8c1">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b3ce0080ee84b2f978c642e022afcc3_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNy0zLTEtMS00ODg_75a6ab6f-f3c9-4ae4-949a-e4038523fa19">54.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b9de190e3684b94a74889bd8f6df7f4_I20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNy01LTEtMS00ODg_82ecb242-8005-46b9-bdd9-c9ab012c4708">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b9de190e3684b94a74889bd8f6df7f4_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNy03LTEtMS00ODg_95988267-fd80-4921-86c2-6021e6009872">49.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at end of the period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b3ce0080ee84b2f978c642e022afcc3_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfOC0xLTEtMS00ODg_bac23722-c03e-4264-a03f-ea3caf05b654">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b3ce0080ee84b2f978c642e022afcc3_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfOC0zLTEtMS00ODg_f96b30b3-a110-4afb-8870-f6c4c51fe3e1">52.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b9de190e3684b94a74889bd8f6df7f4_I20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfOC01LTEtMS00ODg_74693041-a82f-4fe9-bc19-da18e3562120">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b9de190e3684b94a74889bd8f6df7f4_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfOC03LTEtMS00ODg_4ed29149-ebfb-4f0a-8931-f8be6e6d9e28">44.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the weighted-average remaining contractual life for outstanding stock options was <ix:nonNumeric contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg2NQ_e0317c37-cb7e-4b52-bd86-4a21a8bb5362">5.1</ix:nonNumeric> years with an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="ic66942bf9f2549b198eead688af58b58_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg3MA_3d873a22-b858-4fac-bbce-17ab39f1a86b">3.8</ix:nonFraction> million and the weighted-average remaining contractual life for exercisable stock options was <ix:nonNumeric contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjkyNg_5eab3294-562d-496b-94d7-6824172d1dc6">4.9</ix:nonNumeric> years with an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="ic66942bf9f2549b198eead688af58b58_I20220331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjkzMg_f876af45-3c0d-452d-99ac-9ce27df346d6">3.3</ix:nonFraction> million. The unrecognized compensation expense calculated under the fair value method for stock options expected to vest as of March&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="ic66942bf9f2549b198eead688af58b58_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjk0Mw_038ef0f6-95c3-4f5c-85a8-31dc7bfa0abe">0.1</ix:nonFraction> million and is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjk0Nw_b4492403-45a1-4a44-a1bc-973fc19599c3">0.9</ix:nonNumeric> year. For the three months ended March 31, 2022, there was no exercise activity of stock options. For the three months ended March 31, 2021, the Company received $<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzAxOQ_97ba8bc2-69ee-4f2c-9e9a-fca7a09be97d">0.5</ix:nonFraction> million in cash proceeds from the exercise of stock options. The total intrinsic value for stock options exercised during the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ie622384d50f24bd79471044dac2a7bff_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzAyMw_17e114a3-7e74-4be7-a7dc-459065f8112d">2.3</ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued restricted stock to employees and non-employee directors generally with vesting terms up to <ix:nonNumeric contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzA0Ng_ddbec9e4-6f06-4d9b-9db5-d30840b30987">five years</ix:nonNumeric> after the date of grant. The fair value of the restricted stock is equal to the market price of the Company&#8217;s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period.</span></div><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDY0OQ_90822047-4bdc-4976-8358-ecfd1e7babf5" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our restricted stock activity (in thousands, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:29.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.657%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a78198c05df4b5a8deb5385b586ffe7_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNC0xLTEtMS00ODg_645995e6-47f7-4f2c-b6ee-00c8dad88770">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a78198c05df4b5a8deb5385b586ffe7_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNC0zLTEtMS00ODg_e2a993ca-3f74-43a1-b9c2-bb946d3cafd9">183.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec6e288c739f42379b23b2ef8e67c86d_I20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNC01LTEtMS00ODg_13a44197-9301-45c3-8d07-c151d0f47fd6">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iec6e288c739f42379b23b2ef8e67c86d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNC03LTEtMS00ODg_a2d2f077-1be3-4be9-9f9d-18abed6a9711">116.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNS0xLTEtMS00ODg_0fc6c2ac-c0d7-4bb5-9562-821bc769e7b8">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNS0zLTEtMS00ODg_c037e90d-e32d-4128-9fef-dbde698d2634">175.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNS01LTEtMS00ODg_7764ded0-d2a3-4b8a-96fa-cd7df71168e3">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNS03LTEtMS00ODg_d87fea9e-66fc-4db5-a502-f2aae95aed40">253.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNi0xLTEtMS00ODg_108289ed-c700-42e2-9c6c-7f618ae60545">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNi0zLTEtMS00ODg_c373d7a0-b6bd-492c-8051-8ae803534f5d">149.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNi01LTEtMS00ODg_3a3ea31b-afb8-4ee2-b916-187e7f543a71">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNi03LTEtMS00ODg_0949765c-eb8a-4f05-822a-ab24b21e93c7">109.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at end of the period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8da58c43207b48f6a1b9e434f1ac7154_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfOC0xLTEtMS00ODg_c7f2f739-87e9-4896-88ae-387e924c8543">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8da58c43207b48f6a1b9e434f1ac7154_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfOC0zLTEtMS00ODg_3ccbf9b3-c2c4-4352-92ef-439e9ffce9a4">190.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i725856e7f4ec432cacc3baf8010f0fe5_I20210331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfOC01LTEtMS00ODg_7f867bed-9719-4869-95cb-fb5293e4e30d">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i725856e7f4ec432cacc3baf8010f0fe5_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfOC03LTEtMS00ODg_ea5dcc7e-7757-46a7-babb-0566d1b653a5">157.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company withheld approximately <ix:nonFraction unitRef="shares" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="0" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzA4NA_4e2c63e8-1177-4836-bdf0-303150ed32be">8,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="0" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzA5MQ_b5c81af1-6ed4-4b8f-834f-50330c3a51b1">7,000</ix:nonFraction> shares of the Company&#8217;s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of restricted stock for the three months ended March 31, 2022 and 2021, respectively. The total fair value of restricted stock awards vested during the three months ended March 31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfMTA5OTUxMTY0MTg0NQ_d418a0b6-77e8-402e-947c-ea76300bbb2c">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzEzMQ_f95cd9d4-e46b-4c24-accb-ca6a0d22ddc6">3.9</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market and Performance-based Share Awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued market and performance-based share awards to certain key executives who were granted deferred shares and may earn between 0% and 250% of the target number depending upon both the Company's total stockholder return and the Company's performance against predetermined performance goals over a three-year performance period after the date of grant. Market and performance-based share awards that are tied to the Company&#8217;s total stockholder return are valued using the Monte Carlo method and are recognized ratably as expense over the award&#8217;s performance period. The fair value of the performance-based share awards is equal to the market price of the Company&#8217;s common stock on the date of grant adjusted by </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><ix:continuation id="ib3e8bb2493384a2292c5fbca39573250"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected level of achievement over the performance period. Expense for performance-based share awards is amortized ratably over the performance period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is recorded in selling, general, and administrative expense in the accompanying Condensed Consolidated Statements of Income. <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDM5ODA0NjUyNDMyNg_d3e27c7c-56e6-44bc-9128-705af82aece5" continuedAt="i93f97774727042f7bc49bb6f4b6e9489" escape="true">The total expenses during the three months ended March 31, 2022 and 2021 are as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i93f97774727042f7bc49bb6f4b6e9489"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Share-Based Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Share-Based Compensation Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options and restricted stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11d54eafa8284f25ac3bd19cff7f6312_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfMy0xLTEtMS0yMzAxMw_e8bd4ab1-2776-462b-9f95-8de98ac9ff5e">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d54eafa8284f25ac3bd19cff7f6312_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfMy0zLTEtMS0yMzAwNQ_196e9189-605d-4102-80bb-562dcac24ccb">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i709a3e52837649cbbf38c0e95f31cc71_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfMy01LTEtMS0yMzAyMA_44a13463-01f6-40d6-9c5b-e4b76a0ccd57">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709a3e52837649cbbf38c0e95f31cc71_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfMy03LTEtMS0yMzAyMw_cec60a0f-b55e-4f27-8607-2ab39e5a5701">938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7869becf472402087fb85cd424874b6_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNC0xLTEtMS0yMzAxMw_ce480ff7-4675-41a0-a43f-34914f3ad26c">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7869becf472402087fb85cd424874b6_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNC0zLTEtMS0yMzAwNQ_5a356806-5212-4897-8122-cc516922f914">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21d3b43d4638447b812e122f37bd7ad9_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNC01LTEtMS0yMzAyMA_4aacceba-cfcf-4d6b-a310-b874a83d2537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d3b43d4638447b812e122f37bd7ad9_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNC03LTEtMS0yMzAyMw_c59f7b25-3963-4ca5-b698-efabcff9307c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c4d1405e900437a8c01cb40906f7245_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNS0xLTEtMS0yMzAxMw_eef67804-e646-4b2b-a5d4-3a962eb1e25e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4d1405e900437a8c01cb40906f7245_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNS0zLTEtMS0yMzAwNQ_45568252-c098-486a-9efc-ede905fd555d">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie07a6fa52afa4a8a8e828f7b91d96c7b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNS01LTEtMS0yMzAyMA_f750384e-bdb7-4b82-aa80-83d9140903b0">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie07a6fa52afa4a8a8e828f7b91d96c7b_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNS03LTEtMS0yMzAyMw_374789fb-41b1-488b-8381-57c7d05a1e25">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6500946c2204f099dd45b758d12ef35_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi0xLTEtMS0yNTAzMA_bb9c4df4-24ec-45a2-b720-f369a95d1167">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6500946c2204f099dd45b758d12ef35_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi0zLTEtMS0yNTAzOA_fbb749f3-f7b2-4ba1-bb44-2a4e02b61e4f">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4d70137b9f4805a994076e0d6ab3c9_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi01LTEtMS0yNTA5Mg_9875930d-49d2-4716-8717-8b6c84d2666e">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4d70137b9f4805a994076e0d6ab3c9_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi03LTEtMS0yNTEwMg_227cf3dd-dde4-4e1d-afb6-c31e58fe7403">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dd3cc3169134d66a71696dd84d37aa2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi0xLTEtMS0yNDQ5Mg_2eb23019-1f8f-4b52-8778-38f300be9810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd3cc3169134d66a71696dd84d37aa2_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi0zLTEtMS0yNDUxNQ_0da60bb4-36e6-450a-b676-906554d8233b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a672405cc1c46b1ab2da765c6d7a422_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi01LTEtMS0yNDUzNQ_89e6bf4b-7950-447d-a85b-596c2b33928d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a672405cc1c46b1ab2da765c6d7a422_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi03LTEtMS0yNDU1NQ_2b20c817-2277-480e-9c34-6450e2335a99">711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNy0xLTEtMS0yMzAxMw_04662004-dc60-4609-82ce-1abaedfa66bb">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNy0zLTEtMS0yMzAwNQ_a04c7850-2036-430f-a096-78e802fdd864">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNy01LTEtMS0yMzAyMA_9656d455-2594-4c43-88f6-660656b90370">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNy03LTEtMS0yMzAyMw_517fa7e9-f0d9-42e6-9683-e6e758bfceed">2,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total income tax benefit recognized in the accompanying Condensed Consolidated Statements of Income for restricted stock awards was $<ix:nonFraction unitRef="usd" contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfMTA5OTUxMTY0MTg2MA_dacd7c4c-5876-498d-92e8-956f1dd68a6a">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyODM5OQ_1143e1f0-5794-4701-99f1-40debec3e4fc">1.2</ix:nonFraction> million for the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i8da58c43207b48f6a1b9e434f1ac7154_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfMTA5OTUxMTY0MTg3NQ_6ef1ae7e-36c2-4ad8-b7ac-ef524f263296">8.8</ix:nonFraction> million of total unrecognized compensation cost related to restricted stock awards as of March&#160;31, 2022, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfMTA5OTUxMTYzOTUyNA_76115c54-fa08-478a-98f6-2d435e455ded">2.4</ix:nonNumeric> years. There was $<ix:nonFraction unitRef="usd" contextRef="ifb1830bc344d452b941276a1a72aeebc_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyODQ0Ng_fab484b4-ba32-4402-92be-5130adc7a4e3">11.0</ix:nonFraction> million of unrecognized compensation costs related to the <ix:nonFraction unitRef="shares" contextRef="icd9ad4c02af44a4c8285da667d06c96c_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyODQzOQ_93cd8ab1-3a88-47b6-8132-97873fc7f6b6">66,000</ix:nonFraction> performance-based shares discussed above as of March&#160;31, 2022, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="icd9ad4c02af44a4c8285da667d06c96c_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyODQ1MA_fee45fcc-2ed9-4693-94ea-96d1867fd562">2.1</ix:nonNumeric> years.</span></div></ix:continuation><div id="i35e36ffd713d4c4192dc577fa494572d_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfMTQyOQ_74f77f9b-7522-4f59-9374-4b78f0a638de" continuedAt="i57c22847750d46b39814f65b04b6f2d8" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i57c22847750d46b39814f65b04b6f2d8" continuedAt="i61450ef560564a52854768ca818a6c67"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office and warehouse space and certain equipment. In certain of the Company&#8217;s lease agreements, the rental payments are adjusted periodically based on defined terms within the lease. The Company did <ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfMjY4_2c65b672-49d5-43a4-bbb1-506d9c7b8008"><ix:nonFraction unitRef="usd" contextRef="i7a9e8a7828aa4da5bce1881ad3c595da_I20210331" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfMjY4_c0d86698-a044-4e4d-a647-58eb0dbbf8cf">no</ix:nonFraction></ix:nonFraction>t have any finance leases as of March&#160;31, 2022 and 2021, respectively, or for the three-month periods then ended, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases relating to office and warehouse space have lease terms of <ix:nonNumeric contextRef="id40d4dcdbd49490291af588086ec5521_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzY2Mw_286e4f09-3927-4f3e-a917-2787098f5702">18</ix:nonNumeric> months to <ix:nonNumeric contextRef="i0c29fd8c68674ff7803a9bee93d6d42a_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzY2OQ_8c14af2f-d454-41d9-8337-11d70b52dafd">126</ix:nonNumeric> months. Our leases relating to equipment have lease terms of <ix:nonNumeric contextRef="ia1c011b39e09482b9d155a886f684109_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzY3NA_3de5fba5-1c60-4ca9-b028-dfda7e0e319b">24</ix:nonNumeric> months to <ix:nonNumeric contextRef="ie77f1726dab04431a3971d0a6973047b_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzY3OA_61a74316-6c3c-4fa0-8a92-d8c2cd9e99da">203</ix:nonNumeric> months, with certain of them having automatic renewal clauses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s warehouse agreements also contain non-lease components, in the form of payments towards variable logistics services and labor charges, which the Company is obligated to pay based on the services consumed by it. Such amounts are not included in the measurement of the lease liability but are recognized as expenses when they are incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzc5Nw_d2952dda-a314-4eda-b826-705c66d1bbbd">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzc5Mw_25abffea-8989-4371-947f-ef2909ce9bb3">1.0</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><ix:continuation id="i61450ef560564a52854768ca818a6c67"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfMTQzMA_85641d7e-b3ed-47e8-bf66-2070de5dea25" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:63.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurements of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating cash flow used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOjJlMWFjNjA3YzlhMDRhZTc4YzQwNWNmNjU4MjU5ZWFjL3RhYmxlcmFuZ2U6MmUxYWM2MDdjOWEwNGFlNzhjNDA1Y2Y2NTgyNTllYWNfNC0xLTEtMS00ODg_313b6ed1-a96b-4b9b-979d-613e560a7400">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOjJlMWFjNjA3YzlhMDRhZTc4YzQwNWNmNjU4MjU5ZWFjL3RhYmxlcmFuZ2U6MmUxYWM2MDdjOWEwNGFlNzhjNDA1Y2Y2NTgyNTllYWNfNC0zLTEtMS00ODg_0d1da9d4-2bc3-4d5e-9bda-874f2d7ade41">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOjJlMWFjNjA3YzlhMDRhZTc4YzQwNWNmNjU4MjU5ZWFjL3RhYmxlcmFuZ2U6MmUxYWM2MDdjOWEwNGFlNzhjNDA1Y2Y2NTgyNTllYWNfNy0xLTEtMS00ODg_eed18d68-df4c-4ea0-bcbe-59ab4b5ee25c">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOjJlMWFjNjA3YzlhMDRhZTc4YzQwNWNmNjU4MjU5ZWFjL3RhYmxlcmFuZ2U6MmUxYWM2MDdjOWEwNGFlNzhjNDA1Y2Y2NTgyNTllYWNfNy0zLTEtMS00ODg_23610e0a-7fa1-4116-a6dd-5b700b9d931c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the weighted average remaining lease term was <ix:nonNumeric contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzg2NA_60b4fa59-db35-492b-a48f-ee492c9f2019">5.3</ix:nonNumeric> years and the weighted average discount rate was  <ix:nonFraction unitRef="number" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzg2OA_4b3110b0-dd00-4f84-8a62-b2938abb2393">2.1</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfMTQzMQ_afd93b53-7d4b-4fda-b818-ce1c3d75e835" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturity of the Company&#8217;s operating lease liabilities as of March&#160;31, 2022 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:81.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfMC0xLTEtMS00ODg_da8967c4-4cb6-4e08-be04-680e27b48bf2">5,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfMS0xLTEtMS00ODg_8875e7dc-8602-47ce-ae36-59b1e8770027">6,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfMi0xLTEtMS00ODg_5c38963c-ac52-4a25-b97f-a2dfc6136355">5,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfMy0xLTEtMS00ODg_76d32d4a-a485-4c13-a536-bf723d9600e2">5,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfNC0xLTEtMS00ODg_4cf44fc4-f4f0-42b5-ac8e-7902c642441f">4,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="med:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfNS0xLTEtMS00ODg_52f8817f-e01f-493a-b28a-c9ca67462796">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfNi0xLTEtMS00ODg_2c4ed829-743e-42ae-ba33-6ef09026a750">32,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfNy0xLTEtMS00ODg_289507b5-a5fc-4658-a2a6-e1e0538c08c7">1,733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfOC0xLTEtMS00ODg_cee62b9e-52c1-489f-8904-55995396bf6d">31,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i35e36ffd713d4c4192dc577fa494572d_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RleHRyZWdpb246OThkMzI1ZmUyZGJjNDA2ZmIxMTMwNzZmNjE2NjI0YTlfMTgw_ed218144-b820-4ba9-a36d-8b556ca269b0" continuedAt="i2b6f3996a6194a5d87a8f75abe8aef65" escape="true">ACCUMULATED OTHER COMPREHENSIVE INCOME</ix:nonNumeric></span></div><ix:continuation id="i2b6f3996a6194a5d87a8f75abe8aef65"><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RleHRyZWdpb246OThkMzI1ZmUyZGJjNDA2ZmIxMTMwNzZmNjE2NjI0YTlfMTgx_3f415d87-f4b3-4194-ae1f-1198ec70d3a0" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:64.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfMi0xLTEtMS00ODg_f2c10cf4-e800-4977-b383-b40a47f88818">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfMi0zLTEtMS00ODg_fb82ba1a-b00f-4ee4-b9b7-df80eca4cd18">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized gains on investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfMy0xLTEtMS00ODg_4a84a308-c8e9-483b-adb2-22afd91aff0a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfMy0zLTEtMS00ODg_bc99205f-6f7c-4866-b4e5-a3871f111756">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfNC0xLTEtMS00ODg_0f65660e-5bd0-4c1a-b5e3-2c6866f22377">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfNC0zLTEtMS00ODg_f66949e4-5117-48c4-9015-f4c316c45bf0">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i35e36ffd713d4c4192dc577fa494572d_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RleHRyZWdpb246YzU4MmRkNzYwZTNjNDg3ZjhmNzE2MzM2NmEzMWZhODZfMTYyMA_2d975109-9370-472e-a101-bc1877d1414a" continuedAt="ib7a527e0e2454d66bd47df9d5b0d003a" escape="true">FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="ib7a527e0e2454d66bd47df9d5b0d003a" continuedAt="ic8d6629bfc864cf597f8da82f413399a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211; Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211; Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><ix:continuation id="ic8d6629bfc864cf597f8da82f413399a"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211; Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management&#8217;s best estimate of fair value from the perspective of a market participant.</span></div><ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RleHRyZWdpb246YzU4MmRkNzYwZTNjNDg3ZjhmNzE2MzM2NmEzMWZhODZfMTYyMQ_f8c96eff-3577-4e74-8ca4-755f62801270" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investment<br/>Securities</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1737eb3fa34225b424226bad5f803d_I20220331" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMy0xLTEtMS00ODg_27bd4461-8f5d-4d55-a654-ebdc0df6b5f8">107,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1737eb3fa34225b424226bad5f803d_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMy03LTEtMS00ODg_d9a0aaf9-86dd-4a29-b71d-56748844df70">107,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1737eb3fa34225b424226bad5f803d_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMy05LTEtMS00ODg_9448046d-3373-4f36-a433-4923eaa6deb7">107,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8f508f43e54111833213da6455af89_I20220331" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNi0xLTEtMS00ODg_80e8a548-76bc-414f-8d5b-df658927d137">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8f508f43e54111833213da6455af89_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNi03LTEtMS00ODg_4e23279d-ec8d-4b3f-adec-05af25626a3d">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8f508f43e54111833213da6455af89_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNi05LTEtMS00ODg_6d14955a-699f-4cbf-93e6-2b52019f480c">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6407fc628f864d3fa3ae6e4aac9245af_I20220331" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNy0xLTEtMS00ODg_6a1cbd25-97bb-4442-8257-f430d755eef2">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa9fb09240445bf98fca5702ebfec16_D20220101-20220331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNy0zLTEtMS00ODg_d175e125-c379-4c7e-989e-d634f3d06d5c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6407fc628f864d3fa3ae6e4aac9245af_I20220331" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNy01LTEtMS00ODg_8fb47092-4cda-4b92-bd45-2d7b0db35c47">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6407fc628f864d3fa3ae6e4aac9245af_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNy03LTEtMS00ODg_5fe15efc-78c8-4f80-92fe-74fefb2e0745">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6407fc628f864d3fa3ae6e4aac9245af_I20220331" decimals="-3" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNy0xMS0xLTEtNDg4_543bc8eb-621f-44fa-b71e-c62e6df1c522">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8513597370b84626bfb13b09cf0983ee_I20220331" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC0xLTEtMS00ODg_a5279ff8-8984-40c3-89ec-21427b727884">12,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i653038e869054618added697946df31b_D20220101-20220331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC0zLTEtMS00ODg_3ae1acf4-7293-4fce-9dec-fe683f33b7e4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8513597370b84626bfb13b09cf0983ee_I20220331" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC01LTEtMS00ODg_07ac477a-ff9a-491f-ba46-ed7fc5219b96">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8513597370b84626bfb13b09cf0983ee_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC03LTEtMS00ODg_6a3b76f6-123e-4321-bbe5-2be81160c83c">12,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8513597370b84626bfb13b09cf0983ee_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC05LTEtMS00ODg_876c6893-913f-4d02-84ff-426a89e9160a">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8513597370b84626bfb13b09cf0983ee_I20220331" decimals="-3" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC0xMS0xLTEtNDg4_180a9342-187e-4b09-a3dd-02479be78bda">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5e80f0c594a478bfaeab9d9c75376_I20220331" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTEtMS0xLTEtNDg4_c4a77644-5bb3-4e95-8251-763a0624503d">2,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief468fba41754dcfb701ff282f1d7886_D20220101-20220331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTEtMy0xLTEtNDg4_bb9898d8-fdd4-4073-98c2-093b9f28ce70">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5e80f0c594a478bfaeab9d9c75376_I20220331" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTEtNS0xLTEtNDg4_c81511c7-2bd8-43fe-8bfb-c12635f40ce1">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5e80f0c594a478bfaeab9d9c75376_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTEtNy0xLTEtNDg4_dc17f5de-1a46-4ddc-a060-3871a29ce601">2,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a5e80f0c594a478bfaeab9d9c75376_I20220331" decimals="-3" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTEtMTEtMS0xLTQ4OA_1607eee0-c687-4c7e-8036-84bc090cc6ac">2,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtMS0xLTEtNDg4_b940d6a2-c9eb-4e45-9217-2530e91079ef">122,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtMy0xLTEtNDg4_78977b39-978e-406b-96e0-f1380308b62a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtNS0xLTEtNDg4_955bcf8e-e40c-49e8-bf1e-33e37b193328">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtNy0xLTEtNDg4_dde9d688-26ae-4973-a0c6-a741063aae36">122,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtOS0xLTEtNDg4_2f7b5a15-48c8-4d53-890c-2b667f2a1796">118,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331" decimals="-3" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtMTEtMS0xLTQ4OA_bc4d6035-c61a-4656-9741-c3775e526feb">4,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investment<br/>Securities</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974db996e18c46f18311cfb1651cd09d_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMy0xLTEtMS00ODg_da81e825-f505-43be-90af-d732a03fc3b4">94,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974db996e18c46f18311cfb1651cd09d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMy03LTEtMS00ODg_130dd6da-a10f-4b07-84bf-3fc0ab670bb0">94,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974db996e18c46f18311cfb1651cd09d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMy05LTEtMS00ODg_8f049386-d4ef-4ef3-9648-90bfb0f03098">94,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235c14ce303349c8b5bd8fb87f69b715_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNi0xLTEtMS00ODg_cc3b4c65-8221-44d7-ab9f-738e68f434c0">9,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235c14ce303349c8b5bd8fb87f69b715_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNi03LTEtMS00ODg_e1ba2c37-b749-47bb-bb8b-0366d4e723a1">9,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235c14ce303349c8b5bd8fb87f69b715_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNi05LTEtMS00ODg_bea56705-0ae3-40df-a624-88fa1752cc93">9,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife377ae99f2f433eb0a7cf0a05c6b0dd_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNy0xLTEtMS00ODg_509b7d50-48e0-4433-beb6-69dcc439b6af">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79de0bb84114512b113cea98756e693_D20210101-20211231" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNy0zLTEtMS00ODg_8f950135-ae2d-4c7d-92c7-bd21b0ef451f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife377ae99f2f433eb0a7cf0a05c6b0dd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNy03LTEtMS00ODg_b9e3adef-f0b4-4a8d-b57e-141e255e21dc">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife377ae99f2f433eb0a7cf0a05c6b0dd_I20211231" decimals="-3" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNy0xMS0xLTEtNDg4_ae0cb53d-8c6b-4149-8a0d-d916d6cc1d1b">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc62a0c317534ee789386d9dc17785ad_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfOC0xLTEtMS00ODg_ed79de0f-594c-400a-b85d-632a0747a75c">10,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce626a32c3a44f081b4594e23a21964_D20210101-20211231" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfOC0zLTEtMS00ODg_e29c6725-7e69-4b2f-a1c5-feb86454871e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc62a0c317534ee789386d9dc17785ad_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfOC03LTEtMS00ODg_2e087011-10c8-421a-acd0-d4880c887229">10,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc62a0c317534ee789386d9dc17785ad_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfOC05LTEtMS00ODg_af10ef71-90c6-4b9f-b224-e82749c329d4">9,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc62a0c317534ee789386d9dc17785ad_I20211231" decimals="-3" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfOC0xMS0xLTEtNDg4_8f377939-7811-46e1-a45f-7ffc88bfa51b">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de4c2e8202f4fccbc696b8231685861_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTEtMS0xLTEtNDg4_561c6a73-7aa3-4556-bb5f-a43d3aa092eb">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61ff22c30ce4b0caf4653ce9e1255e2_D20210101-20210331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTEtMy0xLTEtNDg4_2f67ba07-ee76-4099-ae26-8a80026364f4">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de4c2e8202f4fccbc696b8231685861_I20211231" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTEtNS0xLTEtNDg4_138dd1bb-501e-4c77-8991-a87a000aabb6">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de4c2e8202f4fccbc696b8231685861_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTEtNy0xLTEtNDg4_b508ee02-d6ee-4a83-a50a-0fbe22eb1bb1">3,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de4c2e8202f4fccbc696b8231685861_I20211231" decimals="-3" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTEtMTEtMS0xLTQ4OA_b68ff0d2-8882-4d9c-bee1-ec2d52d335e5">3,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtMS0xLTEtNDg4_8a1899e0-f06d-49c4-b702-53485742c0a4">109,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68ebc6c33294b0189b4af137724ab7b_D20210101-20211231" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtMy0xLTEtNDg4_236a8df3-9395-4f2c-81e8-e0ae2c105494">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtNS0xLTEtNDg4_fabb1610-c72e-4148-aceb-077295206709">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtNy0xLTEtNDg4_db21ad1f-9146-4912-be7a-cbdd57b393e8">109,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtOS0xLTEtNDg4_efb547bd-5b90-434c-aed0-0c231950d25f">104,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231" decimals="-3" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtMTEtMS0xLTQ4OA_b4b5a052-f45a-438d-8def-f28caa9b214b">5,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" decimals="-3" name="us-gaap:DebtAndEquitySecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RleHRyZWdpb246YzU4MmRkNzYwZTNjNDg3ZjhmNzE2MzM2NmEzMWZhODZfMTQwMw_04eca04f-cace-4e39-b759-0b9e550f750f"><ix:nonFraction unitRef="usd" contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331" decimals="-3" name="us-gaap:DebtAndEquitySecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RleHRyZWdpb246YzU4MmRkNzYwZTNjNDg3ZjhmNzE2MzM2NmEzMWZhODZfMTQwMw_3b648237-2e6b-48b7-8758-8035a7cf6d33">no</ix:nonFraction></ix:nonFraction> realized losses or gains for the three months ended March 31, 2022 and 2021, respectively. As of March&#160;31, 2022, the maturities of the Company&#8217;s investment securities were less than one year for all the municipal bonds, and government and agency securities.</span></div></ix:continuation><div id="i35e36ffd713d4c4192dc577fa494572d_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfMzE1OA_31e49db6-99a7-4397-a59b-3f47536e283a" continuedAt="idcc16eb3f91d45c98a3be4866f68d63d" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="idcc16eb3f91d45c98a3be4866f68d63d" continuedAt="if4734a5423a748d7a35668b0ef2aa766"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;13, 2021, the Company and certain of its subsidiaries (collectively, the &#8220;Guarantors&#8221;) entered into a credit agreement (the &#8220;Credit Agreement&#8221;) among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><ix:continuation id="if4734a5423a748d7a35668b0ef2aa766"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative agent. The Credit Agreement provides for a $<ix:nonFraction unitRef="usd" contextRef="ic11da4d8ef7f495db6691f1262fb8e0c_I20210413" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQwMQ_7c015781-da7a-4073-b00a-9c64ecb44cfd">125.0</ix:nonFraction> million senior secured revolving credit facility with a $<ix:nonFraction unitRef="usd" contextRef="if64b680e548d49b194bcae4857dedc09_I20210413" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQwNQ_597dd149-4038-44ff-8c91-3d99c022a948">20.0</ix:nonFraction> million letter of credit sub-limit. The Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $<ix:nonFraction unitRef="usd" contextRef="icef01955e8974f7697be299053de3a2f_I20210413" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQwOQ_a0b9c67e-f824-4049-8f15-5f626cedf872">100.0</ix:nonFraction> million. The Credit Agreement matures on April&#160;13, 2026.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Credit Agreement are guaranteed by the Guarantors. The obligations of the Company and the Guarantors are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Credit Agreement, the Company will pay to the administrative agent for the account of each revolving lender a commitment fee on a quarterly basis based on amounts committed but unused under the revolving facility from <ix:nonFraction unitRef="number" contextRef="i3fb986de689d4becaae458587ee9b2fd_D20210413-20210413" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQxMw_2802239e-5e51-4fb7-b574-1cf3502eae74">0.20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i450c071fc9504d04b9fc30de60ec4480_D20210413-20210413" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQxNw_74a42841-d6e5-45cd-b06e-2eb707c25a60">0.40</ix:nonFraction>% per annum depending on the Company&#8217;s Total Net Leverage Ratio (as defined in the Credit Agreement). The Company is also obligated to pay the administrative agent customary fees for credit facilities of this size and type.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving borrowings under the Credit Agreement bear interest at a rate per annum equal to (i) the Adjusted LIBOR Rate for the interest period plus the Applicable Rate (as defined in the Credit Agreement) based on the Company&#8217;s Total Net Leverage Ratio (with customary provisions under the Credit Agreement providing for the replacement of LIBOR with a successor rate) or (ii) the Alternate Base Rate (as defined in the Credit Agreement) as in effect from time to time plus the Applicable Rate based on the Company&#8217;s Total Net Leverage Ratio. As of March&#160;31, 2022, the Applicable Rate for Eurodollar Loans is <ix:nonFraction unitRef="number" contextRef="i9c2bfdfda3ad4daa9fd8c347153a8690_D20210413-20210413" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQyNQ_ef9e67e2-6c8e-4312-af32-357402250aa0">1.25</ix:nonFraction>% per annum and the Applicable Rate for ABR Loans is <ix:nonFraction unitRef="number" contextRef="i45f88c0342b14d22baf0e44c2b6dbf25_D20210413-20210413" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQyMQ_ee185dba-ae74-422a-b51f-bfb4e6d6f55e">0.25</ix:nonFraction>% per annum.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Company and its subsidiaries, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments and change the nature of their businesses. The Credit Agreement also contains customary events of default, subject to thresholds and grace periods, including, among others, payment default, covenant default, cross default to other material indebtedness and judgment default. In addition, the Credit Agreement requires the Company to maintain a Total Net Leverage Ratio of no more than <ix:nonFraction unitRef="number" contextRef="if5ac0c800edb46e5a7552707f96539fb_I20210413" decimals="INF" name="med:MaximumTotalNetLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQyOQ_260f0177-2868-474d-8bea-521616b982e1">3.00</ix:nonFraction> to 1.00 and an Interest Coverage Ratio of at least <ix:nonFraction unitRef="number" contextRef="if5ac0c800edb46e5a7552707f96539fb_I20210413" decimals="INF" name="med:MinimumInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQzNw_485b0307-dcb7-49be-a178-b0b4316e035f">3.50</ix:nonFraction> to 1.00.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="usd" contextRef="i57d6fd02196e4a488975ef3607163df9_I20220331" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQ0NQ_3b89bdb7-90d5-406b-8cf3-dbb21e089b2d">no</ix:nonFraction> borrowings under the Credit Agreement as of March&#160;31, 2022.</span></div></ix:continuation><div id="i35e36ffd713d4c4192dc577fa494572d_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note Regarding Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information in this report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend," &#8220;anticipate,&#8221; &#8220;expects&#8221; or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of our management and are subject to certain events, risks, uncertainties and other factors. These risks and uncertainties include, but are not limited to, those described in our 2021 Form 10-K and those described from time to time in our future reports filed with the SEC. Although Medifast believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this report. All of the forward-looking statements contained herein speak only as of the date of this report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and related notes appearing elsewhere herein.</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medifast is the global company behind one of the fastest-growing health and wellness communities, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which offers Lifelong Transformation, One Healthy Habit at a Time</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Reflecting the success of our holistic approach to health and wellness, we have consistently grown revenue over the past five years. Of equal importance, we expect our differentiated model to continue to deliver growth in the foreseeable future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA brand offers a highly competitive and effective lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The program is built around four key components:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Independent OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Coaches: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provide individualized support and guidance to customers on the path to optimal health and wellbeing.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Community</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Community of like-hearted people providing each other with real-time connection and support.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">The Habits of Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Transformational System:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A proprietary system which offers easy steps to a sustainably healthy lifestyle. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Products &amp; Plans: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinically proven plans and scientifically developed products, called &#8220;Fuelings,&#8221; backed by dietitians, scientists and physicians.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We help customers achieve their health goals through a network of approximately 63,900 independent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches, about 90% of whom were customers first, and have impacted more than 2 million lives to date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches introduce customers to a set of healthy habits, in most cases starting with the habit of healthy eating, and offer exclusive Fuelings, which are nutrient-dense, portion-controlled, nutritionally interchangeable and simple to use. They are formulated with high-quality ingredients and are fortified with probiotic cultures, vitamins and minerals, as well as other nutrients essential for good health. Our products support the process of integrating healthy habits into our customer&#8217;s day-to-day lives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA coaching model is customer-centric and boasts an energized health and wellness community. It promotes holistic health and wellness and positions healthy weight as a catalyst to greater lifestyle changes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches provide personalized support to customers and motivate them by sharing their passion for healthy living and lifestyle transformation. We believe this personal coaching is an essential factor in customer success based on findings from a clinical study published in Obesity Science and Practice in 2018, which validated the effectiveness of combining the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA meal plan with education and support consistent with that was provided by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entrepreneurial spirit of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches is another key to our success, as they create a continuous cycle of growth, activating new customers, many of whom go on to become </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches. We offer economic incentives designed to support each </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coach&#8217;s long-term success, which we believe plays an important role in their financial wellness, providing the opportunity to improve their finances while changing the health trajectory of families, communities and generations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches are independent contractors, not employees, who support customers and market our products and services primarily through word of mouth, email and social media channels such as Facebook, Instagram, Twitter and video conferencing platforms. As entrepreneurs, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches market our products to friends, family and other acquaintances.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA products are shipped directly to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA customers who are working with an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coach. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches do not handle or deliver merchandise to customers. This arrangement frees our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches from having to manage inventory and allows them to maintain an arms-length transactional relationship while focusing their attention on support and encouragement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are one of the fastest growing health and wellness companies in the United States ("U.S."), with a large and growing market opportunity. We believe our coach-based model is scalable and drives both customer success and growth. We expect our continued investment in fostering a robust community around our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA brand and our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaching model will continue to drive a sustainable, repeatable business rhythm focused on our mission of offering the world Lifelong Transformation, One Healthy Habit at a Time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are conducted through our wholly owned subsidiaries, Jason Pharmaceuticals, Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA, LLC, Jason Enterprises, Inc., Jason Properties, LLC, Medifast Franchise Systems, Inc., Seven Crondall Associates, LLC, Corporate Events, Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA (Hong Kong) Limited, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA (Singapore) PTE. LTD and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Health Consultation (Shanghai) Co., Ltd. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we previously disclosed, global expansion is an important component of our long-term growth strategy. In July 2019, we commenced our international operations, entering into the Asia Pacific markets of Hong Kong and Singapore. Our decision to enter these markets was based on industry market research that reflects a dynamic shift in how health care is being prioritized </span></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">VIA makes no guarantee of financial success. Success with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">VIA results from successful sales efforts, which require hard work, diligence, skill, persistence, competence, and leadership. Please see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">VIA Income Disclosure Statement (http://bit.ly/ids</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">VIA) for statistics on actual earnings of Coaches.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and consumed in those countries. We outsource a distribution center in Hong Kong to provide adequate product distribution capacity for the foreseeable future in these markets.</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A novel strain of coronavirus (&#8220;COVID-19&#8221;) surfaced in late 2019 and has spread around the world, including to the U.S. In March 2020, the World Health Organization declared COVID-19 a worldwide pandemic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the pandemic, many governments implemented policies intended to stop or slow the further spread of the disease, such as social distancing guidelines, shelter-in-place orders and other measures. Nutritional supplements and health foods have been designated critical/essential infrastructure in the U.S. As a manufacturer and distributor of these products our manufacturing and distribution facilities remain fully operational to date and we have not experienced any meaningful disruption to our worldwide supply chain. The Company&#8217;s priorities during the COVID-19 pandemic continue to be protecting the health and safety of our employees and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches, and their families, and we have undertaken numerous steps and instituted additional precautions to protect their safety and well-being, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enhanced safety protocols, limiting visitation to our plant and distribution center and rolling out additional sick leave (crisis pay) for our onsite essential employees;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">through the majority of 2021, our non-essential employees continued to work from home. Effective October 2021, the Company implemented a hybrid work approach which enables our non-essential employees the flexibility to work partially from home and partially from the office;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">established additional health and safety precautions in our headquarters and manufacturing and distribution centers, including use of personal protective equipment and frequent hand sanitization;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">created process controls in relation to social distancing, visitors, travel and quarantine; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">organized 16 vaccination clinics in partnership with the health department across all our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although vaccines are available in various countries where we operate, it is possible the COVID-19 pandemic could further impact our operations and the operations of our suppliers and vendors, particularly in light of the potential of variant strains of the virus to cause a resumption of high levels of infection and hospitalization. Should that occur, the extent to which the pandemic ultimately impacts the Company&#8217;s business, financial condition, results of operations, cash flows, and liquidity may differ from management&#8217;s current expectations. Factors that could cause actual results to differ from management&#8217;s expectations include inherent uncertainties regarding the duration and further spread of the outbreak, its severity, government actions taken to contain the virus or treat its impact, changes in consumer behavior resulting from the pandemic and how quickly and to what extent normal economic and operating conditions can resume. The senior management team meets regularly to review and assess the status of the Company&#8217;s operations and the health and safety of its various constituencies, and will continue to proactively respond to the situation and communicate with our supply chain partners to identify and mitigate risk and to manage inventory levels. The Company may take further actions that alter its business operations as may be required by governmental authorities, or that are determined to be in the best interests of employees, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches and customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These uncertainties make it challenging for our management to estimate our future business performance. However, we intend to continue to actively monitor the impact of COVID-19 and related developments on our business and will update our practices accordingly, as we have done throughout the pandemic.</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements are prepared in accordance with GAAP. Our significant accounting policies are described in Note 2 to the audited consolidated financial statements included in the 2021 Form 10-K. We consider all of our significant accounting policies and estimates to be critical. There were no significant changes in our critical accounting policies during the first quarter of 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Management develops, and changes periodically, these estimates and assumptions based on historical experience and on various other factors that are believed to be reasonable under </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the circumstances. Actual results may differ from these estimates under different assumptions or conditions. There were no significant changes in our critical estimates during the first quarter of 2022.</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product sales accounted for approximately 98.0% of our revenues for each of the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reflect our income statements (in thousands, except percentages):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">% Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.2)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">302,286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">248,547</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53,739</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26.3%)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52,799</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,288</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other (expense) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest (expense) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(513.0%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other (expense) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184.2%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(364.3%)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Income from operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54,976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52,841</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,417)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.0%)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">41,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">41,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%;text-decoration:underline">% of revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Selling, general, and administrative costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue increased $76.9 million, or 22.6%, to $417.6 million for the three months ended March 31, 2022 from $340.7 million for the three months ended March 31, 2021. The average revenue per active earning </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coach was $6,536 for the three months ended March 31, 2022 compared to $6,454 for the three months ended March 31, 2021. Increase in the productivity per active earning </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coach for the quarter was driven by an increase in both the number of customers supported by each Coach as well as an increase in average customer spend. The year-over-year growth in revenue was primarily driven by the increase in the number of active earning </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches and in the productivity per active earning </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coach.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of sales increased $23.2 million, or 25.2%, to $115.3 million for the three months ended March 31, 2022 from $92.1 million for the three months ended March 31, 2021. The increase in cost of sales was primarily driven by an increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA product sales and higher product costs and shipping costs resulting from </span><span style="background-color:#ffffff;color:#1c1d20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inflation in raw ingredient costs, and freight and labor costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, a</span><span style="background-color:#ffffff;color:#1c1d20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cceleration of demand for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA</span><span style="background-color:#ffffff;color:#1c1d20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-branded products led to the increase in the Company&#8217;s use of co-manufacturers, which further increased cost of sales. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the three months ended March 31, 2022, gross profit increased $53.8 million, or 21.6%, to $302.3 million from $248.5 million for the three months ended March 31, 2021. The increase in gross profit was primarily attributable to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">higher revenue partially offset by increased cost of sales. As a percentage of revenue, gross profit decreased 60 basis points to 72.4% for 2022 from 73.0% for 2021. The decrease in gross margin percentage for the quarter was primarily due to a customer acquisition program and higher product and shipping costs resulting from inflation in raw ingredient costs, and freight and labor costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, general, and administrative: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative (&#8220;SG&amp;A&#8221;) expenses were $247.2 million for the three months ended March 31, 2022, an increase of $51.5 million, or 26.3%, as compared to $195.7 million from the corresponding period in 2021. As a percentage of revenue, SG&amp;A expenses were 59.2% for the three months ended March 31, 2022 as compared to 57.5% for the corresponding period in 2021. The increase in SG&amp;A expenses for the three months ended March 31, 2022 was primarily due to higher </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coach compensation expense, increased salaries and benefits-related expenses for employees, incremental costs related to continued investment in information technology and distribution infrastructure, as well as the increased credit card fees resulting from higher sales. SG&amp;A expenses included research and development costs of $0.9 million and $1.0 million for the three months ended March 31, 2022 and 2021, respectively, in connection with the development of new products and programs and clinical research activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coach compensation expense, which is a variable expense, increased $36.8 million, or 25.2%, to $183.0 million for the three months ended March 31, 2022 from $146.2 million for the corresponding period in 2021. The increase was primarily the result of increased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA product sales. The total number of active earning </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VIA Coaches for the three months ended March 31, 2022 increased to 63,900 from 52,500 for the corresponding period in 2021, an increase of 21.7%. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the three months ended March 31, 2022, income from operations increased $2.3 million to $55.1 million from $52.8 million for the corresponding period in 2021 primarily as a result of increased gross profit partially offset by increased SG&amp;A expenses. Income from operations as a percentage of revenue decreased to 13.2% for the three months ended March 31, 2022 from 15.5% for the corresponding period in 2021 due to the factors described above impacting gross profit and SG&amp;A expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for income taxes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, the Company recorded $13.2 million in income tax expense, an effective tax rate of 24.0%, as compared to $11.8 million in income tax expense, an effective tax rate of 22.3%, for the three months ended March 31, 2021. The increase in the effective tax rate for the three months ended March 31, 2022 was primarily driven by a decrease in the tax benefit of stock compensation and other items as well as an increase in the state income tax rate. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net income was $41.8 million, or $3.59 per diluted share, for the three months ended March 31, 2022 as compared to $41.1 million, or $3.46 per diluted share, for the three months ended March 31, 2021. The period-over-period changes were driven by the factors described above impacting gross profit and SG&amp;A expenses.</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had stockholders&#8217; equity of $216.0 million and working capital of $143.2 million at March&#160;31, 2022 as compared with $202.5 million and $137.0 million at December&#160;31, 2021, respectively. The $13.5 million net increase in stockholders&#8217; equity reflects $41.8 million in net income for the three months ended March 31, 2022 offset by $10.0 million spent on repurchases of the Company&#8217;s common stock and $19.1 million for declared dividends paid to holders of the Company&#8217;s common stock as well as the other equity transactions described in the &#8220;Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity&#8221; included in this report. The Company declared a quarterly dividend of $1.64 per share on March 17, 2022, to stockholders of record as of March 29, 2022 that will be paid in the second quarter of 2022. While we intend to continue the dividend program and believe we will have sufficient liquidity to do so, we can provide no assurance that we will be able to continue to declare and pay dividends. The Company&#8217;s cash, cash equivalents and investment securities increased from $109.5 million at December&#160;31, 2021 to $122.1 million at March&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities decreased by $21.6 million to $43.7 million for the three months ended March 31, 2022 from $65.3 million for the three months ended March 31, 2021 primarily driven by a $22.2 million decrease in accounts payable and accrued expenses and a $6.6 million decrease in other assets partially offset by a $3.4 million increase in prepaid expenses and other current assets, a $1.3 million increase in depreciation and amortization, a $0.9 million increase in prepaid income taxes and a $0.7 million increase in net income. We continued to expand our cloud computing technology capabilities to support our planned growth during the three months ended March 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $1.8 million for the three months ended March 31, 2022 as compared to $0.9 million for the three months ended March 31, 2021. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities increased by $5.9 million to $28.1 million for the three months ended March 31, 2022 from $22.2 million for the three months ended March 31, 2021. This increase was primarily due to a $2.5 million increase in stock repurchases and a $3.3 million increase in cash dividends paid to stockholders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In pursuing its business strategy, the Company may require additional cash for operating and investing activities. The Company expects future cash requirements, if any, to be funded from operating cash flow and financing activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time the Company evaluates potential acquisitions that complement our business. If consummated, any such transactions may use a portion of our working capital or require the issuance of equity or debt. We have no present understandings, commitments or agreements with respect to any material acquisitions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021, the Company entered into a credit agreement, which provides for a $125.0 million senior secured revolving credit facility with a $20.0 million letter of credit sublimit and also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $100.0 million. The credit facility contains affirmative and negative covenants customarily applicable to credit facilities. As of March&#160;31, 2022, the Company was in compliance with all of its debt covenants and there were no borrowings outstanding under the credit facility.</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk is the potential loss arising from adverse changes in market rates and prices, such as interest rates and a decline in the stock market. The Company does not enter into derivatives, foreign exchange transactions or other financial instruments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to market risk related to changes in interest rates and market pricing impacting our investment portfolio. Its current investment policy is to maintain an investment portfolio consisting of municipal bonds and U.S. money market securities directly or through managed funds. Its cash is deposited in and invested through highly rated financial institutions in North America. Its marketable securities are subject to interest rate risk and market pricing risk and will fall in value if market interest rates increase or if market pricing decreases. If market interest rates were to increase and market pricing were to decrease immediately and uniformly by 10% from levels at March&#160;31, 2022, the Company estimates that the fair value of its investment portfolio would decline by an immaterial amount and therefore it would not expect its operating results or cash flows to be affected to any significant degree by the effect of a change in market conditions on our investments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our market risk exposure since December&#160;31, 2021.</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of March&#160;31, 2022. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported accurately and on a timely basis. Based on this evaluation performed in accordance with the criteria established in the 2013 Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, our management concluded that the Company&#8217;s disclosure controls and procedures are effective at the reasonable assurance level as of the end of the period covered by this report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Act) during the fiscal quarter ended March&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><div id="i35e36ffd713d4c4192dc577fa494572d_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:21.6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Part II Other Information</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, from time to time, subject to a variety of litigation and similar proceedings that arise out of the ordinary course of its business. Based upon the Company&#8217;s experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position or liquidity. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that the Company&#8217;s results of operations, financial condition or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions.</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors set forth in Part I, Item 1A of the 2021 Form 10-K.</span></div><div id="i35e36ffd713d4c4192dc577fa494572d_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:19.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.488%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total Number of Shares Purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Number of Shares Purchased<br/>as Part of a Publicly Announced<br/>Plan or Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Maximum Number of Shares that May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Yet Be Purchased Under the Plans or Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">January 1 - January 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,042,616</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">February 1 - February 28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,034,016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">March 1 - March 31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,034,016</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Also included are shares of common stock surrendered by employees and directors to the Company to cover minimum tax liability withholding obligations upon the exercise of stock options or the vesting of shares of restricted stock previously granted to such employees and directors.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">At the outset of the quarter ended March&#160;31, 2022, there were 2,084,480 shares of the Company's common stock eligible for repurchase under the stock repurchase authorization dated September 16, 2014 (the "Stock Repurchase Plan").</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, there were 2,034,016 shares of the Company&#8217;s common stock eligible for repurchase under the Stock Repurchase Plan. There can be no assurances as to the amount, timing or prices of repurchases, which may vary based on market conditions and other factors. The Stock Repurchase Plan does not have an expiration date and can be modified or terminated by the Board of Directors at any time.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><div id="i35e36ffd713d4c4192dc577fa494572d_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Description of Exhibit</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/910329/000114420415012727/v402962_ex3-1.htm">Restated and Amended Certificate of Incorporation of Medifast, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K (File No. 001-31573) filed February 27, 2015).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/910329/000110465919069652/tm1923867d1_ex3-1.htm">Amended and Restated Bylaws of Medifast, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Amendment No. 1 Current Report on Form 8-K (File No. 001-31573) filed on December 4, 2019).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-101medifastformpsuagree.htm">Medifast, Inc. Amended and Restated 2012 Share Incentive Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-101medifastformpsuagree.htm"> Grant Notice Perfo</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-101medifastformpsuagree.htm">rmance Share Units</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-101medifastformpsuagree.htm"> (filed herewith).</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-101medifastformpsuagree.htm"> </a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ex-102medifastformrestrict.htm">Medifast, Inc. Amended and Restated 2012 Share Incentive Plan Grant Notice Nonemployee Director Deferred Shares (filed herewith).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-103medifastformrestrict.htm">Medifast, Inc. Amended and Restated 2012 Share Incentive Plan Grant Notice </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-103medifastformrestrict.htm">Employee Deferred</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-103medifastformrestrict.htm"> Share</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex-103medifastformrestrict.htm">s (filed herewith). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ex-104medifastformrestrict.htm">Medifast, Inc. Amended and Restated 2012 Share Incentive Plan Grant Notice Nonemployee Director Deferred Share Cash Equivalent (filed herewith).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="med-20220331xexx311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="med-20220331xexx312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="med-20220331xexx321.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">The following financial statements from Medifast, Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed May 2, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Income, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Cash Flows, (v) Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity, and (vi) Notes to the Condensed Consolidated Financial Statements (filed herewith).</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with SEC Release No. 33-8238, Exhibit 32.1 is being furnished and not filed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><div id="i35e36ffd713d4c4192dc577fa494572d_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:21.6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i35e36ffd713d4c4192dc577fa494572d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medifast, Inc.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ DANIEL R. CHARD</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Daniel R. Chard</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">May 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ JAMES P. MALONEY</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">James P. Maloney</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex-101medifastformpsuagree.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i05828052f89c4c83b4b108b98714d62d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GRANT NOTICE PERFORMANCE SHARE UNITS </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medifast, Inc. (the &#8220;Company&#8221;) hereby grants to the Participant named below performance-based Deferred Shares (&#8220;Performance Share Units&#8221; or &#8220;PSUs&#8221;) pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the &#8220;Plan&#8221;) in the number specified below (the &#8220;Target Award Opportunity&#8221;) covering the three-year Performance Period specified below and subject to the achievement of Performance Goals, which relate to the Performance Measures specified below. Each PSU relates to and corresponds in value to a single share of Company common stock (&#8220;Share&#8221;) and represents the right to receive one Share for each vested PSU. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The PSUs are subject to all of the terms and conditions as set forth in this Grant Notice, the Performance Share Units Award Agreement (the &#8220;Award Agreement&#8221;) and the Plan, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Award Agreement.</font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;padding-left:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Participant Name&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Grant Date&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Target Award Opportunity&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Performance Period&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vesting Schedule (other than in connection with a Change in Control as provided in Section 8 of the Plan)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Terms&#47;Acknowledgements&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The undersigned Participant acknowledges receipt of, and understands and agrees to the terms set forth in this Grant Notice, the Award Agreement and the Plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">by accepting this Grant Notice and attached Award Agreement electronically, you agree to the terms and conditions in the Grant Notice, Award Agreement and Plan).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant further acknowledges that as of the Grant Date, this Grant Notice, the Award Agreement, the Plan, and any employment or change in control agreement between you and the Company set forth the entire understanding between Participant and the Company regarding the acquisition of Shares in accordance with this Grant Notice, the Award Agreement and the Plan and supersede all prior oral and written Award Agreements on that subject.  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PERFORMANCE SHARE UNITS AWARD AGREEMENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to your Performance Share Units Grant Notice (&#8220;Grant Notice&#8221;) and this Award Agreement, Medifast, Inc. (the &#8220;Company&#8221;) has granted to you performance-based Deferred Shares (&#8220;Performance Share Units&#8221;, &#8220;PSUs&#8221; or &#8220;Award&#8221;) under the Plan covering the number of PSUs indicated in your Grant Notice, which vest in accordance with the Vesting Schedule indicated in your Grant Notice and this Award Agreement. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or your Grant Notice.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">The details of your Performance Share Units are as follows&#58;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Eligibility for Payment or Distribution of Vested PSUs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You must be continuously employed by the Company or any of its subsidiaries from the Grant Date through and up to the last day of the Performance Period specified in your Grant Notice to be eligible for a payment or distribution of your PSUs that vest and become nonforfeitable in accordance with Section 2 of this Award Agreement. If you incur a Termination of Service for any reason other than Retirement prior the last day of the Performance Period, you will forfeit any nonvested PSUs that you then hold and you shall not be entitled to any distribution or payout with respect to such forfeited PSUs, except as otherwise provided in Section 3 of this Award Agreement. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Retirement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If your employment with the Company is terminated by virtue of a Retirement, the PSUs shall continue to vest and be settled as they would have absent an employment termination and shall be eligible to vest at the conclusion of the Performance Period on a pro-rata basis, as set forth in Section 2 below. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means your termination of employment from the Company and its subsidiaries other than for cause, provided that you (i) have attained age 55, (ii) the numerical sum of your age and years of service with the Company or its subsidiaries is equal to at least 70, (iii) you are performing your job duties to the Company&#8217;s satisfaction at the time of notice and until your termination of employment, and (iv) you have given notice to the Company, in form satisfactory to the Company, of your intent to retire specifying the exact intended date of retirement to the Company that is at least 12 months following such notice date (provided that prior to such notice the Company had not already given you notice that you would be terminated), and remained employed by the Company until the earlier of (a) the one year anniversary of the date of such notice or (b) the date on which you are terminated by the Company without Cause. The Chief Executive Officer of the Company (or the Compensation Committee of the Board of Directors of the Company, in the event that you are at the time of notice either of the Chief Executive Officer (&#8220;CEO&#8221;), or the CEO&#8217;s direct report at the Executive Vice President-level or above, or one of the Company&#8217;s &#8220;Named Executive Officers&#8221; in the Company&#8217;s most recent Proxy filing pursuant to Item 402 of Regulation S-K) may, in his or her discretion, waive the requirement that you remain employed until the one year anniversary of the date of such notice.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Determination of Number of Vested PSUs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Subject to the requirements of Section 1 of this Agreement, at the conclusion of the Performance Period the Committee shall determine whether and to what extent you have become vested in your Award in accordance with Appendix A to this Agreement. In the event of your Retirement prior to the conclusion of the Performance Period, you shall be eligible to vest in a number of PSUs equal to the number of PSUs that would have vested if you had remained employed until the end of the Performance Period times a fraction, the numerator of which is the number of full months during the Performance Period that you were employed prior to your Retirement and the denominator of which is the number of months during the Performance Period.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Effect of a Change in Control Prior to a Vesting Date. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The treatment of any nonvested PSUs that you hold upon or after a Change in Control will be determined under Section 8 of the Plan. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Form and Timing of Settlement of PSUs. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As provided for under Section 6(e)(ii) of the Plan, within  two and one-half months after the close of the calendar year in which your shares vest, the Company will issue and deliver to you (at the Company&#8217;s sole discretion) the number of shares of Stock equal to the number of your PSUs that vested on such Vesting Date, subject to satisfaction of applicable tax and&#47;or other obligations as described in Section 9 of this Award Agreement. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In the event that the Company declares and pays a dividend in respect of its outstanding Shares and, on the record date for such dividend, you hold PSUs granted pursuant to this Award Agreement that have not been settled, the Company shall credit to an account maintained by the Company for your benefit an amount equal to the cash dividends you would have received if you were the holder of record, as of such record date, of the number of Shares related to the portion of the PSUs that have not been settled or forfeited as of such record date (the &#8220;Dividend Equivalent&#8221; or &#8220;DER&#8221;). Such account is intended to constitute an &#8220;unfunded&#8221; account, and neither this Section 5 nor any action taken pursuant to or in accordance with this Section 5 shall be construed to create a trust of any kind. Amounts credited to such account with respect to PSUs that vest in accordance with Sections 2 or 3 of this Award Agreement will become vested DERs and will be paid to you in cash, Shares, or a combination thereof, as determined by the Committee in its sole discretion, at the same time as your vested PSUs are settled. You shall not be entitled to receive any interest with respect to the timing of payment of DERs. In the event all or any portion of the PSUs granted to you pursuant to this Award Agreement fail to become vested under Sections 2 or 3 of this Award Agreement, the unvested DERs accumulated in your account with respect to such PSUs shall be forfeited.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Delivery of Shares.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company shall deliver Shares in settlement of your vested PSUs to you in accordance with this Section 6&#59; provided, however, the Company shall not be obligated to deliver Shares to you if (i) you have not satisfied all applicable tax withholding obligations, (ii) Shares are not properly registered or subject to an applicable exemption therefrom, (iii) Shares are not listed on the stock exchanges on which Company Shares are otherwise listed, or (iv) the Company determines that the delivery of Shares would violate any federal or state securities or other applicable laws. At the discretion of the Company, Shares may be delivered to you by book-entry credit to an account in your name established by the Company with the Company&#8217;s transfer agent, or upon written request</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">from you (or your personal representative, beneficiary or estate, as the case may be) in certificates in your name (or your personal representative, beneficiary or estate).You shall not acquire or have any rights as a shareholder of the Company until Shares issuable hereunder are actually issued and delivered to you in accordance with the Award Agreement.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Restrictive Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Without limiting any other&#160;non-competition,&#160;non-solicitation,&#160;non-disparagement&#160;or&#160;non-disclosure&#160;or other similar agreement to which you may be a party, you shall be subject to the confidentiality and restrictive covenants set forth on&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;attached hereto, which&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;is incorporated herein and forms part of this Award Agreement. In the event that you violate any of the restrictive covenants referred to in this Section&#160;8, in addition to any other remedy that may be available at law or in equity, the PSUs shall be automatically forfeited effective as of the date on which such violation first occurs and any payment or delivery with respect to the PSUs during the &#91;6 months&#93; prior to such violation shall be rescinded. The Company shall notify you in writing of any such rescission within two years after such payment or delivery. Within ten days after receiving such a notice from the Company, you shall return the Shares to the Company or pay to the Company any profit or gain your realized in connection with sale of such Shares. The foregoing rights and remedies are in addition to any other rights and remedies that may be available to the Company and shall not prevent (and you shall not assert that they shall prevent) the Company from bringing one or more actions in any applicable jurisdiction to recover damages as a result of your breach of such restrictive covenants.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Forfeiture and Recoupment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Notwithstanding any provision of this Award Agreement or the Plan to the contrary, you agree that your right to retain your Award, to retain any amount received pursuant to your Award and to retain any profit or gain your realized in connection with sale of such Shares, shall be subject to any recoupment or &#8220;clawback&#8221; policy or forfeiture policy adopted by the Company.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Restrictions on Resales of Shares.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company may impose such restrictions, conditions, and limitations as it determines appropriate as to the timing and manner of any resales by you or other subsequent transfers by you of any Shares issued as a result of the settlement of your PSUs, including (i) restrictions under an insider trading policy, (ii) restrictions designed to delay and&#47;or coordinate the timing and manner of sales by you and other PSU holders, and (iii) restrictions as to the use of a specified brokerage firm for such resales or other transfers.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Tax Withholding Obligations.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">At the time your PSUs are settled, you hereby authorize withholding from payroll and any other amounts payable to you by the Company, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(&#8220;Withholding Obligations&#8221;) of the Company, if any, which arise in connection with the settlement of your PSUs. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">Upon your request and subject to approval by the Company, in its sole discretion, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested Shares otherwise issuable to you upon the settlement of your PSUs a number of whole Shares having a Fair Market Value, determined by the Company as of the date of settlement, at least equal to the minimum statutory amount of tax required to be withheld by law but in no event in excess of the maximum statutory amount of tax that is permitted to be withheld by law. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Tax Consequences.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your PSUs or your other compensation. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Applicability of Section&#160;409A of the Internal Revenue Code.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">Your PSUs granted hereunder are not intended to provide for a &#8220;deferral of compensation&#8221; within the meaning of Section 409A of the U.S. Internal Revenue Code (&#8220;Section 409A&#8221;) and shall be interpreted and construed in a manner consistent with that intent. If any provision of this Award Agreement, your Grant Notice or the Plan causes your PSUs to be subject to the requirements of Section 409A, or could otherwise cause you to recognize income or be subject to the interest and penalties under Section 409A, then the provision shall have no effect or, to the extent practicable, the Committee may, in its sole discretion and without the Participant&#8217;s consent, modify the provision to (i) comply with, or avoid being subject to Section 409A, or to avoid the incurrence of any taxes, interest and penalties under Section 409A, and&#47;or (ii) maintain, to the maximum extent practicable, the original intent and economic benefit to you of the applicable provision without materially increasing the cost to the Company or contravening the provisions of Section 409A. This Section 12 does not create an obligation of the Company to modify this Award Agreement, your Grant Notice or the Plan and does not guarantee that your PSUs will not be subject to taxes, interest and penalties under Section 409A.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">If you are a &#8220;specified employee&#8221; as defined under Code Section 409A and your PSUs are to be settled on account of your separation from service (for reasons other than death) and such PSUs constitutes &#8220;deferred compensation&#8221; as defined under Code Section 409A, then any portion of your PSUs that would otherwise be settled during the six-month period commencing on your separation from service shall be settled as soon as practicable following the conclusion of the six-month period (or following your death if it occurs during such six-month period). </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.23pt">Your Termination of Service shall not be deemed to have occurred for purposes of any provision of the Award Agreement providing for the payment of any amounts or benefits that are considered nonqualified deferred compensation under Section 409A upon or following a Termination of Service, unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A and the payment thereof prior to a &#8220;separation from service&#8221; could otherwise cause you to recognize income or be subject to the interest and penalties under Section 409A.  </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Restrictions on Transferability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your PSUs may not be sold, transferred, pledged, assigned, exchanged, encumbered, or otherwise alienated or hypothecated, except (i) by will or by the laws of descent and distribution&#59; (ii) to the extent permitted by the Plan and allowed under applicable law and approved by the Committee in its sole discretion&#59; or (iii) pursuant to a domestic relations order.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Beneficiary Designation.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or successively) to whom any benefit under this Award Agreement is to be paid in case of your death before you receive any or all of such benefit. Each such designation shall revoke all prior designations by you, shall be in a form prescribed by the Company, and will be effective only when filed by you in writing with the Secretary of the Company during your lifetime. In the absence of any such designation, benefits remaining unpaid at the time of your death shall be paid to your estate.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Securities Laws.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Award Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required, or the Committee determines are advisable. You agree to take all steps that the Company determines are necessary to comply with all applicable provisions of federal and state </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">securities law in exercising your rights under this Award Agreement. The Committee may impose such restrictions on any Shares acquired by you under the Award Agreement as it may deem necessary or advisable, under applicable federal securities laws, the requirements of any stock exchange or market upon which such Shares are then listed or traded or any blue sky or state securities laws applicable to such Shares. In addition, the Shares shall be subject to any trading restrictions, stock holding requirements or other policies in effect from time to time as determined by the Committee.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Data Privacy.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To administer the Plan, the Company may process personal data about you. Such data includes the information provided in this Award Agreement, other appropriate personal and financial data about you such as home address and business addresses and other contact information, payroll information and any other information deemed appropriate by the Company to facilitate the administration of the Plan. By accepting this award, you consent to the Company&#8217;s processing of such personal data and the transfer of such data outside the country in which you work or are employed, including, with respect to non-U.S. residents, to the United States, to transferees who shall include the Company and other persons designated by the Company to administer the Plan.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">No Right to Continued Employment or Further Awards.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">Neither the Plan nor this Award Agreement shall (i) alter your status as an &#8220;at-will&#8221; employee of the Company&#59; (ii) be construed as giving you any right to continue in the employ of the Company&#59; or (iii) be construed as giving you any right to be reemployed by the Company following any Termination of Service. The Termination of Service provisions in this Award Agreement shall solely apply to the treatment of your PSUs as specified herein and shall not otherwise affect your employment relationship with the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">The Company has granted your PSUs in its sole discretion. Your Grant Notice, this Award Agreement and the Plan do not confer to you any right or entitlement to receive another grant of PSUs, or any other similar award at any time in the future or in respect of any future period. Your PSU grant does not confer on you any right or entitlement to receive compensation in any specific amount for any future fiscal year, and does not diminish in any way the Company&#8217;s discretion to determine the amount, if any, of your compensation.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Notices.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any notice required or permitted to be given under this Award Agreement, or Grant Notice or the Plan shall be in writing and shall be deemed to have been given when delivered personally or by courier, or sent by certified or registered United States mail, postage prepaid, return receipt requested, duly addressed to the party concerned at the address indicated below or to such changed address as such party may subsequently by similar process give notice of&#58;</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">If to the Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medifast, Inc.<br>100 International Drive</font></div><div style="padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18th Floor</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baltimore, Maryland 21202<br>Attn.&#58; General Counsel</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">If to the Employee&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the last address delivered to the Company by the <br>Employee in the manner set forth herein.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">General Provisions.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Headings.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The headings preceding the text of the sections in this Award Agreement are inserted solely for convenience of reference, and shall not constitute a part of this Award Agreement, nor shall they affect its meaning, construction, or effect. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Severability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If any provision of this Award Agreement is declared to be illegal, invalid, or otherwise unenforceable by a court of competent jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal, valid, and enforceable, or otherwise deleted, and the remainder of the provisions of this Award Agreement shall not be affected except to the extent necessary to reform or delete such illegal, invalid, or unenforceable provision.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.23pt">Governing Documents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Award Agreement is subject to all of the terms and conditions as set forth in your Grant Notice and the Plan, all of which are incorporated herein in their entirety. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Your Grant Notice, this Award Agreement, the Plan, and any employment or change in control agreement between you and the Company constitute the entire understanding between you and the Company regarding the PSUs. Any prior Award Agreements, commitments or negotiations concerning the PSUs are superseded. In the event of any conflict between the provisions of your Grant Notice and this Award Agreement and those of the Plan, the provisions of the Plan shall control. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Binding on Parties.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The provisions of this Award Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Applicable Law.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your Grant Notice and this Award Agreement shall be governed, construed, interpreted, and administered solely in accordance with the laws of the state of Delaware, without regard to principles of conflicts of law, with consent of jurisdiction by you in the State of Maryland.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:12.46pt">Rescission of Award Agreement and PSU Grant.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your PSUs granted under this Award Agreement may be rescinded if necessary to ensure compliance with federal, state or other applicable laws. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Administration of PSUs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All questions arising under your Grant Notice, this Award Agreement and the Plan shall be decided by the Committee in its total and absolute discretion. It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate to the administration of your Grant Notice, this Award Agreement and the Plan&#59; all such determinations shall be binding upon you and your successors.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">No Shareholder Rights.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The PSUs granted to you under pursuant this Award Agreement do not and shall not entitle you to any rights of a holder of a Share of Company common stock prior to the date Shares are issued to you in settlement of the PSUs, if at all (or an appropriate book entry has been made). Except as described in the Plan, no adjustments are made for dividends or other rights if the applicable record date occurs prior to the date Shares are issued to you in settlement of the PSUs (or an appropriate book entry has been made).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:13.01pt">Unfunded Arrangement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The PSUs create a contractual obligation on the part of the Company to distribute to you Shares in connection with the vesting of the PSUs at the time provided for in this Award Agreement. Neither you nor any other party claiming an interest under this Agreement shall have any interest whatsoever in any specific assets of the Company. Your right to receive Shares under this Agreement is that of an unsecured general creditor of Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:13.01pt">Consent to Electronic Delivery.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Certain statutory materials relating to the Plan may be delivered to you in electronic form. By accepting this grant, you consent to electronic delivery and acknowledge receipt of these materials, including the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:136%">This Award Agreement is not a stock certificate or a negotiable instrument. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:124%">Appendix A</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:136%">Unless otherwise provided in the Award Agreement or Plan, set forth below are the Performance Goals applicable to your Award and the method for calculating the number of your PSUs that vest at the conclusion of the Performance Period ending on ________________, 20__.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:124%"> </font></div><div style="padding-left:54pt;text-indent:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex-102medifastformrestrict.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i22618f88172f49fd898600e5c25e02ac_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GRANT NOTICE NONEMPLOYEE DIRECTOR DEFERRED SHARES </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medifast, Inc. (the &#8220;Company&#8221;) hereby grants to the Participant named below Deferred Shares ( &#8220;RSUs&#8221;) pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the &#8220;Plan&#8221;) in the number specified below, which shall vest in accordance with the Vesting Schedule. Each RSU relates and corresponds in value to a single share of Company common stock (&#8220;Share&#8221;) and represents the right to receive one Share for each vested RSU.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The RSUs are subject to all of the terms and conditions as set forth in this Grant Notice, the Deferred Share Award Agreement (the &#8220;Award Agreement&#8221;) and the Plan, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Award Agreement.</font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;padding-left:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Participant Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Number of RSUs Granted&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Terms&#47;Acknowledgements&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The undersigned Participant acknowledges receipt of, and understands and agrees to the terms set forth in this Grant Notice, the Award Agreement and the Plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">by accepting this Grant Notice and attached Award Agreement electronically, you agree to the terms and conditions in the Grant Notice, Award Agreement and Plan).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant further acknowledges that as of the Grant Date, this Grant Notice, the Award Agreement, and the Plan, set forth the entire understanding between Participant and the Company regarding the acquisition of Shares in accordance with this Grant Notice, the Award Agreement and the Plan and supersede all prior oral and written Award Agreements on that subject. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DEFERRED SHARE NONEMPLOYEE DIRECTOR AWARD AGREEMENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to your Deferred Share Grant Notice (&#8220;Grant Notice&#8221;) and this Award Agreement, Medifast, Inc. (the &#8220;Company&#8221;) has granted to you Deferred Shares (&#8220;RSUs&#8221; or &#8220;Award&#8221;) under the Plan covering the number of RSUs indicated in your Grant Notice, which vest in accordance with the Vesting Schedule indicated in your Grant Notice and this Award Agreement. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or your Grant Notice.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">The details of your RSUs are as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Determination of Number of Vested RSUs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your RSUs are subject to the Vesting Schedule set forth in your Grant Notice. On each vesting date (&#8220;Vesting Date&#8221;) set forth in the Vesting Schedule, you will vest in the specified percentage of your RSUs, and your vested RSUs shall be settled in accordance with the terms of this Award Agreement&#59; provided that you satisfy the requirements of Section 2 of this Agreement or vest in your RSUs in accordance with Section 3 of this Award Agreement.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Eligibility for Payment or Distribution.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You must be continuously participating on the Board of Directors of the Company or any of its subsidiaries from the Grant Date through and up to a Vesting Date specified in your Grant Notice to be eligible for a payment or distribution of your RSUs that vest and become nonforfeitable on such Vesting Date. If you incur a Termination of Service prior to a Vesting Date, you will forfeit any non-vested RSUs that you then hold on the date of such Termination of Service and you shall not be entitled to any distribution or payout with respect to such forfeited RSUs, except as otherwise expressly provided in Section 5 of this Award Agreement.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Effect of a Change in Control Prior to a Vesting Date. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The treatment of any nonvested RSUs that you hold upon or after a Change in Control will be determined under Section 8 of the Plan. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Form and Timing of Settlement of RSUs. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except to the extent that an election to defer the RSUs has been made pursuant to the Company&#8217;s Director Deferred Compensation Plan,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within thirty (30) days of a Vesting Date, the Company will issue and deliver to you the number of shares of Stock equal to the number of your RSUs that vested on such Vesting Date, subject to satisfaction of applicable tax and&#47;or other obligations as described in Section 9 of this Award Agreement. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In the event that the Company declares and pays a dividend in respect of its outstanding Shares and, on the record date for such dividend, you hold RSUs granted pursuant to this Award Agreement that have not been settled, the Company shall credit to an account maintained by the Company for your benefit an amount equal to the cash dividends you would have received if you were the holder of record, as of such record date, of the number of Shares related to the portion of the RSUs that have not been settled or forfeited as of such record date (the &#8220;Dividend Equivalent&#8221; or &#8220;DER&#8221;). Such account is intended to constitute an &#8220;unfunded&#8221; account, and neither this Section 5 nor any action taken pursuant to or in accordance with this Section 5 shall be construed to create a trust of any kind. Amounts credited to such account with respect to RSUs that vest in accordance with Sections 2 or 3 of this Award Agreement will become vested DERs and will be paid to you in cash, Shares, or a combination thereof, as determined by the Committee in its sole discretion, at the same time as your vested RSUs are settled. You shall not be entitled to receive any interest with respect to the timing of payment of DERs. In the event all or any portion of the RSUs granted to you pursuant to this Award Agreement fail to become vested under Sections 2 or 3 of this Award Agreement, the unvested DERs accumulated in your account with respect to such RSUs shall be forfeited.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Delivery of Shares.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company shall deliver such Shares in settlement of your vested RSUs to you in accordance with this Section 6&#59; provided, however, the Company shall not be obligated to deliver Shares to you if (i) you have not satisfied all applicable tax withholding obligations, (ii) Shares are not properly registered or subject to an applicable exemption therefrom, (iii) Shares are not listed on the stock exchanges on which Company Shares are otherwise listed, or (iv) the Company determines that the delivery of Shares would violate any federal or state securities or other applicable laws. At the discretion of the Company, Shares may be delivered to you by book-entry credit to an account in your name established by the Company with the Company&#8217;s transfer agent, or upon written request</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">from you (or your personal representative, beneficiary or estate, as the case may be) in certificates in your name (or your personal representative, beneficiary or estate).You shall not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">acquire or have any rights as a shareholder of the Company until Shares issuable hereunder are actually issued and delivered to you in accordance with the Award Agreement.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Forfeiture and Recoupment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Notwithstanding any provision of this Award Agreement or the Plan to the contrary, you agree that your right to retain your Award, to retain any amount received pursuant to your Award and to retain any profit or gain you realized in connection with sale of such Shares, shall be subject to any recoupment or &#8220;clawback&#8221; policy or forfeiture policy adopted by the Company.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Restrictions on Resales of Shares.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company may impose such restrictions, conditions, and limitations as it determines appropriate as to the timing and manner of any resales by you or other subsequent transfers by you of any Shares issued as a result of the settlement of your RSUs, including (i) restrictions under an insider trading policy, (ii) restrictions designed to delay and&#47;or coordinate the timing and manner of sales by you and other RSU holders, and (iii) restrictions as to the use of a specified brokerage firm for such resales or other transfers.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Tax Consequences.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your RSUs or your other compensation. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Restrictions on Transferability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your RSUs may not be sold, transferred, pledged, assigned, exchanged, encumbered, or otherwise alienated or hypothecated, except (i) by will or by the laws of descent and distribution&#59; (ii) to the extent permitted by the Plan and allowed under applicable law and approved by the Committee in its sole discretion&#59; or (iii) pursuant to a domestic relations order.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Beneficiary Designation.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or successively) to whom any benefit under this Award Agreement is to be paid in case of your death before you receive any or all of such benefit. Each such designation shall revoke all prior designations by you, shall be in a form prescribed by the Company, and will be effective only when filed by you in writing with the Secretary of the Company during your lifetime. In the absence of any such designation, benefits remaining unpaid at the time of your death shall be paid to your estate.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Securities Laws.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Award Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required, or the Committee determines are advisable. You agree to take all steps that the Company determines are necessary to comply with all applicable provisions of federal and state securities law in exercising your rights under this Award Agreement. The Committee may impose such restrictions on any Shares acquired by you under the Award Agreement as it may deem necessary or advisable, under applicable federal securities laws, the requirements of any stock exchange or market upon which such Shares are then listed or traded or any blue sky or state securities laws applicable to such Shares. In addition, the Shares shall be subject to any trading restrictions, stock holding requirements or other policies in effect from time to time as determined by the Committee.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Data Privacy.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To administer the Plan, the Company may process personal data about you. Such data includes the information provided in this Award Agreement, other appropriate personal and financial data about you such as home address and business addresses and other contact information, payroll information and any other information deemed appropriate by the Company to facilitate the administration of the Plan. By accepting this award, you consent to the Company&#8217;s processing of such personal data and the transfer of such data outside the country in which you work or are employed, including, with respect to non-U.S. residents, to the United States, to transferees who shall include the Company and other persons designated by the Company to administer the Plan.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">No Right to Further Awards.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company has granted your RSUs in its sole discretion. Your Grant Notice, this Award Agreement and the Plan do not confer to you any right or entitlement to receive another grant of RSUs, or any other similar award at any time in the future or in respect of any future period. Your RSU grant does not confer on you any right or entitlement to receive compensation in any specific amount for any future fiscal year, and does not diminish in any way the Company&#8217;s discretion to determine the amount, if any, of your compensation.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Notices.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any notice required or permitted to be given under this Award Agreement, or Grant Notice or the Plan shall be in writing and shall be deemed to have been given when delivered personally or by courier, or sent by certified or registered United States mail, postage prepaid, return receipt </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">requested, duly addressed to the party concerned at the address indicated below or to such changed address as such party may subsequently by similar process give notice of&#58;</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">If to the Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medifast, Inc.<br>100 International Drive</font></div><div style="padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18th Floor</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baltimore, Maryland 21202<br>Attn.&#58; General Counsel</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">If to the Participant&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the last address delivered to the Company by the <br>Participant in the manner set forth herein.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">General Provisions.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Headings.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The headings preceding the text of the sections in this Award Agreement are inserted solely for convenience of reference, and shall not constitute a part of this Award Agreement, nor shall they affect its meaning, construction, or effect. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Severability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If any provision of this Award Agreement is declared to be illegal, invalid, or otherwise unenforceable by a court of competent jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal, valid, and enforceable, or otherwise deleted, and the remainder of the provisions of this Award Agreement shall not be affected except to the extent necessary to reform or delete such illegal, invalid, or unenforceable provision.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.23pt">Governing Documents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Award Agreement is subject to all of the terms and conditions as set forth in your Grant Notice and the Plan, all of which are incorporated herein in their entirety. Your Grant Notice, this Award Agreement and the Plan constitute the entire understanding between you and the Company regarding the RSU&#8217;s.  Any prior Award Agreements, commitments or negotiations concerning the RSUs are superseded. In the event of any conflict between the provisions of your Grant Notice and this Award Agreement and those of the Plan, the provisions of the Plan shall control. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Binding on Parties.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The provisions of this Award Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Applicable Law.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your Grant Notice and this Award Agreement shall be governed, construed, interpreted, and administered solely in accordance with the laws of the state of Delaware, without regard to principles of conflicts of law, with consent of jurisdiction by you in the State of Maryland.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:12.46pt">Rescission of Award Agreement and RSU Grant.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your RSUs granted under this Award Agreement may be rescinded if necessary to ensure compliance with federal, state or other applicable laws. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Administration of RSUs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All questions arising under your Grant Notice, this Award Agreement and the Plan shall be decided by the Committee in its total and absolute discretion. It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate to the administration of your Grant Notice, this Award Agreement and the Plan&#59; all such determinations shall be binding upon you and your successors.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">No Shareholder Rights.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The RSUs granted to you under pursuant this Award Agreement do not and shall not entitle you to any rights of a holder of a Share of Company common stock prior to the date Shares are issued to you in settlement of the RSUs, if at all (or an appropriate book entry has been made). Except as described in the Plan, no adjustments are made for dividends or other rights if the applicable record date occurs prior to the date Shares are issued to you in settlement of the RSUs (or an appropriate book entry has been made).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:13.01pt">Unfunded Arrangement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The RSUs create a contractual obligation on the part of the Company to distribute to you Shares in connection with the vesting of the RSUs at the time provided for in this Award Agreement. Neither you nor any other party claiming an interest under this Agreement shall have any interest whatsoever in any specific assets of the Company. Your right to receive Shares under this Agreement is that of an unsecured general creditor of Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:13.01pt">Consent to Electronic Delivery.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Certain statutory materials relating to the Plan may be delivered to you in electronic form. By accepting this grant, you consent to electronic delivery and acknowledge receipt of these materials, including the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:136%">This Award Agreement is not a stock certificate or a negotiable instrument. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex-103medifastformrestrict.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia067bb249be84492be012a2c35412ed8_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GRANT NOTICE EMPLOYEE DEFERRED SHARES </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medifast, Inc. (the &#8220;Company&#8221;) hereby grants to the Participant named below Deferred Shares ( &#8220;RSUs&#8221;) pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the &#8220;Plan&#8221;) in the number specified below, which shall vest in accordance with the Vesting Schedule. Each RSU relates and corresponds in value to a single share of Company common stock (&#8220;Share&#8221;) and represents the right to receive one Share for each vested RSU.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The RSUs are subject to all of the terms and conditions as set forth in this Grant Notice, the Deferred Share Award Agreement (the &#8220;Award Agreement&#8221;) and the Plan, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Award Agreement.</font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;padding-left:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Participant Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Number of RSUs Granted&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Terms&#47;Acknowledgements&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The undersigned Participant acknowledges receipt of, and understands and agrees to the terms set forth in this Grant Notice, the Award Agreement and the Plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">by accepting this Grant Notice and attached Award Agreement electronically, you agree to the terms and conditions in the Grant Notice, Award Agreement and Plan).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant further acknowledges that as of the Grant Date, this Grant Notice, the Award Agreement, the Plan, and any employment or change in control agreement between you and the Company set forth the entire understanding between Participant and the Company regarding the acquisition of Shares in accordance with this Grant Notice, the Award Agreement and the Plan and supersede all prior oral and written Award Agreements on that subject. </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DEFERRED SHARE EMPLOYEE AWARD AGREEMENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to your Deferred Share Grant Notice (&#8220;Grant Notice&#8221;) and this Award Agreement, Medifast, Inc. (the &#8220;Company&#8221;) has granted to you Deferred Shares (&#8220;RSUs&#8221; or &#8220;Award&#8221;) under the Plan covering the number of RSUs indicated in your Grant Notice, which vest in accordance with the Vesting Schedule indicated in your Grant Notice and this Award Agreement. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or your Grant Notice.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">The details of your RSUs are as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Determination of Number of Vested RSUs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your RSUs are subject to the Vesting Schedule set forth in your Grant Notice. On each vesting date (&#8220;Vesting Date&#8221;) set forth in the Vesting Schedule, you will vest in the specified percentage of your RSUs, and your vested RSUs shall be settled in accordance with the terms of this Award Agreement&#59; provided that you satisfy the requirements of Section 2 or 3 of this Agreement or vest in your RSUs in accordance with Section 4 of this Award Agreement.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Eligibility for Payment or Distribution.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You must be continuously employed by the Company or any of its subsidiaries from the Grant Date through and up to a Vesting Date specified in your Grant Notice to be eligible for a payment or distribution of your RSUs that vest and become nonforfeitable on such Vesting Date. If you incur a Termination of Service for any reason other than Retirement prior to a Vesting Date, you will forfeit any non-vested RSUs that you then hold on the date of such Termination of Service and you shall not be entitled to any distribution or payout with respect to such forfeited RSUs, except as otherwise expressly provided in Section 4 of this Award Agreement.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Retirement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If your employment with the Company is terminated by virtue of a Retirement, a number of the RSUs shall vest and be settled on the date of your Retirement equal to the total number of RSUs granted pursuant to this Award that remain unvested on the date of your Retirement times a fraction, the numerator of which is the number of full months between the prior Vesting Date (or the Grant Date, if there has been no Vesting Date) and the date of your Retirement and the denominator of which is the number of months between the prior Vesting Date (or the Grant Date, if there has been no Vesting Date) and the final Vesting Date. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Retirement&#8221; means your termination of employment from the Company and its subsidiaries other than for cause, provided that you (i) have attained age 55, (ii) the numerical sum of your age and years of service with the Company or its subsidiaries is equal to at least 70, (iii) you are performing your job duties to the Company&#8217;s satisfaction at the time of notice and until your termination of employment, and (iv) you have given notice to the Company, in form satisfactory to the Company, of your intent to retire specifying the exact intended date of retirement to the Company that is at least 12 months following such notice date (provided that prior to such notice the Company had not already given you notice that you would be terminated), and remained employed by the Company until the earlier of (a) the one year anniversary of the date of such notice or (b) the date on which you are terminated by the Company without Cause. The Chief Executive Officer of the Company (or the Compensation Committee of the Board of Directors of the Company, in the event that you are at the time of notice either of the Chief Executive Officer &#8220;(CEO&#8221;) of the CEO&#8217;s direct reports at the Executive Vice President-level or above, or one of the Company&#8217;s &#8220;Named Executive Officers&#8221; in the Company&#8217;s most recent Proxy filing pursuant to Item 402 of Regulation S-K) may, in his or her discretion, waive the requirement that you remain employed until the one year anniversary of the date of such notice.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Effect of a Change in Control Prior to a Vesting Date. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The treatment of any nonvested RSUs that you hold upon or after a Change in Control will be determined under Section 8 of the Plan. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Form and Timing of Settlement of RSUs. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within thirty (30) days of a Vesting Date (or, if applicable, the date of your Retirement), the Company will issue and deliver to you the number of shares of Stock equal to the number of your RSUs that vested on such Vesting Date, subject to satisfaction of applicable tax and&#47;or other obligations as described in Section 9 of this Award Agreement. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In the event that the Company declares and pays a dividend in respect of its outstanding Shares and, on the record date for such dividend, you hold RSUs granted pursuant to this Award Agreement that have not been settled, the Company shall credit to an account maintained </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by the Company for your benefit an amount equal to the cash dividends you would have received if you were the holder of record, as of such record date, of the number of Shares related to the portion of the RSUs that have not been settled or forfeited as of such record date (the &#8220;Dividend Equivalent&#8221; or &#8220;DER&#8221;). Such account is intended to constitute an &#8220;unfunded&#8221; account, and neither this Section 6 nor any action taken pursuant to or in accordance with this Section 5 shall be construed to create a trust of any kind. Amounts credited to such account with respect to RSUs that vest in accordance with Sections 2, 3, or 4 of this Award Agreement will become vested DERs and will be paid to you in cash, Shares, or a combination thereof, as determined by the Committee in its sole discretion, at the same time as your vested RSUs are settled. You shall not be entitled to receive any interest with respect to the timing of payment of DERs. In the event all or any portion of the RSUs granted to you pursuant to this Award Agreement fail to become vested under Sections 2, 3, or 4 of this Award Agreement, the unvested DERs accumulated in your account with respect to such RSUs shall be forfeited.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Delivery of Shares.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company shall deliver such Shares in settlement of your vested RSUs to you in accordance with this Section 6&#59; provided, however, the Company shall not be obligated to deliver Shares to you if (i) you have not satisfied all applicable tax withholding obligations, (ii) Shares are not properly registered or subject to an applicable exemption therefrom, (iii) Shares are not listed on the stock exchanges on which Company Shares are otherwise listed, or (iv) the Company determines that the delivery of Shares would violate any federal or state securities or other applicable laws. At the discretion of the Company, Shares may be delivered to you by book-entry credit to an account in your name established by the Company with the Company&#8217;s transfer agent, or upon written request</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">from you (or your personal representative, beneficiary or estate, as the case may be) in certificates in your name (or your personal representative, beneficiary or estate).You shall not acquire or have any rights as a shareholder of the Company until Shares issuable hereunder are actually issued and delivered to you in accordance with the Award Agreement.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Restrictive Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Without limiting any other&#160;non-competition,&#160;non-solicitation,&#160;non-disparagement&#160;or&#160;non-disclosure&#160;or other similar agreement to which you may be a party, you shall be subject to the confidentiality and restrictive covenants set forth on&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;attached hereto, which&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;is incorporated herein and forms part of this Award Agreement. In the event that you violate any of the restrictive covenants referred to in this Section&#160;8, in addition to any other remedy that may be available at law or in equity, the RSUs shall be automatically forfeited effective as of the date on which such violation first occurs and any payment or delivery with respect to the RSUs during the &#91;6 months&#93; prior to such violation shall be rescinded. The Company shall notify you in writing of any such rescission within two years after such payment or delivery. Within ten days after receiving such a notice from the Company, you shall return the Shares to the Company or pay to the Company any profit or gain your realized in connection with sale of such Shares. The foregoing rights and remedies are in addition to any other rights and remedies that may be available to the Company and shall not prevent (and you shall not assert that they shall prevent) the Company from bringing one or more actions in any applicable jurisdiction to recover damages as a result of your breach of such restrictive covenants.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Forfeiture and Recoupment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Notwithstanding any provision of this Award Agreement or the Plan to the contrary, you agree that your right to retain your Award, to retain any amount received pursuant to your Award and to retain any profit or gain your realized in connection with sale of such Shares, shall be subject to any recoupment or &#8220;clawback&#8221; policy or forfeiture policy adopted by the Company.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Restrictions on Resales of Shares.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Company may impose such restrictions, conditions, and limitations as it determines appropriate as to the timing and manner of any resales by you or other subsequent transfers by you of any Shares issued as a result of the settlement of your RSUs, including (i) restrictions under an insider trading policy, (ii) restrictions designed to delay and&#47;or coordinate the timing and manner of sales by you and other RSU holders, and (iii) restrictions as to the use of a specified brokerage firm for such resales or other transfers.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Tax Withholding Obligations.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">At the time your RSUs are settled, you hereby authorize withholding from payroll and any other amounts payable to you by the Company, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations (&#8220;Withholding Obligations&#8221;) of the Company, if any, which arise in connection with the settlement of your RSUs. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">Upon your request and subject to approval by the Company, in its sole discretion, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares otherwise issuable to you upon the settlement of your RSUs a number of whole Shares having a Fair Market Value, determined by the Company as of the date of settlement, at least equal to the minimum statutory amount of tax required to be withheld by law but in no event in excess of the maximum statutory amount of tax that is permitted to be withheld by law. </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Tax Consequences.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your RSUs or your other compensation. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Applicability of Section&#160;409A of the Internal Revenue Code.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">Your RSUs granted hereunder are not intended to provide for a &#8220;deferral of compensation&#8221; within the meaning of Section 409A of the U.S. Internal Revenue Code (&#8220;Section 409A&#8221;) and shall be interpreted and construed in a manner consistent with that intent. If any provision of this Award Agreement, your Grant Notice or the Plan causes your RSUs to be subject to the requirements of Section 409A, or could otherwise cause you to recognize income or be subject to the interest and penalties under Section 409A, then the provision shall have no effect or, to the extent practicable, the Committee may, in its sole discretion and without the Participant&#8217;s consent, modify the provision to (i) comply with, or avoid being subject to Section 409A, or to avoid the incurrence of any taxes, interest and penalties under Section 409A, and&#47;or (ii) maintain, to the maximum extent practicable, the original intent and economic benefit to you of the applicable provision without materially increasing the cost to the Company or contravening the provisions of Section 409A. This Section 12 does not create an obligation of the Company to modify this Award Agreement, your Grant Notice or the Plan and does not guarantee that your RSUs will not be subject to taxes, interest and penalties under Section 409A.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">If you are a &#8220;specified employee&#8221; as defined under Code Section 409A and your RSUs are to be settled on account of your separation from service (for reasons other than death) and such RSUs constitutes &#8220;deferred compensation&#8221; as defined under Code Section 409A, then any portion of your RSUs that would otherwise be settled during the six-month period commencing on your separation from service shall be settled as soon as practicable following the conclusion of the six-month period (or following your death if it occurs during such six-month period). </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.23pt">Your Termination of Service shall not be deemed to have occurred for purposes of any provision of the Award Agreement providing for the payment of any amounts or benefits that are considered nonqualified deferred compensation under Section 409A upon or following a Termination of Service, unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A and the payment thereof prior to a &#8220;separation from service&#8221; could otherwise cause you to recognize income or be subject to the interest and penalties under Section 409A.  </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Restrictions on Transferability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your RSUs may not be sold, transferred, pledged, assigned, exchanged, encumbered, or otherwise alienated or hypothecated, except (i) by will or by the laws of descent and distribution&#59; (ii) to the extent permitted by the Plan and allowed under applicable law and approved by the Committee in its sole discretion&#59; or (iii) pursuant to a domestic relations order.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Beneficiary Designation.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or successively) to whom any benefit under this Award Agreement is to be paid in case of your death before you receive any or all of such benefit. Each such designation shall revoke all prior designations by you, shall be in a form prescribed by the Company, and will be effective only when filed by you in writing with the Secretary of the Company during your lifetime. In the absence of any such designation, benefits remaining unpaid at the time of your death shall be paid to your estate.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Securities Laws.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Award Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required, or the Committee determines are advisable. You agree to take all steps that the Company determines are necessary to comply with all applicable provisions of federal and state securities law in exercising your rights under this Award Agreement. The Committee may impose such restrictions on any Shares acquired by you under the Award Agreement as it may deem necessary or advisable, under applicable federal securities laws, the requirements of any stock exchange or market upon which such Shares are then listed or traded or any blue sky or state securities laws applicable to such Shares. In addition, the Shares shall be subject to any trading </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">restrictions, stock holding requirements or other policies in effect from time to time as determined by the Committee.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Data Privacy.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To administer the Plan, the Company may process personal data about you. Such data includes the information provided in this Award Agreement, other appropriate personal and financial data about you such as home address and business addresses and other contact information, payroll information and any other information deemed appropriate by the Company to facilitate the administration of the Plan. By accepting this award, you consent to the Company&#8217;s processing of such personal data and the transfer of such data outside the country in which you work or are employed, including, with respect to non-U.S. residents, to the United States, to transferees who shall include the Company and other persons designated by the Company to administer the Plan.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">No Right to Continued Employment or Further Awards.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">Neither the Plan nor this Award Agreement shall (i) alter your status as an &#8220;at-will&#8221; employee of the Company&#59; (ii) be construed as giving you any right to continue in the employ of the Company&#59; or (iii) be construed as giving you any right to be reemployed by the Company following any Termination of Service. The Termination of Service provisions in this Award Agreement shall solely apply to the treatment of your RSUs as specified herein and shall not otherwise affect your employment relationship with the Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">The Company has granted your RSUs in its sole discretion. Your Grant Notice, this Award Agreement and the Plan do not confer to you any right or entitlement to receive another grant of RSUs, or any other similar award at any time in the future or in respect of any future period. Your RSU grant does not confer on you any right or entitlement to receive compensation in any specific amount for any future fiscal year, and does not diminish in any way the Company&#8217;s discretion to determine the amount, if any, of your compensation.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Notices.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any notice required or permitted to be given under this Award Agreement, or Grant Notice or the Plan shall be in writing and shall be deemed to have been given when delivered personally or by courier, or sent by certified or registered United States mail, postage prepaid, return receipt requested, duly addressed to the party concerned at the address indicated below or to such changed address as such party may subsequently by similar process give notice of&#58;</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">If to the Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medifast, Inc.<br>100 International Drive</font></div><div style="padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18th Floor</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baltimore, Maryland 21202<br>Attn.&#58; General Counsel</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">If to the Employee&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the last address delivered to the Company by the <br>Employee in the manner set forth herein.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">General Provisions.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Headings.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The headings preceding the text of the sections in this Award Agreement are inserted solely for convenience of reference, and shall not constitute a part of this Award Agreement, nor shall they affect its meaning, construction, or effect. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Severability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If any provision of this Award Agreement is declared to be illegal, invalid, or otherwise unenforceable by a court of competent jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal, valid, and enforceable, or otherwise deleted, and the remainder of the provisions of this Award Agreement shall not be affected except to the extent necessary to reform or delete such illegal, invalid, or unenforceable provision.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.23pt">Governing Documents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Award Agreement is subject to all of the terms and conditions as set forth in your Grant Notice and the Plan, all of which are incorporated herein in their entirety. Your Grant Notice, this Award Agreement, the Plan, and any employment or change in control agreement between you and the Company constitute the entire understanding between you and the Company regarding the RSUs. Any prior Award Agreements, commitments or negotiations concerning the RSUs are superseded. In the event of any conflict between the provisions of your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant Notice and this Award Agreement and those of the Plan, the provisions of the Plan shall control. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Binding on Parties.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The provisions of this Award Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Applicable Law.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your Grant Notice and this Award Agreement shall be governed, construed, interpreted, and administered solely in accordance with the laws of the state of Delaware, without regard to principles of conflicts of law, with consent of jurisdiction by you in the State of Maryland.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:12.46pt">Rescission of Award Agreement and RSU Grant.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your RSUs granted under this Award Agreement may be rescinded if necessary to ensure compliance with federal, state or other applicable laws. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Administration of RSUs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All questions arising under your Grant Notice, this Award Agreement and the Plan shall be decided by the Committee in its total and absolute discretion. It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate to the administration of your Grant Notice, this Award Agreement and the Plan&#59; all such determinations shall be binding upon you and your successors.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">No Shareholder Rights.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The RSUs granted to you under pursuant this Award Agreement do not and shall not entitle you to any rights of a holder of a Share of Company common stock prior to the date Shares are issued to you in settlement of the RSUs, if at all (or an appropriate book entry has been made). Except as described in the Plan, no adjustments are made for dividends or other rights if the applicable record date occurs prior to the date Shares are issued to you in settlement of the RSUs (or an appropriate book entry has been made).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:13.01pt">Unfunded Arrangement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The RSUs create a contractual obligation on the part of the Company to distribute to you Shares in connection with the vesting of the RSUs at the time provided for in this Award Agreement. Neither you nor any other party claiming an interest under this Agreement shall have any interest whatsoever in any specific assets of the Company. Your right to receive Shares under this Agreement is that of an unsecured general creditor of Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:13.01pt">Consent to Electronic Delivery.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Certain statutory materials relating to the Plan may be delivered to you in electronic form. By accepting this grant, you consent to electronic delivery and acknowledge receipt of these materials, including the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:136%">This Award Agreement is not a stock certificate or a negotiable instrument. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ex-104medifastformrestrict.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie150b05324af4ad2b4ab64c75cb4f1d8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GRANT NOTICE NONEMPLOYEE DIRECTOR DEFERRED SHARE CASH EQUIVALENT</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medifast, Inc. (the &#8220;Company&#8221;) hereby grants to the Participant named below Deferred Shares ( &#8220;RSUs&#8221;) pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the &#8220;Plan&#8221;) in the number specified below, which shall vest in accordance with the Vesting Schedule. Each RSU corresponds in value to a single share of Company common stock (&#8220;Share&#8221;) and represents the right to receive the cash equivalent of a Share for each vested RSU.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The RSUs are subject to all of the terms and conditions as set forth in this Grant Notice, the Deferred Share Award Agreement (the &#8220;Award Agreement&#8221;) and the Plan, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or the Award Agreement.</font></div><div style="margin-bottom:0.1pt;padding-left:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Participant Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Grant Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Number of RSUs Granted&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">________________________________</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Terms&#47;Acknowledgements&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The undersigned Participant acknowledges receipt of, and understands and agrees to the terms set forth in this Grant Notice, the Award Agreement and the Plan (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">by accepting this Grant Notice and attached Award Agreement electronically, you agree to the terms and conditions in the Grant Notice, Award Agreement and Plan).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participant further acknowledges that as of the Grant Date, this Grant Notice, the Award Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the acquisition of Shares in accordance with this Grant Notice, the Award Agreement and the Plan and supersede all prior oral and written Award Agreements on that subject. </font></div><div style="margin-bottom:0.1pt;padding-left:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:49.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.578%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Participant&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Medifast, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_________________________________________</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">By&#58; _________________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Signature</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Signature</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Date&#58;_____________________________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Title&#58;_____________________________________</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Residence Address&#58; _________________________________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Date&#58;_____________________________________</font></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Attachments&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Nonemployee Director Restricted Share Cash Equivalent Award Agreement and Medifast, Inc. Amended and Restated 2012 Share Incentive Plan</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MEDIFAST, INC. AMENDED AND RESTATED 2012 SHARE INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NONEMPLOYEE DIRECTOR DEFERRED SHARE CASH EQUIVALENT <br>AWARD AGREEMENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to your Restricted Share Units Grant Notice (&#8220;Grant Notice&#8221;) and this Award Agreement, Medifast, Inc. (the &#8220;Company&#8221;) has granted to you Deferred Shares (&#8220;RSUs&#8221; or &#8220;Award&#8221;) under the Plan covering the number of RSUs indicated in your Grant Notice, which vest in accordance with the Vesting Schedule indicated in your Grant Notice and this Award Agreement. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan or your Grant Notice.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:153%">The details of your RSUs are as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Determination of Number of Vested RSUs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your RSUs are subject to the Vesting Schedule set forth in your Grant Notice. On each vesting date (&#8220;Vesting Date&#8221;) set forth in the Vesting Schedule, you will vest in the specified percentage of your RSUs, and your vested RSUs shall be settled in accordance with the terms of this Award Agreement&#59; provided that you satisfy the requirements of Section 2 of this Agreement or vest in your RSUs in accordance with Section 3 of this Award Agreement.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Eligibility for Payment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You must continuously serve as a nonemployee director on the Company&#8217;s Board from the Grant Date through and up to a Vesting Date specified in your Grant Notice to be eligible for a payment of your RSUs that vest and become nonforfeitable on such Vesting Date. If you incur a Termination of Service prior to a Vesting Date, you will forfeit any nonvested RSUs that you then hold on the date of such Termination of Service and you shall not be entitled to any payout with respect to such forfeited RSUs, except as otherwise expressly provided in Section 3 of this Award Agreement.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Effect of a Change in Control Prior to a Vesting Date. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The treatment of any nonvested RSUs that you hold upon or after a Change in Control will be determined under Section 8 of the Plan. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Form and Timing of Settlement of RSUs. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except to the extent that an election to defer the RSUs has been made pursuant to the Company&#8217;s Director Deferred Compensation Plan,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within thirty (30) days of a Vesting Date, the Company will pay to you the cash equivalent of the number of RSUs that vested on such Vesting Date. For this purpose, the cash equivalent of each RSU shall be equal to the New York Stock Exchange closing price of a Share on the Vesting Date (or if the Vesting Date is a date on which the Stock is not traded, based on the closing price on the last date immediately preceding the Vesting Date on which the Stock was traded), subject to satisfaction of applicable tax and&#47;or other obligations as described in Section 7 of this Award Agreement. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Dividend Equivalents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In the event that the Company declares and pays a dividend in respect of its outstanding Shares and, on the record date for such dividend, you hold RSUs granted pursuant to this Award Agreement that have not been settled, the Company shall credit to an account maintained by the Company for your benefit an amount equal to the cash dividends you would have received if you were the holder of record, as of such record date, of the number of Shares related to the portion of the RSUs that have not been settled or forfeited as of such record date (the &#8220;Dividend Equivalent&#8221; or &#8220;DER&#8221;). Such account is intended to constitute an &#8220;unfunded&#8221; account, and neither this Section 5 nor any action taken pursuant to or in accordance with this Section 5 shall be construed to create a trust of any kind. Amounts credited to such account with respect to RSUs that vest in accordance with Sections 2 or 3 of this Award Agreement will become vested DERs and will be paid to you in cash at the same time as your vested RSUs are settled. You shall not be entitled to receive any interest with respect to the timing of payment of DERs. In the event all or any portion of the RSUs granted to you pursuant to this Award Agreement fail to become vested under Sections 2 or 3 of this Award Agreement, the unvested DERs accumulated in your account with respect to such RSUs shall be forfeited.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Forfeiture and Recoupment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Notwithstanding any provision of this Award Agreement or the Plan to the contrary, you agree that your right to retain your Award or to retain any amount received pursuant to your Award shall be subject to any recoupment or &#8220;clawback&#8221; policy or forfeiture policy adopted by the Company.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Tax Withholding Obligations.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> At the time your RSUs are settled, you hereby agree to make adequate provision for any sums required to satisfy any applicable foreign tax withholding obligations of the Company, if any, which arise in connection with the settlement of your RSUs.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Tax Consequences.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its officers, directors, employees or subsidiaries related to tax liabilities arising from your RSUs or your other compensation. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Applicability of Section&#160;409A of the Internal Revenue Code.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">Your RSUs granted hereunder are not intended to provide for a &#8220;deferral of compensation&#8221; within the meaning of Section 409A of the U.S. Internal Revenue Code (&#8220;Section 409A&#8221;) and shall be interpreted and construed in a manner consistent with that intent. If any provision of this Award Agreement, your Grant Notice or the Plan causes your RSUs to be subject to the requirements of Section 409A, or could otherwise cause you to recognize income or be subject to the interest and penalties under Section 409A, then the provision shall have no effect or, to the extent practicable, the Committee may, in its sole discretion and without the Participant&#8217;s consent, modify the provision to (i) comply with, or avoid being subject to Section 409A, or to avoid the incurrence of any taxes, interest and penalties under Section 409A, and&#47;or (ii) maintain, to the maximum extent practicable, the original intent and economic benefit to you of the applicable provision without materially increasing the cost to the Company or contravening the provisions of Section 409A. This Section 9 does not create an obligation of the Company to modify this Award Agreement, your Grant Notice or the Plan and does not guarantee that your RSUs will not be subject to taxes, interest and penalties under Section 409A.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.67pt">Your Termination of Service shall not be deemed to have occurred for purposes of any provision of the Award Agreement providing for the payment of any amounts or benefits that are considered nonqualified deferred compensation under Section 409A upon or following a Termination of Service, unless such termination is also a &#8220;separation from service&#8221; within the meaning of Section 409A and the payment thereof prior to a &#8220;separation from service&#8221; could otherwise cause you to recognize income or be subject to the interest and penalties under Section 409A.  </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Restrictions on Transferability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your RSUs may not be sold, transferred, pledged, assigned, exchanged, encumbered, or otherwise alienated or hypothecated, except (i) by will or by the laws of descent and distribution&#59; (ii) to the extent permitted by the Plan and allowed under applicable law and approved by the Committee in its sole discretion&#59; or (iii) pursuant to a domestic relations order.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Beneficiary Designation.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> You may, from time to time, name any beneficiary or beneficiaries (who may be named contingently or successively) to whom any benefit under this Award Agreement is to be paid in case of your death before you receive any or all of such benefit. Each such designation shall revoke all prior designations by you, shall be in a form prescribed by the Company, and will be effective only when filed by you in writing with the Secretary of the Company during your lifetime. In the absence of any such designation, benefits remaining unpaid at the time of your death shall be paid to your estate.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Securities Laws.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Award Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required, or the Committee determines are advisable. You agree to take all steps that the Company determines are necessary to comply with all applicable provisions of U.S. federal and state securities laws and foreign securities law in exercising your rights under this Award Agreement. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Data Privacy.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To administer the Plan, the Company may process personal data about you. Such data includes the information provided in this Award Agreement, other appropriate personal and financial data about you such as home address and business addresses and other contact information, payroll information and any other information deemed appropriate by the Company to facilitate the administration of the Plan. By accepting this award, you consent to the Company&#8217;s processing of such personal data and the transfer of such data outside the country in which you work or are employed, including, with respect to non-U.S. residents, to the United States, to transferees who shall include the Company and other persons designated by the Company to administer the Plan.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">No Right to Further Awards.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The Board has granted your RSUs in its sole discretion. Your Grant Notice, this Award Agreement and the Plan do not confer to you any right or entitlement to receive another grant of RSUs, or any other similar award at any time in the future or in respect of any future </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">period. Your RSU grant does not confer on you any right or entitlement to receive compensation in any specific amount for any future fiscal year, and does not diminish in any way the Board&#8217;s discretion to determine the amount, if any, of your compensation.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">Notices.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Any notice required or permitted to be given under this Award Agreement, Grant Notice or Plan shall be in writing and shall be deemed to have been given when delivered personally or by courier, or sent by certified or registered United States mail, postage prepaid, return receipt requested, duly addressed to the party concerned at the address indicated below or to such changed address as such party may subsequently by similar process give notice of&#58;</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">If to the Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medifast, Inc.<br>100 International Drive</font></div><div style="padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18th Floor</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baltimore, Maryland 21202<br>Attn.&#58; General Counsel</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">If to the Participant&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the last address delivered to the Company by the <br>Participant in the manner set forth herein.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:4.11pt">General Provisions.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Headings.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The headings preceding the text of the sections in this Award Agreement are inserted solely for convenience of reference, and shall not constitute a part of this Award Agreement, nor shall they affect its meaning, construction, or effect. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Severability.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If any provision of this Award Agreement is declared to be illegal, invalid, or otherwise unenforceable by a court of competent jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal, valid, and enforceable, or otherwise deleted, and the remainder of the provisions of this Award Agreement shall not be affected except to the extent necessary to reform or delete such illegal, invalid, or unenforceable provision.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.23pt">Governing Documents.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Award Agreement is subject to all of the terms and conditions as set forth in your Grant Notice and the Plan, all of which are incorporated herein in their entirety. Your Grant Notice, this Award Agreement and the Plan constitute the entire understanding between you and the Company regarding the RSUs. Any prior Award Agreements, commitments or negotiations concerning the RSUs are superseded. In the event of any conflict between the provisions of your Grant Notice and this Award Agreement and those of the Plan, the provisions of the Plan shall control.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Binding on Parties.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The provisions of this Award Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Applicable Law.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your Grant Notice and this Award Agreement shall be governed, construed, interpreted, and administered solely in accordance with the laws of the state of Delaware, without regard to principles of conflicts of law, with consent of jurisdiction by you in the state of Maryland.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:12.46pt">Rescission of Award Agreement and RSU Grant.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Your RSUs granted under this Award Agreement may be rescinded if necessary to ensure compliance with federal, state or other applicable laws. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Administration of RSUs.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> All questions arising under your Grant Notice, this Award Agreement and the Plan shall be decided by the Committee in its total and absolute discretion. It is expressly understood that the Committee is authorized to administer, construe, and make all determinations necessary or appropriate to the administration of your Grant Notice, this Award Agreement and the Plan&#59; all such determinations shall be binding upon you and your successors.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">No Shareholder Rights.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The RSUs granted to you under pursuant this Award Agreement do not and shall not entitle you to any rights of a holder of a Share of Company common stock. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:13.01pt">Unfunded Arrangement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The RSUs create a contractual obligation on the part of the Company to pay to you cash in connection with the vesting of the RSUs at the time provided for in this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Award Agreement. Neither you nor any other party claiming an interest under this Agreement shall have any interest whatsoever in any specific assets of the Company. Your right to be paid cash under this Agreement is that of an unsecured general creditor of Company.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:13.01pt">Consent to Electronic Delivery.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Certain statutory materials relating to the Plan may be delivered to you in electronic form. By accepting this grant, you consent to electronic delivery and acknowledge receipt of these materials, including the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:136%">This Award Agreement is not a stock certificate or a negotiable instrument. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>med-20220331xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic83f6a04e05c4d0aaf2c5a2cb957bdb4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULE 13a-14(a) CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel R. Chard, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this report on Form 10-Q of Medifast, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;Daniel R. Chard</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel R. Chard</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>med-20220331xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibab8b4f72c3c438982fec62d2d49c714_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULE 13a-14(a) CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James P. Maloney, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this report on Form 10-Q of Medifast, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;James P. Maloney</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James P. Maloney</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>med-20220331xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id09db3f325d8440fab38739fbfb85e5e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q (the &#8220;Report&#8221;) for the quarter ended March 31, 2022 of Medifast, Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Daniel R. Chard, Chief Executive Officer and I, James P. Maloney, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of the operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; DANIEL R. CHARD</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel R. Chard</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JAMES P. MALONEY</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James P. Maloney</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>med-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:232fca58-02a7-458a-8362-c56d4dfdb306,g:546ed23b-bace-40f2-b1e1-3b5a5060da68-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:med="http://www.medifast1.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.medifast1.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="med-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="med-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="med-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="med-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.medifast1.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.medifast1.com/role/INVENTORIES">
        <link:definition>2103102 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.medifast1.com/role/INVENTORIESTables">
        <link:definition>2304301 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESDetails" roleURI="http://www.medifast1.com/role/INVENTORIESDetails">
        <link:definition>2405401 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARE" roleURI="http://www.medifast1.com/role/EARNINGSPERSHARE">
        <link:definition>2106103 - Disclosure - EARNINGS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARETables" roleURI="http://www.medifast1.com/role/EARNINGSPERSHARETables">
        <link:definition>2307302 - Disclosure - EARNINGS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" roleURI="http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails">
        <link:definition>2408402 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERSHARENarrativeDetails" roleURI="http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails">
        <link:definition>2409403 - Disclosure - EARNINGS PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>2110104 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>2311303 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2412404 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails">
        <link:definition>2413405 - Disclosure - SHARE-BASED COMPENSATION - Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails">
        <link:definition>2414406 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails">
        <link:definition>2415407 - Disclosure - SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.medifast1.com/role/LEASES">
        <link:definition>2116105 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.medifast1.com/role/LEASESTables">
        <link:definition>2317304 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.medifast1.com/role/LEASESNarrativeDetails">
        <link:definition>2418408 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSupplementalCashFlowInformationDetails" roleURI="http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails">
        <link:definition>2419409 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2420410 - Disclosure - LEASES - Future Minimum Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVEINCOME" roleURI="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME">
        <link:definition>2121106 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables" roleURI="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables">
        <link:definition>2322305 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2423411 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.medifast1.com/role/FINANCIALINSTRUMENTS">
        <link:definition>2124107 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.medifast1.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>2325306 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.medifast1.com/role/FINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>2426412 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails" roleURI="http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails">
        <link:definition>2427413 - Disclosure - FINANCIAL INSTRUMENTS - Cash and Financial Assets That are Measured at Fair Value on a Recurring Basis for Each of the Hierarchy Levels (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.medifast1.com/role/DEBT">
        <link:definition>2128108 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://www.medifast1.com/role/DEBTNarrativeDetails">
        <link:definition>2429414 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="med_MaximumTotalNetLeverageRatio" abstract="false" name="MaximumTotalNetLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="med_GrantedIn2021Member" abstract="true" name="GrantedIn2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="med_OperatingLeaseArrangementForRealEstateMember" abstract="true" name="OperatingLeaseArrangementForRealEstateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="med_GovernmentAgencySecuritiesMember" abstract="true" name="GovernmentAgencySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="med_AmortizationOfPremiumOnInvestmentSecurities" abstract="false" name="AmortizationOfPremiumOnInvestmentSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="med_UncommittedIncrementalFacilityMember" abstract="true" name="UncommittedIncrementalFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="med_OperatingLeaseExpenseNonCash" abstract="false" name="OperatingLeaseExpenseNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="med_OptionsAndRestrictedStockMember" abstract="true" name="OptionsAndRestrictedStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="med_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="med_GrantedIn2019Member" abstract="true" name="GrantedIn2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="med_MinimumInterestCoverageRatio" abstract="false" name="MinimumInterestCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="med_InventoryNonFoodFinishedGoods" abstract="false" name="InventoryNonFoodFinishedGoods" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="med_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="med_OperatingLeaseArrangementForEquipmentMember" abstract="true" name="OperatingLeaseArrangementForEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems" abstract="true" name="CashAndCashEquivalentsAndMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="med_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="med_CashAndCashEquivalentsAndMarketableSecuritiesTable" abstract="true" name="CashAndCashEquivalentsAndMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="med_GrantedIn2020Member" abstract="true" name="GrantedIn2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="med_GrantedIn2022Member" abstract="true" name="GrantedIn2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>med-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:232fca58-02a7-458a-8362-c56d4dfdb306,g:546ed23b-bace-40f2-b1e1-3b5a5060da68-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b4c005ae-4bc7-44a0-bc0f-9f8b59243c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_66a3e0e1-c88b-44c4-8b10-2702256adb40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b4c005ae-4bc7-44a0-bc0f-9f8b59243c90" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_66a3e0e1-c88b-44c4-8b10-2702256adb40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ab7a3f69-a3aa-4b31-a5f6-3cacf83980bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b4c005ae-4bc7-44a0-bc0f-9f8b59243c90" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ab7a3f69-a3aa-4b31-a5f6-3cacf83980bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_acd0feab-acaf-42d4-9524-f04ed8eaa24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0f5e3d81-730f-4356-8271-bde979e3640d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_acd0feab-acaf-42d4-9524-f04ed8eaa24f" xlink:to="loc_us-gaap_OperatingIncomeLoss_0f5e3d81-730f-4356-8271-bde979e3640d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a14c7298-0bcc-41a3-a40c-1d7920407a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_acd0feab-acaf-42d4-9524-f04ed8eaa24f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a14c7298-0bcc-41a3-a40c-1d7920407a6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7ea109e2-f83e-4826-b518-2240083aa189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f836b71-5324-4ac9-86d0-7977fcc489f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7ea109e2-f83e-4826-b518-2240083aa189" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f836b71-5324-4ac9-86d0-7977fcc489f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e31b1653-26cf-4aee-80a3-2d56fe01b432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7ea109e2-f83e-4826-b518-2240083aa189" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e31b1653-26cf-4aee-80a3-2d56fe01b432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e85ee3a4-b6ff-40d6-8daf-33a4066bea6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_cd16c500-2012-4a9b-babc-46dde67e22ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e85ee3a4-b6ff-40d6-8daf-33a4066bea6d" xlink:to="loc_us-gaap_GrossProfit_cd16c500-2012-4a9b-babc-46dde67e22ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7ce56f79-614a-45c2-ae21-586ef61ddead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e85ee3a4-b6ff-40d6-8daf-33a4066bea6d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7ce56f79-614a-45c2-ae21-586ef61ddead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_4e8b7721-6329-4597-8dfc-ab15e7aee157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_410a117b-9a2f-4fcc-a432-349e332d10a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_4e8b7721-6329-4597-8dfc-ab15e7aee157" xlink:to="loc_us-gaap_Revenues_410a117b-9a2f-4fcc-a432-349e332d10a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_da360639-2c3a-4773-bd27-2b112441186b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_4e8b7721-6329-4597-8dfc-ab15e7aee157" xlink:to="loc_us-gaap_CostOfRevenue_da360639-2c3a-4773-bd27-2b112441186b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_55da4448-9c2b-4cb1-97d3-1828211c8c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_19408ff0-ab8b-42ff-a64e-18f3bff6145e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_55da4448-9c2b-4cb1-97d3-1828211c8c2f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_19408ff0-ab8b-42ff-a64e-18f3bff6145e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_05453b20-fdd8-4349-9889-ab5e08323971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_55da4448-9c2b-4cb1-97d3-1828211c8c2f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_05453b20-fdd8-4349-9889-ab5e08323971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_21146841-b942-4e15-af46-dfb3593f5845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_782c821a-ff9f-4b3b-af47-16e475f23da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_21146841-b942-4e15-af46-dfb3593f5845" xlink:to="loc_us-gaap_NetIncomeLoss_782c821a-ff9f-4b3b-af47-16e475f23da8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4ad00421-dd15-4fb9-88b8-f82116e3dbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_21146841-b942-4e15-af46-dfb3593f5845" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4ad00421-dd15-4fb9-88b8-f82116e3dbfc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2bb3531e-bbf6-447a-851d-5ee7f97fb62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_53345d47-49c5-4647-a497-0fe364ba2c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2bb3531e-bbf6-447a-851d-5ee7f97fb62f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_53345d47-49c5-4647-a497-0fe364ba2c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_93e4552a-d95f-465e-b459-e1db02b3b69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2bb3531e-bbf6-447a-851d-5ee7f97fb62f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_93e4552a-d95f-465e-b459-e1db02b3b69c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e580c830-eed8-497e-8d9d-fccb42d2c172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2bb3531e-bbf6-447a-851d-5ee7f97fb62f" xlink:to="loc_us-gaap_CommonStockValue_e580c830-eed8-497e-8d9d-fccb42d2c172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_354cc06b-81f8-4e98-a0c5-49f3d76b3679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2bb3531e-bbf6-447a-851d-5ee7f97fb62f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_354cc06b-81f8-4e98-a0c5-49f3d76b3679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_249de3e1-106f-4d06-ad74-472b0c023756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9ee2e4fb-a590-4fd3-9e12-0fdbfc7e2011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_249de3e1-106f-4d06-ad74-472b0c023756" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9ee2e4fb-a590-4fd3-9e12-0fdbfc7e2011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c51e7fba-c286-4170-8f58-9f968c6ba67f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_249de3e1-106f-4d06-ad74-472b0c023756" xlink:to="loc_us-gaap_LiabilitiesCurrent_c51e7fba-c286-4170-8f58-9f968c6ba67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_939ffc24-a6cb-4010-ac89-c9a8b5c85a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_649db9f3-75f3-4594-98f9-b6d4d077d151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_939ffc24-a6cb-4010-ac89-c9a8b5c85a8f" xlink:to="loc_us-gaap_ShortTermInvestments_649db9f3-75f3-4594-98f9-b6d4d077d151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_580f9fd6-114e-48ae-bc62-45fe105fc3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_939ffc24-a6cb-4010-ac89-c9a8b5c85a8f" xlink:to="loc_us-gaap_InventoryNet_580f9fd6-114e-48ae-bc62-45fe105fc3ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_b5d22860-89e6-4fb9-b0dc-575fbff5fe82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_939ffc24-a6cb-4010-ac89-c9a8b5c85a8f" xlink:to="loc_us-gaap_PrepaidTaxes_b5d22860-89e6-4fb9-b0dc-575fbff5fe82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_acab8caf-57ef-49f7-ae93-4b4a7787a01a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_939ffc24-a6cb-4010-ac89-c9a8b5c85a8f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_acab8caf-57ef-49f7-ae93-4b4a7787a01a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4e9d7deb-b40f-4cf5-8f94-0dbb1e72360e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_939ffc24-a6cb-4010-ac89-c9a8b5c85a8f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4e9d7deb-b40f-4cf5-8f94-0dbb1e72360e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4cf8f0e4-986b-4ec2-9010-2b94670b7823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_13921ded-48e5-44b1-b898-30109c6caa49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4cf8f0e4-986b-4ec2-9010-2b94670b7823" xlink:to="loc_us-gaap_AssetsCurrent_13921ded-48e5-44b1-b898-30109c6caa49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_67e2e6b1-720b-4c84-9e71-37ac9ebbd405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4cf8f0e4-986b-4ec2-9010-2b94670b7823" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_67e2e6b1-720b-4c84-9e71-37ac9ebbd405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bfcbe9bd-f5a9-428b-a284-256eb1774fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4cf8f0e4-986b-4ec2-9010-2b94670b7823" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bfcbe9bd-f5a9-428b-a284-256eb1774fb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1abef833-1d1e-41c0-b5dd-fca1ca113057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4cf8f0e4-986b-4ec2-9010-2b94670b7823" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1abef833-1d1e-41c0-b5dd-fca1ca113057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_45135c51-c7f2-478b-9441-27c6c90d9940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4cf8f0e4-986b-4ec2-9010-2b94670b7823" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_45135c51-c7f2-478b-9441-27c6c90d9940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_487c1cc0-ea4d-452b-8d82-89b366747e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6635afac-2f78-4c28-99b4-f099d3220d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_487c1cc0-ea4d-452b-8d82-89b366747e8f" xlink:to="loc_us-gaap_Liabilities_6635afac-2f78-4c28-99b4-f099d3220d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d3949420-a88d-4bf8-a1d9-e82c819e9ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_487c1cc0-ea4d-452b-8d82-89b366747e8f" xlink:to="loc_us-gaap_StockholdersEquity_d3949420-a88d-4bf8-a1d9-e82c819e9ee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_27e9bb10-ea6b-4cb1-9105-e68af3d26591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d851f295-0f7a-4b42-b8f0-33a8b9485d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_27e9bb10-ea6b-4cb1-9105-e68af3d26591" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d851f295-0f7a-4b42-b8f0-33a8b9485d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_27df7237-47cb-4e64-8e84-320da90aec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_27e9bb10-ea6b-4cb1-9105-e68af3d26591" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_27df7237-47cb-4e64-8e84-320da90aec2e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2c43f03-9cc8-4790-a7e0-32889107d7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0bdc7ee4-ac42-4f08-bb44-32f55b129ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2c43f03-9cc8-4790-a7e0-32889107d7e8" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_0bdc7ee4-ac42-4f08-bb44-32f55b129ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6cb45a1c-43a1-4504-a452-97da47fb6d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2c43f03-9cc8-4790-a7e0-32889107d7e8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6cb45a1c-43a1-4504-a452-97da47fb6d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5f20e2e3-097d-4d74-812f-b7a8c23ad502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15af6bf6-6bd7-477c-b349-dd1b7bc230f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5f20e2e3-097d-4d74-812f-b7a8c23ad502" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15af6bf6-6bd7-477c-b349-dd1b7bc230f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c8bccb44-da42-4636-afc9-fd368baf839c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5f20e2e3-097d-4d74-812f-b7a8c23ad502" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c8bccb44-da42-4636-afc9-fd368baf839c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6bb74c6d-b9f6-4501-ac3f-7c27ead7d711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5f20e2e3-097d-4d74-812f-b7a8c23ad502" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6bb74c6d-b9f6-4501-ac3f-7c27ead7d711" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_772d4235-0701-47d6-ad0c-28edf2d80789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5f20e2e3-097d-4d74-812f-b7a8c23ad502" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_772d4235-0701-47d6-ad0c-28edf2d80789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23b261d3-132c-4938-9ba4-f2c05a7c596b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:to="loc_us-gaap_NetIncomeLoss_23b261d3-132c-4938-9ba4-f2c05a7c596b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e9c426cc-0b4c-4196-86f5-9c8f8e62dcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e9c426cc-0b4c-4196-86f5-9c8f8e62dcf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_OperatingLeaseExpenseNonCash_58e04e03-957c-4b0e-b456-1758d6595647" xlink:href="med-20220331.xsd#med_OperatingLeaseExpenseNonCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:to="loc_med_OperatingLeaseExpenseNonCash_58e04e03-957c-4b0e-b456-1758d6595647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_abaa240e-9b1c-4b1e-b35f-d7ee348a276d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:to="loc_us-gaap_ShareBasedCompensation_abaa240e-9b1c-4b1e-b35f-d7ee348a276d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_AmortizationOfPremiumOnInvestmentSecurities_e8c4e7b3-f982-4cc6-83a8-405cbe40076e" xlink:href="med-20220331.xsd#med_AmortizationOfPremiumOnInvestmentSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:to="loc_med_AmortizationOfPremiumOnInvestmentSecurities_e8c4e7b3-f982-4cc6-83a8-405cbe40076e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7431c0a7-42e5-46fb-8cd1-f7fa57c4e672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7431c0a7-42e5-46fb-8cd1-f7fa57c4e672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_08000868-6fab-4a1b-9925-6f52b4a5c301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_08000868-6fab-4a1b-9925-6f52b4a5c301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5b2207c0-ffc0-4fd7-a462-0f9a7f44916b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5b2207c0-ffc0-4fd7-a462-0f9a7f44916b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f4c0b2e6-aa9c-47e4-9a80-8b969a707d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f4c0b2e6-aa9c-47e4-9a80-8b969a707d99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e327db3f-b312-4462-8e33-78b91e466d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_aa6aa3e0-d718-4560-b2ae-22c952831d76" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e327db3f-b312-4462-8e33-78b91e466d06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0a484cb-3bfa-4949-a9c5-1a3f2dbcef23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_ca737e70-021e-42cc-9d6f-0b4f35081ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0a484cb-3bfa-4949-a9c5-1a3f2dbcef23" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_ca737e70-021e-42cc-9d6f-0b4f35081ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a52ce8f9-7b99-4ef0-bb68-b397c0485c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0a484cb-3bfa-4949-a9c5-1a3f2dbcef23" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a52ce8f9-7b99-4ef0-bb68-b397c0485c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9968b807-8b4b-4197-a785-1b837f78d11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0a484cb-3bfa-4949-a9c5-1a3f2dbcef23" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9968b807-8b4b-4197-a785-1b837f78d11d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_b733b9e4-2f4d-48c0-b72c-7cefa7450024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0a484cb-3bfa-4949-a9c5-1a3f2dbcef23" xlink:to="loc_us-gaap_PaymentsOfDividends_b733b9e4-2f4d-48c0-b72c-7cefa7450024" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="med-20220331.xsd#INVENTORIESDetails"/>
  <link:calculationLink xlink:role="http://www.medifast1.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b2f1c4ab-57a0-48c2-889b-887b023f81d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_5ded335b-19f1-4685-8fbc-cad4f7d95069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b2f1c4ab-57a0-48c2-889b-887b023f81d5" xlink:to="loc_us-gaap_InventoryRawMaterials_5ded335b-19f1-4685-8fbc-cad4f7d95069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_19db3228-04fb-43c5-b1e9-957d603724e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b2f1c4ab-57a0-48c2-889b-887b023f81d5" xlink:to="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_19db3228-04fb-43c5-b1e9-957d603724e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_InventoryNonFoodFinishedGoods_2bc4ae90-af75-41dd-aa42-96b128b8889e" xlink:href="med-20220331.xsd#med_InventoryNonFoodFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b2f1c4ab-57a0-48c2-889b-887b023f81d5" xlink:to="loc_med_InventoryNonFoodFinishedGoods_2bc4ae90-af75-41dd-aa42-96b128b8889e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_2d00c5b1-511f-4057-89fa-113078591c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b2f1c4ab-57a0-48c2-889b-887b023f81d5" xlink:to="loc_us-gaap_InventoryFinishedGoods_2d00c5b1-511f-4057-89fa-113078591c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_58bb8c33-e513-4380-ad0a-7ba6f8a1c2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b2f1c4ab-57a0-48c2-889b-887b023f81d5" xlink:to="loc_us-gaap_InventoryValuationReserves_58bb8c33-e513-4380-ad0a-7ba6f8a1c2f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="med-20220331.xsd#EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_41552ee5-059f-4f6f-9871-7265ae76eb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7615c0a7-cd26-4cca-bce8-5beda1afc8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_41552ee5-059f-4f6f-9871-7265ae76eb1d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7615c0a7-cd26-4cca-bce8-5beda1afc8e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e76fe940-3099-4283-a9e6-21ea89b17b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_41552ee5-059f-4f6f-9871-7265ae76eb1d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e76fe940-3099-4283-a9e6-21ea89b17b46" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="med-20220331.xsd#LEASESFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab17ee93-0c9a-4e40-a11b-3951d188ee95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7ab6999a-e240-4e46-a140-27bec960135e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab17ee93-0c9a-4e40-a11b-3951d188ee95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7ab6999a-e240-4e46-a140-27bec960135e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_92bd52b5-d698-4f0b-bc03-80fe073943c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab17ee93-0c9a-4e40-a11b-3951d188ee95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_92bd52b5-d698-4f0b-bc03-80fe073943c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_560f75d9-b024-4c44-a88d-f4d22b9e53da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab17ee93-0c9a-4e40-a11b-3951d188ee95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_560f75d9-b024-4c44-a88d-f4d22b9e53da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_33bbe591-0925-43bf-a66a-e5642188821c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab17ee93-0c9a-4e40-a11b-3951d188ee95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_33bbe591-0925-43bf-a66a-e5642188821c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_591aa5ff-f5e4-4bae-94ed-27fd860427a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab17ee93-0c9a-4e40-a11b-3951d188ee95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_591aa5ff-f5e4-4bae-94ed-27fd860427a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_c2cba2b8-d384-4a60-9fd4-ddcefc7023be" xlink:href="med-20220331.xsd#med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab17ee93-0c9a-4e40-a11b-3951d188ee95" xlink:to="loc_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_c2cba2b8-d384-4a60-9fd4-ddcefc7023be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cab77227-b6ae-4f7b-9d4a-25c84d9452e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_49b5c0b8-f990-42cc-9786-a567b2f90183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cab77227-b6ae-4f7b-9d4a-25c84d9452e0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_49b5c0b8-f990-42cc-9786-a567b2f90183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_ff0b64ed-4c44-49e7-bd50-a4ca8cf86f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cab77227-b6ae-4f7b-9d4a-25c84d9452e0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_ff0b64ed-4c44-49e7-bd50-a4ca8cf86f1c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>med-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:232fca58-02a7-458a-8362-c56d4dfdb306,g:546ed23b-bace-40f2-b1e1-3b5a5060da68-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i687e3f687f664163954674b44c300025_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_9acafbb5-f36b-4e14-9f17-4906c184861c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_SharesIssued_9acafbb5-f36b-4e14-9f17-4906c184861c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0056ba19-fe2e-4d34-a1d5-370548b80239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_StockholdersEquity_0056ba19-fe2e-4d34-a1d5-370548b80239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c014bbc-c3a8-4fcf-b856-0acefb89d83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_NetIncomeLoss_2c014bbc-c3a8-4fcf-b856-0acefb89d83b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_e8ed9ec9-6dbe-459d-8e9d-b42e050c6127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_e8ed9ec9-6dbe-459d-8e9d-b42e050c6127" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_557069c1-d05b-4614-a506-7fbc690bbbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_557069c1-d05b-4614-a506-7fbc690bbbbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aafc6747-7b8c-47af-a0d8-e3d19318e531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aafc6747-7b8c-47af-a0d8-e3d19318e531" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ced4bc7c-c06e-48ff-adce-70d70b6bb357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ced4bc7c-c06e-48ff-adce-70d70b6bb357" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_02194e5a-7834-4887-a93d-d0df4ecd4d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_02194e5a-7834-4887-a93d-d0df4ecd4d42" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f8bb9126-e8bd-4a76-b03f-d2f6eda33370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f8bb9126-e8bd-4a76-b03f-d2f6eda33370" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_aa3dfde0-882f-4d13-a7a9-a22aba1fc79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_aa3dfde0-882f-4d13-a7a9-a22aba1fc79e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_4f956c51-11e5-4139-8227-ebcb318432e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_4f956c51-11e5-4139-8227-ebcb318432e1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e6f9322a-23b5-40fc-8a1f-471b5414ae28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e6f9322a-23b5-40fc-8a1f-471b5414ae28" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5832e293-db08-4471-966c-bf5306a0c7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5832e293-db08-4471-966c-bf5306a0c7ad" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_416dd500-8e58-4aed-a606-3b29b6006044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_DividendsCommonStockCash_416dd500-8e58-4aed-a606-3b29b6006044" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a3af5a2b-d6ea-498b-a333-791f22b93c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_87dd6c42-975e-43f5-ba64-1f1c8d5add2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_54d67535-9ad5-41a6-88bd-a55e00fbf2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_StatementTable_54d67535-9ad5-41a6-88bd-a55e00fbf2d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4edbc383-9130-4dc2-a17d-30137d7448b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_54d67535-9ad5-41a6-88bd-a55e00fbf2d7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4edbc383-9130-4dc2-a17d-30137d7448b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4edbc383-9130-4dc2-a17d-30137d7448b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4edbc383-9130-4dc2-a17d-30137d7448b3" xlink:to="loc_us-gaap_EquityComponentDomain_4edbc383-9130-4dc2-a17d-30137d7448b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4edbc383-9130-4dc2-a17d-30137d7448b3" xlink:to="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e1799416-8013-473a-bf72-a8d71ef374a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:to="loc_us-gaap_CommonStockMember_e1799416-8013-473a-bf72-a8d71ef374a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d85f94f-e817-47f0-9056-0adb6df5246f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d85f94f-e817-47f0-9056-0adb6df5246f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68c5bba6-6984-4012-bb7b-b2242641b73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68c5bba6-6984-4012-bb7b-b2242641b73b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9fac89c6-7cdc-4c30-b753-5f0cb807aa14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:to="loc_us-gaap_RetainedEarningsMember_9fac89c6-7cdc-4c30-b753-5f0cb807aa14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_7fa6fc60-442a-4f47-a238-26dbef328248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:to="loc_us-gaap_TreasuryStockMember_7fa6fc60-442a-4f47-a238-26dbef328248" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#EARNINGSPERSHARENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails" xlink:type="extended" id="i84a62c559a624879bcb425a59794c781_EARNINGSPERSHARENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1325ea1c-5fef-4679-a55f-2366a4938f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1a829ee2-6827-4139-891a-c0050b82e9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1325ea1c-5fef-4679-a55f-2366a4938f0e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1a829ee2-6827-4139-891a-c0050b82e9a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_13ea085e-0534-4920-af90-594dc1d535d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1325ea1c-5fef-4679-a55f-2366a4938f0e" xlink:to="loc_us-gaap_StatementTable_13ea085e-0534-4920-af90-594dc1d535d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c9bb008-1d66-4234-ae66-0d00c05f71fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_13ea085e-0534-4920-af90-594dc1d535d3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c9bb008-1d66-4234-ae66-0d00c05f71fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9c9bb008-1d66-4234-ae66-0d00c05f71fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c9bb008-1d66-4234-ae66-0d00c05f71fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9c9bb008-1d66-4234-ae66-0d00c05f71fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3cac1ea-7aad-4ef0-ab07-c2bf57977bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c9bb008-1d66-4234-ae66-0d00c05f71fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3cac1ea-7aad-4ef0-ab07-c2bf57977bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_fb1c6648-c0ce-4954-add4-785cd7de93ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3cac1ea-7aad-4ef0-ab07-c2bf57977bc5" xlink:to="loc_us-gaap_RestrictedStockMember_fb1c6648-c0ce-4954-add4-785cd7de93ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="ieaf433a2ec004727990d9abcc161e452_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0681d93b-8af5-4199-93f2-1c56df04bfad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0681d93b-8af5-4199-93f2-1c56df04bfad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c8649883-4085-4978-8742-b02877aa54ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c8649883-4085-4978-8742-b02877aa54ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_24e9e14f-ab7a-4dab-aeb9-80bed7933fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_24e9e14f-ab7a-4dab-aeb9-80bed7933fa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_28fb3477-085a-4fe3-9f71-959fa61b7ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_28fb3477-085a-4fe3-9f71-959fa61b7ddc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ea403f9a-46b2-4261-a899-47c397431c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ea403f9a-46b2-4261-a899-47c397431c46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c5662688-ba0f-4f93-ba1a-739229afa619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c5662688-ba0f-4f93-ba1a-739229afa619" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_493816b8-b91a-41dd-b095-15058910779f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_493816b8-b91a-41dd-b095-15058910779f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3cf5d05c-aece-4e9a-9213-316f9b6b6f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3cf5d05c-aece-4e9a-9213-316f9b6b6f38" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_afa74823-301b-4683-8939-4aa365c0ab84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_afa74823-301b-4683-8939-4aa365c0ab84" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fbc0c971-cbe4-4060-8e83-429c2943d8af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fbc0c971-cbe4-4060-8e83-429c2943d8af" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e645c67d-b18b-4986-a45e-78e88339e299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e645c67d-b18b-4986-a45e-78e88339e299" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_10682464-420e-4052-9942-c1f3ff1d28cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_10682464-420e-4052-9942-c1f3ff1d28cb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2fa88e3a-91a2-4e73-a246-0ef094bcc75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2fa88e3a-91a2-4e73-a246-0ef094bcc75f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b36bc419-156d-45df-a3bc-733f30404706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b36bc419-156d-45df-a3bc-733f30404706" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f90d8a0b-176f-4598-ab4b-b6993d447b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f90d8a0b-176f-4598-ab4b-b6993d447b85" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ac41042d-dfba-42cd-9fef-c6c9094c306a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ac41042d-dfba-42cd-9fef-c6c9094c306a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_28c7f012-dbba-4731-9b67-027fa639d031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_28c7f012-dbba-4731-9b67-027fa639d031" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d3917c77-62db-4b3e-99ae-247520d90e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d3917c77-62db-4b3e-99ae-247520d90e6a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea9a7bf2-705b-4a21-8046-b233de039c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea9a7bf2-705b-4a21-8046-b233de039c60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c73c0f08-6d37-46b6-a102-6ba8f1f7a332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea9a7bf2-705b-4a21-8046-b233de039c60" xlink:to="loc_us-gaap_AwardTypeAxis_c73c0f08-6d37-46b6-a102-6ba8f1f7a332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c73c0f08-6d37-46b6-a102-6ba8f1f7a332_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c73c0f08-6d37-46b6-a102-6ba8f1f7a332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c73c0f08-6d37-46b6-a102-6ba8f1f7a332_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acce889c-39f0-4ca4-ac4a-337f05296db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c73c0f08-6d37-46b6-a102-6ba8f1f7a332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acce889c-39f0-4ca4-ac4a-337f05296db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_99004907-1ab5-47ad-8297-278abc5e1017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acce889c-39f0-4ca4-ac4a-337f05296db5" xlink:to="loc_us-gaap_RestrictedStockMember_99004907-1ab5-47ad-8297-278abc5e1017" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_25ddcc16-620d-4874-9b58-d60a67dfb361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acce889c-39f0-4ca4-ac4a-337f05296db5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_25ddcc16-620d-4874-9b58-d60a67dfb361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_766e1e4e-7122-4db8-9eae-c3f46abcbf45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acce889c-39f0-4ca4-ac4a-337f05296db5" xlink:to="loc_us-gaap_PerformanceSharesMember_766e1e4e-7122-4db8-9eae-c3f46abcbf45" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" xlink:type="simple" xlink:href="med-20220331.xsd#SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" xlink:type="extended" id="i41b811a85193454e9acc25f2f8e47761_SHAREBASEDCOMPENSATIONStockOptionsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3fa05dd5-8a92-473b-b414-aed5215b3b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3fa05dd5-8a92-473b-b414-aed5215b3b86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9eb53320-d640-423a-b1ee-80de8c00dd67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9eb53320-d640-423a-b1ee-80de8c00dd67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3148693-c9dc-41f7-a1d3-21268c6ea38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_aed719b3-35f1-49d4-8b13-6044f30551aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_aed719b3-35f1-49d4-8b13-6044f30551aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14d753f4-7465-46d1-ac64-21d3dd498bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14d753f4-7465-46d1-ac64-21d3dd498bcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5fd4a42e-105e-463a-94ef-55e986fdc5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5fd4a42e-105e-463a-94ef-55e986fdc5b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1bdf9bbc-3ea2-4b23-8fa2-0b332781379f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4e0edbbf-b9a4-49e8-950f-a702bb03520e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4e0edbbf-b9a4-49e8-950f-a702bb03520e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6904f2c8-7261-4d45-906d-afac05a1e631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6904f2c8-7261-4d45-906d-afac05a1e631" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1d2592ee-6c2f-4c29-b122-214ec2133ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6904f2c8-7261-4d45-906d-afac05a1e631" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1d2592ee-6c2f-4c29-b122-214ec2133ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1d2592ee-6c2f-4c29-b122-214ec2133ff4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1d2592ee-6c2f-4c29-b122-214ec2133ff4" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_1d2592ee-6c2f-4c29-b122-214ec2133ff4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_bc1b4cba-037e-45b0-8f73-1875bdccdf51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1d2592ee-6c2f-4c29-b122-214ec2133ff4" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_bc1b4cba-037e-45b0-8f73-1875bdccdf51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_db0ba631-930c-466b-aaf9-8b370f5f7112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_bc1b4cba-037e-45b0-8f73-1875bdccdf51" xlink:to="loc_us-gaap_EmployeeStockOptionMember_db0ba631-930c-466b-aaf9-8b370f5f7112" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="simple" xlink:href="med-20220331.xsd#SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="extended" id="iea3c10df9af847709d4f0c79e1762af1_SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eddbaeb4-744b-4380-9d7d-ec4a433ce5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eddbaeb4-744b-4380-9d7d-ec4a433ce5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_164633dc-fc4f-4872-a804-0b7c276fe7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_164633dc-fc4f-4872-a804-0b7c276fe7b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ac70bc52-c023-4819-96a7-a5487acb859c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ac70bc52-c023-4819-96a7-a5487acb859c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4060d845-e898-4317-a425-f0309b3d0326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4060d845-e898-4317-a425-f0309b3d0326" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b0debd9-1c26-4ab4-b71b-d2907334bf92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eddbaeb4-744b-4380-9d7d-ec4a433ce5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4df487ad-d195-4cc8-869a-081e23db06ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4df487ad-d195-4cc8-869a-081e23db06ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ba486a95-0c26-440b-9f88-132229155198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ba486a95-0c26-440b-9f88-132229155198" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c279ecc9-db2f-4fde-8308-8073ab80f41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c279ecc9-db2f-4fde-8308-8073ab80f41a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f651b229-80ce-49c8-a04e-937f195afd17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4a7f9f7-1e6b-48b2-9e3d-a86d1cd8d2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eddbaeb4-744b-4380-9d7d-ec4a433ce5ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4a7f9f7-1e6b-48b2-9e3d-a86d1cd8d2b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f3b54453-4d06-4c3e-a451-38acd3423e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4a7f9f7-1e6b-48b2-9e3d-a86d1cd8d2b9" xlink:to="loc_us-gaap_AwardTypeAxis_f3b54453-4d06-4c3e-a451-38acd3423e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3b54453-4d06-4c3e-a451-38acd3423e30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f3b54453-4d06-4c3e-a451-38acd3423e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3b54453-4d06-4c3e-a451-38acd3423e30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6281193-3376-4d36-bea6-ecd68f317ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f3b54453-4d06-4c3e-a451-38acd3423e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6281193-3376-4d36-bea6-ecd68f317ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e372abbb-1d19-4ea2-a051-5ef68cdd8e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6281193-3376-4d36-bea6-ecd68f317ea6" xlink:to="loc_us-gaap_RestrictedStockMember_e372abbb-1d19-4ea2-a051-5ef68cdd8e53" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" xlink:type="simple" xlink:href="med-20220331.xsd#SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" xlink:type="extended" id="i5b1ec4f7e7374294a7e4772708fe8294_SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0482be1-7ab3-4940-9f18-98aeb6511c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b941d5e2-9dbc-496c-9f56-7da1aa9785e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0482be1-7ab3-4940-9f18-98aeb6511c05" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b941d5e2-9dbc-496c-9f56-7da1aa9785e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6eb0ecb0-aae8-4053-aaa2-2e015b1c4da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0482be1-7ab3-4940-9f18-98aeb6511c05" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6eb0ecb0-aae8-4053-aaa2-2e015b1c4da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4739a852-1125-4519-8265-1e0f266a3eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0482be1-7ab3-4940-9f18-98aeb6511c05" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4739a852-1125-4519-8265-1e0f266a3eca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4873b42a-602c-47a6-b083-5dbd45e7dea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4739a852-1125-4519-8265-1e0f266a3eca" xlink:to="loc_us-gaap_AwardTypeAxis_4873b42a-602c-47a6-b083-5dbd45e7dea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4873b42a-602c-47a6-b083-5dbd45e7dea0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4873b42a-602c-47a6-b083-5dbd45e7dea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4873b42a-602c-47a6-b083-5dbd45e7dea0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd4857b2-dc2f-415d-b4e4-afeb96f980db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4873b42a-602c-47a6-b083-5dbd45e7dea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd4857b2-dc2f-415d-b4e4-afeb96f980db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_OptionsAndRestrictedStockMember_f2787ed1-36b6-49aa-99ce-6f502c4fe14c" xlink:href="med-20220331.xsd#med_OptionsAndRestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd4857b2-dc2f-415d-b4e4-afeb96f980db" xlink:to="loc_med_OptionsAndRestrictedStockMember_f2787ed1-36b6-49aa-99ce-6f502c4fe14c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0c99b21f-6dae-41ea-bd7e-09634ecd4357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd4857b2-dc2f-415d-b4e4-afeb96f980db" xlink:to="loc_us-gaap_PerformanceSharesMember_0c99b21f-6dae-41ea-bd7e-09634ecd4357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_2e47edc5-823b-4c4b-a451-08dae83cf662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4739a852-1125-4519-8265-1e0f266a3eca" xlink:to="loc_us-gaap_AwardDateAxis_2e47edc5-823b-4c4b-a451-08dae83cf662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_2e47edc5-823b-4c4b-a451-08dae83cf662_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_2e47edc5-823b-4c4b-a451-08dae83cf662" xlink:to="loc_us-gaap_AwardDateDomain_2e47edc5-823b-4c4b-a451-08dae83cf662_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_2e47edc5-823b-4c4b-a451-08dae83cf662" xlink:to="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2022Member_fcb98303-a5e9-475d-a4dc-a65fb773962a" xlink:href="med-20220331.xsd#med_GrantedIn2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:to="loc_med_GrantedIn2022Member_fcb98303-a5e9-475d-a4dc-a65fb773962a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2021Member_4390c5f7-f079-40de-abc5-4efdb4edfffa" xlink:href="med-20220331.xsd#med_GrantedIn2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:to="loc_med_GrantedIn2021Member_4390c5f7-f079-40de-abc5-4efdb4edfffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2020Member_b54352cb-74f4-4501-a682-f5023e0cf16e" xlink:href="med-20220331.xsd#med_GrantedIn2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:to="loc_med_GrantedIn2020Member_b54352cb-74f4-4501-a682-f5023e0cf16e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2019Member_cc7a9064-b6ff-4bec-bc2e-7c7fbea1c197" xlink:href="med-20220331.xsd#med_GrantedIn2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:to="loc_med_GrantedIn2019Member_cc7a9064-b6ff-4bec-bc2e-7c7fbea1c197" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medifast1.com/role/LEASESNarrativeDetails" xlink:type="extended" id="i21c21f7f28834fd686f6897087bcb34a_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b14cb5e-95e5-417f-8611-6bce89f57d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_cf293fce-411e-4311-8be3-cffca1cf63af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b14cb5e-95e5-417f-8611-6bce89f57d6f" xlink:to="loc_us-gaap_FinanceLeaseLiability_cf293fce-411e-4311-8be3-cffca1cf63af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_80798204-578a-4479-bfc8-85056ae2e7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b14cb5e-95e5-417f-8611-6bce89f57d6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_80798204-578a-4479-bfc8-85056ae2e7de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_8a9fcb89-d54e-4491-af29-ee31b22218d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b14cb5e-95e5-417f-8611-6bce89f57d6f" xlink:to="loc_us-gaap_OperatingLeaseExpense_8a9fcb89-d54e-4491-af29-ee31b22218d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_32861519-9187-4696-a845-eee9c6e610fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b14cb5e-95e5-417f-8611-6bce89f57d6f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_32861519-9187-4696-a845-eee9c6e610fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b30ffbdc-4a2c-4c58-af39-5a279fa8e805" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_32861519-9187-4696-a845-eee9c6e610fe" xlink:to="loc_srt_RangeAxis_b30ffbdc-4a2c-4c58-af39-5a279fa8e805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b30ffbdc-4a2c-4c58-af39-5a279fa8e805_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b30ffbdc-4a2c-4c58-af39-5a279fa8e805" xlink:to="loc_srt_RangeMember_b30ffbdc-4a2c-4c58-af39-5a279fa8e805_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ec5aa74-c910-4deb-8de1-cc16cbfc6837" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b30ffbdc-4a2c-4c58-af39-5a279fa8e805" xlink:to="loc_srt_RangeMember_7ec5aa74-c910-4deb-8de1-cc16cbfc6837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8fde76f6-ba7a-4226-9cbb-098b36a2b4a8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7ec5aa74-c910-4deb-8de1-cc16cbfc6837" xlink:to="loc_srt_MinimumMember_8fde76f6-ba7a-4226-9cbb-098b36a2b4a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bad65fa6-ce89-4acd-8a55-915a120f80d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7ec5aa74-c910-4deb-8de1-cc16cbfc6837" xlink:to="loc_srt_MaximumMember_bad65fa6-ce89-4acd-8a55-915a120f80d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20b4d36b-4608-4c2a-9b08-c8bb03280c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_32861519-9187-4696-a845-eee9c6e610fe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20b4d36b-4608-4c2a-9b08-c8bb03280c8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20b4d36b-4608-4c2a-9b08-c8bb03280c8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20b4d36b-4608-4c2a-9b08-c8bb03280c8b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20b4d36b-4608-4c2a-9b08-c8bb03280c8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36d56f8e-aff7-4a3c-9fe4-83a21822c078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20b4d36b-4608-4c2a-9b08-c8bb03280c8b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36d56f8e-aff7-4a3c-9fe4-83a21822c078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_OperatingLeaseArrangementForRealEstateMember_6d0fd61c-3070-48c4-9b0e-54baae8d1d72" xlink:href="med-20220331.xsd#med_OperatingLeaseArrangementForRealEstateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36d56f8e-aff7-4a3c-9fe4-83a21822c078" xlink:to="loc_med_OperatingLeaseArrangementForRealEstateMember_6d0fd61c-3070-48c4-9b0e-54baae8d1d72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_OperatingLeaseArrangementForEquipmentMember_033c8162-1f1b-4e4f-88ed-0df9d4cf38b9" xlink:href="med-20220331.xsd#med_OperatingLeaseArrangementForEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36d56f8e-aff7-4a3c-9fe4-83a21822c078" xlink:to="loc_med_OperatingLeaseArrangementForEquipmentMember_033c8162-1f1b-4e4f-88ed-0df9d4cf38b9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails" xlink:type="simple" xlink:href="med-20220331.xsd#FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"/>
  <link:definitionLink xlink:role="http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails" xlink:type="extended" id="i85bf6b0bb46a45fdbdcbaa1393ff40a6_FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:href="med-20220331.xsd#med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_baaa9204-c87a-4946-a77a-576eefcfd7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_MarketableSecurities_baaa9204-c87a-4946-a77a-576eefcfd7a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_cbedaf12-35e3-4044-ab14-341e98ba1f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_cbedaf12-35e3-4044-ab14-341e98ba1f0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_ed454225-fd0a-4093-9d0d-64e4fae9c9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_InterestReceivable_ed454225-fd0a-4093-9d0d-64e4fae9c9db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_17c49ea6-6318-4dbb-bfb9-054224b4c771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_17c49ea6-6318-4dbb-bfb9-054224b4c771" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b5c22e9e-41bd-433a-88b3-fbc80ca8168b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b5c22e9e-41bd-433a-88b3-fbc80ca8168b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_0129489d-eea2-4e7f-8726-7d01ddd676c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_0129489d-eea2-4e7f-8726-7d01ddd676c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:href="med-20220331.xsd#med_CashAndCashEquivalentsAndMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e40ac00c-d688-48fc-bfc6-2fc70a9185ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e40ac00c-d688-48fc-bfc6-2fc70a9185ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e40ac00c-d688-48fc-bfc6-2fc70a9185ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e40ac00c-d688-48fc-bfc6-2fc70a9185ab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e40ac00c-d688-48fc-bfc6-2fc70a9185ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa5324b-6b00-4d1e-b264-fb5613276997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e40ac00c-d688-48fc-bfc6-2fc70a9185ab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa5324b-6b00-4d1e-b264-fb5613276997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a22e1300-c1b2-4148-ae42-a6b0fb8ea7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa5324b-6b00-4d1e-b264-fb5613276997" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a22e1300-c1b2-4148-ae42-a6b0fb8ea7a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5108b967-535e-4c7d-9b53-b789f5ca41b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa5324b-6b00-4d1e-b264-fb5613276997" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5108b967-535e-4c7d-9b53-b789f5ca41b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3f61094c-ae8d-4f1a-a705-9e4951a982d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3f61094c-ae8d-4f1a-a705-9e4951a982d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3f61094c-ae8d-4f1a-a705-9e4951a982d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3f61094c-ae8d-4f1a-a705-9e4951a982d9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3f61094c-ae8d-4f1a-a705-9e4951a982d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d6732dbe-d860-43b0-bdc0-7e4fdb6bc634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3f61094c-ae8d-4f1a-a705-9e4951a982d9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d6732dbe-d860-43b0-bdc0-7e4fdb6bc634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_2a28bc26-dc22-4f5e-b0c2-18c061a490bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d6732dbe-d860-43b0-bdc0-7e4fdb6bc634" xlink:to="loc_us-gaap_CashMember_2a28bc26-dc22-4f5e-b0c2-18c061a490bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0b46181c-d2ff-47b0-9a32-5ab4b31ecf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d6732dbe-d860-43b0-bdc0-7e4fdb6bc634" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0b46181c-d2ff-47b0-9a32-5ab4b31ecf14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_GovernmentAgencySecuritiesMember_3ea1a279-cf99-4ed4-942e-1a536ddaa047" xlink:href="med-20220331.xsd#med_GovernmentAgencySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d6732dbe-d860-43b0-bdc0-7e4fdb6bc634" xlink:to="loc_med_GovernmentAgencySecuritiesMember_3ea1a279-cf99-4ed4-942e-1a536ddaa047" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bbfd1200-99fa-4767-bd1f-3c5f15ce247f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:to="loc_us-gaap_InvestmentTypeAxis_bbfd1200-99fa-4767-bd1f-3c5f15ce247f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bbfd1200-99fa-4767-bd1f-3c5f15ce247f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_bbfd1200-99fa-4767-bd1f-3c5f15ce247f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bbfd1200-99fa-4767-bd1f-3c5f15ce247f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_9daba5b1-6d47-438f-a510-8af3a6798b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_bbfd1200-99fa-4767-bd1f-3c5f15ce247f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_9daba5b1-6d47-438f-a510-8af3a6798b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_8fb9c60b-ec38-4f12-98bc-855771ca7c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_9daba5b1-6d47-438f-a510-8af3a6798b19" xlink:to="loc_us-gaap_MunicipalBondsMember_8fb9c60b-ec38-4f12-98bc-855771ca7c28" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#DEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.medifast1.com/role/DEBTNarrativeDetails" xlink:type="extended" id="i6186fda73157400e8f4971b983b700e3_DEBTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e822101c-4a46-46d1-ac70-3c2bd51a3739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e822101c-4a46-46d1-ac70-3c2bd51a3739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_15470973-54a5-4c79-817c-88a2adcb7c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_15470973-54a5-4c79-817c-88a2adcb7c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba0626c3-baed-4046-ac60-7cbf5848bb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba0626c3-baed-4046-ac60-7cbf5848bb2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_MaximumTotalNetLeverageRatio_ff1720ed-cc42-41ae-a6bf-0443293e8d79" xlink:href="med-20220331.xsd#med_MaximumTotalNetLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_med_MaximumTotalNetLeverageRatio_ff1720ed-cc42-41ae-a6bf-0443293e8d79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_MinimumInterestCoverageRatio_f4f359fd-66c3-4ea5-bcaf-05cc1377abd6" xlink:href="med-20220331.xsd#med_MinimumInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_med_MinimumInterestCoverageRatio_f4f359fd-66c3-4ea5-bcaf-05cc1377abd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1be4162e-3552-431c-b48f-bd562848973f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1be4162e-3552-431c-b48f-bd562848973f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_060d3ef3-23cd-49bd-8d06-48f5ac3aaf77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:to="loc_srt_RangeAxis_060d3ef3-23cd-49bd-8d06-48f5ac3aaf77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_060d3ef3-23cd-49bd-8d06-48f5ac3aaf77_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_060d3ef3-23cd-49bd-8d06-48f5ac3aaf77" xlink:to="loc_srt_RangeMember_060d3ef3-23cd-49bd-8d06-48f5ac3aaf77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a7291eb-7727-4eb6-befb-b572e64a867b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_060d3ef3-23cd-49bd-8d06-48f5ac3aaf77" xlink:to="loc_srt_RangeMember_6a7291eb-7727-4eb6-befb-b572e64a867b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6bf6fabe-114d-40d4-a11a-996022b818a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a7291eb-7727-4eb6-befb-b572e64a867b" xlink:to="loc_srt_MinimumMember_6bf6fabe-114d-40d4-a11a-996022b818a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8cc70545-25c8-4c74-9dea-e538d273ee21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a7291eb-7727-4eb6-befb-b572e64a867b" xlink:to="loc_srt_MaximumMember_8cc70545-25c8-4c74-9dea-e538d273ee21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a56ab865-87c4-46da-9196-84ff27c71528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:to="loc_us-gaap_DebtInstrumentAxis_a56ab865-87c4-46da-9196-84ff27c71528" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a56ab865-87c4-46da-9196-84ff27c71528_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a56ab865-87c4-46da-9196-84ff27c71528" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a56ab865-87c4-46da-9196-84ff27c71528_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8ba1f88-dc23-4d65-88b0-3863a5923d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a56ab865-87c4-46da-9196-84ff27c71528" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8ba1f88-dc23-4d65-88b0-3863a5923d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_CreditAgreementMember_ae7b37f4-fe60-4d06-bfff-e6d88ef9328d" xlink:href="med-20220331.xsd#med_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8ba1f88-dc23-4d65-88b0-3863a5923d71" xlink:to="loc_med_CreditAgreementMember_ae7b37f4-fe60-4d06-bfff-e6d88ef9328d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_bc7dad79-44bf-4445-8e88-461194e5edf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:to="loc_us-gaap_CreditFacilityAxis_bc7dad79-44bf-4445-8e88-461194e5edf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bc7dad79-44bf-4445-8e88-461194e5edf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_bc7dad79-44bf-4445-8e88-461194e5edf3" xlink:to="loc_us-gaap_CreditFacilityDomain_bc7dad79-44bf-4445-8e88-461194e5edf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_38f9edd5-ea02-4249-a425-806543939a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_bc7dad79-44bf-4445-8e88-461194e5edf3" xlink:to="loc_us-gaap_CreditFacilityDomain_38f9edd5-ea02-4249-a425-806543939a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_55b11f6c-f00e-4dcb-8594-d7ed8498be18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_38f9edd5-ea02-4249-a425-806543939a68" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_55b11f6c-f00e-4dcb-8594-d7ed8498be18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_2a51b43a-10cb-48f9-9868-8593a5d1a6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_55b11f6c-f00e-4dcb-8594-d7ed8498be18" xlink:to="loc_us-gaap_LetterOfCreditMember_2a51b43a-10cb-48f9-9868-8593a5d1a6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_UncommittedIncrementalFacilityMember_23a69496-ae33-4d5b-9ce5-d66d0fa0884d" xlink:href="med-20220331.xsd#med_UncommittedIncrementalFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_55b11f6c-f00e-4dcb-8594-d7ed8498be18" xlink:to="loc_med_UncommittedIncrementalFacilityMember_23a69496-ae33-4d5b-9ce5-d66d0fa0884d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2b21d0c4-395c-4f53-8298-b8c4b87ac5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:to="loc_us-gaap_VariableRateAxis_2b21d0c4-395c-4f53-8298-b8c4b87ac5d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2b21d0c4-395c-4f53-8298-b8c4b87ac5d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_2b21d0c4-395c-4f53-8298-b8c4b87ac5d4" xlink:to="loc_us-gaap_VariableRateDomain_2b21d0c4-395c-4f53-8298-b8c4b87ac5d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_17486884-0c38-4f39-a520-079bc5b4717e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_2b21d0c4-395c-4f53-8298-b8c4b87ac5d4" xlink:to="loc_us-gaap_VariableRateDomain_17486884-0c38-4f39-a520-079bc5b4717e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_a9018b78-f4e2-4944-8b4c-7acbbc265abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_17486884-0c38-4f39-a520-079bc5b4717e" xlink:to="loc_us-gaap_EurodollarMember_a9018b78-f4e2-4944-8b4c-7acbbc265abd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_70acdd47-0427-4035-b9dc-297909b09343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_17486884-0c38-4f39-a520-079bc5b4717e" xlink:to="loc_us-gaap_BaseRateMember_70acdd47-0427-4035-b9dc-297909b09343" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>med-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:232fca58-02a7-458a-8362-c56d4dfdb306,g:546ed23b-bace-40f2-b1e1-3b5a5060da68-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_ffd35b2f-07f3-454a-85b9-3a53723940cb_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE INCOME</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d69fb709-2b70-44c9-ab05-dc169c99cb69_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0d445283-0437-4cae-8cd3-21be416abc45_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligations, net of current lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_164d36fa-dc1d-4b35-8be9-ea5058c2f382_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6a59c82d-eb9a-4deb-9fd4-412b1a37ff15_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cbf9e2f4-d178-4796-a41d-b83fb7b79dcf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9fdc391c-a025-498a-a0cd-5618649e536f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_dabf657c-e416-4f2c-968f-34a0cffeb418_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8b177b22-3cf0-4bdc-ad36-5b5476a57b8a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_642ff288-7c13-4de6-a5ab-e61423c51534_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_med_MaximumTotalNetLeverageRatio_6bc3b26c-ba0c-494d-bbdc-8929d1d1582d_terseLabel_en-US" xlink:label="lab_med_MaximumTotalNetLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Total Net Leverage Ratio</link:label>
    <link:label id="lab_med_MaximumTotalNetLeverageRatio_label_en-US" xlink:label="lab_med_MaximumTotalNetLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Total Net Leverage Ratio</link:label>
    <link:label id="lab_med_MaximumTotalNetLeverageRatio_documentation_en-US" xlink:label="lab_med_MaximumTotalNetLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ratio as of any date, of (a) Total Net Funded Indebtedness on such date to (b) Consolidated EBITDA for the Reference Period ended on such date under credit facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_MaximumTotalNetLeverageRatio" xlink:href="med-20220331.xsd#med_MaximumTotalNetLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_MaximumTotalNetLeverageRatio" xlink:to="lab_med_MaximumTotalNetLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cadc8866-6747-4f9f-9c36-6959d70bad52_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_09b89ebc-2c1d-4f87-9def-c3308f708675_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax benefit recognized related to restricted stock awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0af6fe81-8745-4963-bceb-f2a3fdcff6b6_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_70a6e517-8b55-4c85-878c-518f1947cc41_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_514320fa-d0a1-4ae8-a3fc-4aa01e102c6b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b430935c-ec61-440f-bc04-616a21b76448_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ba90d10c-2650-43f4-8779-7fcd857357f9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_37342322-cc1d-4106-ba52-b7463e3ded6e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_9f00d878-3219-46fc-bcc2-87a85ea12eb4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_5227c2c2-b5e6-4975-b1b3-16a66b9d0b6f_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared to stockholders</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b4350508-3759-4cd6-8df1-db0ad451e0b7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4b1ae697-ccb5-45fb-bee5-96ce9b8ebc16_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_med_OperatingLeaseArrangementForEquipmentMember_5ed8702e-9c5b-4708-9156-217bf9a414dc_terseLabel_en-US" xlink:label="lab_med_OperatingLeaseArrangementForEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Arrangement for Equipment</link:label>
    <link:label id="lab_med_OperatingLeaseArrangementForEquipmentMember_label_en-US" xlink:label="lab_med_OperatingLeaseArrangementForEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Arrangement For Equipment [Member]</link:label>
    <link:label id="lab_med_OperatingLeaseArrangementForEquipmentMember_documentation_en-US" xlink:label="lab_med_OperatingLeaseArrangementForEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the operating lease arrangement for equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_OperatingLeaseArrangementForEquipmentMember" xlink:href="med-20220331.xsd#med_OperatingLeaseArrangementForEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_OperatingLeaseArrangementForEquipmentMember" xlink:to="lab_med_OperatingLeaseArrangementForEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b9ac3833-2c4c-43d1-adee-ba73d90d7243_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c5f82de4-b471-4bc7-bbf7-3916fc0b4822_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_032c13e2-2fee-4ed1-9ed4-1c242c4fa8d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_dfb1b7d8-8f5c-43c4-b3f9-bdf4a5b0acae_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_med_OptionsAndRestrictedStockMember_1ebd8aeb-caea-460c-8b85-4baf615edab7_terseLabel_en-US" xlink:label="lab_med_OptionsAndRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options And Restricted Stock</link:label>
    <link:label id="lab_med_OptionsAndRestrictedStockMember_label_en-US" xlink:label="lab_med_OptionsAndRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options And Restricted Stock [Member]</link:label>
    <link:label id="lab_med_OptionsAndRestrictedStockMember_documentation_en-US" xlink:label="lab_med_OptionsAndRestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options And Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_OptionsAndRestrictedStockMember" xlink:href="med-20220331.xsd#med_OptionsAndRestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_OptionsAndRestrictedStockMember" xlink:to="lab_med_OptionsAndRestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity_4e2f019c-a275-4328-81ba-310d5335ae85_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net shares repurchased for taxes</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Other Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_775e4aaf-8041-49b3-99f5-83bdc41f3f16_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1a19a0de-49dc-434b-834e-55043fb3fd9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d23f0be0-1b44-4342-a68a-ae4ec09a79f4_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised by executives and directors</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6a7a5987-0e73-45e1-91a8-60a00fd4d25d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_fc5eecf6-edc0-4b23-8a96-83a3f73d473a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b3e66f2-5d3f-407a-801c-5a2319539471_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d3f048b1-a5f1-439c-9421-35463ce8912c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e57bd4bd-00ad-4b3e-899c-d5aba818ddff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b412ddd1-2f23-4f5c-b1e9-f43a63d621d9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_38420755-c17b-4aa5-b235-c8ca10fcbfb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c454bf9c-42e4-4149-92b5-3d640b3f2aa4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5de3ddf2-5d7f-4c9c-b4b9-142cc5c4fe5e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_med_AmortizationOfPremiumOnInvestmentSecurities_8a467d96-46ca-4a0a-b2c7-4c208c7966c3_terseLabel_en-US" xlink:label="lab_med_AmortizationOfPremiumOnInvestmentSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium on investment securities</link:label>
    <link:label id="lab_med_AmortizationOfPremiumOnInvestmentSecurities_label_en-US" xlink:label="lab_med_AmortizationOfPremiumOnInvestmentSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Premium on Investment Securities</link:label>
    <link:label id="lab_med_AmortizationOfPremiumOnInvestmentSecurities_documentation_en-US" xlink:label="lab_med_AmortizationOfPremiumOnInvestmentSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expense charged against amortization of premium on investment securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_AmortizationOfPremiumOnInvestmentSecurities" xlink:href="med-20220331.xsd#med_AmortizationOfPremiumOnInvestmentSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_AmortizationOfPremiumOnInvestmentSecurities" xlink:to="lab_med_AmortizationOfPremiumOnInvestmentSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_5ce19090-a649-44db-843a-1287df17bf89_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c7793c7d-8556-4932-a8e3-4b2cb64ca543_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_099360eb-8af0-410c-b98c-c190c4cd1263_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_245ef373-6b3e-42ad-8e5e-4eb00468a160_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_med_GrantedIn2020Member_05af92af-84ff-45b8-a496-ae4e8d6e7888_terseLabel_en-US" xlink:label="lab_med_GrantedIn2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2020</link:label>
    <link:label id="lab_med_GrantedIn2020Member_label_en-US" xlink:label="lab_med_GrantedIn2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2020 [Member]</link:label>
    <link:label id="lab_med_GrantedIn2020Member_documentation_en-US" xlink:label="lab_med_GrantedIn2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2020Member" xlink:href="med-20220331.xsd#med_GrantedIn2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_GrantedIn2020Member" xlink:to="lab_med_GrantedIn2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3ba89b29-a310-4129-8f67-ca53b62d6ebf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8a8f8b9d-3f4a-4a8b-a53e-2e6d994d2da3_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_df7793db-5961-4bae-8a98-a326570c7f9f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, shares authorized under stock option plans, exercise price range, lower range limit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_98ce993f-daca-4c2e-8463-27bf99074f26_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_9bb083f3-ced6-4377-b873-855215203262_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_df376ae8-0367-4aed-ac59-ebb76f0a8f24_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fc3c610f-ee33-43a0-93f2-c799bd9fd162_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_13d8a259-54db-470f-b6a2-a2268d80153b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5b6cd2a2-0357-4b25-b1c9-dffca2fc27fb_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive awards</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_09783d01-99ae-40af-b343-9375584d2bf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_45154dab-734f-4be6-9978-e95d6fcdcd86_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes, prepaid</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c97dc9ae-42f3-42a0-9097-192f13d6a29c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_b096760a-9476-4754-8f6c-52ed6bb1c1d1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4480dc74-29fd-4ebf-acbe-167936db1621_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_41ac3028-264c-4667-9ec2-d91aedd4b6b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement, fair value of awards vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fb1cc934-94d1-4c55-a967-b958b806542a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_med_CreditAgreementMember_8d93a718-272b-415a-8b74-d30750174be3_terseLabel_en-US" xlink:label="lab_med_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_med_CreditAgreementMember_label_en-US" xlink:label="lab_med_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_med_CreditAgreementMember_documentation_en-US" xlink:label="lab_med_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_CreditAgreementMember" xlink:href="med-20220331.xsd#med_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_CreditAgreementMember" xlink:to="lab_med_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_a1552ed5-06a6-4754-8182-0184e11d5de2_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_3904e13a-8664-4bc1-be83-7039298fc314_terseLabel_en-US" xlink:label="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Marketable securities [Line Items]</link:label>
    <link:label id="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Marketable securities [Line Items]</link:label>
    <link:label id="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">N/A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems" xlink:href="med-20220331.xsd#med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3f29756f-95e9-44b5-879a-2d0a89937018_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_00e6645b-d0d3-4d7c-9f1e-59a93aaffe1a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_535f62e8-d059-48f4-80bf-1e73fd257632_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10b9c534-2e7c-4518-8c5f-72b5e3113174_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d6fcd60a-b960-4242-a7a3-fdc71ae42682_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3c95a229-06ea-414d-a6e7-7c987f40d500_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_15e151d7-eb31-40d1-88af-056852c60c86_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7fc23636-2d9d-4612-8744-9a2280de45f3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d29b5bf1-df61-460d-8ed2-d616e05134e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Financial Assets That are Measured at Fair Value on a Recurring Basis for Each of the Hierarchy Levels</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c9ce22af-5a4c-4d97-8a52-9cc5c2a3f8a1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercisable at end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a4cb8889-6072-4ad2-90ad-f3fc651103e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_998331e2-e37f-4e4a-a9a0-dd1581bbc46c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted in period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c52ae82c-2fbe-4491-8fed-0aecc78001a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCash_e6fc8354-739f-4a04-80c4-4d3c7cf03e0d_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared included in accounts payable</link:label>
    <link:label id="lab_us-gaap_DividendsCash_label_en-US" xlink:label="lab_us-gaap_DividendsCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCash" xlink:to="lab_us-gaap_DividendsCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6d31365-1392-44f4-a72b-8a71e4a1874a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cdddc850-7f63-461c-a176-a924c1bfbda5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding at end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_847e05ea-73dd-4669-aad8-66f7af580e8c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cea19507-f953-4639-bfb7-713946315e41_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_28aca9f9-6ba8-40d7-9c26-48d32ff999d9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_ac419c79-3204-457a-b4fa-b63b05b0b249_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock retired from stock repurchases</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_09bb2664-a0a4-4b53-a989-41b81c0d2acc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9a91039f-5cac-49b7-b86e-6d863cff552e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_8b27c3f2-3330-40c1-968b-816eb7e13dad_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7f823ddb-3bee-406f-bf76-8004b8e548de_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_664f6bc8-f70b-40e9-baaa-1b9c58483851_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b8d03215-5f33-4f77-9296-8f36791b2296_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_04a46181-26f1-47a8-b423-bb84c20bd8a1_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations - Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6c978e26-ac7a-4eb7-b133-71837a4c243b_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_med_UncommittedIncrementalFacilityMember_e59e1ea8-6d77-4568-bb92-39fe21268b8e_terseLabel_en-US" xlink:label="lab_med_UncommittedIncrementalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncommitted Incremental Facility</link:label>
    <link:label id="lab_med_UncommittedIncrementalFacilityMember_label_en-US" xlink:label="lab_med_UncommittedIncrementalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncommitted Incremental Facility [Member]</link:label>
    <link:label id="lab_med_UncommittedIncrementalFacilityMember_documentation_en-US" xlink:label="lab_med_UncommittedIncrementalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncommitted Incremental Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_UncommittedIncrementalFacilityMember" xlink:href="med-20220331.xsd#med_UncommittedIncrementalFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_UncommittedIncrementalFacilityMember" xlink:to="lab_med_UncommittedIncrementalFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_273aa43c-9b6f-4579-b09f-4507ad71e9c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, grants in period, gross</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cb699ff4-06a6-4b16-ba02-a0c816c6f630_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Table Sets Forth the Computation of Basic and Diluted EPS</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_03f57681-a4cf-429c-a7b7-2044f4ac71b8_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net shares repurchased for employee taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_dec1adc4-6dfd-46ab-8c33-70d6a1b0888e_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld for employee taxes</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_15ff0d47-697e-401f-a873-bbad64b3c456_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_med_GrantedIn2019Member_fc73f069-de71-4cf4-8c7f-c76c4cd29941_terseLabel_en-US" xlink:label="lab_med_GrantedIn2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2019</link:label>
    <link:label id="lab_med_GrantedIn2019Member_label_en-US" xlink:label="lab_med_GrantedIn2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2019 [Member]</link:label>
    <link:label id="lab_med_GrantedIn2019Member_documentation_en-US" xlink:label="lab_med_GrantedIn2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2019Member" xlink:href="med-20220331.xsd#med_GrantedIn2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_GrantedIn2019Member" xlink:to="lab_med_GrantedIn2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ddd2e76a-e98b-4507-a20a-42508a12f824_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9f964249-97e8-4b14-825c-a8a588bae06f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_med_NumeratorAbstract_d88ed22e-cc23-4209-8612-f535c5de1cb7_verboseLabel_en-US" xlink:label="lab_med_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_med_NumeratorAbstract_label_en-US" xlink:label="lab_med_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_med_NumeratorAbstract_documentation_en-US" xlink:label="lab_med_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_NumeratorAbstract" xlink:href="med-20220331.xsd#med_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_NumeratorAbstract" xlink:to="lab_med_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_02e2af08-ab31-41d1-a0c0-94839e5c82d1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_med_OperatingLeaseExpenseNonCash_30381b85-fc0a-4ff8-89dc-53dfc6a52b9c_terseLabel_en-US" xlink:label="lab_med_OperatingLeaseExpenseNonCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_med_OperatingLeaseExpenseNonCash_label_en-US" xlink:label="lab_med_OperatingLeaseExpenseNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense, Non-Cash</link:label>
    <link:label id="lab_med_OperatingLeaseExpenseNonCash_documentation_en-US" xlink:label="lab_med_OperatingLeaseExpenseNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense, Non-Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_OperatingLeaseExpenseNonCash" xlink:href="med-20220331.xsd#med_OperatingLeaseExpenseNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_OperatingLeaseExpenseNonCash" xlink:to="lab_med_OperatingLeaseExpenseNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_f3160fde-a9e7-4379-a854-b4965e421073_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3904ecae-a0c8-450d-9be5-775436279188_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_04ef21e5-3913-47ba-9c2a-63813e4bd454_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_358fe086-2b8b-4a90-8967-84510f26aee7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2e03256b-b4f6-4842-99e2-ea65230cf310_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d94695ac-58ea-43ef-ae8a-7ec8e5f64f5e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_e5f19e06-5acc-4eb2-9f97-f40b3b854a61_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_846f945a-f240-4513-8bc2-44b13ecfd278_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_62a17177-f942-4193-9f1f-674fda23499a_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97d0c4cb-1e1e-4703-ba85-3608d331dc4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_50c50815-86c9-4eb6-8ca2-e6e1b0dd3d99_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8d35f31a-0e84-461b-be1c-9022db91183b_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_79f96730-9f74-4ba6-bb99-f6abe178cfcd_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ecd7f387-6ac5-44a4-a78c-550bfe88f7e1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_med_OperatingLeaseArrangementForRealEstateMember_302e91fe-8da5-46df-9fa4-86a779b00153_terseLabel_en-US" xlink:label="lab_med_OperatingLeaseArrangementForRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Arrangement for Real Estate</link:label>
    <link:label id="lab_med_OperatingLeaseArrangementForRealEstateMember_label_en-US" xlink:label="lab_med_OperatingLeaseArrangementForRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Arrangement For Real Estate [Member]</link:label>
    <link:label id="lab_med_OperatingLeaseArrangementForRealEstateMember_documentation_en-US" xlink:label="lab_med_OperatingLeaseArrangementForRealEstateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the operating lease arrangement for real estate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_OperatingLeaseArrangementForRealEstateMember" xlink:href="med-20220331.xsd#med_OperatingLeaseArrangementForRealEstateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_OperatingLeaseArrangementForRealEstateMember" xlink:to="lab_med_OperatingLeaseArrangementForRealEstateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_78d2b08e-b05c-4c1d-841e-3f0bd189d5f4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_a2d391a5-016e-4289-9878-b8b6e2d4b7b0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_842f4296-5d8d-41c6-9478-b2ab05b4be33_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net shares repurchased for taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_4656d8c3-da17-455f-bc18-1522d9129499_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurements of lease liabilities - Operating cash flow used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_3da01291-7cf9-487f-8538-6ad633e45f2f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e85a920-aca1-4188-85a5-ce7d36eae7a3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c3929db0-fcde-4d46-bbd2-9a589c4b7073_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_379d4c61-e469-4d6c-b36c-42be73bead18_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4d8b5d6d-a8e2-422d-8b73-9b9d63535355_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive common stock equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_6c825473-6807-40cd-8980-e2c866dd9aef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_8861cb7f-fe9d-4387-bfe8-aa91a7b22cbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_med_MinimumInterestCoverageRatio_60d171a4-c565-4fc7-be55-8bcdb8917373_terseLabel_en-US" xlink:label="lab_med_MinimumInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Interest Coverage Ratio</link:label>
    <link:label id="lab_med_MinimumInterestCoverageRatio_label_en-US" xlink:label="lab_med_MinimumInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Interest Coverage Ratio</link:label>
    <link:label id="lab_med_MinimumInterestCoverageRatio_documentation_en-US" xlink:label="lab_med_MinimumInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Interest Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_MinimumInterestCoverageRatio" xlink:href="med-20220331.xsd#med_MinimumInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_MinimumInterestCoverageRatio" xlink:to="lab_med_MinimumInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0e6a2985-7a05-47c4-a2fb-c43055fbc27e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_7079f106-654e-49f1-a9b0-163b7130fa6d_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_med_GovernmentAgencySecuritiesMember_5d2d7157-384c-4bc2-aae4-5a712808c0d9_terseLabel_en-US" xlink:label="lab_med_GovernmentAgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government &amp; agency securities</link:label>
    <link:label id="lab_med_GovernmentAgencySecuritiesMember_label_en-US" xlink:label="lab_med_GovernmentAgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Agency Securities [Member]</link:label>
    <link:label id="lab_med_GovernmentAgencySecuritiesMember_documentation_en-US" xlink:label="lab_med_GovernmentAgencySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Agency Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_GovernmentAgencySecuritiesMember" xlink:href="med-20220331.xsd#med_GovernmentAgencySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_GovernmentAgencySecuritiesMember" xlink:to="lab_med_GovernmentAgencySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4b05ee4b-8ea2-46ef-8926-7eb1dbad3b79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1:</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1cf3cae4-c7be-43e9-aa68-de5e4de1fa0b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_cccce699-1fc4-4375-ba0f-79d3c35f674a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e58615b4-5239-4586-bff4-1dc605968250_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3febed09-a141-480a-988e-43347bbb1065_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding -</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6415946e-a728-429f-af79-2e052e0e458a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_72a10a09-7ef7-405f-b62e-1bf0fc714f90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a71115f5-5fd5-4928-8fce-2e0c1b0c0efe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_3e66d49e-8330-4eed-b5ac-4d178b2709f9_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1b4c5424-4a18-4d97-ba94-facac8a13f71_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9e8c7621-f327-42fd-8a96-4bf1674b4d79_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3a2ad8ac-7dd2-4d0c-a9cb-1ab4fdfa8bb8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4177540d-1cc2-4e08-81dd-925b24c46351_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_f6533fe7-5d71-4e5c-9962-60a3b772d610_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6af43569-fd81-41c3-b215-67159dd14348_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34bbcb53-15dd-42a1-aa50-b08e0240d3e8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_fc2af905-e703-4599-9d67-964600028571_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_417dc2cd-721b-41b5-8b87-263bf74d132d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_d50712c5-9414-45c7-a5af-fb6cb01c6601_terseLabel_en-US" xlink:label="lab_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Packaging</link:label>
    <link:label id="lab_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_label_en-US" xlink:label="lab_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retail Related Inventory, Packaging and Other Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies" xlink:to="lab_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_09bd110e-50a3-41ef-ad92-1df461c2e859_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3de1d12b-771f-479f-b6cc-f1d829c41a30_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_07dda0d8-7fc2-411e-bb7b-e9cbadaa05d5_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock from stock repurchases</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_9af246c1-20b6-421f-98d7-fe15eade95db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock retire from stock repurchases (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_cb68fe99-52d2-47cf-a802-8554c005a1f2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_75090ecd-57e6-4b32-b2ab-f58fda905a8e_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ce34b303-e171-4910-96d6-715f161340ac_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1229c80c-2111-4880-a318-651edf74d8fa_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised by executives and directors</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_22229463-fa67-4a2d-8276-469ddf1c299f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4b2d4bc3-046a-4c17-8de5-58273e4c8342_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a1f9aed6-f88d-4126-a949-9fd6b7713688_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_657df217-2b2e-4324-adc0-7b0e22220549_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on investment securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_8cbccbf9-d144-453d-8244-4b98d24b6ca7_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dcdf282c-a0ff-4f7f-beca-74128a9ee4ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_048802c2-5a73-4e1e-8b18-20f8bac6e641_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency impact</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_a11765b4-41d3-4603-95c0-98d18ad69d83_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_e824512c-dc28-44ab-a98c-fb9085a42b24_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_4c4f7458-8907-446a-9329-11c0b53cfadb_verboseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_a1c1e97a-9f17-43ca-b888-c7dd08a25678_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, shares authorized under stock option plans, exercise price range, upper range limit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_627cfb92-d2f2-4c71-9d06-9d50343793e7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2b27e7fa-b852-4191-adf1-55f4e8770502_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_ae01eaf4-3f24-4f4c-94e4-f441b3e5a3af_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1216c2a1-c3f5-45d1-bf07-c54a8909b90e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment - net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_12dc7d59-250b-4f64-8587-3b7ae68ea397_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_57c487e0-c6f1-4659-bcad-dc3a2b616d74_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_95c00c20-0491-4f42-9ec8-47c33747a365_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_110c3613-2756-4814-a8e5-bf4ffb6f75d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_8069903f-3260-460c-84b8-679b1a03bcca_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bb891e12-18e6-4de6-9ca5-c46dae9b1040_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3b71fe52-9f5c-4f87-8e27-7debda8b5363_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fa3d809c-7f98-4bf7-b23e-f3a0d40a714d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price, Exercisable at end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5b3b79a6-85b9-4ab6-8bc4-539d6a0c2a47_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_76baa54a-6a32-478d-9601-7b4bc7aadf2a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b8485ff4-8622-4daf-9413-877d951d8e64_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d99191ea-8618-4997-8d82-8c4b5af17e12_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_40a63720-7a0b-4015-84d7-72fbd325625d_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b873a7a4-0b8e-4e02-8398-b20147a14b82_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on investment securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3500a3b3-147f-410c-9672-9522c5ef9582_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life of options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_4f8732c5-3c8f-4a16-8a63-f123dbfef545_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_295c8b95-c86c-4d01-8303-31ef7c9ab134_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_be036662-28c0-4324-a2e9-b425cfb09f5b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c87a1bc-ac1b-461b-aca1-3db5a362f350_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price, Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b7e70eff-4e98-4fc7-8d33-9590d91cbe68_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price, Outstanding at end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_079897c7-4c0c-4ffc-886e-e0a051f22fca_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $.001 per share: 20,000 shares authorized; 11,594 and 11,594 issued and 11,593 and 11,593 outstanding at March&#160;31, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7a1c2f13-f034-4768-9006-a8d5b9680cfa_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_07ba0e8f-f95d-422b-8256-6bd7b742b1f1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost recognition weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_25692340-d2fb-45cd-91a0-f725f58ffb3d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8ae17dc3-d06c-44d0-902f-7c9b24915868_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d887479c-0b0f-41d1-9c8d-6768602e96bb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_3dd3e14d-9ca7-4787-8635-56cedf175c64_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_2e726c3c-431e-4d92-b20f-4d136d90ef14_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2cbe9784-ba4e-41f5-9c2d-a4d3d73ad21f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4287e373-327c-4624-83de-8d1f70408c9c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34b43d89-ad4d-4356-92bd-6571f68e6ef5_totalLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_86eb36d8-8688-4b7c-be63-8aa711c4ed8b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_16e77882-8198-481a-a766-588643a71f31_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life of options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_242f6998-2564-468c-abe0-b978b7ca40b4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtFairValue_af2c9546-c016-44b4-a022-5aa82eda5f3e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtFairValue_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtFairValue" xlink:to="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bd4b6871-3e31-4f36-a35a-7abfb0ee3f4c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the three months ended March&#160;31, 2022)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3842323a-7a92-4d2e-aa29-099ba5c0e9a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_fff992e1-b490-4f56-8a5b-c24c290a9c7f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_med_InventoryNonFoodFinishedGoods_de9f3ca6-6159-49d9-b5b1-e80a052c73f1_verboseLabel_en-US" xlink:label="lab_med_InventoryNonFoodFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-food finished goods</link:label>
    <link:label id="lab_med_InventoryNonFoodFinishedGoods_label_en-US" xlink:label="lab_med_InventoryNonFoodFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Non Food Finished Goods</link:label>
    <link:label id="lab_med_InventoryNonFoodFinishedGoods_documentation_en-US" xlink:label="lab_med_InventoryNonFoodFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before last-in first-out (LIFO) and valuation reserves of (Non-food) merchandise or goods held by the entity that are readily available for sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_InventoryNonFoodFinishedGoods" xlink:href="med-20220331.xsd#med_InventoryNonFoodFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_InventoryNonFoodFinishedGoods" xlink:to="lab_med_InventoryNonFoodFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_608b15f7-2066-4f0c-9a3d-7f33d31db484_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_a3d4e319-ef62-4d82-848f-25bc23b80405_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes, prepaid</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_med_GrantedIn2022Member_705b9b1e-46af-41c1-a618-cc46c4c179fe_terseLabel_en-US" xlink:label="lab_med_GrantedIn2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2022</link:label>
    <link:label id="lab_med_GrantedIn2022Member_label_en-US" xlink:label="lab_med_GrantedIn2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2022 [Member]</link:label>
    <link:label id="lab_med_GrantedIn2022Member_documentation_en-US" xlink:label="lab_med_GrantedIn2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2022Member" xlink:href="med-20220331.xsd#med_GrantedIn2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_GrantedIn2022Member" xlink:to="lab_med_GrantedIn2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f7d95a23-dcf8-4b28-b9dd-ff4f35655dc2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_c8669c82-cc09-4b2a-9e56-695f75998f33_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for obsolete inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b06989d9-3c25-4470-82ed-1592318aef0b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79684e6a-1a79-4c36-9e08-88ccee5fec4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents - beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49bcf4d8-a194-44c2-8204-53657bab31d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents - end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_b137930d-07b4-462e-a8db-4dbf6717001e_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_b82ae69e-a081-41dd-8d9b-f3745c9bdd6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4bbe16b0-214d-4597-9b2f-028a2cfd5ef8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_de82a50a-acb3-44cb-900e-ae1bbf9a17cd_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d2334e48-f838-4588-a9ae-11c148fc1f97_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_48337c7d-cd27-451d-b446-5d27c40fdc40_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f9d386ed-a968-43b7-b611-0691ba24da0e_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_e901535c-2de1-4d5e-b0c4-982e5a9bde46_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_359e7720-1203-46aa-bc80-90925a8ac1eb_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_7044e278-252c-4380-86f8-2989216da67d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cedaae5e-18de-484e-9b88-9142f0a14974_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8905afdd-bf03-4f6f-9b77-17c2e687e00b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised by executives and directors (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_06361d71-60b3-4579-988b-473464a3e597_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dcdfb7b2-cb84-47a6-89b4-e7cae2357cb6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_05300bfa-b8fb-4cb6-bba1-10db5c272f75_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6509d3e0-4bcd-4d1a-b790-07036060d9ef_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_76ff7d72-67c9-4744-a927-04fee972d7e2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_831b5422-5d46-4858-a98a-ddd8d51d0d2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_a0414ab8-3cf2-4047-b3fa-360ecdc5f0cf_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss_c0ed6006-d5d2-43da-9ebc-9683fa4e85d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss or gains</link:label>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndEquitySecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_med_DenominatorAbstract_94650561-68a5-4a0e-8138-5427f186895d_verboseLabel_en-US" xlink:label="lab_med_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_med_DenominatorAbstract_label_en-US" xlink:label="lab_med_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_med_DenominatorAbstract_documentation_en-US" xlink:label="lab_med_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_DenominatorAbstract" xlink:href="med-20220331.xsd#med_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_DenominatorAbstract" xlink:to="lab_med_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d9065392-b0cb-42b4-be54-a7316cffaacf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_89de34e3-24b3-4898-ba4f-e181d8f7b20a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid to stockholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_044eee87-c718-4bc4-9947-4e7853bf5cf0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_faf56ec5-c3f1-4285-b982-813ae6d3e49a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_med_GrantedIn2021Member_dd7f78fc-507b-4e0f-a725-b56b6386fac2_terseLabel_en-US" xlink:label="lab_med_GrantedIn2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2021</link:label>
    <link:label id="lab_med_GrantedIn2021Member_label_en-US" xlink:label="lab_med_GrantedIn2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2021 [Member]</link:label>
    <link:label id="lab_med_GrantedIn2021Member_documentation_en-US" xlink:label="lab_med_GrantedIn2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted In 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2021Member" xlink:href="med-20220331.xsd#med_GrantedIn2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_GrantedIn2021Member" xlink:to="lab_med_GrantedIn2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_83887023-5985-4e2f-b37c-5f85a15f49ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d121a01b-aa7a-4818-bf13-1ea0e5784ad8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7cb0b189-29fb-4775-9a1e-708678361de0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_e69fe073-e916-4905-9fed-cbdb6bc783ff_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_aaf875a6-313e-422f-94c3-715f9a50ad52_terseLabel_en-US" xlink:label="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Marketable securities [Table]</link:label>
    <link:label id="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_label_en-US" xlink:label="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Marketable securities [Table]</link:label>
    <link:label id="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">N/A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable" xlink:href="med-20220331.xsd#med_CashAndCashEquivalentsAndMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable" xlink:to="lab_med_CashAndCashEquivalentsAndMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_5c828ff8-86ea-4dc4-8234-a8ed1691613f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and maturities of investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_8c853803-ab9e-49be-8293-53e66503f61d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ad1f5608-94fd-4e21-a350-d6ddb77ff289_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_46ac186a-bcf2-4554-89fa-ccf2418d47fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_807b7d30-2ef9-405d-892e-4efec09a2a2d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_584a300d-1770-4c3e-b7a6-3c1b63781484_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9fc8661b-d45b-4111-ac28-ab11bb199d63_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e11eb2e-e305-445c-a7fd-2d2d438e81d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c0e9eec9-24ab-43d3-a747-9b1ffaef9c4c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ff79365d-1bef-4818-8710-f1db66e52590_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8d97f651-d7c2-4a3d-8c58-276387b64fce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fab8da78-1871-40fa-abb3-c1de6c22e36d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_00521ac3-4fb5-4731-97bf-d0ab4cbdcf27_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_8fd6e2ed-2867-4c85-bf99-95ceb5eada64_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Presentation of Financial Statements</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3e9102cd-0acb-4900-a5be-87eceb3baf92_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_aedccb9b-a51b-43b8-af93-e87b0196d1cc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_acbcd289-ee31-4e4f-82d1-6caac4d53a34_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_eefb6b1c-ba04-4fcb-861f-4d7d5f81456c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Recognition and Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_71d31c14-4575-4f83-aff1-00550a809bb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_34167a10-aa10-43ce-a21b-e32812a667e2_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_50305914-d5bd-4111-9b5a-cbee0a077060_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_99952bd3-0f35-44a4-be16-299200ba0b88_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_21d58279-83e3-4212-994e-39e898678ccc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash &amp; Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4e1dc13f-0a0c-499a-a8ea-6b90287bc0dc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9d94a579-da74-4890-8f82-0427d3f841e5_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market accounts</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_82d477d2-4c0c-4270-a4e0-773304edea81_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e00f8bcf-e02d-40ca-b719-1263ba09f8fb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_29deaf00-5157-41f0-98d8-00ad2a87355b_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_324f96a1-3cb2-45d1-885c-921756de2267_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d1f976c1-0f93-4416-98af-175fb3ccab49_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c569b461-1806-40be-96c2-3eb29c78dfa9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_40bd844d-21a4-4f58-beb4-ed08580f97ef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_e86b7781-3cee-4203-a6cf-dbd1e81d06d1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_abe68bc9-3f1e-4e40-8f38-5c6e3fed76bd_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8d969040-5d0f-4692-9605-5af283a7d47f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b076fdfa-0c57-4181-9b3d-fc970b50a4e2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share based compensation nonvested awards total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_78459996-b3ed-47be-a9c8-1fd2b24a18db_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99da6648-6533-4847-8a34-6439d96bde3a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ba800d40-8d17-41c1-9386-f171e23035a9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_1c244f04-eb23-4028-a2eb-52b7016bfd4e_terseLabel_en-US" xlink:label="lab_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_label_en-US" xlink:label="lab_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Five And After Year Five</link:label>
    <link:label id="lab_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_documentation_en-US" xlink:label="lab_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Five And After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:href="med-20220331.xsd#med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:to="lab_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5ed4c33c-a368-446e-a487-133f4c2c0a35_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3a654341-ca11-49a4-b03b-21d24234a57e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f9b9210-18b7-46f6-87c7-b4942a412090_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_89e03e24-20f5-4d69-8560-400bb21b224f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5b779c04-7662-4fd2-bee7-5dad82b7ff93_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturity of the Company's Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ff946c41-86b1-4092-b198-14ae6435728d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1b942916-e37b-4443-a216-8c035b44004b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_559ff035-367f-40da-bbfd-542bba47421b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_80f3ec7e-371f-4cba-869c-8712bb02f8b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f5dd583e-7747-43c9-94cf-57e77ef6c818_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f2d1c389-3001-4181-8d97-45da2f60f096_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ee05f94b-81d4-4e38-837a-f2a2ee1a71aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18c81ffc-701c-4a76-91d6-b2bbb69e42de_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_69ea2390-2591-427c-90a3-6978a71032aa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_0fc65acf-5054-4036-942a-94bf68df2f67_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_51d0923c-6f94-4496-baa4-4ad66b3a3b8a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_80dfffb3-6cde-4313-8167-5e4721e75ce7_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0f3f5ea4-f70b-4a9d-9a5b-4779f91e08ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7d426b0d-523a-417a-98c4-6d77337e5151_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>med-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:232fca58-02a7-458a-8362-c56d4dfdb306,g:546ed23b-bace-40f2-b1e1-3b5a5060da68-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.medifast1.com/role/Cover" xlink:type="simple" xlink:href="med-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1f0afd9c-49dc-4421-88f3-50c265b122e9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_DocumentType_1f0afd9c-49dc-4421-88f3-50c265b122e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9a40f7dd-f2e1-49a7-ac58-b9b4e32a784e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_DocumentQuarterlyReport_9a40f7dd-f2e1-49a7-ac58-b9b4e32a784e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_de80dc1c-2cfc-42e3-b338-98f675de2b32" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_DocumentPeriodEndDate_de80dc1c-2cfc-42e3-b338-98f675de2b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_80f9e320-c350-42c1-b3e8-8dfd5f858283" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_DocumentTransitionReport_80f9e320-c350-42c1-b3e8-8dfd5f858283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ac598a7a-25be-4c9c-9e77-800b9b1f1525" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityFileNumber_ac598a7a-25be-4c9c-9e77-800b9b1f1525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4c9afeb9-6284-4a20-9556-d24b25ce3c6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityRegistrantName_4c9afeb9-6284-4a20-9556-d24b25ce3c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2dde192d-e8d1-4abf-b9d6-b81bc9dd7146" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2dde192d-e8d1-4abf-b9d6-b81bc9dd7146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2bb48ddd-dd94-4655-bd56-f11baed90de8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityTaxIdentificationNumber_2bb48ddd-dd94-4655-bd56-f11baed90de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_26b5cb35-e5ed-46c2-bebc-668880c230f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityAddressAddressLine1_26b5cb35-e5ed-46c2-bebc-668880c230f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_24355cb5-8522-41c3-91e1-389ff633b238" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityAddressCityOrTown_24355cb5-8522-41c3-91e1-389ff633b238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fc47939b-d45e-4811-9ec3-2d3d62819a72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityAddressStateOrProvince_fc47939b-d45e-4811-9ec3-2d3d62819a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bb003527-8ca6-4897-a9d0-62d5dc4441c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityAddressPostalZipCode_bb003527-8ca6-4897-a9d0-62d5dc4441c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_636a5ec3-1bda-4acb-863b-78623276273e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_CityAreaCode_636a5ec3-1bda-4acb-863b-78623276273e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_89c4fd9a-6e1e-463a-bd93-643313f151bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_LocalPhoneNumber_89c4fd9a-6e1e-463a-bd93-643313f151bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fc72ad8e-3203-4d27-9797-ead2dbd02c2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_Security12bTitle_fc72ad8e-3203-4d27-9797-ead2dbd02c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_25d1b5d1-5163-4566-8e15-5cb0d958b3e4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_TradingSymbol_25d1b5d1-5163-4566-8e15-5cb0d958b3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_85fd37c7-7f83-4163-a05b-a778baee8ecd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_SecurityExchangeName_85fd37c7-7f83-4163-a05b-a778baee8ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7fb3da14-622c-4628-8a92-14d0364caf90" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityCurrentReportingStatus_7fb3da14-622c-4628-8a92-14d0364caf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b85ea03e-501f-4571-8297-1f32d1c72554" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityInteractiveDataCurrent_b85ea03e-501f-4571-8297-1f32d1c72554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_19ebe554-00f4-44cc-bbe5-6cdc0b48c95a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityFilerCategory_19ebe554-00f4-44cc-bbe5-6cdc0b48c95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2b825484-f6b6-457c-9751-fa9b3fb1440b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntitySmallBusiness_2b825484-f6b6-457c-9751-fa9b3fb1440b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9053614f-7db8-4e26-b836-bbaf65f289e4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityEmergingGrowthCompany_9053614f-7db8-4e26-b836-bbaf65f289e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_688951fa-5391-487a-862a-eff827c029ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityShellCompany_688951fa-5391-487a-862a-eff827c029ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_80f817a6-00d7-4031-b7d9-105c1c1f9ac0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_80f817a6-00d7-4031-b7d9-105c1c1f9ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2126eea9-5ea1-46c8-befa-ad0adbd1bf6f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_EntityCentralIndexKey_2126eea9-5ea1-46c8-befa-ad0adbd1bf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f86ed76c-334c-4813-bdac-c6a20c70c136" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_CurrentFiscalYearEndDate_f86ed76c-334c-4813-bdac-c6a20c70c136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0f6b3898-28ec-4cd7-95df-cdffaf9448f9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_DocumentFiscalYearFocus_0f6b3898-28ec-4cd7-95df-cdffaf9448f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fb17ca15-3f20-4bc3-8b62-cea8863b970c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fb17ca15-3f20-4bc3-8b62-cea8863b970c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3fb39207-e866-4b76-8905-d94ab2b9c794" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1a6968cf-dbaa-4ae6-93b5-ce0794998191" xlink:to="loc_dei_AmendmentFlag_3fb39207-e866-4b76-8905-d94ab2b9c794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ee43427b-4908-45de-918c-d621b8d78854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7b063b30-22c8-4620-9ecf-2b7df70b3fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee43427b-4908-45de-918c-d621b8d78854" xlink:to="loc_us-gaap_Revenues_7b063b30-22c8-4620-9ecf-2b7df70b3fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_68d19ade-f1a6-4173-a855-c29d4d86cdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee43427b-4908-45de-918c-d621b8d78854" xlink:to="loc_us-gaap_CostOfRevenue_68d19ade-f1a6-4173-a855-c29d4d86cdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c3eb8568-be77-4119-be44-197513e5496f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee43427b-4908-45de-918c-d621b8d78854" xlink:to="loc_us-gaap_GrossProfit_c3eb8568-be77-4119-be44-197513e5496f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2434be6-495b-42b8-a3a2-872c4ab1e7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee43427b-4908-45de-918c-d621b8d78854" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2434be6-495b-42b8-a3a2-872c4ab1e7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_449fc88d-b140-4f5e-8d15-165d7df7ec89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee43427b-4908-45de-918c-d621b8d78854" xlink:to="loc_us-gaap_OperatingIncomeLoss_449fc88d-b140-4f5e-8d15-165d7df7ec89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4edc75f2-07db-40d3-83de-c45320a6ac12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee43427b-4908-45de-918c-d621b8d78854" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4edc75f2-07db-40d3-83de-c45320a6ac12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7724101f-ae45-40fa-a39b-d89f9e91a092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4edc75f2-07db-40d3-83de-c45320a6ac12" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7724101f-ae45-40fa-a39b-d89f9e91a092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1c0a4928-44d9-4c2f-b6b8-c9f334665639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4edc75f2-07db-40d3-83de-c45320a6ac12" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1c0a4928-44d9-4c2f-b6b8-c9f334665639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7b3c9a92-dbb8-4fe9-9860-e147bed4de8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4edc75f2-07db-40d3-83de-c45320a6ac12" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7b3c9a92-dbb8-4fe9-9860-e147bed4de8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ffcce691-fdff-4477-9e46-5031cbb13bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4edc75f2-07db-40d3-83de-c45320a6ac12" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ffcce691-fdff-4477-9e46-5031cbb13bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_03262363-cd3f-4a01-9da5-cedfe330d798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4edc75f2-07db-40d3-83de-c45320a6ac12" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_03262363-cd3f-4a01-9da5-cedfe330d798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_100846d7-e44d-4b9d-b948-c122c3a18d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4edc75f2-07db-40d3-83de-c45320a6ac12" xlink:to="loc_us-gaap_NetIncomeLoss_100846d7-e44d-4b9d-b948-c122c3a18d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_4ecf799f-71b1-42d7-98c6-0a10ea7f69a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4edc75f2-07db-40d3-83de-c45320a6ac12" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_4ecf799f-71b1-42d7-98c6-0a10ea7f69a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ec9b9b73-bdb2-4256-95ca-ee0ef38f7112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4ecf799f-71b1-42d7-98c6-0a10ea7f69a7" xlink:to="loc_us-gaap_EarningsPerShareBasic_ec9b9b73-bdb2-4256-95ca-ee0ef38f7112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_165e8ebd-1589-4bab-83c3-fc05cc139526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4edc75f2-07db-40d3-83de-c45320a6ac12" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_165e8ebd-1589-4bab-83c3-fc05cc139526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4b2a04e9-3b82-42a0-8148-e533c0196d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_165e8ebd-1589-4bab-83c3-fc05cc139526" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4b2a04e9-3b82-42a0-8148-e533c0196d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6c312c59-a257-4f8e-aec9-679141bed0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee43427b-4908-45de-918c-d621b8d78854" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6c312c59-a257-4f8e-aec9-679141bed0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d1b49c0e-e335-42e1-97db-710a846441ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6c312c59-a257-4f8e-aec9-679141bed0ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d1b49c0e-e335-42e1-97db-710a846441ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f62a8e1-d71f-4b43-92ad-0ac31d24e702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6c312c59-a257-4f8e-aec9-679141bed0ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f62a8e1-d71f-4b43-92ad-0ac31d24e702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_6071d199-ff5f-45ef-aa9f-8ea47137359e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ee43427b-4908-45de-918c-d621b8d78854" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_6071d199-ff5f-45ef-aa9f-8ea47137359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_22dbe821-0bb9-4811-9a4b-f5388d798091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aaf1de49-76f5-4a47-9425-f3bef5681394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_22dbe821-0bb9-4811-9a4b-f5388d798091" xlink:to="loc_us-gaap_NetIncomeLoss_aaf1de49-76f5-4a47-9425-f3bef5681394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_efa5ab11-24e0-48ad-a974-67b376f9880b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_22dbe821-0bb9-4811-9a4b-f5388d798091" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_efa5ab11-24e0-48ad-a974-67b376f9880b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_599fa502-10d2-4841-b9b0-518cf2291e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_efa5ab11-24e0-48ad-a974-67b376f9880b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_599fa502-10d2-4841-b9b0-518cf2291e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_796e7b02-b5cf-4029-8388-6c581ecd686e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_efa5ab11-24e0-48ad-a974-67b376f9880b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_796e7b02-b5cf-4029-8388-6c581ecd686e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_80c7273a-c095-4afc-9123-8a130de4988a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_efa5ab11-24e0-48ad-a974-67b376f9880b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_80c7273a-c095-4afc-9123-8a130de4988a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0f121278-32df-4684-ad83-91a4425d96a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_efa5ab11-24e0-48ad-a974-67b376f9880b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0f121278-32df-4684-ad83-91a4425d96a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_867db11c-1a97-45ba-9884-ec6ebc27e156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0f70caec-24e5-4942-998c-dfc2c99d2938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_867db11c-1a97-45ba-9884-ec6ebc27e156" xlink:to="loc_us-gaap_AssetsAbstract_0f70caec-24e5-4942-998c-dfc2c99d2938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_823b8408-3e04-4384-a805-a0d718f70687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0f70caec-24e5-4942-998c-dfc2c99d2938" xlink:to="loc_us-gaap_AssetsCurrentAbstract_823b8408-3e04-4384-a805-a0d718f70687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7dfe1214-5159-4891-b9d8-fa426c557b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_823b8408-3e04-4384-a805-a0d718f70687" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7dfe1214-5159-4891-b9d8-fa426c557b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_dfc61b73-0140-4db2-add1-29e525027044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_823b8408-3e04-4384-a805-a0d718f70687" xlink:to="loc_us-gaap_InventoryNet_dfc61b73-0140-4db2-add1-29e525027044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_10ee6706-c786-4a2d-bdab-69991e74fdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_823b8408-3e04-4384-a805-a0d718f70687" xlink:to="loc_us-gaap_ShortTermInvestments_10ee6706-c786-4a2d-bdab-69991e74fdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_d7019b73-e4d0-419a-8ad9-ed70fba98ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_823b8408-3e04-4384-a805-a0d718f70687" xlink:to="loc_us-gaap_PrepaidTaxes_d7019b73-e4d0-419a-8ad9-ed70fba98ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c904f475-efc9-47ec-b16c-f9e10cd3a678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_823b8408-3e04-4384-a805-a0d718f70687" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c904f475-efc9-47ec-b16c-f9e10cd3a678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e8a09a7f-7332-45b0-b477-17ff6a40b4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0f70caec-24e5-4942-998c-dfc2c99d2938" xlink:to="loc_us-gaap_AssetsCurrent_e8a09a7f-7332-45b0-b477-17ff6a40b4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3f95c1f0-a8cd-4d6d-ae8f-c1b4195f58f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0f70caec-24e5-4942-998c-dfc2c99d2938" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3f95c1f0-a8cd-4d6d-ae8f-c1b4195f58f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e3345ea-f3ef-410a-bccc-664bcdcd385d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0f70caec-24e5-4942-998c-dfc2c99d2938" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1e3345ea-f3ef-410a-bccc-664bcdcd385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_03fc8a14-fd25-4ada-a818-af58db559386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0f70caec-24e5-4942-998c-dfc2c99d2938" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_03fc8a14-fd25-4ada-a818-af58db559386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b7a82203-9bec-409c-8571-9716df62f2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0f70caec-24e5-4942-998c-dfc2c99d2938" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b7a82203-9bec-409c-8571-9716df62f2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_696535a4-894b-4bab-8302-2ee247f88cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0f70caec-24e5-4942-998c-dfc2c99d2938" xlink:to="loc_us-gaap_Assets_696535a4-894b-4bab-8302-2ee247f88cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c571e77e-939f-4edd-824b-33ca3625f2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_867db11c-1a97-45ba-9884-ec6ebc27e156" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c571e77e-939f-4edd-824b-33ca3625f2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_245cc7f9-63dd-4a99-b523-b27219abc407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c571e77e-939f-4edd-824b-33ca3625f2db" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_245cc7f9-63dd-4a99-b523-b27219abc407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_be0c946d-487e-456b-97dc-e7dd2b34ad02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_245cc7f9-63dd-4a99-b523-b27219abc407" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_be0c946d-487e-456b-97dc-e7dd2b34ad02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_66d7829a-6ebf-4280-8391-6b9c922cb951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_245cc7f9-63dd-4a99-b523-b27219abc407" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_66d7829a-6ebf-4280-8391-6b9c922cb951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d8f7c6c9-9dca-4fb6-8e02-51bbf8075292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_245cc7f9-63dd-4a99-b523-b27219abc407" xlink:to="loc_us-gaap_LiabilitiesCurrent_d8f7c6c9-9dca-4fb6-8e02-51bbf8075292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6c85b1e0-1b57-4571-b108-c265b628ab41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c571e77e-939f-4edd-824b-33ca3625f2db" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6c85b1e0-1b57-4571-b108-c265b628ab41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_260242e2-8071-4f04-a81c-5314ffe8a697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c571e77e-939f-4edd-824b-33ca3625f2db" xlink:to="loc_us-gaap_Liabilities_260242e2-8071-4f04-a81c-5314ffe8a697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_fc2d39a2-768e-47d7-a209-96afbb0c50b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c571e77e-939f-4edd-824b-33ca3625f2db" xlink:to="loc_us-gaap_StockholdersEquityAbstract_fc2d39a2-768e-47d7-a209-96afbb0c50b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_07a19b2a-8e9b-4610-a713-cb32c56800b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fc2d39a2-768e-47d7-a209-96afbb0c50b4" xlink:to="loc_us-gaap_CommonStockValue_07a19b2a-8e9b-4610-a713-cb32c56800b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ba59a4a8-7c31-4f1d-a449-bac8c565cb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fc2d39a2-768e-47d7-a209-96afbb0c50b4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ba59a4a8-7c31-4f1d-a449-bac8c565cb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7f4c435b-30c2-4433-9dd1-34351533429b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fc2d39a2-768e-47d7-a209-96afbb0c50b4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7f4c435b-30c2-4433-9dd1-34351533429b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_413b5b07-8f7c-42d7-9df0-ab833e934db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fc2d39a2-768e-47d7-a209-96afbb0c50b4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_413b5b07-8f7c-42d7-9df0-ab833e934db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dfd9558e-ac3f-4d94-93c3-c983144e54b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fc2d39a2-768e-47d7-a209-96afbb0c50b4" xlink:to="loc_us-gaap_StockholdersEquity_dfd9558e-ac3f-4d94-93c3-c983144e54b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b6949311-5b7b-4bd8-9b9f-68ce3c03e300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c571e77e-939f-4edd-824b-33ca3625f2db" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b6949311-5b7b-4bd8-9b9f-68ce3c03e300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0d9f91e1-3798-46da-91f3-7a5f5a04e189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bdad632d-57b1-4b37-9ffa-3bc1297b5db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d9f91e1-3798-46da-91f3-7a5f5a04e189" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bdad632d-57b1-4b37-9ffa-3bc1297b5db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0a293cee-434d-4246-8841-c1d80a340acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d9f91e1-3798-46da-91f3-7a5f5a04e189" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0a293cee-434d-4246-8841-c1d80a340acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1b8bd10b-243c-48d9-a009-af829043cb70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d9f91e1-3798-46da-91f3-7a5f5a04e189" xlink:to="loc_us-gaap_CommonStockSharesIssued_1b8bd10b-243c-48d9-a009-af829043cb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f59886db-7bbd-4a3c-8454-41509e97abfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0d9f91e1-3798-46da-91f3-7a5f5a04e189" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f59886db-7bbd-4a3c-8454-41509e97abfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a9fea0ba-d0ee-4346-8e5d-aefff9233c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ca442fe-4ed9-4b0e-8ad8-d3f10a3b4142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9fea0ba-d0ee-4346-8e5d-aefff9233c81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ca442fe-4ed9-4b0e-8ad8-d3f10a3b4142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_628c5862-3e4d-49d3-ad5f-b33be0b94ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ca442fe-4ed9-4b0e-8ad8-d3f10a3b4142" xlink:to="loc_us-gaap_NetIncomeLoss_628c5862-3e4d-49d3-ad5f-b33be0b94ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b2c2d66b-d97c-4a2f-a5ef-f54bb993ce08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ca442fe-4ed9-4b0e-8ad8-d3f10a3b4142" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b2c2d66b-d97c-4a2f-a5ef-f54bb993ce08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_578738d4-9a07-49bb-9c18-129fec4a51d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b2c2d66b-d97c-4a2f-a5ef-f54bb993ce08" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_578738d4-9a07-49bb-9c18-129fec4a51d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_OperatingLeaseExpenseNonCash_e40c0b1d-5ca6-4684-83f0-063ff268f78e" xlink:href="med-20220331.xsd#med_OperatingLeaseExpenseNonCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b2c2d66b-d97c-4a2f-a5ef-f54bb993ce08" xlink:to="loc_med_OperatingLeaseExpenseNonCash_e40c0b1d-5ca6-4684-83f0-063ff268f78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8c6c4f2a-42ef-416b-8b58-c810f16db733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b2c2d66b-d97c-4a2f-a5ef-f54bb993ce08" xlink:to="loc_us-gaap_ShareBasedCompensation_8c6c4f2a-42ef-416b-8b58-c810f16db733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_AmortizationOfPremiumOnInvestmentSecurities_3aadadb3-a592-449f-8047-73a992574a11" xlink:href="med-20220331.xsd#med_AmortizationOfPremiumOnInvestmentSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b2c2d66b-d97c-4a2f-a5ef-f54bb993ce08" xlink:to="loc_med_AmortizationOfPremiumOnInvestmentSecurities_3aadadb3-a592-449f-8047-73a992574a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5918088-ec18-4453-b352-fb2cdb46d88a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b2c2d66b-d97c-4a2f-a5ef-f54bb993ce08" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5918088-ec18-4453-b352-fb2cdb46d88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_75e67934-3ed4-45bd-a261-f90d8acd925c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5918088-ec18-4453-b352-fb2cdb46d88a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_75e67934-3ed4-45bd-a261-f90d8acd925c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_9c53b4b5-22cc-4f76-b4d5-edf2ab161023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5918088-ec18-4453-b352-fb2cdb46d88a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_9c53b4b5-22cc-4f76-b4d5-edf2ab161023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f9ba0621-e78e-46bd-8ee9-ec15283ce821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5918088-ec18-4453-b352-fb2cdb46d88a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f9ba0621-e78e-46bd-8ee9-ec15283ce821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_99d8b3c7-1cbf-4386-bdd1-383cef52e6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5918088-ec18-4453-b352-fb2cdb46d88a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_99d8b3c7-1cbf-4386-bdd1-383cef52e6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dd5d90b3-4b07-49ea-8322-2f6dd76cfd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5918088-ec18-4453-b352-fb2cdb46d88a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_dd5d90b3-4b07-49ea-8322-2f6dd76cfd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38dd4af-7d16-458c-9d25-95fc1ff8b2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5918088-ec18-4453-b352-fb2cdb46d88a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38dd4af-7d16-458c-9d25-95fc1ff8b2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_000040fa-c4bc-421a-a9fe-205b0fd9c50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9fea0ba-d0ee-4346-8e5d-aefff9233c81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_000040fa-c4bc-421a-a9fe-205b0fd9c50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_b2a4058f-e9a0-4ca1-8a72-f42a5cf468d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_000040fa-c4bc-421a-a9fe-205b0fd9c50c" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_b2a4058f-e9a0-4ca1-8a72-f42a5cf468d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_abf7a2d9-4ab6-466f-8d34-de85f7366d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_000040fa-c4bc-421a-a9fe-205b0fd9c50c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_abf7a2d9-4ab6-466f-8d34-de85f7366d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_012efbc8-b701-4d23-ac7f-0fc8e798fcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_000040fa-c4bc-421a-a9fe-205b0fd9c50c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_012efbc8-b701-4d23-ac7f-0fc8e798fcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7e35021-1c0b-4c43-81a5-8cf6a12ddabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9fea0ba-d0ee-4346-8e5d-aefff9233c81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7e35021-1c0b-4c43-81a5-8cf6a12ddabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0f883e2d-7706-4fce-8b0f-5c769bc8c971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7e35021-1c0b-4c43-81a5-8cf6a12ddabd" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0f883e2d-7706-4fce-8b0f-5c769bc8c971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_240e598f-bc43-4f55-a46c-c95148dd6db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7e35021-1c0b-4c43-81a5-8cf6a12ddabd" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_240e598f-bc43-4f55-a46c-c95148dd6db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_4e98baa7-6103-426e-a8a9-67302fcb6cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7e35021-1c0b-4c43-81a5-8cf6a12ddabd" xlink:to="loc_us-gaap_PaymentsOfDividends_4e98baa7-6103-426e-a8a9-67302fcb6cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e8d50a3f-d09b-4c15-864c-64bb6a5839d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7e35021-1c0b-4c43-81a5-8cf6a12ddabd" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e8d50a3f-d09b-4c15-864c-64bb6a5839d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_57277277-9a50-46de-9d08-0a3beab0bde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7e35021-1c0b-4c43-81a5-8cf6a12ddabd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_57277277-9a50-46de-9d08-0a3beab0bde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_986f5adf-09f3-44ca-b0b4-bb226ab8789f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9fea0ba-d0ee-4346-8e5d-aefff9233c81" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_986f5adf-09f3-44ca-b0b4-bb226ab8789f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_020139d7-8aa9-4fbf-9882-9afbb9c00024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9fea0ba-d0ee-4346-8e5d-aefff9233c81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_020139d7-8aa9-4fbf-9882-9afbb9c00024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa5f77cf-e5b7-46c4-ae3e-aa606d2d2950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9fea0ba-d0ee-4346-8e5d-aefff9233c81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa5f77cf-e5b7-46c4-ae3e-aa606d2d2950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab0e04da-f3a9-46b0-970e-1b7f4d123616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9fea0ba-d0ee-4346-8e5d-aefff9233c81" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab0e04da-f3a9-46b0-970e-1b7f4d123616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd45129e-ee28-42b5-9093-65afec1703e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9fea0ba-d0ee-4346-8e5d-aefff9233c81" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd45129e-ee28-42b5-9093-65afec1703e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_187ab5f8-c0a2-4c6b-8238-860e6b350d02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd45129e-ee28-42b5-9093-65afec1703e7" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_187ab5f8-c0a2-4c6b-8238-860e6b350d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCash_9c376a6d-0b6b-4734-b6d2-5bcb74a84e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fd45129e-ee28-42b5-9093-65afec1703e7" xlink:to="loc_us-gaap_DividendsCash_9c376a6d-0b6b-4734-b6d2-5bcb74a84e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="med-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c087a3e0-bae7-478b-83bc-f2d1644ecbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_54d67535-9ad5-41a6-88bd-a55e00fbf2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c087a3e0-bae7-478b-83bc-f2d1644ecbc8" xlink:to="loc_us-gaap_StatementTable_54d67535-9ad5-41a6-88bd-a55e00fbf2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4edbc383-9130-4dc2-a17d-30137d7448b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54d67535-9ad5-41a6-88bd-a55e00fbf2d7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4edbc383-9130-4dc2-a17d-30137d7448b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4edbc383-9130-4dc2-a17d-30137d7448b3" xlink:to="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e1799416-8013-473a-bf72-a8d71ef374a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:to="loc_us-gaap_CommonStockMember_e1799416-8013-473a-bf72-a8d71ef374a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d85f94f-e817-47f0-9056-0adb6df5246f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d85f94f-e817-47f0-9056-0adb6df5246f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68c5bba6-6984-4012-bb7b-b2242641b73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68c5bba6-6984-4012-bb7b-b2242641b73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9fac89c6-7cdc-4c30-b753-5f0cb807aa14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:to="loc_us-gaap_RetainedEarningsMember_9fac89c6-7cdc-4c30-b753-5f0cb807aa14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_7fa6fc60-442a-4f47-a238-26dbef328248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d8b1c04f-77c9-40c5-97f7-540ef3179d77" xlink:to="loc_us-gaap_TreasuryStockMember_7fa6fc60-442a-4f47-a238-26dbef328248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54d67535-9ad5-41a6-88bd-a55e00fbf2d7" xlink:to="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_9acafbb5-f36b-4e14-9f17-4906c184861c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_SharesIssued_9acafbb5-f36b-4e14-9f17-4906c184861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0056ba19-fe2e-4d34-a1d5-370548b80239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_StockholdersEquity_0056ba19-fe2e-4d34-a1d5-370548b80239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c014bbc-c3a8-4fcf-b856-0acefb89d83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_NetIncomeLoss_2c014bbc-c3a8-4fcf-b856-0acefb89d83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_e8ed9ec9-6dbe-459d-8e9d-b42e050c6127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_e8ed9ec9-6dbe-459d-8e9d-b42e050c6127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_557069c1-d05b-4614-a506-7fbc690bbbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_557069c1-d05b-4614-a506-7fbc690bbbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aafc6747-7b8c-47af-a0d8-e3d19318e531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aafc6747-7b8c-47af-a0d8-e3d19318e531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ced4bc7c-c06e-48ff-adce-70d70b6bb357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ced4bc7c-c06e-48ff-adce-70d70b6bb357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_02194e5a-7834-4887-a93d-d0df4ecd4d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_02194e5a-7834-4887-a93d-d0df4ecd4d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f8bb9126-e8bd-4a76-b03f-d2f6eda33370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f8bb9126-e8bd-4a76-b03f-d2f6eda33370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_aa3dfde0-882f-4d13-a7a9-a22aba1fc79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_aa3dfde0-882f-4d13-a7a9-a22aba1fc79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_4f956c51-11e5-4139-8227-ebcb318432e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_4f956c51-11e5-4139-8227-ebcb318432e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e6f9322a-23b5-40fc-8a1f-471b5414ae28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_e6f9322a-23b5-40fc-8a1f-471b5414ae28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5832e293-db08-4471-966c-bf5306a0c7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5832e293-db08-4471-966c-bf5306a0c7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_416dd500-8e58-4aed-a606-3b29b6006044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_DividendsCommonStockCash_416dd500-8e58-4aed-a606-3b29b6006044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a3af5a2b-d6ea-498b-a333-791f22b93c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_SharesIssued_a3af5a2b-d6ea-498b-a333-791f22b93c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_87dd6c42-975e-43f5-ba64-1f1c8d5add2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_53f0b966-501e-42ab-8707-50bb9558d5e0" xlink:to="loc_us-gaap_StockholdersEquity_87dd6c42-975e-43f5-ba64-1f1c8d5add2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="med-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ae64bf72-d791-4730-b508-2ebe2ac4a55a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f9492b28-6d7a-42f5-9ab4-7eb42bc1f211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae64bf72-d791-4730-b508-2ebe2ac4a55a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f9492b28-6d7a-42f5-9ab4-7eb42bc1f211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="med-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c32073aa-9994-485e-a4b5-5fb01764ce65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e5ac1b5f-8f81-44d4-9076-c919e71fa427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c32073aa-9994-485e-a4b5-5fb01764ce65" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e5ac1b5f-8f81-44d4-9076-c919e71fa427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_5107f9fa-93ab-448b-9066-8c8a488b3a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c32073aa-9994-485e-a4b5-5fb01764ce65" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_5107f9fa-93ab-448b-9066-8c8a488b3a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f8f2969e-c1be-425c-a91f-152ce7abaca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c32073aa-9994-485e-a4b5-5fb01764ce65" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f8f2969e-c1be-425c-a91f-152ce7abaca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f77dd199-06e6-46ba-a8ea-7930c2091726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c32073aa-9994-485e-a4b5-5fb01764ce65" xlink:to="loc_us-gaap_UseOfEstimates_f77dd199-06e6-46ba-a8ea-7930c2091726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a89a133d-70fd-4ad0-bc0d-ef3e143b7726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c32073aa-9994-485e-a4b5-5fb01764ce65" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a89a133d-70fd-4ad0-bc0d-ef3e143b7726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/INVENTORIES" xlink:type="simple" xlink:href="med-20220331.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_90028e26-a776-4715-995b-e71dbda177c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_eb49bfa3-7114-4c06-b9c1-d73f6b19fd09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_90028e26-a776-4715-995b-e71dbda177c5" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_eb49bfa3-7114-4c06-b9c1-d73f6b19fd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="med-20220331.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d89c6fc1-1db0-4bdb-9601-e2fffdffb8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3815e734-5a05-4e65-8c82-4b566c2b017d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d89c6fc1-1db0-4bdb-9601-e2fffdffb8b8" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3815e734-5a05-4e65-8c82-4b566c2b017d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="med-20220331.xsd#INVENTORIESDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_26ac8e42-0442-4461-9fc3-01833a730b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_3af27310-273e-4685-9fac-599e3656a22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_26ac8e42-0442-4461-9fc3-01833a730b11" xlink:to="loc_us-gaap_InventoryRawMaterials_3af27310-273e-4685-9fac-599e3656a22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_11815f73-867c-4a7e-86bc-ecdbd374da1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_26ac8e42-0442-4461-9fc3-01833a730b11" xlink:to="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_11815f73-867c-4a7e-86bc-ecdbd374da1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_InventoryNonFoodFinishedGoods_753c7898-e7b9-4d5f-9e0f-9659622774d6" xlink:href="med-20220331.xsd#med_InventoryNonFoodFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_26ac8e42-0442-4461-9fc3-01833a730b11" xlink:to="loc_med_InventoryNonFoodFinishedGoods_753c7898-e7b9-4d5f-9e0f-9659622774d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_bb355b16-6e70-4e7a-ad76-641f4c23817d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_26ac8e42-0442-4461-9fc3-01833a730b11" xlink:to="loc_us-gaap_InventoryFinishedGoods_bb355b16-6e70-4e7a-ad76-641f4c23817d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_9c8e11ca-9f53-4dc8-9a18-bc4e53bc9d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_26ac8e42-0442-4461-9fc3-01833a730b11" xlink:to="loc_us-gaap_InventoryValuationReserves_9c8e11ca-9f53-4dc8-9a18-bc4e53bc9d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4511901e-caa2-4262-8c9a-62ad8deb7858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_26ac8e42-0442-4461-9fc3-01833a730b11" xlink:to="loc_us-gaap_InventoryNet_4511901e-caa2-4262-8c9a-62ad8deb7858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/EARNINGSPERSHARE" xlink:type="simple" xlink:href="med-20220331.xsd#EARNINGSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/EARNINGSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ac9a7100-8a18-4789-9ab5-b527b1900c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_26471417-1241-4411-b029-03a70d7601ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ac9a7100-8a18-4789-9ab5-b527b1900c00" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_26471417-1241-4411-b029-03a70d7601ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/EARNINGSPERSHARETables" xlink:type="simple" xlink:href="med-20220331.xsd#EARNINGSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/EARNINGSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_989ee4bb-aac6-4197-aa0b-79ead2c64273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_640f3344-e7a7-425e-b952-bdd81879264e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_989ee4bb-aac6-4197-aa0b-79ead2c64273" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_640f3344-e7a7-425e-b952-bdd81879264e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="med-20220331.xsd#EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_50f4c96e-8d9f-4faa-a180-380e8bd32f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_NumeratorAbstract_197a01e7-d7d4-4244-8b00-4f4aa3bfb94b" xlink:href="med-20220331.xsd#med_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_50f4c96e-8d9f-4faa-a180-380e8bd32f6c" xlink:to="loc_med_NumeratorAbstract_197a01e7-d7d4-4244-8b00-4f4aa3bfb94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b63a47a6-766c-4a21-8efb-b5265cb4e164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_NumeratorAbstract_197a01e7-d7d4-4244-8b00-4f4aa3bfb94b" xlink:to="loc_us-gaap_NetIncomeLoss_b63a47a6-766c-4a21-8efb-b5265cb4e164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_DenominatorAbstract_aa6e0f6f-688b-42bc-acd2-29758de57b21" xlink:href="med-20220331.xsd#med_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_50f4c96e-8d9f-4faa-a180-380e8bd32f6c" xlink:to="loc_med_DenominatorAbstract_aa6e0f6f-688b-42bc-acd2-29758de57b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5aae239f-b379-4a1f-8562-2419cfa9f223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_DenominatorAbstract_aa6e0f6f-688b-42bc-acd2-29758de57b21" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5aae239f-b379-4a1f-8562-2419cfa9f223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_02f83d0b-ce27-47ce-917c-20f8da09cc66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_DenominatorAbstract_aa6e0f6f-688b-42bc-acd2-29758de57b21" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_02f83d0b-ce27-47ce-917c-20f8da09cc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_45409c38-4a6a-44b2-bfdc-f1bf5fb4933b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_DenominatorAbstract_aa6e0f6f-688b-42bc-acd2-29758de57b21" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_45409c38-4a6a-44b2-bfdc-f1bf5fb4933b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_7bf65131-77fc-4275-b115-2195bd0a0421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_DenominatorAbstract_aa6e0f6f-688b-42bc-acd2-29758de57b21" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_7bf65131-77fc-4275-b115-2195bd0a0421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6246cb0f-dd6d-474f-8469-96f57fe589b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7bf65131-77fc-4275-b115-2195bd0a0421" xlink:to="loc_us-gaap_EarningsPerShareBasic_6246cb0f-dd6d-474f-8469-96f57fe589b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_d94c16b5-55c1-4167-bb7c-9851ed14bfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_DenominatorAbstract_aa6e0f6f-688b-42bc-acd2-29758de57b21" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_d94c16b5-55c1-4167-bb7c-9851ed14bfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_586676dd-50c7-4a45-8eff-c0786d6d7488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d94c16b5-55c1-4167-bb7c-9851ed14bfbb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_586676dd-50c7-4a45-8eff-c0786d6d7488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#EARNINGSPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a6069d0c-9011-4d26-9925-9f3f88d2c251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_13ea085e-0534-4920-af90-594dc1d535d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a6069d0c-9011-4d26-9925-9f3f88d2c251" xlink:to="loc_us-gaap_StatementTable_13ea085e-0534-4920-af90-594dc1d535d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c9bb008-1d66-4234-ae66-0d00c05f71fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_13ea085e-0534-4920-af90-594dc1d535d3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c9bb008-1d66-4234-ae66-0d00c05f71fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3cac1ea-7aad-4ef0-ab07-c2bf57977bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9c9bb008-1d66-4234-ae66-0d00c05f71fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3cac1ea-7aad-4ef0-ab07-c2bf57977bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_fb1c6648-c0ce-4954-add4-785cd7de93ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3cac1ea-7aad-4ef0-ab07-c2bf57977bc5" xlink:to="loc_us-gaap_RestrictedStockMember_fb1c6648-c0ce-4954-add4-785cd7de93ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1325ea1c-5fef-4679-a55f-2366a4938f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_13ea085e-0534-4920-af90-594dc1d535d3" xlink:to="loc_us-gaap_StatementLineItems_1325ea1c-5fef-4679-a55f-2366a4938f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1a829ee2-6827-4139-891a-c0050b82e9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1325ea1c-5fef-4679-a55f-2366a4938f0e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1a829ee2-6827-4139-891a-c0050b82e9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="med-20220331.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4913849c-c7e4-4e87-b062-6f0ec554b3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_815229ec-6f13-473a-9609-697376f7f5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4913849c-c7e4-4e87-b062-6f0ec554b3ce" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_815229ec-6f13-473a-9609-697376f7f5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="med-20220331.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74f6467b-dff9-495e-a5bc-ee6e0c8638eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f83b4463-a34e-476d-b20b-f2ad6778639e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74f6467b-dff9-495e-a5bc-ee6e0c8638eb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f83b4463-a34e-476d-b20b-f2ad6778639e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_6734c78c-a459-4674-a40c-8fbedd0f0cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74f6467b-dff9-495e-a5bc-ee6e0c8638eb" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_6734c78c-a459-4674-a40c-8fbedd0f0cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_5624e44e-ffdd-4b50-9eaa-14d50856a74c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74f6467b-dff9-495e-a5bc-ee6e0c8638eb" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_5624e44e-ffdd-4b50-9eaa-14d50856a74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bdeede52-4497-4d88-94c3-8465b443743b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea9a7bf2-705b-4a21-8046-b233de039c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bdeede52-4497-4d88-94c3-8465b443743b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea9a7bf2-705b-4a21-8046-b233de039c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c73c0f08-6d37-46b6-a102-6ba8f1f7a332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea9a7bf2-705b-4a21-8046-b233de039c60" xlink:to="loc_us-gaap_AwardTypeAxis_c73c0f08-6d37-46b6-a102-6ba8f1f7a332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acce889c-39f0-4ca4-ac4a-337f05296db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c73c0f08-6d37-46b6-a102-6ba8f1f7a332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acce889c-39f0-4ca4-ac4a-337f05296db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_99004907-1ab5-47ad-8297-278abc5e1017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acce889c-39f0-4ca4-ac4a-337f05296db5" xlink:to="loc_us-gaap_RestrictedStockMember_99004907-1ab5-47ad-8297-278abc5e1017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_25ddcc16-620d-4874-9b58-d60a67dfb361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acce889c-39f0-4ca4-ac4a-337f05296db5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_25ddcc16-620d-4874-9b58-d60a67dfb361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_766e1e4e-7122-4db8-9eae-c3f46abcbf45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acce889c-39f0-4ca4-ac4a-337f05296db5" xlink:to="loc_us-gaap_PerformanceSharesMember_766e1e4e-7122-4db8-9eae-c3f46abcbf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea9a7bf2-705b-4a21-8046-b233de039c60" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0681d93b-8af5-4199-93f2-1c56df04bfad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0681d93b-8af5-4199-93f2-1c56df04bfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c8649883-4085-4978-8742-b02877aa54ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c8649883-4085-4978-8742-b02877aa54ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_24e9e14f-ab7a-4dab-aeb9-80bed7933fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_24e9e14f-ab7a-4dab-aeb9-80bed7933fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_28fb3477-085a-4fe3-9f71-959fa61b7ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_28fb3477-085a-4fe3-9f71-959fa61b7ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ea403f9a-46b2-4261-a899-47c397431c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ea403f9a-46b2-4261-a899-47c397431c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c5662688-ba0f-4f93-ba1a-739229afa619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c5662688-ba0f-4f93-ba1a-739229afa619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_493816b8-b91a-41dd-b095-15058910779f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_493816b8-b91a-41dd-b095-15058910779f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3cf5d05c-aece-4e9a-9213-316f9b6b6f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3cf5d05c-aece-4e9a-9213-316f9b6b6f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_afa74823-301b-4683-8939-4aa365c0ab84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_afa74823-301b-4683-8939-4aa365c0ab84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fbc0c971-cbe4-4060-8e83-429c2943d8af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fbc0c971-cbe4-4060-8e83-429c2943d8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e645c67d-b18b-4986-a45e-78e88339e299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e645c67d-b18b-4986-a45e-78e88339e299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_10682464-420e-4052-9942-c1f3ff1d28cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_10682464-420e-4052-9942-c1f3ff1d28cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2fa88e3a-91a2-4e73-a246-0ef094bcc75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2fa88e3a-91a2-4e73-a246-0ef094bcc75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b36bc419-156d-45df-a3bc-733f30404706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b36bc419-156d-45df-a3bc-733f30404706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f90d8a0b-176f-4598-ab4b-b6993d447b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f90d8a0b-176f-4598-ab4b-b6993d447b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ac41042d-dfba-42cd-9fef-c6c9094c306a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ac41042d-dfba-42cd-9fef-c6c9094c306a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_28c7f012-dbba-4731-9b67-027fa639d031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_28c7f012-dbba-4731-9b67-027fa639d031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d3917c77-62db-4b3e-99ae-247520d90e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b6ce78d-707f-4b31-ade6-d80dff995322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d3917c77-62db-4b3e-99ae-247520d90e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" xlink:type="simple" xlink:href="med-20220331.xsd#SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0c69838-d0e8-411b-b3ee-c9210dcbc5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6904f2c8-7261-4d45-906d-afac05a1e631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0c69838-d0e8-411b-b3ee-c9210dcbc5d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6904f2c8-7261-4d45-906d-afac05a1e631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1d2592ee-6c2f-4c29-b122-214ec2133ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6904f2c8-7261-4d45-906d-afac05a1e631" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1d2592ee-6c2f-4c29-b122-214ec2133ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_bc1b4cba-037e-45b0-8f73-1875bdccdf51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_1d2592ee-6c2f-4c29-b122-214ec2133ff4" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_bc1b4cba-037e-45b0-8f73-1875bdccdf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_db0ba631-930c-466b-aaf9-8b370f5f7112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_bc1b4cba-037e-45b0-8f73-1875bdccdf51" xlink:to="loc_us-gaap_EmployeeStockOptionMember_db0ba631-930c-466b-aaf9-8b370f5f7112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6904f2c8-7261-4d45-906d-afac05a1e631" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3fa05dd5-8a92-473b-b414-aed5215b3b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3fa05dd5-8a92-473b-b414-aed5215b3b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9eb53320-d640-423a-b1ee-80de8c00dd67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9eb53320-d640-423a-b1ee-80de8c00dd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3148693-c9dc-41f7-a1d3-21268c6ea38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3148693-c9dc-41f7-a1d3-21268c6ea38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_aed719b3-35f1-49d4-8b13-6044f30551aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_aed719b3-35f1-49d4-8b13-6044f30551aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14d753f4-7465-46d1-ac64-21d3dd498bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14d753f4-7465-46d1-ac64-21d3dd498bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5fd4a42e-105e-463a-94ef-55e986fdc5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5fd4a42e-105e-463a-94ef-55e986fdc5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1bdf9bbc-3ea2-4b23-8fa2-0b332781379f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1bdf9bbc-3ea2-4b23-8fa2-0b332781379f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4e0edbbf-b9a4-49e8-950f-a702bb03520e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dcb676a-194d-4a95-8085-cab069fd4c3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4e0edbbf-b9a4-49e8-950f-a702bb03520e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="simple" xlink:href="med-20220331.xsd#SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e586305-5922-412e-bf4b-49ac638c7edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4a7f9f7-1e6b-48b2-9e3d-a86d1cd8d2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7e586305-5922-412e-bf4b-49ac638c7edd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4a7f9f7-1e6b-48b2-9e3d-a86d1cd8d2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f3b54453-4d06-4c3e-a451-38acd3423e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4a7f9f7-1e6b-48b2-9e3d-a86d1cd8d2b9" xlink:to="loc_us-gaap_AwardTypeAxis_f3b54453-4d06-4c3e-a451-38acd3423e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6281193-3376-4d36-bea6-ecd68f317ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f3b54453-4d06-4c3e-a451-38acd3423e30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6281193-3376-4d36-bea6-ecd68f317ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e372abbb-1d19-4ea2-a051-5ef68cdd8e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6281193-3376-4d36-bea6-ecd68f317ea6" xlink:to="loc_us-gaap_RestrictedStockMember_e372abbb-1d19-4ea2-a051-5ef68cdd8e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eddbaeb4-744b-4380-9d7d-ec4a433ce5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b4a7f9f7-1e6b-48b2-9e3d-a86d1cd8d2b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eddbaeb4-744b-4380-9d7d-ec4a433ce5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eddbaeb4-744b-4380-9d7d-ec4a433ce5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_164633dc-fc4f-4872-a804-0b7c276fe7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_164633dc-fc4f-4872-a804-0b7c276fe7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ac70bc52-c023-4819-96a7-a5487acb859c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ac70bc52-c023-4819-96a7-a5487acb859c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4060d845-e898-4317-a425-f0309b3d0326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4060d845-e898-4317-a425-f0309b3d0326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b0debd9-1c26-4ab4-b71b-d2907334bf92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_41296a2c-15f3-4ea2-91a8-9af759e432ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b0debd9-1c26-4ab4-b71b-d2907334bf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_eddbaeb4-744b-4380-9d7d-ec4a433ce5ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4df487ad-d195-4cc8-869a-081e23db06ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4df487ad-d195-4cc8-869a-081e23db06ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ba486a95-0c26-440b-9f88-132229155198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ba486a95-0c26-440b-9f88-132229155198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c279ecc9-db2f-4fde-8308-8073ab80f41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c279ecc9-db2f-4fde-8308-8073ab80f41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f651b229-80ce-49c8-a04e-937f195afd17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0de59b86-44f2-434a-b3ab-d73b79a2b9f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f651b229-80ce-49c8-a04e-937f195afd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" xlink:type="simple" xlink:href="med-20220331.xsd#SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f05378f9-6bdf-4dfe-b032-87d77da501ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4739a852-1125-4519-8265-1e0f266a3eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f05378f9-6bdf-4dfe-b032-87d77da501ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4739a852-1125-4519-8265-1e0f266a3eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4873b42a-602c-47a6-b083-5dbd45e7dea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4739a852-1125-4519-8265-1e0f266a3eca" xlink:to="loc_us-gaap_AwardTypeAxis_4873b42a-602c-47a6-b083-5dbd45e7dea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd4857b2-dc2f-415d-b4e4-afeb96f980db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4873b42a-602c-47a6-b083-5dbd45e7dea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd4857b2-dc2f-415d-b4e4-afeb96f980db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_OptionsAndRestrictedStockMember_f2787ed1-36b6-49aa-99ce-6f502c4fe14c" xlink:href="med-20220331.xsd#med_OptionsAndRestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd4857b2-dc2f-415d-b4e4-afeb96f980db" xlink:to="loc_med_OptionsAndRestrictedStockMember_f2787ed1-36b6-49aa-99ce-6f502c4fe14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0c99b21f-6dae-41ea-bd7e-09634ecd4357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd4857b2-dc2f-415d-b4e4-afeb96f980db" xlink:to="loc_us-gaap_PerformanceSharesMember_0c99b21f-6dae-41ea-bd7e-09634ecd4357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_2e47edc5-823b-4c4b-a451-08dae83cf662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4739a852-1125-4519-8265-1e0f266a3eca" xlink:to="loc_us-gaap_AwardDateAxis_2e47edc5-823b-4c4b-a451-08dae83cf662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_2e47edc5-823b-4c4b-a451-08dae83cf662" xlink:to="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2022Member_fcb98303-a5e9-475d-a4dc-a65fb773962a" xlink:href="med-20220331.xsd#med_GrantedIn2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:to="loc_med_GrantedIn2022Member_fcb98303-a5e9-475d-a4dc-a65fb773962a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2021Member_4390c5f7-f079-40de-abc5-4efdb4edfffa" xlink:href="med-20220331.xsd#med_GrantedIn2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:to="loc_med_GrantedIn2021Member_4390c5f7-f079-40de-abc5-4efdb4edfffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2020Member_b54352cb-74f4-4501-a682-f5023e0cf16e" xlink:href="med-20220331.xsd#med_GrantedIn2020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:to="loc_med_GrantedIn2020Member_b54352cb-74f4-4501-a682-f5023e0cf16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_GrantedIn2019Member_cc7a9064-b6ff-4bec-bc2e-7c7fbea1c197" xlink:href="med-20220331.xsd#med_GrantedIn2019Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_aa556b73-fc77-42c1-83ea-e4c1ad1be27d" xlink:to="loc_med_GrantedIn2019Member_cc7a9064-b6ff-4bec-bc2e-7c7fbea1c197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0482be1-7ab3-4940-9f18-98aeb6511c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4739a852-1125-4519-8265-1e0f266a3eca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0482be1-7ab3-4940-9f18-98aeb6511c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b941d5e2-9dbc-496c-9f56-7da1aa9785e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0482be1-7ab3-4940-9f18-98aeb6511c05" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b941d5e2-9dbc-496c-9f56-7da1aa9785e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6eb0ecb0-aae8-4053-aaa2-2e015b1c4da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0482be1-7ab3-4940-9f18-98aeb6511c05" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6eb0ecb0-aae8-4053-aaa2-2e015b1c4da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/LEASES" xlink:type="simple" xlink:href="med-20220331.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3e1f36f0-48e6-4ea1-8027-dea8ee5aa8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_5553b9b2-1769-47dc-b35b-705fa71bde74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e1f36f0-48e6-4ea1-8027-dea8ee5aa8fe" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_5553b9b2-1769-47dc-b35b-705fa71bde74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/LEASESTables" xlink:type="simple" xlink:href="med-20220331.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_edfc561c-9757-429a-aa1d-a9fd97f52ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_47e9bec7-a1f8-4389-b16a-1c29c429a247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edfc561c-9757-429a-aa1d-a9fd97f52ae8" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_47e9bec7-a1f8-4389-b16a-1c29c429a247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_20cc3456-88b3-4cf8-8283-15f6520c28b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_edfc561c-9757-429a-aa1d-a9fd97f52ae8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_20cc3456-88b3-4cf8-8283-15f6520c28b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_df5b5c9d-6d9d-450a-b181-274d5a63fe28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_32861519-9187-4696-a845-eee9c6e610fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df5b5c9d-6d9d-450a-b181-274d5a63fe28" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_32861519-9187-4696-a845-eee9c6e610fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b30ffbdc-4a2c-4c58-af39-5a279fa8e805" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_32861519-9187-4696-a845-eee9c6e610fe" xlink:to="loc_srt_RangeAxis_b30ffbdc-4a2c-4c58-af39-5a279fa8e805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ec5aa74-c910-4deb-8de1-cc16cbfc6837" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b30ffbdc-4a2c-4c58-af39-5a279fa8e805" xlink:to="loc_srt_RangeMember_7ec5aa74-c910-4deb-8de1-cc16cbfc6837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8fde76f6-ba7a-4226-9cbb-098b36a2b4a8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7ec5aa74-c910-4deb-8de1-cc16cbfc6837" xlink:to="loc_srt_MinimumMember_8fde76f6-ba7a-4226-9cbb-098b36a2b4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bad65fa6-ce89-4acd-8a55-915a120f80d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7ec5aa74-c910-4deb-8de1-cc16cbfc6837" xlink:to="loc_srt_MaximumMember_bad65fa6-ce89-4acd-8a55-915a120f80d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20b4d36b-4608-4c2a-9b08-c8bb03280c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_32861519-9187-4696-a845-eee9c6e610fe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20b4d36b-4608-4c2a-9b08-c8bb03280c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36d56f8e-aff7-4a3c-9fe4-83a21822c078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20b4d36b-4608-4c2a-9b08-c8bb03280c8b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36d56f8e-aff7-4a3c-9fe4-83a21822c078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_OperatingLeaseArrangementForRealEstateMember_6d0fd61c-3070-48c4-9b0e-54baae8d1d72" xlink:href="med-20220331.xsd#med_OperatingLeaseArrangementForRealEstateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36d56f8e-aff7-4a3c-9fe4-83a21822c078" xlink:to="loc_med_OperatingLeaseArrangementForRealEstateMember_6d0fd61c-3070-48c4-9b0e-54baae8d1d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_OperatingLeaseArrangementForEquipmentMember_033c8162-1f1b-4e4f-88ed-0df9d4cf38b9" xlink:href="med-20220331.xsd#med_OperatingLeaseArrangementForEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36d56f8e-aff7-4a3c-9fe4-83a21822c078" xlink:to="loc_med_OperatingLeaseArrangementForEquipmentMember_033c8162-1f1b-4e4f-88ed-0df9d4cf38b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b14cb5e-95e5-417f-8611-6bce89f57d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_32861519-9187-4696-a845-eee9c6e610fe" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b14cb5e-95e5-417f-8611-6bce89f57d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_cf293fce-411e-4311-8be3-cffca1cf63af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b14cb5e-95e5-417f-8611-6bce89f57d6f" xlink:to="loc_us-gaap_FinanceLeaseLiability_cf293fce-411e-4311-8be3-cffca1cf63af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_80798204-578a-4479-bfc8-85056ae2e7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b14cb5e-95e5-417f-8611-6bce89f57d6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_80798204-578a-4479-bfc8-85056ae2e7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_8a9fcb89-d54e-4491-af29-ee31b22218d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b14cb5e-95e5-417f-8611-6bce89f57d6f" xlink:to="loc_us-gaap_OperatingLeaseExpense_8a9fcb89-d54e-4491-af29-ee31b22218d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="med-20220331.xsd#LEASESSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_37fab8ed-3392-4904-86cb-928775d7ea07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3e41860d-74dd-4c8f-bd81-285e10a3be1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_37fab8ed-3392-4904-86cb-928775d7ea07" xlink:to="loc_us-gaap_OperatingLeasePayments_3e41860d-74dd-4c8f-bd81-285e10a3be1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_95f26825-8ce0-481d-84fb-4a039d0f4179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_37fab8ed-3392-4904-86cb-928775d7ea07" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_95f26825-8ce0-481d-84fb-4a039d0f4179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f15f6cb8-951c-4409-8c70-c5b7b2235bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_37fab8ed-3392-4904-86cb-928775d7ea07" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f15f6cb8-951c-4409-8c70-c5b7b2235bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_43bd881c-5f33-4b9f-834a-7ea594f3601a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_37fab8ed-3392-4904-86cb-928775d7ea07" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_43bd881c-5f33-4b9f-834a-7ea594f3601a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="med-20220331.xsd#LEASESFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_170199af-d3d9-41ac-8bdb-eb56dc9c9a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_170199af-d3d9-41ac-8bdb-eb56dc9c9a76" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4c61df6b-dc0d-47b1-9fa4-64aab3b2153b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4c61df6b-dc0d-47b1-9fa4-64aab3b2153b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b6f01703-ce3d-478b-bff2-daf58fef2725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b6f01703-ce3d-478b-bff2-daf58fef2725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_946626a9-8ad6-4ab7-a106-74a8044cbfb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_946626a9-8ad6-4ab7-a106-74a8044cbfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c9462c26-5626-4718-8c03-ac735bf0543b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c9462c26-5626-4718-8c03-ac735bf0543b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f817f8b4-ab29-4a96-8dc6-da4078e6e976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f817f8b4-ab29-4a96-8dc6-da4078e6e976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_c61ef16a-0173-4c97-abc5-8be13ec8e10e" xlink:href="med-20220331.xsd#med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:to="loc_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_c61ef16a-0173-4c97-abc5-8be13ec8e10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08ece22b-4479-431d-a7ea-5afff43d2d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08ece22b-4479-431d-a7ea-5afff43d2d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0c702f40-9af9-484f-938e-ba6a2298e513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0c702f40-9af9-484f-938e-ba6a2298e513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2691ef9a-20c8-446b-84af-5ccf600e60e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe4c5e24-318b-4bb2-aae5-5d996e579af1" xlink:to="loc_us-gaap_OperatingLeaseLiability_2691ef9a-20c8-446b-84af-5ccf600e60e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="med-20220331.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_b825d880-5c00-4e18-9924-84810505ded4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_a39b7fc4-e962-4253-b515-cf0227d94b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_b825d880-5c00-4e18-9924-84810505ded4" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_a39b7fc4-e962-4253-b515-cf0227d94b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables" xlink:type="simple" xlink:href="med-20220331.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_79b5d2fc-61ef-404f-a49d-2f0d6d3a8b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05a618ea-3922-43b8-a3a6-62d193e75f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_79b5d2fc-61ef-404f-a49d-2f0d6d3a8b30" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_05a618ea-3922-43b8-a3a6-62d193e75f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_42514ae4-f735-46b4-807b-3daa11bf3ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_ea5f1407-6c3d-49a2-a08f-86f587cb482f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_42514ae4-f735-46b4-807b-3daa11bf3ea6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_ea5f1407-6c3d-49a2-a08f-86f587cb482f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9d0c81b7-b2b6-42cc-9beb-f7161f5f357c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_42514ae4-f735-46b4-807b-3daa11bf3ea6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9d0c81b7-b2b6-42cc-9beb-f7161f5f357c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e5a6b0d9-af8f-49d0-8b7f-3742b185cda4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_42514ae4-f735-46b4-807b-3daa11bf3ea6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e5a6b0d9-af8f-49d0-8b7f-3742b185cda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="med-20220331.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_30464e10-300f-420f-a2c4-b6e7f91dfa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_ba3080d0-273d-4bf0-8eca-c2431779a1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_30464e10-300f-420f-a2c4-b6e7f91dfa2c" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_ba3080d0-273d-4bf0-8eca-c2431779a1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="med-20220331.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_da7c2a84-32a3-40d0-9575-5cb6657d0616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_952b9732-26bb-4941-888a-61f9c3a58ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_da7c2a84-32a3-40d0-9575-5cb6657d0616" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_952b9732-26bb-4941-888a-61f9c3a58ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2a3cdbf9-f232-4525-b109-df9574d00e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss_5d7836ca-b447-4fca-b2d4-d22f0345b571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtAndEquitySecuritiesRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2a3cdbf9-f232-4525-b109-df9574d00e13" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss_5d7836ca-b447-4fca-b2d4-d22f0345b571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails" xlink:type="simple" xlink:href="med-20220331.xsd#FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_686eb8e3-41be-4a6c-a044-539ccd014148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:href="med-20220331.xsd#med_CashAndCashEquivalentsAndMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_686eb8e3-41be-4a6c-a044-539ccd014148" xlink:to="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e40ac00c-d688-48fc-bfc6-2fc70a9185ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e40ac00c-d688-48fc-bfc6-2fc70a9185ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa5324b-6b00-4d1e-b264-fb5613276997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e40ac00c-d688-48fc-bfc6-2fc70a9185ab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa5324b-6b00-4d1e-b264-fb5613276997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a22e1300-c1b2-4148-ae42-a6b0fb8ea7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa5324b-6b00-4d1e-b264-fb5613276997" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a22e1300-c1b2-4148-ae42-a6b0fb8ea7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5108b967-535e-4c7d-9b53-b789f5ca41b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa5324b-6b00-4d1e-b264-fb5613276997" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5108b967-535e-4c7d-9b53-b789f5ca41b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3f61094c-ae8d-4f1a-a705-9e4951a982d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3f61094c-ae8d-4f1a-a705-9e4951a982d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d6732dbe-d860-43b0-bdc0-7e4fdb6bc634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3f61094c-ae8d-4f1a-a705-9e4951a982d9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d6732dbe-d860-43b0-bdc0-7e4fdb6bc634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_2a28bc26-dc22-4f5e-b0c2-18c061a490bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d6732dbe-d860-43b0-bdc0-7e4fdb6bc634" xlink:to="loc_us-gaap_CashMember_2a28bc26-dc22-4f5e-b0c2-18c061a490bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0b46181c-d2ff-47b0-9a32-5ab4b31ecf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d6732dbe-d860-43b0-bdc0-7e4fdb6bc634" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0b46181c-d2ff-47b0-9a32-5ab4b31ecf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_GovernmentAgencySecuritiesMember_3ea1a279-cf99-4ed4-942e-1a536ddaa047" xlink:href="med-20220331.xsd#med_GovernmentAgencySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d6732dbe-d860-43b0-bdc0-7e4fdb6bc634" xlink:to="loc_med_GovernmentAgencySecuritiesMember_3ea1a279-cf99-4ed4-942e-1a536ddaa047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bbfd1200-99fa-4767-bd1f-3c5f15ce247f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:to="loc_us-gaap_InvestmentTypeAxis_bbfd1200-99fa-4767-bd1f-3c5f15ce247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_9daba5b1-6d47-438f-a510-8af3a6798b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_bbfd1200-99fa-4767-bd1f-3c5f15ce247f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_9daba5b1-6d47-438f-a510-8af3a6798b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_8fb9c60b-ec38-4f12-98bc-855771ca7c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_9daba5b1-6d47-438f-a510-8af3a6798b19" xlink:to="loc_us-gaap_MunicipalBondsMember_8fb9c60b-ec38-4f12-98bc-855771ca7c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:href="med-20220331.xsd#med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesTable_d70cad20-6594-4772-a92c-072f6b0d9032" xlink:to="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_baaa9204-c87a-4946-a77a-576eefcfd7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_MarketableSecurities_baaa9204-c87a-4946-a77a-576eefcfd7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_cbedaf12-35e3-4044-ab14-341e98ba1f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_cbedaf12-35e3-4044-ab14-341e98ba1f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_ed454225-fd0a-4093-9d0d-64e4fae9c9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_InterestReceivable_ed454225-fd0a-4093-9d0d-64e4fae9c9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_17c49ea6-6318-4dbb-bfb9-054224b4c771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_17c49ea6-6318-4dbb-bfb9-054224b4c771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b5c22e9e-41bd-433a-88b3-fbc80ca8168b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b5c22e9e-41bd-433a-88b3-fbc80ca8168b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_0129489d-eea2-4e7f-8726-7d01ddd676c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems_dcac56b3-bfb2-4e5d-8855-4728295adb48" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_0129489d-eea2-4e7f-8726-7d01ddd676c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/DEBT" xlink:type="simple" xlink:href="med-20220331.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b5c8d844-50af-45b5-8a97-762e4dee4ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_fb8fad27-ddab-4203-96a3-f74cd768ad2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b5c8d844-50af-45b5-8a97-762e4dee4ebc" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_fb8fad27-ddab-4203-96a3-f74cd768ad2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.medifast1.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="med-20220331.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bfb8f7f1-d78b-48ff-8ab9-edf31ad0e106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bfb8f7f1-d78b-48ff-8ab9-edf31ad0e106" xlink:to="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_060d3ef3-23cd-49bd-8d06-48f5ac3aaf77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:to="loc_srt_RangeAxis_060d3ef3-23cd-49bd-8d06-48f5ac3aaf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a7291eb-7727-4eb6-befb-b572e64a867b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_060d3ef3-23cd-49bd-8d06-48f5ac3aaf77" xlink:to="loc_srt_RangeMember_6a7291eb-7727-4eb6-befb-b572e64a867b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6bf6fabe-114d-40d4-a11a-996022b818a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a7291eb-7727-4eb6-befb-b572e64a867b" xlink:to="loc_srt_MinimumMember_6bf6fabe-114d-40d4-a11a-996022b818a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8cc70545-25c8-4c74-9dea-e538d273ee21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a7291eb-7727-4eb6-befb-b572e64a867b" xlink:to="loc_srt_MaximumMember_8cc70545-25c8-4c74-9dea-e538d273ee21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a56ab865-87c4-46da-9196-84ff27c71528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:to="loc_us-gaap_DebtInstrumentAxis_a56ab865-87c4-46da-9196-84ff27c71528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8ba1f88-dc23-4d65-88b0-3863a5923d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a56ab865-87c4-46da-9196-84ff27c71528" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8ba1f88-dc23-4d65-88b0-3863a5923d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_CreditAgreementMember_ae7b37f4-fe60-4d06-bfff-e6d88ef9328d" xlink:href="med-20220331.xsd#med_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b8ba1f88-dc23-4d65-88b0-3863a5923d71" xlink:to="loc_med_CreditAgreementMember_ae7b37f4-fe60-4d06-bfff-e6d88ef9328d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_bc7dad79-44bf-4445-8e88-461194e5edf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:to="loc_us-gaap_CreditFacilityAxis_bc7dad79-44bf-4445-8e88-461194e5edf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_38f9edd5-ea02-4249-a425-806543939a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_bc7dad79-44bf-4445-8e88-461194e5edf3" xlink:to="loc_us-gaap_CreditFacilityDomain_38f9edd5-ea02-4249-a425-806543939a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_55b11f6c-f00e-4dcb-8594-d7ed8498be18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_38f9edd5-ea02-4249-a425-806543939a68" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_55b11f6c-f00e-4dcb-8594-d7ed8498be18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_2a51b43a-10cb-48f9-9868-8593a5d1a6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_55b11f6c-f00e-4dcb-8594-d7ed8498be18" xlink:to="loc_us-gaap_LetterOfCreditMember_2a51b43a-10cb-48f9-9868-8593a5d1a6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_UncommittedIncrementalFacilityMember_23a69496-ae33-4d5b-9ce5-d66d0fa0884d" xlink:href="med-20220331.xsd#med_UncommittedIncrementalFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_55b11f6c-f00e-4dcb-8594-d7ed8498be18" xlink:to="loc_med_UncommittedIncrementalFacilityMember_23a69496-ae33-4d5b-9ce5-d66d0fa0884d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2b21d0c4-395c-4f53-8298-b8c4b87ac5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:to="loc_us-gaap_VariableRateAxis_2b21d0c4-395c-4f53-8298-b8c4b87ac5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_17486884-0c38-4f39-a520-079bc5b4717e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_2b21d0c4-395c-4f53-8298-b8c4b87ac5d4" xlink:to="loc_us-gaap_VariableRateDomain_17486884-0c38-4f39-a520-079bc5b4717e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_a9018b78-f4e2-4944-8b4c-7acbbc265abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_17486884-0c38-4f39-a520-079bc5b4717e" xlink:to="loc_us-gaap_EurodollarMember_a9018b78-f4e2-4944-8b4c-7acbbc265abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_70acdd47-0427-4035-b9dc-297909b09343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_17486884-0c38-4f39-a520-079bc5b4717e" xlink:to="loc_us-gaap_BaseRateMember_70acdd47-0427-4035-b9dc-297909b09343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_93529b7f-1780-4a89-82d1-bf8521ea0c7b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e822101c-4a46-46d1-ac70-3c2bd51a3739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e822101c-4a46-46d1-ac70-3c2bd51a3739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_15470973-54a5-4c79-817c-88a2adcb7c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_15470973-54a5-4c79-817c-88a2adcb7c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba0626c3-baed-4046-ac60-7cbf5848bb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba0626c3-baed-4046-ac60-7cbf5848bb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_MaximumTotalNetLeverageRatio_ff1720ed-cc42-41ae-a6bf-0443293e8d79" xlink:href="med-20220331.xsd#med_MaximumTotalNetLeverageRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_med_MaximumTotalNetLeverageRatio_ff1720ed-cc42-41ae-a6bf-0443293e8d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_med_MinimumInterestCoverageRatio_f4f359fd-66c3-4ea5-bcaf-05cc1377abd6" xlink:href="med-20220331.xsd#med_MinimumInterestCoverageRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_med_MinimumInterestCoverageRatio_f4f359fd-66c3-4ea5-bcaf-05cc1377abd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1be4162e-3552-431c-b48f-bd562848973f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f70c4023-64db-4e46-8536-700beff8ecbf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1be4162e-3552-431c-b48f-bd562848973f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820097806968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Medifast, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3714405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 International Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Baltimore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">581-8042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,513,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000910329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820097816136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 417,600<span></span>
</td>
<td class="nump">$ 340,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">115,314<span></span>
</td>
<td class="nump">92,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">302,286<span></span>
</td>
<td class="nump">248,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">247,199<span></span>
</td>
<td class="nump">195,748<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">55,087<span></span>
</td>
<td class="nump">52,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense) income</a></td>
<td class="num">(95)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(111)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from operations before income taxes</a></td>
<td class="nump">54,976<span></span>
</td>
<td class="nump">52,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">13,195<span></span>
</td>
<td class="nump">11,778<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 41,781<span></span>
</td>
<td class="nump">$ 41,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share - basic (in dollars per share)</a></td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">11,557<span></span>
</td>
<td class="nump">11,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">11,638<span></span>
</td>
<td class="nump">11,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per share (in dollars per share)</a></td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="nump">$ 1.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820103171560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 41,781<span></span>
</td>
<td class="nump">$ 41,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized losses on investment securities</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 41,797<span></span>
</td>
<td class="nump">$ 41,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820097815496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 118,003<span></span>
</td>
<td class="nump">$ 104,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">188,972<span></span>
</td>
<td class="nump">180,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investment securities</a></td>
<td class="nump">4,057<span></span>
</td>
<td class="nump">5,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Income taxes, prepaid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">13,227<span></span>
</td>
<td class="nump">16,334<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">324,259<span></span>
</td>
<td class="nump">306,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment - net of accumulated depreciation</a></td>
<td class="nump">57,804<span></span>
</td>
<td class="nump">56,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">22,942<span></span>
</td>
<td class="nump">24,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">12,026<span></span>
</td>
<td class="nump">6,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">4,404<span></span>
</td>
<td class="nump">4,404<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">421,435<span></span>
</td>
<td class="nump">398,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">174,369<span></span>
</td>
<td class="nump">163,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease obligations</a></td>
<td class="nump">6,663<span></span>
</td>
<td class="nump">6,523<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">181,032<span></span>
</td>
<td class="nump">169,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations, net of current lease obligations</a></td>
<td class="nump">24,379<span></span>
</td>
<td class="nump">26,020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">205,411<span></span>
</td>
<td class="nump">195,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $.001 per share: 20,000 shares authorized; 11,594 and 11,594 issued and 11,593 and 11,593 outstanding at March&#160;31, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">12,834<span></span>
</td>
<td class="nump">12,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">203,051<span></span>
</td>
<td class="nump">190,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">216,024<span></span>
</td>
<td class="nump">202,474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 421,435<span></span>
</td>
<td class="nump">$ 398,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820103057240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">11,553<span></span>
</td>
<td class="nump">11,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">11,552<span></span>
</td>
<td class="nump">11,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820097861368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 41,781<span></span>
</td>
<td class="nump">$ 41,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to cash provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,444<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_OperatingLeaseExpenseNonCash', window );">Non-cash lease expense</a></td>
<td class="nump">1,619<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">2,275<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_AmortizationOfPremiumOnInvestmentSecurities', window );">Amortization of premium on investment securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(8,929)<span></span>
</td>
<td class="num">(8,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidTaxes', window );">Income taxes, prepaid</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,107<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(6,632)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">7,052<span></span>
</td>
<td class="nump">29,202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by operating activities</a></td>
<td class="nump">43,673<span></span>
</td>
<td class="nump">65,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Sale and maturities of investment securities</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">3,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(3,009)<span></span>
</td>
<td class="num">(4,598)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow used in investing activities</a></td>
<td class="num">(1,764)<span></span>
</td>
<td class="num">(878)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Options exercised by executives and directors</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfOtherEquity', window );">Net shares repurchased for taxes</a></td>
<td class="num">(1,459)<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Cash dividends paid to stockholders</a></td>
<td class="num">(16,660)<span></span>
</td>
<td class="num">(13,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Stock repurchases</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow used in financing activities</a></td>
<td class="num">(28,119)<span></span>
</td>
<td class="num">(22,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Foreign currency impact</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash and cash equivalents</a></td>
<td class="nump">13,820<span></span>
</td>
<td class="nump">42,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of the period</a></td>
<td class="nump">104,183<span></span>
</td>
<td class="nump">163,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">118,003<span></span>
</td>
<td class="nump">206,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends declared included in accounts payable</a></td>
<td class="nump">$ 19,663<span></span>
</td>
<td class="nump">$ 17,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_med_AmortizationOfPremiumOnInvestmentSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense charged against amortization of premium on investment securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">med_AmortizationOfPremiumOnInvestmentSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>med_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_med_OperatingLeaseExpenseNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Expense, Non-Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">med_OperatingLeaseExpenseNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>med_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to reacquire equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820097451688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,822,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 157,246<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 7,842<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 154,351<span></span>
</td>
<td class="num">$ (5,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">41,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Share-based compensation</a></td>
<td class="nump">2,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised by executives and directors (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised by executives and directors</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net shares repurchased for employee taxes (in shares)</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net shares repurchased for taxes</a></td>
<td class="num">$ (1,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock from stock repurchases</a></td>
<td class="num">(7,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared to stockholders</a></td>
<td class="num">(16,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">174,891<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">8,714<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">178,562<span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">202,474<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">12,018<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">190,333<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">41,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Share-based compensation</a></td>
<td class="nump">$ 2,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net shares repurchased for employee taxes (in shares)</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net shares repurchased for taxes</a></td>
<td class="num">$ (1,459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock from stock repurchases</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Treasury stock retire from stock repurchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Treasury stock retired from stock repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared to stockholders</a></td>
<td class="num">(19,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,553,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 216,024<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12,834<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 203,051<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101728552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (&#8220;Medifast,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from the audited consolidated financial statements at that date included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 (&#8220;2021 Form 10-K&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2022 are not necessarily indicative of results that may be expected for the fiscal year ending December&#160;31, 2022. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the 2021 audited consolidated financial statements and notes thereto, which are included in the 2021 Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Presentation of Financial Statements -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the condensed consolidated financial statements had a material impact on the presentation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Adopted in 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span>, which provides optional guidance for a limited time to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying accounting principles under GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met and to other derivative instruments if there is a change to the interest rates used for discounting, margining or contract price alignment. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. We adopted Topic 848 beginning in the first quarter of fiscal 2022 without any material impact on the Company's financial position and results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101727112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIESInventories consist principally of raw materials, non-food finished goods and packaged meal replacements held in the Company&#8217;s warehouses and outsourced distribution centers. Inventories are stated at the lower of cost or net realizable value, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventories for unsalable or obsolete inventories.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:56.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.450%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,340</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,196</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Packaging</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,640</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,641</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-food finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13,316</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,991</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">161,698</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">152,687</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Reserve for obsolete inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(5,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(7,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">188,972</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">180,043</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101900376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text">EARNINGS PER SHARE<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) computations are calculated utilizing the weighted average number of shares of the Company&#8217;s common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of the Company&#8217;s common stock outstanding adjusted for the effect of dilutive common stock equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:55.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.398%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Effect of dilutive common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.46&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The calculation of diluted EPS excluded 44 and 267 antidilutive restricted stock awards for the three months ended March 31, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101843128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified and incentive stock options to employees and non-employee directors. The fair value of these options are estimated on the date of grant using the Black-Scholes option pricing model, which requires estimates of the expected term of the option, the risk-free interest rate, the expected volatility of the price of the Company&#8217;s common stock, and dividend yield. Options outstanding as of March&#160;31, 2022 generally vest over a period of three years and expire ten years from the date of grant. The exercise price of these options ranges from $26.52 to $66.68. Due to the Company&#8217;s lack of option exercise history on the date of grant, the expected term is calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each option. The risk free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant that most closely corresponds to the expected term of the option. The expected volatility is based on the historical volatility of the Company&#8217;s common stock over the period of time equivalent to the expected </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term for each award. The dividend yield is computed as the annualized dividend rate at the grant date divided by the strike price of the stock option. For the three months ended March 31, 2022 and 2021, the Company did not grant stock options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of our stock option activity (in thousands, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:29.481%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.934%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at end of the period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the weighted-average remaining contractual life for outstanding stock options was 5.1 years with an aggregate intrinsic value of $3.8 million and the weighted-average remaining contractual life for exercisable stock options was 4.9 years with an aggregate intrinsic value of $3.3 million. The unrecognized compensation expense calculated under the fair value method for stock options expected to vest as of March&#160;31, 2022 was $0.1 million and is expected to be recognized over a weighted-average period of 0.9 year. For the three months ended March 31, 2022, there was no exercise activity of stock options. For the three months ended March 31, 2021, the Company received $0.5 million in cash proceeds from the exercise of stock options. The total intrinsic value for stock options exercised during the three months ended March 31, 2021 was $2.3 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued restricted stock to employees and non-employee directors generally with vesting terms up to five years after the date of grant. The fair value of the restricted stock is equal to the market price of the Company&#8217;s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our restricted stock activity (in thousands, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:29.918%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at end of the period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157.80&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company withheld approximately 8,000 and 7,000 shares of the Company&#8217;s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of restricted stock for the three months ended March 31, 2022 and 2021, respectively. The total fair value of restricted stock awards vested during the three months ended March 31, 2022 and 2021 was $3.2 million and $3.9 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market and Performance-based Share Awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued market and performance-based share awards to certain key executives who were granted deferred shares and may earn between 0% and 250% of the target number depending upon both the Company's total stockholder return and the Company's performance against predetermined performance goals over a three-year performance period after the date of grant. Market and performance-based share awards that are tied to the Company&#8217;s total stockholder return are valued using the Monte Carlo method and are recognized ratably as expense over the award&#8217;s performance period. The fair value of the performance-based share awards is equal to the market price of the Company&#8217;s common stock on the date of grant adjusted by </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected level of achievement over the performance period. Expense for performance-based share awards is amortized ratably over the performance period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is recorded in selling, general, and administrative expense in the accompanying Condensed Consolidated Statements of Income. The total expenses during the three months ended March 31, 2022 and 2021 are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Share-Based Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Share-Based Compensation Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options and restricted stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total income tax benefit recognized in the accompanying Condensed Consolidated Statements of Income for restricted stock awards was $0.5 million and $1.2 million for the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $8.8 million of total unrecognized compensation cost related to restricted stock awards as of March&#160;31, 2022, which is expected to be recognized over a weighted-average period of 2.4 years. There was $11.0 million of unrecognized compensation costs related to the 66,000 performance-based shares discussed above as of March&#160;31, 2022, which is expected to be recognized over a weighted-average period of 2.1 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101900376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office and warehouse space and certain equipment. In certain of the Company&#8217;s lease agreements, the rental payments are adjusted periodically based on defined terms within the lease. The Company did not have any finance leases as of March&#160;31, 2022 and 2021, respectively, or for the three-month periods then ended, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases relating to office and warehouse space have lease terms of 18 months to 126 months. Our leases relating to equipment have lease terms of 24 months to 203 months, with certain of them having automatic renewal clauses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s warehouse agreements also contain non-lease components, in the form of payments towards variable logistics services and labor charges, which the Company is obligated to pay based on the services consumed by it. Such amounts are not included in the measurement of the lease liability but are recognized as expenses when they are incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease expense was $1.8 million and $1.0 million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:63.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurements of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating cash flow used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the weighted average remaining lease term was 5.3 years and the weighted average discount rate was  2.1%.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturity of the Company&#8217;s operating lease liabilities as of March&#160;31, 2022 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:81.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,042&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101717176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE INCOME<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE INCOME</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE INCOME<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:64.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.138%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized gains on investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101724232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">FINANCIAL INSTRUMENTS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211; Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211; Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211; Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management&#8217;s best estimate of fair value from the perspective of a market participant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investment<br/>Securities</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,062&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,075&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investment<br/>Securities</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,772&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no realized losses or gains for the three months ended March 31, 2022 and 2021, respectively. As of March&#160;31, 2022, the maturities of the Company&#8217;s investment securities were less than one year for all the municipal bonds, and government and agency securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101881416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;13, 2021, the Company and certain of its subsidiaries (collectively, the &#8220;Guarantors&#8221;) entered into a credit agreement (the &#8220;Credit Agreement&#8221;) among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative agent. The Credit Agreement provides for a $125.0 million senior secured revolving credit facility with a $20.0 million letter of credit sub-limit. The Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $100.0 million. The Credit Agreement matures on April&#160;13, 2026.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Credit Agreement are guaranteed by the Guarantors. The obligations of the Company and the Guarantors are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Credit Agreement, the Company will pay to the administrative agent for the account of each revolving lender a commitment fee on a quarterly basis based on amounts committed but unused under the revolving facility from 0.20% to 0.40% per annum depending on the Company&#8217;s Total Net Leverage Ratio (as defined in the Credit Agreement). The Company is also obligated to pay the administrative agent customary fees for credit facilities of this size and type.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving borrowings under the Credit Agreement bear interest at a rate per annum equal to (i) the Adjusted LIBOR Rate for the interest period plus the Applicable Rate (as defined in the Credit Agreement) based on the Company&#8217;s Total Net Leverage Ratio (with customary provisions under the Credit Agreement providing for the replacement of LIBOR with a successor rate) or (ii) the Alternate Base Rate (as defined in the Credit Agreement) as in effect from time to time plus the Applicable Rate based on the Company&#8217;s Total Net Leverage Ratio. As of March&#160;31, 2022, the Applicable Rate for Eurodollar Loans is 1.25% per annum and the Applicable Rate for ABR Loans is 0.25% per annum.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Company and its subsidiaries, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments and change the nature of their businesses. The Credit Agreement also contains customary events of default, subject to thresholds and grace periods, including, among others, payment default, covenant default, cross default to other material indebtedness and judgment default. In addition, the Credit Agreement requires the Company to maintain a Total Net Leverage Ratio of no more than 3.00 to 1.00 and an Interest Coverage Ratio of at least 3.50 to 1.00.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no borrowings under the Credit Agreement as of March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820097765880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (&#8220;Medifast,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from the audited consolidated financial statements at that date included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 (&#8220;2021 Form 10-K&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2022 are not necessarily indicative of results that may be expected for the fiscal year ending December&#160;31, 2022. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the 2021 audited consolidated financial statements and notes thereto, which are included in the 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Presentation of Financial Statements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Presentation of Financial Statements -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the condensed consolidated financial statements had a material impact on the presentation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements Adopted in 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span>, which provides optional guidance for a limited time to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying accounting principles under GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met and to other derivative instruments if there is a change to the interest rates used for discounting, margining or contract price alignment. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. We adopted Topic 848 beginning in the first quarter of fiscal 2022 without any material impact on the Company's financial position and results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820103214264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:56.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.450%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,340</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,196</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Packaging</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,640</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,641</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-food finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13,316</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,991</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">161,698</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">152,687</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Reserve for obsolete inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(5,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(7,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">188,972</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">180,043</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101724952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the Table Sets Forth the Computation of Basic and Diluted EPS</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:55.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.398%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Effect of dilutive common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.46&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101914824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of our stock option activity (in thousands, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:29.481%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.411%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.934%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at end of the period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our restricted stock activity (in thousands, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:29.918%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at end of the period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157.80&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award</a></td>
<td class="text">The total expenses during the three months ended March 31, 2022 and 2021 are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Share-Based Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Share-Based Compensation Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options and restricted stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820103202824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:63.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurements of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating cash flow used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturity of the Company's Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturity of the Company&#8217;s operating lease liabilities as of March&#160;31, 2022 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:81.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.415%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2022 (excluding the three months ended March&#160;31, 2022)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,042&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101684232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:64.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.138%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized gains on investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101858056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Cash and Financial Assets That are Measured at Fair Value on a Recurring Basis for Each of the Hierarchy Levels</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investment<br/>Securities</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,062&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,075&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investment<br/>Securities</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Government &amp; agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,772&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820103083208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 15,340<span></span>
</td>
<td class="nump">$ 15,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies', window );">Packaging</a></td>
<td class="nump">3,640<span></span>
</td>
<td class="nump">3,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_InventoryNonFoodFinishedGoods', window );">Non-food finished goods</a></td>
<td class="nump">13,316<span></span>
</td>
<td class="nump">15,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">161,698<span></span>
</td>
<td class="nump">152,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for obsolete inventory</a></td>
<td class="num">(5,022)<span></span>
</td>
<td class="num">(7,472)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 188,972<span></span>
</td>
<td class="nump">$ 180,043<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_med_InventoryNonFoodFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before last-in first-out (LIFO) and valuation reserves of (Non-food) merchandise or goods held by the entity that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">med_InventoryNonFoodFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>med_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of items used in storage, presentation or transportation of physical goods that are targeted for sale to end users.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820103114568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 41,781<span></span>
</td>
<td class="nump">$ 41,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding (in shares)</a></td>
<td class="nump">11,557,000<span></span>
</td>
<td class="nump">11,772,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive common stock equivalents (in shares)</a></td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding (in shares)</a></td>
<td class="nump">11,638,000<span></span>
</td>
<td class="nump">11,881,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share - basic (in dollars per share)</a></td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_med_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">med_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>med_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_med_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">med_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>med_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820101771560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive awards</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820097478504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based compensation arrangement by share-based payment award, options, grants in period, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld for employee taxes</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost recognition weighted average period</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-based compensation arrangement, fair value of awards vested</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted in period</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Total income tax benefit recognized related to restricted stock awards</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-based compensation, shares authorized under stock option plans, exercise price range, lower range limit</a></td>
<td class="nump">$ 26.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-based compensation, shares authorized under stock option plans, exercise price range, upper range limit</a></td>
<td class="nump">$ 66.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life of options outstanding</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life of options exercisable</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share based compensation nonvested awards total compensation cost not yet recognized</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost recognition weighted average period</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost recognition weighted average period</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted in period</a></td>
<td class="nump">66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820103086216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Options Activity (Details) - Stock Options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding at beginning of period (in shares)</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding at end of the period (in shares)</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable at end of the period (in shares)</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 54.98<span></span>
</td>
<td class="nump">$ 48.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding at end of the period (in dollars per share)</a></td>
<td class="nump">54.98<span></span>
</td>
<td class="nump">49.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable at end of the period (in dollars per share)</a></td>
<td class="nump">$ 52.76<span></span>
</td>
<td class="nump">$ 44.93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820094528728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 183.51<span></span>
</td>
<td class="nump">$ 116.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">175.66<span></span>
</td>
<td class="nump">253.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">149.95<span></span>
</td>
<td class="nump">109.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">$ 190.20<span></span>
</td>
<td class="nump">$ 157.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820097501896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options and restricted stock (in shares)</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 2,275<span></span>
</td>
<td class="nump">$ 2,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=med_OptionsAndRestrictedStockMember', window );">Options And Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options and restricted stock (in shares)</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 1,087<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Granted In 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options and restricted stock (in shares)</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Granted In 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options and restricted stock (in shares)</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Granted In 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options and restricted stock (in shares)</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 469<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Granted In 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options and restricted stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=med_OptionsAndRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=med_OptionsAndRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=med_GrantedIn2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=med_GrantedIn2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=med_GrantedIn2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=med_GrantedIn2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=med_GrantedIn2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=med_GrantedIn2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=med_GrantedIn2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=med_GrantedIn2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820094546792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Operating Lease Arrangement for Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Operating Lease Arrangement for Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Operating Lease Arrangement for Real Estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">126 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Operating Lease Arrangement for Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">203 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=med_OperatingLeaseArrangementForRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=med_OperatingLeaseArrangementForRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=med_OperatingLeaseArrangementForEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=med_OperatingLeaseArrangementForEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820094422776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurements of lease liabilities - Operating cash flow used in operating leases</a></td>
<td class="nump">$ 1,756<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations - Operating leases</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820103137672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Future Minimum Lease Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (excluding the three months ended March&#160;31, 2022)</a></td>
<td class="nump">$ 5,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">6,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">5,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">5,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">4,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">32,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,733)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 31,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due Year Five And After Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>med_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820096398600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE INCOME - Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains on investment securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820102643416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss', window );">Realized loss or gains</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820099178392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Cash and Financial Assets That are Measured at Fair Value on a Recurring Basis for Each of the Hierarchy Levels (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash And Cash Equivalents And Marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Cost</a></td>
<td class="nump">$ 122,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued Interest</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">122,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">118,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment Securities</a></td>
<td class="nump">4,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash And Cash Equivalents And Marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Cost</a></td>
<td class="nump">107,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">107,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">107,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash And Cash Equivalents And Marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Cost</a></td>
<td class="nump">12,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued Interest</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">12,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">10,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment Securities</a></td>
<td class="nump">1,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1: | Money market accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash And Cash Equivalents And Marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Cost</a></td>
<td class="nump">10,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">10,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">10,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1: | Government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash And Cash Equivalents And Marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Cost</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued Interest</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">1,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment Securities</a></td>
<td class="nump">1,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2: | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash And Cash Equivalents And Marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Cost</a></td>
<td class="nump">2,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued Interest</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">2,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment Securities</a></td>
<td class="nump">$ 2,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>med_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5D<br> -Subparagraph (SX 210.12-13D(Column C))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=SL120429264-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=med_GovernmentAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=med_GovernmentAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139820094484456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Narrative (Details) - Credit Agreement<br></strong></div></th>
<th class="th">
<div>Apr. 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_MaximumTotalNetLeverageRatio', window );">Maximum Total Net Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_med_MinimumInterestCoverageRatio', window );">Minimum Interest Coverage Ratio</a></td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=med_CreditAgreementMember', window );">Eurodollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Applicable Rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=med_CreditAgreementMember', window );">Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Applicable Rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=med_CreditAgreementMember', window );">Senior Secured Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility maximum borrowing capacity</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=med_CreditAgreementMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility maximum borrowing capacity</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=med_CreditAgreementMember', window );">Uncommitted Incremental Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility maximum borrowing capacity</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_med_MaximumTotalNetLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum ratio as of any date, of (a) Total Net Funded Indebtedness on such date to (b) Consolidated EBITDA for the Reference Period ended on such date under credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">med_MaximumTotalNetLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>med_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_med_MinimumInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Interest Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">med_MinimumInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>med_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=med_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=med_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=med_UncommittedIncrementalFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=med_UncommittedIncrementalFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>med-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:med="http://www.medifast1.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="med-20220331.xsd" xlink:type="simple"/>
    <context id="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6e537e172aa24299ab41085f17256d35_I20220425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="i3de035571620420bb741ec985a844201_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i82c8748a0dca4006b1fc0390e3411793_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic92fe6c57a504e2dbbad3803d0be8e31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a9e8a7828aa4da5bce1881ad3c595da_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i27de280f347a42329dd3679897047b8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ec04f01121844a2a66d23c8da8a89bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib222e481175248a4bef2b9ea56746606_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if06713cb95b949a49641dbf1aa583e7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5fd06983c614bf0a83447b06a1785d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa03549ad0aa4903a08e29e78ed12366_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib5d670baf3e44e3eb7b81105877274fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie692dfbd3ece4eac8ee8cdea802b204e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ea0b38550ff4a6db4e7c2f402dd7f1d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i497f48ef092c4f08a729248571d78cb2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i52f07595224e43ba81c8686f0fa8a13a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4629aa81a2fc409b96bd6ec6da4b9822_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibefafab12e4a4838bfdac00e2c56ea5f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i39886d8f6ad44174b5479a2615523738_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie2a9b2a18a7b4e56ab717cb5e1d08b9d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5f1f4b37e28c44289b679e4cf804f107_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ab9310916204a50b1fb226d4d9ed1ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2724646ee9f747a9b9f3dc65301854ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if88269ad30744ca48e26fa63c42b1e63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1426349a333471bb4ed8e3f0ea276ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb60d524f67d49a7a0c81ec19020ec38_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibf7bc84211b14477af22b912ebaf38e6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie967876d049142cfbde149fe84c69778_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if25fc543e5b44b6490ed11b7fda2ada2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ide80a5cd921c4800b5bfab2a45d02323_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icf170ac1a1024a05892c136030ccc3d3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia47fc4a92db64d20830468f635bbde08_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8e02779182f94724b5916bd946bfe720_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3d2306fe85c8431f9cf6ad772507e0c7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i79e50c2945b94470bc8362df60bf8e6d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4a53f9a4936845ba8bdfa229ddc8998c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id3d0f3fdadff47b4afb4b4e30c9150cd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie2bb291e995d4d86b1e75f18f4e74ee5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c217599ebec4b3589ddacf77b65907d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2b6de404d154f3f8c233c0224e3b3e7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if341a78362b04aefa35a1524227f0dcc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2b3ce0080ee84b2f978c642e022afcc3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6b9de190e3684b94a74889bd8f6df7f4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic66942bf9f2549b198eead688af58b58_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie622384d50f24bd79471044dac2a7bff_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9500da6417d34000ac404737b417d8bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9a78198c05df4b5a8deb5385b586ffe7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec6e288c739f42379b23b2ef8e67c86d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8da58c43207b48f6a1b9e434f1ac7154_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i725856e7f4ec432cacc3baf8010f0fe5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i11d54eafa8284f25ac3bd19cff7f6312_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">med:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i709a3e52837649cbbf38c0e95f31cc71_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">med:OptionsAndRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if7869becf472402087fb85cd424874b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i21d3b43d4638447b812e122f37bd7ad9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5c4d1405e900437a8c01cb40906f7245_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie07a6fa52afa4a8a8e828f7b91d96c7b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id6500946c2204f099dd45b758d12ef35_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifd4d70137b9f4805a994076e0d6ab3c9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9dd3cc3169134d66a71696dd84d37aa2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a672405cc1c46b1ab2da765c6d7a422_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">med:GrantedIn2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifb1830bc344d452b941276a1a72aeebc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icd9ad4c02af44a4c8285da667d06c96c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id40d4dcdbd49490291af588086ec5521_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">med:OperatingLeaseArrangementForRealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0c29fd8c68674ff7803a9bee93d6d42a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">med:OperatingLeaseArrangementForRealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia1c011b39e09482b9d155a886f684109_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">med:OperatingLeaseArrangementForEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie77f1726dab04431a3971d0a6973047b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">med:OperatingLeaseArrangementForEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6f1737eb3fa34225b424226bad5f803d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibe8f508f43e54111833213da6455af89_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6407fc628f864d3fa3ae6e4aac9245af_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">med:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icaa9fb09240445bf98fca5702ebfec16_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">med:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8513597370b84626bfb13b09cf0983ee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i653038e869054618added697946df31b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64a5e80f0c594a478bfaeab9d9c75376_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ief468fba41754dcfb701ff282f1d7886_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i974db996e18c46f18311cfb1651cd09d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i235c14ce303349c8b5bd8fb87f69b715_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife377ae99f2f433eb0a7cf0a05c6b0dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">med:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia79de0bb84114512b113cea98756e693_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">med:GovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc62a0c317534ee789386d9dc17785ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ce626a32c3a44f081b4594e23a21964_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7de4c2e8202f4fccbc696b8231685861_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib61ff22c30ce4b0caf4653ce9e1255e2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia68ebc6c33294b0189b4af137724ab7b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic11da4d8ef7f495db6691f1262fb8e0c_I20210413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-13</instant>
        </period>
    </context>
    <context id="if64b680e548d49b194bcae4857dedc09_I20210413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-13</instant>
        </period>
    </context>
    <context id="icef01955e8974f7697be299053de3a2f_I20210413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">med:UncommittedIncrementalFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-13</instant>
        </period>
    </context>
    <context id="i3fb986de689d4becaae458587ee9b2fd_D20210413-20210413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-13</startDate>
            <endDate>2021-04-13</endDate>
        </period>
    </context>
    <context id="i450c071fc9504d04b9fc30de60ec4480_D20210413-20210413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-13</startDate>
            <endDate>2021-04-13</endDate>
        </period>
    </context>
    <context id="i9c2bfdfda3ad4daa9fd8c347153a8690_D20210413-20210413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-13</startDate>
            <endDate>2021-04-13</endDate>
        </period>
    </context>
    <context id="i45f88c0342b14d22baf0e44c2b6dbf25_D20210413-20210413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-13</startDate>
            <endDate>2021-04-13</endDate>
        </period>
    </context>
    <context id="if5ac0c800edb46e5a7552707f96539fb_I20210413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-13</instant>
        </period>
    </context>
    <context id="i57d6fd02196e4a488975ef3607163df9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">med:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80L2ZyYWc6NDljYjg2MWYwZmNhNDllYmEzZjg2ZjNiMTkyMmEyM2MvdGFibGU6MWZjODNkNzI2NTM3NDk2ZWFmZDlhNTcwODMyNTNkY2UvdGFibGVyYW5nZToxZmM4M2Q3MjY1Mzc0OTZlYWZkOWE1NzA4MzI1M2RjZV8yNi0xLTEtMS00ODg_640388b1-19bd-420f-8499-ca50d432d6aa">0000910329</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80L2ZyYWc6NDljYjg2MWYwZmNhNDllYmEzZjg2ZjNiMTkyMmEyM2MvdGFibGU6MWZjODNkNzI2NTM3NDk2ZWFmZDlhNTcwODMyNTNkY2UvdGFibGVyYW5nZToxZmM4M2Q3MjY1Mzc0OTZlYWZkOWE1NzA4MzI1M2RjZV8yNy0xLTEtMS00ODg_a2c931e0-59af-4f69-bb27-a7545a2387fc">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80L2ZyYWc6NDljYjg2MWYwZmNhNDllYmEzZjg2ZjNiMTkyMmEyM2MvdGFibGU6MWZjODNkNzI2NTM3NDk2ZWFmZDlhNTcwODMyNTNkY2UvdGFibGVyYW5nZToxZmM4M2Q3MjY1Mzc0OTZlYWZkOWE1NzA4MzI1M2RjZV8yOC0xLTEtMS00ODg_0f686f11-115a-4fc3-87a4-f5ea427a97e4">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80L2ZyYWc6NDljYjg2MWYwZmNhNDllYmEzZjg2ZjNiMTkyMmEyM2MvdGFibGU6MWZjODNkNzI2NTM3NDk2ZWFmZDlhNTcwODMyNTNkY2UvdGFibGVyYW5nZToxZmM4M2Q3MjY1Mzc0OTZlYWZkOWE1NzA4MzI1M2RjZV8yOS0xLTEtMS00ODg_0f6c1937-8114-4a21-9977-09e04abe61df">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80L2ZyYWc6NDljYjg2MWYwZmNhNDllYmEzZjg2ZjNiMTkyMmEyM2MvdGFibGU6MWZjODNkNzI2NTM3NDk2ZWFmZDlhNTcwODMyNTNkY2UvdGFibGVyYW5nZToxZmM4M2Q3MjY1Mzc0OTZlYWZkOWE1NzA4MzI1M2RjZV8zMC0xLTEtMS00ODg_d862e4b4-0758-456b-8749-8e8ec9e25cf6">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzM2_db1edae4-0542-4531-8b4d-d3a4edfc646a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzMy_2e7034d1-a947-41f3-a847-06fbd0adb9e8">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF82MDQ3MzEzOTU1MTU0_268b4bb8-9bfa-432a-8449-abce7b0cfee8">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzI4_9e961826-445e-4354-b481-eb81c6e0fc7c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzI1_86795076-931c-4fe3-aea6-30ed6c10dd3e">001-31573</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzI2_297c6fa4-b2f1-4cd8-9b20-3c0ca1cd70f2">Medifast, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6ODgxMWVjNmY1MWJlNDdkZWE3YTAxMGUwM2Q3NWVkNDgvdGFibGVyYW5nZTo4ODExZWM2ZjUxYmU0N2RlYTdhMDEwZTAzZDc1ZWQ0OF8wLTAtMS0xLTQ4OA_a1abcf96-7ace-4657-aefa-2a51708c0b4e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6ODgxMWVjNmY1MWJlNDdkZWE3YTAxMGUwM2Q3NWVkNDgvdGFibGVyYW5nZTo4ODExZWM2ZjUxYmU0N2RlYTdhMDEwZTAzZDc1ZWQ0OF8wLTItMS0xLTQ4OA_41998647-6d89-4846-9ab7-bc462d9d3192">13-3714405</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzMz_69e446b8-7abc-4dc7-a272-b8a3374743dd">100 International Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzI5_afd6a4b2-55be-4d67-9528-2333f0e914a7">Baltimore</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzI3_b11cafff-0aba-4dce-944d-bcd7c2d56a85">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzM3_248e95c7-639f-4194-a9a8-3cea56aec107">21202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzM4_7e0f08c6-28bd-4be3-94f9-6109ae6e70e5">410</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzM5_c39b8354-31c2-4334-a37c-a270f1a93235">581-8042</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6YTNmN2M4MGYzOWM5NDk3MmJkMzFjZDQ4MTkxYmU4NDkvdGFibGVyYW5nZTphM2Y3YzgwZjM5Yzk0OTcyYmQzMWNkNDgxOTFiZTg0OV8xLTAtMS0xLTI4MDg1_1fcdd646-eb94-4da9-ab84-41396fb71014">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6YTNmN2M4MGYzOWM5NDk3MmJkMzFjZDQ4MTkxYmU4NDkvdGFibGVyYW5nZTphM2Y3YzgwZjM5Yzk0OTcyYmQzMWNkNDgxOTFiZTg0OV8xLTItMS0xLTI4MDg1_9d3582bf-a26d-4504-91f3-3dbb9a798006">MED</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6YTNmN2M4MGYzOWM5NDk3MmJkMzFjZDQ4MTkxYmU4NDkvdGFibGVyYW5nZTphM2Y3YzgwZjM5Yzk0OTcyYmQzMWNkNDgxOTFiZTg0OV8xLTQtMS0xLTI4MDg1_ef5b6693-68c7-4777-960f-73508e32c5cd">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzMw_e6138fe8-a92a-4595-97f1-66b97042e4e8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzMx_67c49a8d-e770-423a-b172-be529c1ef021">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6NmE5MzJlZTU2NzQyNDY5N2ExM2IzZTIyNmIzMTU1N2IvdGFibGVyYW5nZTo2YTkzMmVlNTY3NDI0Njk3YTEzYjNlMjI2YjMxNTU3Yl8wLTAtMS0xLTIwNzI1_dc89fef2-f40e-4030-a68a-9eea58a38aab">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6NmE5MzJlZTU2NzQyNDY5N2ExM2IzZTIyNmIzMTU1N2IvdGFibGVyYW5nZTo2YTkzMmVlNTY3NDI0Njk3YTEzYjNlMjI2YjMxNTU3Yl8xLTMtMS0xLTIyMzE2_cff34600-08e3-4760-9691-8faed833e125">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGFibGU6NmE5MzJlZTU2NzQyNDY5N2ExM2IzZTIyNmIzMTU1N2IvdGFibGVyYW5nZTo2YTkzMmVlNTY3NDI0Njk3YTEzYjNlMjI2YjMxNTU3Yl8yLTEtMS0xLTIyMzE2_1b2bef68-9784-4509-969a-4405707a1f40">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8yMzM0_0839d407-e636-480e-a4da-6f3de18ca644">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i6e537e172aa24299ab41085f17256d35_I20220425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xL2ZyYWc6ODlhZWM3YTdmZjQ5NDE2ZTlkNjI1ZmMwMmFkM2MzZDQvdGV4dHJlZ2lvbjo4OWFlYzdhN2ZmNDk0MTZlOWQ2MjVmYzAyYWQzYzNkNF8xNjQ5MjY3NDQ0MTE1_c0ae6415-d4c0-493d-a927-3e8eb13c66fa"
      unitRef="shares">11513656</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMy0xLTEtMS00ODg_344b7bf5-b4a6-41c0-8876-144620ff52e6"
      unitRef="usd">417600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMy0zLTEtMS00ODg_3afd07db-41d6-4e72-8f28-343437dae382"
      unitRef="usd">340669000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNC0xLTEtMS00ODg_ade938a3-610e-4eb4-bc8c-b0870d1613ba"
      unitRef="usd">115314000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNC0zLTEtMS00ODg_f7183791-6646-4bb1-952b-abd13191a2a5"
      unitRef="usd">92122000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNS0xLTEtMS00ODg_e0ef6118-d359-439c-8c83-31f172ccca04"
      unitRef="usd">302286000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNS0zLTEtMS00ODg_d6237054-9aa7-4b6a-bef3-119ddca32aca"
      unitRef="usd">248547000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNy0xLTEtMS00ODg_fba5e72b-6cdf-4e39-9b3b-b06fb91a6170"
      unitRef="usd">247199000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfNy0zLTEtMS00ODg_70636431-db68-49ab-b577-ee3356eff502"
      unitRef="usd">195748000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfOS0xLTEtMS00ODg_c108dd20-4131-47fd-9965-986531e8ca5b"
      unitRef="usd">55087000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfOS0zLTEtMS00ODg_787be65f-206e-4720-94f9-22b420d9b630"
      unitRef="usd">52799000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTItMS0xLTEtNDg4_100b9294-e10d-40b9-a22a-07439c60e2d9"
      unitRef="usd">-95000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTItMy0xLTEtNDg4_9bee5753-d2b8-4300-a1ac-4b4edd84d9ae"
      unitRef="usd">23000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTMtMS0xLTEtNDg4_8890fa79-19c9-42da-b3da-cd30e9826dd2"
      unitRef="usd">-16000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTMtMy0xLTEtNDg4_e101696d-88c0-46d0-afc1-318d23a7b8d8"
      unitRef="usd">19000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTQtMS0xLTEtNDg4_e9e4b45e-62f3-4cd3-a369-63c9396b9716"
      unitRef="usd">-111000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTQtMy0xLTEtNDg4_5eb02821-57af-4c54-b0ae-aadfcce6bd80"
      unitRef="usd">42000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTYtMS0xLTEtNDg4_096cc62f-3775-441a-9983-9e364b59e785"
      unitRef="usd">54976000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTYtMy0xLTEtNDg4_22092e3d-3e92-45e2-a465-5e66a5657077"
      unitRef="usd">52841000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTgtMS0xLTEtNDg4_4040120e-bd11-4fac-85a1-5301e0d19ecf"
      unitRef="usd">13195000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMTgtMy0xLTEtNDg4_54502c86-4b6a-4196-8207-1650837fb431"
      unitRef="usd">11778000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjAtMS0xLTEtNDg4_f7cc0f58-46b8-4539-841c-2b0f73fc0492"
      unitRef="usd">41781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjAtMy0xLTEtNDg4_b394e038-c3a5-49ac-8ec2-69fc4f8a5bd9"
      unitRef="usd">41063000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjItMS0xLTEtNDg4_d67fb4d4-36c7-4341-911d-96860e609b5b"
      unitRef="usdPerShare">3.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjItMy0xLTEtNDg4_e68fa3c1-acd0-4bd6-8d63-7abaa9503819"
      unitRef="usdPerShare">3.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjQtMS0xLTEtNDg4_6249ef22-9187-453f-aba6-6e96f68afbb5"
      unitRef="usdPerShare">3.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjQtMy0xLTEtNDg4_fd3c7ab4-49d8-4cb4-a45b-403107e82305"
      unitRef="usdPerShare">3.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjctMS0xLTEtNDg4_66ac087a-1851-4504-9580-3db9de666195"
      unitRef="shares">11557000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjctMy0xLTEtNDg4_039ed7b9-ff95-42c5-812b-af1b8c3aeaed"
      unitRef="shares">11772000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjgtMS0xLTEtNDg4_5903fdaf-944f-4734-a6a2-2e7b4f8d457f"
      unitRef="shares">11638000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMjgtMy0xLTEtNDg4_b0804eaf-33d0-4560-b1aa-a45587fdd4a3"
      unitRef="shares">11881000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMzAtMS0xLTEtNDg4_612787bf-4e7a-4409-9cf8-6200152df65d"
      unitRef="usdPerShare">1.64</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xNi9mcmFnOmNlZDNiY2MwMWUyNTRlMWFiODNjN2ZiYmNlOTQ5ZDNhL3RhYmxlOmU2Nzc0YzIyMDFjMTRmMDU5NDQ5Nzk3ODI5ZWJjMzYzL3RhYmxlcmFuZ2U6ZTY3NzRjMjIwMWMxNGYwNTk0NDk3OTc4MjllYmMzNjNfMzAtMy0xLTEtNDg4_7c2af0a6-53af-4967-bc35-68529533ed15"
      unitRef="usdPerShare">1.42</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:NetIncomeLoss
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfMy0xLTEtMS00ODg_7ae051ac-2885-49e7-8f13-83d848f0bb54"
      unitRef="usd">41781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfMy0zLTEtMS00ODg_8514ef19-9b49-4ea2-87e7-0422355ee362"
      unitRef="usd">41063000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfNS0xLTEtMS00ODg_9fa2870e-46a2-4994-b863-9d5ffb279d03"
      unitRef="usd">30000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfNS0zLTEtMS00ODg_01d477a4-be07-4cab-b4bc-d86837d455a9"
      unitRef="usd">78000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfNi0xLTEtMS00ODg_9685e839-be41-44f3-ac90-22b187885668"
      unitRef="usd">-14000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfNi0zLTEtMS00ODg_bb348928-d750-45e5-b9c8-3643dfda796c"
      unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfOC0xLTEtMS00ODg_efb54e78-087c-48c1-8e8f-3733f32bd4d5"
      unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfOC0zLTEtMS00ODg_12334ae1-a0e7-4ebe-8157-1d8f4044d8d9"
      unitRef="usd">62000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfMTAtMS0xLTEtNDg4_66db0b74-a3be-4565-bc87-da7afa03994b"
      unitRef="usd">41797000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8xOS9mcmFnOmE0NmMyZDY0YTVlNDQ1NzFhMjcwNGE3YWNlZmY5ZTM4L3RhYmxlOjM5M2QyYzlmZDk2NjQ0OTRiOTgyYmNhYTg3YjQ4ZTU2L3RhYmxlcmFuZ2U6MzkzZDJjOWZkOTY2NDQ5NGI5ODJiY2FhODdiNDhlNTZfMTAtMy0xLTEtNDg4_bd5b2aad-8119-47c7-a8e8-f41fafff3d0c"
      unitRef="usd">41125000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNC0xLTEtMS00ODg_5bcdaf3b-4561-4317-adc0-9559f6ec89e0"
      unitRef="usd">118003000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNC0zLTEtMS00ODg_9ad75895-fcc4-41d2-8fe2-58b4df528345"
      unitRef="usd">104183000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InventoryNet
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNS0xLTEtMS00ODg_63bce763-b8d3-4dbc-a230-124bede4269e"
      unitRef="usd">188972000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNS0zLTEtMS00ODg_b236e9d7-11f4-4b9e-bcb2-16ed3fd84b86"
      unitRef="usd">180043000</us-gaap:InventoryNet>
    <us-gaap:ShortTermInvestments
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNi0xLTEtMS00ODg_95366ff2-1a83-49f8-9fb5-76e93c8ac240"
      unitRef="usd">4057000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNi0zLTEtMS00ODg_bc2e05e7-a92c-4c4b-9ca8-334e9296aa6f"
      unitRef="usd">5361000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidTaxes
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNy0xLTEtMS0yMDczNw_fdc1fcba-6f4d-4f6f-8dad-2749eca4cfc5"
      unitRef="usd">0</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNy0zLTEtMS0xNzcxMA_4a6114ea-a2e1-408c-afc4-d941233c76ec"
      unitRef="usd">945000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNy0xLTEtMS00ODg_0f90b59f-6cef-46ad-afbd-4931fb7000f1"
      unitRef="usd">13227000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfNy0zLTEtMS00ODg_8c61d1d4-739c-45b4-aebf-9129412abe03"
      unitRef="usd">16334000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfOC0xLTEtMS00ODg_a4d43e37-4261-46a1-80eb-af22ff572fee"
      unitRef="usd">324259000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfOC0zLTEtMS00ODg_2a234fd5-01f9-4585-ae9b-bd4cd91f5eaf"
      unitRef="usd">306866000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTAtMS0xLTEtNDg4_b050d9c1-cad7-4c7f-adb6-d89a4206a4d3"
      unitRef="usd">57804000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTAtMy0xLTEtNDg4_fd947738-937b-446a-9c4e-14d877066c37"
      unitRef="usd">56131000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTEtMS0xLTEtNDg4_cafc16e5-1d3f-43de-969d-54f11da3a712"
      unitRef="usd">22942000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTEtMy0xLTEtNDg4_5b42aaa7-4500-41d1-baf4-311b5ecbfb25"
      unitRef="usd">24457000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTItMS0xLTEtNDg4_346574b7-0aa4-4380-b1d1-ab8f85f36979"
      unitRef="usd">12026000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTItMy0xLTEtNDg4_a3882975-e2f1-4b13-8495-3575b922a7e3"
      unitRef="usd">6468000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTMtMS0xLTEtNDg4_3a6bb291-37f4-4281-9a26-513d4c7a5de1"
      unitRef="usd">4404000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTMtMy0xLTEtNDg4_65616f5e-1046-4474-b580-c437ba5d7bf1"
      unitRef="usd">4404000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Assets
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTYtMS0xLTEtNDg4_03a13e62-d10b-4543-bbc9-4d61ffb2d946"
      unitRef="usd">421435000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMTYtMy0xLTEtNDg4_56cadadf-127d-41cf-aae9-e1c8d934b4d9"
      unitRef="usd">398326000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjAtMS0xLTEtNDg4_cdb43eaf-ba64-42f7-b1cb-e2aed2f350b3"
      unitRef="usd">174369000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjAtMy0xLTEtNDg4_a0cedf41-367d-4f22-8fc9-f3dc5553dda3"
      unitRef="usd">163309000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjEtMS0xLTEtNDg4_647ed1d9-9178-4931-9ed6-41a24a1acffe"
      unitRef="usd">6663000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjEtMy0xLTEtNDg4_c049fbbd-abdc-4725-ac50-5a9bc5bb40fe"
      unitRef="usd">6523000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjItMS0xLTEtNDg4_2f8f9f69-155b-4288-b9f3-15de05974993"
      unitRef="usd">181032000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjItMy0xLTEtNDg4_31d60c74-9f26-4eda-941a-d3b697a815de"
      unitRef="usd">169832000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjQtMS0xLTEtNDg4_4b39eb0c-5c43-4703-bbe7-0ed7d1441813"
      unitRef="usd">24379000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjQtMy0xLTEtNDg4_012bd12e-c660-4ee6-9691-4296cc475123"
      unitRef="usd">26020000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjUtMS0xLTEtNDg4_802bc970-5775-4c39-905c-e5fccaa9d43a"
      unitRef="usd">205411000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjUtMy0xLTEtNDg4_74c33ab7-1c02-4c3a-9852-0281d66ffd93"
      unitRef="usd">195852000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjgtMC0xLTEtNDg4L3RleHRyZWdpb246YjY1ZWQzNTA2OGUyNDUwYjk5NWFhOTNlODlhYjgzYjZfODc5NjA5MzAyMjI5Nw_3fd3682d-c4b5-4ade-9474-18a333cc8579"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjgtMC0xLTEtNDg4L3RleHRyZWdpb246YjY1ZWQzNTA2OGUyNDUwYjk5NWFhOTNlODlhYjgzYjZfODc5NjA5MzAyMjI5Nw_a7cadb76-16d0-4513-9b8a-09495da0bdb7"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjgtMC0xLTEtNDg4L3RleHRyZWdpb246YjY1ZWQzNTA2OGUyNDUwYjk5NWFhOTNlODlhYjgzYjZfODc5NjA5MzAyMjMwNg_725d07ce-47cd-4745-be24-84eab321f91f"
      unitRef="shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjgtMC0xLTEtNDg4L3RleHRyZWdpb246YjY1ZWQzNTA2OGUyNDUwYjk5NWFhOTNlODlhYjgzYjZfODc5NjA5MzAyMjMwNg_d3e55c11-8792-4f51-b718-81bac2bbafe6"
      unitRef="shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjktMC0xLTEtNDg4L3RleHRyZWdpb246MWJiZDMwZTgxMGUwNDE1Zjk3NGIyZDE2ODNiZmEzM2ZfODc5NjA5MzAyMjI3Ng_4fb589f9-68a3-4c68-90ea-93fa553347a4"
      unitRef="shares">11553000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjktMC0xLTEtNDg4L3RleHRyZWdpb246MWJiZDMwZTgxMGUwNDE1Zjk3NGIyZDE2ODNiZmEzM2ZfODc5NjA5MzAyMjI4NQ_9897552a-bd92-4857-95cb-dc2497b3af1c"
      unitRef="shares">11594000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjktMC0xLTEtNDg4L3RleHRyZWdpb246MWJiZDMwZTgxMGUwNDE1Zjk3NGIyZDE2ODNiZmEzM2ZfODc5NjA5MzAyMjMxMA_3eb03341-669f-4319-8799-b777aa9141d7"
      unitRef="shares">11552000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMjktMC0xLTEtNDg4L3RleHRyZWdpb246MWJiZDMwZTgxMGUwNDE1Zjk3NGIyZDE2ODNiZmEzM2ZfODc5NjA5MzAyMjMwNQ_7b1a755a-3b4f-4838-aa67-95dbe3d5383e"
      unitRef="shares">11593000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzAtMS0xLTEtNDg4_77bdd7c9-3252-4f72-9c6c-8419b559fa79"
      unitRef="usd">12000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzAtMy0xLTEtNDg4_6d7df3fc-4141-45fd-9e03-aad4bcdbe00e"
      unitRef="usd">12000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzEtMS0xLTEtNDg4_baf4298d-40af-4be2-b619-d507c1d21224"
      unitRef="usd">12834000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzEtMy0xLTEtNDg4_fae4a467-8dfe-4d7c-b863-f09f7182fec9"
      unitRef="usd">12018000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzItMS0xLTEtNDg4_b7fabd1c-abac-4408-aaf2-8696dea565eb"
      unitRef="usd">127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzItMy0xLTEtNDg4_fdf38dbb-bd64-4788-b04e-f54f0bc2681c"
      unitRef="usd">111000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzMtMS0xLTEtNDg4_97412d59-049a-4d8e-aa1c-f3953e66099e"
      unitRef="usd">203051000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzMtMy0xLTEtNDg4_f0b4f4a0-09d8-42f6-8063-a70194bb7fdb"
      unitRef="usd">190333000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzUtMS0xLTEtNDg4_f367f032-d4f3-4a87-a29e-86d2ca891d57"
      unitRef="usd">216024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzUtMy0xLTEtNDg4_17ee29b0-56fb-427f-8c48-651e334f2211"
      unitRef="usd">202474000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzctMS0xLTEtNDg4_97f4d09b-a352-4f44-b193-6ff2a15c401a"
      unitRef="usd">421435000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yMi9mcmFnOjhjNzkyMDkyMzA4ZjQ4N2ZiODY3MGMwMGExM2ZiNTg2L3RhYmxlOjdmMWIwZDhlZDMyZDRhNTNiMzI5YjU2MGRmYTFiMWMyL3RhYmxlcmFuZ2U6N2YxYjBkOGVkMzJkNGE1M2IzMjliNTYwZGZhMWIxYzJfMzctMy0xLTEtNDg4_52939c0a-3a3e-4e5c-b4ec-9d01365af23f"
      unitRef="usd">398326000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNC0xLTEtMS00ODg_b912d8bc-2ee3-4e6b-81bb-03a178566b34"
      unitRef="usd">41781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNC0zLTEtMS00ODg_739485ea-9108-4c87-8032-c429eeb9512d"
      unitRef="usd">41063000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNi0xLTEtMS00ODg_89d14652-4d12-4fd7-a81d-2549857beba0"
      unitRef="usd">2444000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNi0zLTEtMS00ODg_2e1a640d-4933-4e8e-973a-4d5e43ccff38"
      unitRef="usd">1124000</us-gaap:DepreciationDepletionAndAmortization>
    <med:OperatingLeaseExpenseNonCash
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNy0xLTEtMS0yMTc5Nw_0005c318-69f5-4789-87e4-3182157f3163"
      unitRef="usd">1619000</med:OperatingLeaseExpenseNonCash>
    <med:OperatingLeaseExpenseNonCash
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNy0zLTEtMS0yNDA2NQ_94423c80-5dac-4546-976c-49f5bdefecd7"
      unitRef="usd">889000</med:OperatingLeaseExpenseNonCash>
    <us-gaap:ShareBasedCompensation
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNy0xLTEtMS00ODg_1f40749b-586c-4ab6-ae85-26f649f45438"
      unitRef="usd">2275000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfNy0zLTEtMS00ODg_47346595-f354-449a-810c-9ef9a65cd461"
      unitRef="usd">2198000</us-gaap:ShareBasedCompensation>
    <med:AmortizationOfPremiumOnInvestmentSecurities
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfOC0xLTEtMS00ODg_2e214302-75d4-4da1-8c88-2d6185991a0b"
      unitRef="usd">11000</med:AmortizationOfPremiumOnInvestmentSecurities>
    <med:AmortizationOfPremiumOnInvestmentSecurities
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfOC0zLTEtMS00ODg_67339b3f-b824-4a0f-b562-a756217e8d82"
      unitRef="usd">28000</med:AmortizationOfPremiumOnInvestmentSecurities>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTEtMS0xLTEtNDg4_33fec060-f1fc-437c-8e80-4e8b59233641"
      unitRef="usd">8929000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTEtMy0xLTEtNDg4_030cf1e7-cd8a-4a89-8d3d-422ef5180615"
      unitRef="usd">8842000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTItMS0xLTEtNDg4_9beaa105-969e-455a-ae0b-42dca3180e87"
      unitRef="usd">-945000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTItMy0xLTEtNDg4_386d4122-9cd8-4b67-959f-719572b43a69"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTMtMS0xLTEtNDg4_c51de5bc-7697-4538-9966-47130858fc97"
      unitRef="usd">-3107000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTMtMy0xLTEtNDg4_2f71fda4-f038-443c-816a-af30fec709e1"
      unitRef="usd">266000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTQtMS0xLTEtNDg4_41b87597-d330-42f8-8e13-e30b901544fe"
      unitRef="usd">6632000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTQtMy0xLTEtNDg4_975eb954-12f4-47a0-aeee-754dc03d7e3d"
      unitRef="usd">70000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTUtMS0xLTEtNDg4_f5192eab-b681-4c41-b921-b5d27cbd1cb2"
      unitRef="usd">7052000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTUtMy0xLTEtNDg4_a4fefa44-d319-4753-b678-6f16fc3f8f30"
      unitRef="usd">29202000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTYtMS0xLTEtNDg4_4d6a1059-10a2-4736-bc7f-79356068f857"
      unitRef="usd">43673000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTYtMy0xLTEtNDg4_e51b3257-5e10-432d-b7f8-3e0e530b3093"
      unitRef="usd">65326000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTktMS0xLTEtNDg4_4cd48fc5-82f8-4da7-920f-831db1a8c62e"
      unitRef="usd">1245000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMTktMy0xLTEtNDg4_4127217a-ad3b-4b37-a087-78f22d2662df"
      unitRef="usd">3720000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjAtMS0xLTEtNDg4_fe9aa438-5787-42c4-99e9-c662a709f537"
      unitRef="usd">3009000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjAtMy0xLTEtNDg4_bb3dee5b-f929-4d25-8d2c-808a4b91287d"
      unitRef="usd">4598000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjEtMS0xLTEtNDg4_57d39338-2668-4aca-ad19-368142189561"
      unitRef="usd">-1764000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjEtMy0xLTEtNDg4_7e8455a3-0ea9-4c6d-94e9-9a123b066af1"
      unitRef="usd">-878000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjQtMS0xLTEtNDg4_7e5a6742-ae0b-4f38-8c75-936890cfae3c"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjQtMy0xLTEtNDg4_2644f32a-d4ec-4b87-98de-021a223c4b62"
      unitRef="usd">481000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjUtMS0xLTEtNDg4_9c7332d2-6e21-4c2b-8152-bb4dfc02a24b"
      unitRef="usd">1459000</us-gaap:PaymentsForRepurchaseOfOtherEquity>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjUtMy0xLTEtNDg4_56a924ab-591f-41ed-b451-52c294f08214"
      unitRef="usd">1807000</us-gaap:PaymentsForRepurchaseOfOtherEquity>
    <us-gaap:PaymentsOfDividends
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjYtMS0xLTEtNDg4_720dccb1-1859-495e-b08a-2befededf572"
      unitRef="usd">16660000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjYtMy0xLTEtNDg4_b4d64719-1393-4811-857e-5195328c1e5b"
      unitRef="usd">13392000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjctMS0xLTEtNDg4_30babda1-91de-49c8-ac26-0910f302a006"
      unitRef="usd">10000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjctMy0xLTEtNDg4_7d7b6133-04aa-422e-b15e-67d6eb585e0b"
      unitRef="usd">7500000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjgtMS0xLTEtNDg4_40739665-4111-44ad-a802-e5a306a85e16"
      unitRef="usd">-28119000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMjgtMy0xLTEtNDg4_fde27235-9eb4-4cb5-8c6b-b43dd19ce313"
      unitRef="usd">-22218000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzAtMS0xLTEtNDg4_63577b4d-3d1e-4759-9e76-311760527757"
      unitRef="usd">30000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzAtMy0xLTEtNDg4_0b5676f3-1ac5-488e-ab9c-d9040144a22d"
      unitRef="usd">78000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzItMS0xLTEtNDg4_c438e240-6852-467a-b120-6822d9744ea0"
      unitRef="usd">13820000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzItMy0xLTEtNDg4_e1f5ded0-4e1d-4299-9f9e-7a96b667908a"
      unitRef="usd">42308000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzMtMS0xLTEtNDg4_78c1e1a8-6fc0-42e6-9df7-28c0520c6180"
      unitRef="usd">104183000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic92fe6c57a504e2dbbad3803d0be8e31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzMtMy0xLTEtNDg4_81dd79f3-81a4-46df-b366-3d25bec43e9d"
      unitRef="usd">163723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzQtMS0xLTEtNDg4_296c4e69-a6f9-4051-8dcc-557ace3be4cf"
      unitRef="usd">118003000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a9e8a7828aa4da5bce1881ad3c595da_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzQtMy0xLTEtNDg4_efadf8f8-fdab-48ba-8b78-e79f43b29392"
      unitRef="usd">206031000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzctMS0xLTEtNDg4_8d742a74-38fc-4eff-9e79-c90e6153952e"
      unitRef="usd">62000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzctMy0xLTEtNDg4_18d0306a-4a3c-45e1-8feb-0d5f764beaa8"
      unitRef="usd">56000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:DividendsCash
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzgtMS0xLTEtNDg4_8eda104c-70d5-4d2b-b022-6b5a66d87c14"
      unitRef="usd">19663000</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yNS9mcmFnOjM0ZjRlMzZkMzIxNjQ1OTNiOGU2MzMzOTk0OGQyMjUwL3RhYmxlOmY0NGNjNmJhYmFiYjRjOTliOGEzY2JhOTNjOWM3ZDNiL3RhYmxlcmFuZ2U6ZjQ0Y2M2YmFiYWJiNGM5OWI4YTNjYmE5M2M5YzdkM2JfMzgtMy0xLTEtNDg4_aec4eb8a-9582-4825-8421-c6728d5581e3"
      unitRef="usd">17292000</us-gaap:DividendsCash>
    <us-gaap:SharesIssued
      contextRef="i27de280f347a42329dd3679897047b8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy0xLTEtMS00ODg_965a7176-93ed-44c5-93d3-f1b2edb7f35e"
      unitRef="shares">11594000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i27de280f347a42329dd3679897047b8e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy0zLTEtMS00ODg_bf856fa6-fd62-4663-b1e2-8bd7586efca8"
      unitRef="usd">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3ec04f01121844a2a66d23c8da8a89bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy01LTEtMS00ODg_c52c19ff-a356-4739-9ef7-6420097d9d62"
      unitRef="usd">12018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib222e481175248a4bef2b9ea56746606_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy03LTEtMS00ODg_9341a118-274d-44ae-85d3-0b161bc3b2db"
      unitRef="usd">111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if06713cb95b949a49641dbf1aa583e7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy05LTEtMS00ODg_3e862ec8-20b8-40b9-ab5f-36254d0c8b77"
      unitRef="usd">190333000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5fd06983c614bf0a83447b06a1785d5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy0xMS0xLTEtNDg4_acebc2c0-96e4-4196-a9a5-616b25d9a86a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMy0xMy0xLTEtNDg4_d53c8e93-73e0-4aad-ade8-78d969be0e05"
      unitRef="usd">202474000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iaa03549ad0aa4903a08e29e78ed12366_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNC05LTEtMS00ODg_bbe07c6b-4ee0-41c0-8e3c-429c1293a706"
      unitRef="usd">41781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNC0xMy0xLTEtNDg4_cf0c25ff-9aae-47b7-a6a2-10fc7874b6e7"
      unitRef="usd">41781000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ib5d670baf3e44e3eb7b81105877274fb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNS0xLTEtMS00ODg_92c6666c-bb11-4817-b01d-20ccf3a82aad"
      unitRef="shares">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="ie692dfbd3ece4eac8ee8cdea802b204e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNS01LTEtMS00ODg_3d4924c0-d880-4c86-8450-579ae1f5cc68"
      unitRef="usd">2275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNS0xMy0xLTEtNDg4_34670cd9-e78b-479a-b570-c1f39ec09084"
      unitRef="usd">2275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ib5d670baf3e44e3eb7b81105877274fb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNi0xLTEtMS00ODg_44438c89-3a1a-4b50-9fb7-34c620a2107a"
      unitRef="shares">8000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie692dfbd3ece4eac8ee8cdea802b204e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNi01LTEtMS00ODg_bb05c756-a29a-4d1f-8f72-65968c5f225a"
      unitRef="usd">1459000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNi0xMy0xLTEtNDg4_a01d81a6-51b6-4fc8-890d-9c88c7d86c9e"
      unitRef="usd">1459000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3ea0b38550ff4a6db4e7c2f402dd7f1d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNy0xMS0xLTEtNDg4_88cb6120-eb23-4678-b9a6-8679ba1e3eaf"
      unitRef="usd">10000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfNy0xMy0xLTEtNDg4_7a594ec6-934d-4e64-8e69-2c2a88528d7b"
      unitRef="usd">10000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="ib5d670baf3e44e3eb7b81105877274fb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOC0xLTEtMS00ODg_f798f281-3a7e-49b4-9d9b-167ae6be0233"
      unitRef="shares">51000</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="iaa03549ad0aa4903a08e29e78ed12366_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOC05LTEtMS00ODg_abd80191-37f2-4a46-87bd-37735bb842d6"
      unitRef="usd">10000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i3ea0b38550ff4a6db4e7c2f402dd7f1d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOC0xMS0xLTEtNDg4_bff9f551-e232-419f-94e6-5f08711bf0ef"
      unitRef="usd">-10000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOC0xMy0xLTEtNDg4_3d1aa150-00dd-4b69-b938-ecd8d597adb4"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i497f48ef092c4f08a729248571d78cb2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOS03LTEtMS00ODg_9aa23059-e56e-4fc7-a275-f00b611779f7"
      unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfOS0xMy0xLTEtNDg4_e2ca21d1-852a-482f-8cf5-54e6d76530d6"
      unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="iaa03549ad0aa4903a08e29e78ed12366_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTAtOS0xLTEtNDg4_6582e932-763b-4f36-82bd-36d0d7c9b976"
      unitRef="usd">19063000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTAtMTMtMS0xLTQ4OA_5d32c72b-c97d-455b-a827-a8ee36fe955a"
      unitRef="usd">19063000</us-gaap:DividendsCommonStockCash>
    <us-gaap:SharesIssued
      contextRef="i52f07595224e43ba81c8686f0fa8a13a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItMS0xLTEtNDg4_8b776187-1820-49fc-a5d0-d3c09305ed43"
      unitRef="shares">11553000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i52f07595224e43ba81c8686f0fa8a13a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItMy0xLTEtNDg4_4b3fe7ef-1a1d-44b8-b880-1bf0c0b1a035"
      unitRef="usd">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4629aa81a2fc409b96bd6ec6da4b9822_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItNS0xLTEtNDg4_25df164d-d78e-4bdb-ab4f-48751fff69fc"
      unitRef="usd">12834000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibefafab12e4a4838bfdac00e2c56ea5f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItNy0xLTEtNDg4_ff8741fd-e15a-4bba-bdfd-655bb40630e2"
      unitRef="usd">127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i39886d8f6ad44174b5479a2615523738_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItOS0xLTEtNDg4_0b96e1a7-06d7-4e12-a429-92178ab4fa7a"
      unitRef="usd">203051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie2a9b2a18a7b4e56ab717cb5e1d08b9d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItMTEtMS0xLTQ4OA_ba6998c1-2142-4328-91eb-6658f3ee7d3a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjE3ZDFhZDdlNzJkODRhOTJiNTQwMzNhZTg4NzkxZjhiL3RhYmxlcmFuZ2U6MTdkMWFkN2U3MmQ4NGE5MmI1NDAzM2FlODg3OTFmOGJfMTItMTMtMS0xLTQ4OA_e609e587-0cad-4c7d-b645-e055a60a0a59"
      unitRef="usd">216024000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i5f1f4b37e28c44289b679e4cf804f107_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy0xLTEtMS00ODg_32dd5146-157b-465c-a1bf-359175ce0f99"
      unitRef="shares">11822000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5f1f4b37e28c44289b679e4cf804f107_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy0zLTEtMS00ODg_156d8c11-8ebd-44f8-9304-b334ef18aa91"
      unitRef="usd">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ab9310916204a50b1fb226d4d9ed1ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy01LTEtMS00ODg_1081cf24-7ceb-47e9-b03b-5f0fbce71821"
      unitRef="usd">7842000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2724646ee9f747a9b9f3dc65301854ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy03LTEtMS00ODg_9246d596-f29a-48a6-820a-69ab8027d90f"
      unitRef="usd">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if88269ad30744ca48e26fa63c42b1e63_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy05LTEtMS00ODg_933e3704-55db-46d1-b318-49e85d614c67"
      unitRef="usd">154351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1426349a333471bb4ed8e3f0ea276ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy0xMS0xLTEtNDg4_a0f93db2-6974-4701-b9cb-e8b124a52e09"
      unitRef="usd">-5000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic92fe6c57a504e2dbbad3803d0be8e31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMy0xMy0xLTEtNDg4_834cc743-e97b-4eb5-9e43-926481364295"
      unitRef="usd">157246000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="idb60d524f67d49a7a0c81ec19020ec38_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTItOS0xLTEtNDg4_288a8b01-1dc3-468a-a253-8de94f0bdead"
      unitRef="usd">41063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTItMTMtMS0xLTQ4OA_af8623dd-e243-4eb5-ba33-390145486374"
      unitRef="usd">41063000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ibf7bc84211b14477af22b912ebaf38e6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTMtMS0xLTEtNDg4_c12a94db-fad3-48a9-bb5f-9bafacd43628"
      unitRef="shares">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="ie967876d049142cfbde149fe84c69778_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTMtNS0xLTEtNDg4_e4d32566-dfcf-4746-bf63-3eaf5b4ceca7"
      unitRef="usd">2198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTMtMTMtMS0xLTQ4OA_9e0d3d38-bc67-4f5a-9248-83aa11e5ac58"
      unitRef="usd">2198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibf7bc84211b14477af22b912ebaf38e6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTQtMS0xLTEtNDg4_347a568b-e5bc-49aa-bc83-eb4adbcad401"
      unitRef="shares">11000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie967876d049142cfbde149fe84c69778_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTQtNS0xLTEtNDg4_a8d58c95-d5dc-48b3-9371-8eb9bf22db8f"
      unitRef="usd">481000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTQtMTMtMS0xLTQ4OA_488d4431-6cf2-4404-ad43-4deb79d31134"
      unitRef="usd">481000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ibf7bc84211b14477af22b912ebaf38e6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTUtMS0xLTEtNDg4_69433408-e574-4b48-93e1-791c916e8a14"
      unitRef="shares">7000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie967876d049142cfbde149fe84c69778_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTUtNS0xLTEtNDg4_caad9f57-11cd-4e72-a0c4-d6ed97a49726"
      unitRef="usd">1807000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTUtMTMtMS0xLTQ4OA_96a7f88a-a3c0-4ca2-bac3-ebe2cf8ffedb"
      unitRef="usd">1807000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if25fc543e5b44b6490ed11b7fda2ada2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTYtMTEtMS0xLTE3NDAx_68094ad1-17b7-49ab-910d-ffbbe66fb8ef"
      unitRef="usd">7500000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTYtMTMtMS0xLTE3NDAx_fc960f50-3fe4-40a1-8f9d-03981c7f006d"
      unitRef="usd">7500000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide80a5cd921c4800b5bfab2a45d02323_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTYtNy0xLTEtNDg4_90ba7023-cd29-45bd-ad3b-f52ea7ea12a0"
      unitRef="usd">62000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTYtMTMtMS0xLTQ4OA_bdef63d9-d486-4339-8bd9-4ee05fe4afdd"
      unitRef="usd">62000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="idb60d524f67d49a7a0c81ec19020ec38_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTgtOS0xLTEtNDg4_5050a0c4-3890-4cfb-8f1c-6c409269b8c0"
      unitRef="usd">16852000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMTgtMTMtMS0xLTQ4OA_5ba5f0f8-aae3-4b7b-a961-1f84679f7be4"
      unitRef="usd">16852000</us-gaap:DividendsCommonStockCash>
    <us-gaap:SharesIssued
      contextRef="icf170ac1a1024a05892c136030ccc3d3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtMS0xLTEtNDg4_1bd2e7da-9b11-4e21-827f-838b61787f4e"
      unitRef="shares">11839000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="icf170ac1a1024a05892c136030ccc3d3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtMy0xLTEtNDg4_313dcf7b-46ff-4c00-b972-6127481991bd"
      unitRef="usd">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia47fc4a92db64d20830468f635bbde08_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtNS0xLTEtNDg4_9267b03d-6e34-4b02-bf8c-73f434b26a48"
      unitRef="usd">8714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e02779182f94724b5916bd946bfe720_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtNy0xLTEtNDg4_00db51d1-44e3-4fa4-b8df-7b7141753769"
      unitRef="usd">103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d2306fe85c8431f9cf6ad772507e0c7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtOS0xLTEtNDg4_e9e5caa3-1d64-4333-8614-4096174c41e2"
      unitRef="usd">178562000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i79e50c2945b94470bc8362df60bf8e6d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtMTEtMS0xLTQ4OA_10e53be5-6ab3-4058-a614-252162d36433"
      unitRef="usd">-12500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a9e8a7828aa4da5bce1881ad3c595da_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8yOC9mcmFnOmE2MDBhMTFjZTQwZDQwZjNiNGE3YjI5ODI2ZDhhOTc5L3RhYmxlOjFhNDVhYTczZGQwYTQxZjY4NTVkNGU2ZTNiZTFjZjQ5L3RhYmxlcmFuZ2U6MWE0NWFhNzNkZDBhNDFmNjg1NWQ0ZTZlM2JlMWNmNDlfMjAtMTMtMS0xLTQ4OA_ef7df276-e326-467e-bbe3-d7e7bfa04720"
      unitRef="usd">174891000</us-gaap:StockholdersEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgwOA_ea6eb08c-6318-44e6-a5d5-1e5e9d6cb4d1">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (&#x201c;Medifast,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from the audited consolidated financial statements at that date included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 (&#x201c;2021 Form 10-K&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three months ended March 31, 2022 are not necessarily indicative of results that may be expected for the fiscal year ending December&#160;31, 2022. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the 2021 audited consolidated financial statements and notes thereto, which are included in the 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Presentation of Financial Statements -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the condensed consolidated financial statements had a material impact on the presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Adopted in 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;, which provides optional guidance for a limited time to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying accounting principles under GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met and to other derivative instruments if there is a change to the interest rates used for discounting, margining or contract price alignment. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. We adopted Topic 848 beginning in the first quarter of fiscal 2022 without any material impact on the Company's financial position and results of operations.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgwOQ_831848a6-2f38-4961-9304-aa30057c76e5">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (&#x201c;Medifast,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December&#160;31, 2021 has been derived from the audited consolidated financial statements at that date included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021 (&#x201c;2021 Form 10-K&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three months ended March 31, 2022 are not necessarily indicative of results that may be expected for the fiscal year ending December&#160;31, 2022. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the 2021 audited consolidated financial statements and notes thereto, which are included in the 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgxMA_73ee7742-1d07-4aed-bf6a-a92c52a77cbc">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Presentation of Financial Statements -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.&lt;/span&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgxMQ_8c1d6ae7-db89-4717-8a47-c8fb156fb6b0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the condensed consolidated financial statements had a material impact on the presentation.&lt;/span&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgxMg_d78f6123-fb38-4dbd-9014-f0896131e44a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNC9mcmFnOjhhNWEyYTI3NTQ3OTQyYTJhM2NmNTdiMTkxZWI0YmVmL3RleHRyZWdpb246OGE1YTJhMjc1NDc5NDJhMmEzY2Y1N2IxOTFlYjRiZWZfNDgxMw_caf51a6e-0cca-4c5b-b7c5-1659164a6446">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Adopted in 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;, which provides optional guidance for a limited time to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying accounting principles under GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met and to other derivative instruments if there is a change to the interest rates used for discounting, margining or contract price alignment. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. We adopted Topic 848 beginning in the first quarter of fiscal 2022 without any material impact on the Company's financial position and results of operations.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RleHRyZWdpb246N2QwMWYxY2IxMmQ3NDMxYTk5NDE1ZmRhNjIwYTM4OWVfNjAy_124ae758-94d8-4b5b-b390-6b9c79b5f138">INVENTORIESInventories consist principally of raw materials, non-food finished goods and packaged meal replacements held in the Company&#x2019;s warehouses and outsourced distribution centers. Inventories are stated at the lower of cost or net realizable value, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventories for unsalable or obsolete inventories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,340&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,196&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Packaging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,640&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,641&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Non-food finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;13,316&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,991&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;161,698&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;152,687&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Reserve for obsolete inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(5,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(7,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;188,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;180,043&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RleHRyZWdpb246N2QwMWYxY2IxMmQ3NDMxYTk5NDE1ZmRhNjIwYTM4OWVfNjAz_9cef8361-8bb4-4278-89df-c99300213983">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,340&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,196&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Packaging&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,640&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,641&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Non-food finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;13,316&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,991&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;161,698&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;152,687&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Reserve for obsolete inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(5,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(7,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;188,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;180,043&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfMi0xLTEtMS00ODg_36398977-5e9f-481c-bcf1-cf482c293188"
      unitRef="usd">15340000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfMi0zLTEtMS00ODg_272f1397-545b-4423-8388-f13890edde15"
      unitRef="usd">15196000</us-gaap:InventoryRawMaterials>
    <us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfMy0xLTEtMS00ODg_6df5cec3-4205-4965-a5e5-a960f823dd87"
      unitRef="usd">3640000</us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies>
    <us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfMy0zLTEtMS00ODg_f09ebc78-81f1-4409-bdbb-0b029e33ee75"
      unitRef="usd">3641000</us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies>
    <med:InventoryNonFoodFinishedGoods
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNC0xLTEtMS00ODg_b83a1b49-7f12-4ce1-9425-aff6ec8ffe03"
      unitRef="usd">13316000</med:InventoryNonFoodFinishedGoods>
    <med:InventoryNonFoodFinishedGoods
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNC0zLTEtMS00ODg_a45eb039-1857-4403-93dd-f97336959d91"
      unitRef="usd">15991000</med:InventoryNonFoodFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNS0xLTEtMS00ODg_9b56926b-56ca-4e21-bed9-ee50955ccc22"
      unitRef="usd">161698000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNS0zLTEtMS00ODg_9afccdf4-d578-4608-b4a4-236a67f5e620"
      unitRef="usd">152687000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryValuationReserves
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNi0xLTEtMS00ODg_7818aa36-5afe-4f81-843c-783b6449fe1c"
      unitRef="usd">5022000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNi0zLTEtMS00ODg_e5e0cbe2-2d26-40c8-a0a1-05cf746e47f7"
      unitRef="usd">7472000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNy0xLTEtMS00ODg_7d6c526c-4d49-4d9d-adbb-20682b3b64da"
      unitRef="usd">188972000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF8zNy9mcmFnOjdkMDFmMWNiMTJkNzQzMWE5OTQxNWZkYTYyMGEzODllL3RhYmxlOmZkNTBkMGNlOWFlZjRhNzNiZjQ2MDJjMjE3ZjgwNjVhL3RhYmxlcmFuZ2U6ZmQ1MGQwY2U5YWVmNGE3M2JmNDYwMmMyMTdmODA2NWFfNy0zLTEtMS00ODg_e32d7afa-de6a-4bcb-87a3-64178f13e3bd"
      unitRef="usd">180043000</us-gaap:InventoryNet>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RleHRyZWdpb246ZjdhM2MwMWU1OTg4NDJiZDhkMzlkZWE0ZTI5OGEwYjFfMTEyMw_3119b9e6-ac74-4e22-be11-5f036815a280">EARNINGS PER SHARE&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) computations are calculated utilizing the weighted average number of shares of the Company&#x2019;s common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of the Company&#x2019;s common stock outstanding adjusted for the effect of dilutive common stock equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Weighted average shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Effect of dilutive common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Weighted average shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Earnings per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Earnings per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The calculation of diluted EPS excluded 44 and 267 antidilutive restricted stock awards for the three months ended March 31, 2022 and 2021, respectively.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RleHRyZWdpb246ZjdhM2MwMWU1OTg4NDJiZDhkMzlkZWE0ZTI5OGEwYjFfMTEyNA_2b98b2ed-8601-4abf-963f-a741fe503d3c">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Weighted average shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Effect of dilutive common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Weighted average shares of common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Earnings per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Earnings per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfNC0xLTEtMS00ODg_f7cc0f58-46b8-4539-841c-2b0f73fc0492"
      unitRef="usd">41781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfNC0zLTEtMS00ODg_b394e038-c3a5-49ac-8ec2-69fc4f8a5bd9"
      unitRef="usd">41063000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfNy0xLTEtMS00ODg_66ac087a-1851-4504-9580-3db9de666195"
      unitRef="shares">11557000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfNy0zLTEtMS00ODg_039ed7b9-ff95-42c5-812b-af1b8c3aeaed"
      unitRef="shares">11772000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfOC0xLTEtMS00ODg_040447d5-3a06-41a3-9616-e046b513a7b2"
      unitRef="shares">81000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfOC0zLTEtMS00ODg_55d08ec3-2989-4d86-b4e7-d26c21cc8fbb"
      unitRef="shares">109000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfOS0xLTEtMS00ODg_5903fdaf-944f-4734-a6a2-2e7b4f8d457f"
      unitRef="shares">11638000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfOS0zLTEtMS00ODg_b0804eaf-33d0-4560-b1aa-a45587fdd4a3"
      unitRef="shares">11881000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfMTEtMS0xLTEtNDg4_c6b995f7-e541-4c09-8650-8c93d747804e"
      unitRef="usdPerShare">3.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfMTEtMy0xLTEtNDg4_9e2359a0-bec9-472a-8503-e96129673f99"
      unitRef="usdPerShare">3.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfMTMtMS0xLTEtNDg4_ce581a74-121f-467e-af33-f0ad4ffb7437"
      unitRef="usdPerShare">3.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RhYmxlOmQzMzhmM2ZmY2I2NDQ4ZjE4ODBlNDA1OTc3NDk5YjE3L3RhYmxlcmFuZ2U6ZDMzOGYzZmZjYjY0NDhmMTg4MGU0MDU5Nzc0OTliMTdfMTMtMy0xLTEtNDg4_c4f3d095-87e2-4c60-9988-d23385e0962e"
      unitRef="usdPerShare">3.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4a53f9a4936845ba8bdfa229ddc8998c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RleHRyZWdpb246ZjdhM2MwMWU1OTg4NDJiZDhkMzlkZWE0ZTI5OGEwYjFfODc5NjA5MzAyMzc1NQ_44e183b6-c333-4133-9cb7-07bc418f332b"
      unitRef="shares">44</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id3d0f3fdadff47b4afb4b4e30c9150cd_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80MC9mcmFnOmY3YTNjMDFlNTk4ODQyYmQ4ZDM5ZGVhNGUyOThhMGIxL3RleHRyZWdpb246ZjdhM2MwMWU1OTg4NDJiZDhkMzlkZWE0ZTI5OGEwYjFfODc5NjA5MzAyMzc0OQ_b09a286c-fda2-40ce-b0d7-2f2e00cbbab1"
      unitRef="shares">267</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDY1MQ_37e0fd90-4748-4b04-883d-d652af0b819d">SHARE-BASED COMPENSATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued non-qualified and incentive stock options to employees and non-employee directors. The fair value of these options are estimated on the date of grant using the Black-Scholes option pricing model, which requires estimates of the expected term of the option, the risk-free interest rate, the expected volatility of the price of the Company&#x2019;s common stock, and dividend yield. Options outstanding as of March&#160;31, 2022 generally vest over a period of three years and expire ten years from the date of grant. The exercise price of these options ranges from $26.52 to $66.68. Due to the Company&#x2019;s lack of option exercise history on the date of grant, the expected term is calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each option. The risk free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant that most closely corresponds to the expected term of the option. The expected volatility is based on the historical volatility of the Company&#x2019;s common stock over the period of time equivalent to the expected &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;term for each award. The dividend yield is computed as the annualized dividend rate at the grant date divided by the strike price of the stock option. For the three months ended March 31, 2022 and 2021, the Company did not grant stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of our stock option activity (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercisable at end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the weighted-average remaining contractual life for outstanding stock options was 5.1 years with an aggregate intrinsic value of $3.8 million and the weighted-average remaining contractual life for exercisable stock options was 4.9 years with an aggregate intrinsic value of $3.3 million. The unrecognized compensation expense calculated under the fair value method for stock options expected to vest as of March&#160;31, 2022 was $0.1 million and is expected to be recognized over a weighted-average period of 0.9 year. For the three months ended March 31, 2022, there was no exercise activity of stock options. For the three months ended March 31, 2021, the Company received $0.5 million in cash proceeds from the exercise of stock options. The total intrinsic value for stock options exercised during the three months ended March 31, 2021 was $2.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued restricted stock to employees and non-employee directors generally with vesting terms up to five years after the date of grant. The fair value of the restricted stock is equal to the market price of the Company&#x2019;s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our restricted stock activity (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company withheld approximately 8,000 and 7,000 shares of the Company&#x2019;s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of restricted stock for the three months ended March 31, 2022 and 2021, respectively. The total fair value of restricted stock awards vested during the three months ended March 31, 2022 and 2021 was $3.2 million and $3.9 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Market and Performance-based Share Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued market and performance-based share awards to certain key executives who were granted deferred shares and may earn between 0% and 250% of the target number depending upon both the Company's total stockholder return and the Company's performance against predetermined performance goals over a three-year performance period after the date of grant. Market and performance-based share awards that are tied to the Company&#x2019;s total stockholder return are valued using the Monte Carlo method and are recognized ratably as expense over the award&#x2019;s performance period. The fair value of the performance-based share awards is equal to the market price of the Company&#x2019;s common stock on the date of grant adjusted by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expected level of achievement over the performance period. Expense for performance-based share awards is amortized ratably over the performance period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense is recorded in selling, general, and administrative expense in the accompanying Condensed Consolidated Statements of Income. The total expenses during the three months ended March 31, 2022 and 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options and restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Performance-based share awards granted in 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Performance-based share awards granted in 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Performance-based share awards granted in 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Performance-based share awards granted in 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total income tax benefit recognized in the accompanying Condensed Consolidated Statements of Income for restricted stock awards was $0.5 million and $1.2 million for the three months ended March 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $8.8 million of total unrecognized compensation cost related to restricted stock awards as of March&#160;31, 2022, which is expected to be recognized over a weighted-average period of 2.4 years. There was $11.0 million of unrecognized compensation costs related to the 66,000 performance-based shares discussed above as of March&#160;31, 2022, which is expected to be recognized over a weighted-average period of 2.1 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg4MQ_b31e7ab3-db6f-4ff3-8557-3beb82e66631">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg4Ng_8a4e1635-f887-4dce-aaaf-5179d238551a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg5MQ_70b7d88d-4a20-418d-90b5-748f84fd3394"
      unitRef="usdPerShare">26.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg5NQ_f61982d4-1613-439b-baec-f75ee55e1d35"
      unitRef="usdPerShare">66.68</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDM5ODA0NjUyNDQ1Nw_83fa08fd-b902-47a4-9b0b-01363256cd06"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDM5ODA0NjUyNDQ1Nw_ff1f768f-bcf1-4c03-a406-e7eb9a1a5381"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDY0OA_e1e78f13-341a-448a-863b-10d4efc24b25">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of our stock option activity (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercisable at end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie2bb291e995d4d86b1e75f18f4e74ee5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNC0xLTEtMS00ODg_ce48a462-f571-4e53-a542-d2a33650d2af"
      unitRef="shares">32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie2bb291e995d4d86b1e75f18f4e74ee5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNC0zLTEtMS00ODg_ede6d234-c3ef-42ae-bf9b-7d182da2b2ad"
      unitRef="usdPerShare">54.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9c217599ebec4b3589ddacf77b65907d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNC01LTEtMS00ODg_0e38bfcf-9545-4752-bb6c-952388ce105d"
      unitRef="shares">61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9c217599ebec4b3589ddacf77b65907d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNC03LTEtMS00ODg_309eeb60-a3da-4361-953a-45e2f5f9e047"
      unitRef="usdPerShare">48.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie2b6de404d154f3f8c233c0224e3b3e7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNS0xLTEtMS00ODg_0df8c33e-0b6c-4234-873d-63df8282d20d"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie2b6de404d154f3f8c233c0224e3b3e7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNS0zLTEtMS00ODg_b6dde6fc-e2b8-4877-8c52-486d119f5ecd"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if341a78362b04aefa35a1524227f0dcc_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNS01LTEtMS00ODg_f6172879-bac6-428f-a66f-f773e1461f16"
      unitRef="shares">11</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if341a78362b04aefa35a1524227f0dcc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNS03LTEtMS00ODg_ed0829c8-8488-411e-bbee-9c60d17c9da3"
      unitRef="usdPerShare">42.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2b3ce0080ee84b2f978c642e022afcc3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNy0xLTEtMS00ODg_cecd9722-86c5-438d-9ae9-f24c7582e8c1"
      unitRef="shares">32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2b3ce0080ee84b2f978c642e022afcc3_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNy0zLTEtMS00ODg_75a6ab6f-f3c9-4ae4-949a-e4038523fa19"
      unitRef="usdPerShare">54.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6b9de190e3684b94a74889bd8f6df7f4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNy01LTEtMS00ODg_82ecb242-8005-46b9-bdd9-c9ab012c4708"
      unitRef="shares">50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6b9de190e3684b94a74889bd8f6df7f4_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfNy03LTEtMS00ODg_95988267-fd80-4921-86c2-6021e6009872"
      unitRef="usdPerShare">49.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2b3ce0080ee84b2f978c642e022afcc3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfOC0xLTEtMS00ODg_bac23722-c03e-4264-a03f-ea3caf05b654"
      unitRef="shares">28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2b3ce0080ee84b2f978c642e022afcc3_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfOC0zLTEtMS00ODg_f96b30b3-a110-4afb-8870-f6c4c51fe3e1"
      unitRef="usdPerShare">52.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6b9de190e3684b94a74889bd8f6df7f4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfOC01LTEtMS00ODg_74693041-a82f-4fe9-bc19-da18e3562120"
      unitRef="shares">41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6b9de190e3684b94a74889bd8f6df7f4_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjE3MTZjMmU4MzUzZTQ5MThiY2I1YWJkNzI0ZjBlMmJkL3RhYmxlcmFuZ2U6MTcxNmMyZTgzNTNlNDkxOGJjYjVhYmQ3MjRmMGUyYmRfOC03LTEtMS00ODg_4ed29149-ebfb-4f0a-8931-f8be6e6d9e28"
      unitRef="usdPerShare">44.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg2NQ_e0317c37-cb7e-4b52-bd86-4a21a8bb5362">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic66942bf9f2549b198eead688af58b58_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjg3MA_3d873a22-b858-4fac-bbce-17ab39f1a86b"
      unitRef="usd">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjkyNg_5eab3294-562d-496b-94d7-6824172d1dc6">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ic66942bf9f2549b198eead688af58b58_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjkzMg_f876af45-3c0d-452d-99ac-9ce27df346d6"
      unitRef="usd">3300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic66942bf9f2549b198eead688af58b58_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjk0Mw_038ef0f6-95c3-4f5c-85a8-31dc7bfa0abe"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ifb2698c9181b42fb9bfdb178e247fb09_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNjk0Nw_b4492403-45a1-4a44-a1bc-973fc19599c3">P0Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzAxOQ_97ba8bc2-69ee-4f2c-9e9a-fca7a09be97d"
      unitRef="usd">500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie622384d50f24bd79471044dac2a7bff_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzAyMw_17e114a3-7e74-4be7-a7dc-459065f8112d"
      unitRef="usd">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzA0Ng_ddbec9e4-6f06-4d9b-9db5-d30840b30987">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDY0OQ_90822047-4bdc-4976-8358-ecfd1e7babf5">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our restricted stock activity (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9a78198c05df4b5a8deb5385b586ffe7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNC0xLTEtMS00ODg_645995e6-47f7-4f2c-b6ee-00c8dad88770"
      unitRef="shares">43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9a78198c05df4b5a8deb5385b586ffe7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNC0zLTEtMS00ODg_e2a993ca-3f74-43a1-b9c2-bb946d3cafd9"
      unitRef="usdPerShare">183.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iec6e288c739f42379b23b2ef8e67c86d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNC01LTEtMS00ODg_13a44197-9301-45c3-8d07-c151d0f47fd6"
      unitRef="shares">50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iec6e288c739f42379b23b2ef8e67c86d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNC03LTEtMS00ODg_a2d2f077-1be3-4be9-9f9d-18abed6a9711"
      unitRef="usdPerShare">116.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNS0xLTEtMS00ODg_0fc6c2ac-c0d7-4bb5-9562-821bc769e7b8"
      unitRef="shares">29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNS0zLTEtMS00ODg_c037e90d-e32d-4128-9fef-dbde698d2634"
      unitRef="usdPerShare">175.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNS01LTEtMS00ODg_7764ded0-d2a3-4b8a-96fa-cd7df71168e3"
      unitRef="shares">17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNS03LTEtMS00ODg_d87fea9e-66fc-4db5-a502-f2aae95aed40"
      unitRef="usdPerShare">253.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNi0xLTEtMS00ODg_108289ed-c700-42e2-9c6c-7f618ae60545"
      unitRef="shares">18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNi0zLTEtMS00ODg_c373d7a0-b6bd-492c-8051-8ae803534f5d"
      unitRef="usdPerShare">149.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNi01LTEtMS00ODg_3a3ea31b-afb8-4ee2-b916-187e7f543a71"
      unitRef="shares">14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfNi03LTEtMS00ODg_0949765c-eb8a-4f05-822a-ab24b21e93c7"
      unitRef="usdPerShare">109.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8da58c43207b48f6a1b9e434f1ac7154_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfOC0xLTEtMS00ODg_c7f2f739-87e9-4896-88ae-387e924c8543"
      unitRef="shares">54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8da58c43207b48f6a1b9e434f1ac7154_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfOC0zLTEtMS00ODg_3ccbf9b3-c2c4-4352-92ef-439e9ffce9a4"
      unitRef="usdPerShare">190.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i725856e7f4ec432cacc3baf8010f0fe5_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfOC01LTEtMS00ODg_7f867bed-9719-4869-95cb-fb5293e4e30d"
      unitRef="shares">53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i725856e7f4ec432cacc3baf8010f0fe5_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOjhmMDg1YTgzMjBiYjRmMDBhNDViZDkyZjlmYzk3Y2NiL3RhYmxlcmFuZ2U6OGYwODVhODMyMGJiNGYwMGE0NWJkOTJmOWZjOTdjY2JfOC03LTEtMS00ODg_ea5dcc7e-7757-46a7-babb-0566d1b653a5"
      unitRef="usdPerShare">157.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzA4NA_4e2c63e8-1177-4836-bdf0-303150ed32be"
      unitRef="shares">8000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzA5MQ_b5c81af1-6ed4-4b8f-834f-50330c3a51b1"
      unitRef="shares">7000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfMTA5OTUxMTY0MTg0NQ_d418a0b6-77e8-402e-947c-ea76300bbb2c"
      unitRef="usd">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyNzEzMQ_f95cd9d4-e46b-4c24-accb-ca6a0d22ddc6"
      unitRef="usd">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfNDM5ODA0NjUyNDMyNg_d3e27c7c-56e6-44bc-9128-705af82aece5">The total expenses during the three months ended March 31, 2022 and 2021 are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options and restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Performance-based share awards granted in 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Performance-based share awards granted in 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Performance-based share awards granted in 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Performance-based share awards granted in 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i11d54eafa8284f25ac3bd19cff7f6312_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfMy0xLTEtMS0yMzAxMw_e8bd4ab1-2776-462b-9f95-8de98ac9ff5e"
      unitRef="shares">86000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11d54eafa8284f25ac3bd19cff7f6312_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfMy0zLTEtMS0yMzAwNQ_196e9189-605d-4102-80bb-562dcac24ccb"
      unitRef="usd">1087000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i709a3e52837649cbbf38c0e95f31cc71_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfMy01LTEtMS0yMzAyMA_44a13463-01f6-40d6-9c5b-e4b76a0ccd57"
      unitRef="shares">103000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i709a3e52837649cbbf38c0e95f31cc71_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfMy03LTEtMS0yMzAyMw_cec60a0f-b55e-4f27-8607-2ab39e5a5701"
      unitRef="usd">938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if7869becf472402087fb85cd424874b6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNC0xLTEtMS0yMzAxMw_ce480ff7-4675-41a0-a43f-34914f3ad26c"
      unitRef="shares">25000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7869becf472402087fb85cd424874b6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNC0zLTEtMS0yMzAwNQ_5a356806-5212-4897-8122-cc516922f914"
      unitRef="usd">79000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i21d3b43d4638447b812e122f37bd7ad9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNC01LTEtMS0yMzAyMA_4aacceba-cfcf-4d6b-a310-b874a83d2537"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i21d3b43d4638447b812e122f37bd7ad9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNC03LTEtMS0yMzAyMw_c59f7b25-3963-4ca5-b698-efabcff9307c"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5c4d1405e900437a8c01cb40906f7245_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNS0xLTEtMS0yMzAxMw_eef67804-e646-4b2b-a5d4-3a962eb1e25e"
      unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5c4d1405e900437a8c01cb40906f7245_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNS0zLTEtMS0yMzAwNQ_45568252-c098-486a-9efc-ede905fd555d"
      unitRef="usd">640000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie07a6fa52afa4a8a8e828f7b91d96c7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNS01LTEtMS0yMzAyMA_f750384e-bdb7-4b82-aa80-83d9140903b0"
      unitRef="shares">14000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie07a6fa52afa4a8a8e828f7b91d96c7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNS03LTEtMS0yMzAyMw_374789fb-41b1-488b-8381-57c7d05a1e25"
      unitRef="usd">54000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id6500946c2204f099dd45b758d12ef35_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi0xLTEtMS0yNTAzMA_bb9c4df4-24ec-45a2-b720-f369a95d1167"
      unitRef="shares">26000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id6500946c2204f099dd45b758d12ef35_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi0zLTEtMS0yNTAzOA_fbb749f3-f7b2-4ba1-bb44-2a4e02b61e4f"
      unitRef="usd">469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ifd4d70137b9f4805a994076e0d6ab3c9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi01LTEtMS0yNTA5Mg_9875930d-49d2-4716-8717-8b6c84d2666e"
      unitRef="shares">28000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd4d70137b9f4805a994076e0d6ab3c9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi03LTEtMS0yNTEwMg_227cf3dd-dde4-4e1d-afb6-c31e58fe7403"
      unitRef="usd">495000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9dd3cc3169134d66a71696dd84d37aa2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi0xLTEtMS0yNDQ5Mg_2eb23019-1f8f-4b52-8778-38f300be9810"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9dd3cc3169134d66a71696dd84d37aa2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi0zLTEtMS0yNDUxNQ_0da60bb4-36e6-450a-b676-906554d8233b"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8a672405cc1c46b1ab2da765c6d7a422_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi01LTEtMS0yNDUzNQ_89e6bf4b-7950-447d-a85b-596c2b33928d"
      unitRef="shares">17000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8a672405cc1c46b1ab2da765c6d7a422_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNi03LTEtMS0yNDU1NQ_2b20c817-2277-480e-9c34-6450e2335a99"
      unitRef="usd">711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNy0xLTEtMS0yMzAxMw_04662004-dc60-4609-82ce-1abaedfa66bb"
      unitRef="shares">152000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNy0zLTEtMS0yMzAwNQ_a04c7850-2036-430f-a096-78e802fdd864"
      unitRef="usd">2275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNy01LTEtMS0yMzAyMA_9656d455-2594-4c43-88f6-660656b90370"
      unitRef="shares">162000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RhYmxlOmViMWE0NjMzZjY1ODRlNzM5MzQ4YzQwZDc1ODhlNTk3L3RhYmxlcmFuZ2U6ZWIxYTQ2MzNmNjU4NGU3MzkzNDhjNDBkNzU4OGU1OTdfNy03LTEtMS0yMzAyMw_517fa7e9-f0d9-42e6-9683-e6e758bfceed"
      unitRef="usd">2198000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfMTA5OTUxMTY0MTg2MA_dacd7c4c-5876-498d-92e8-956f1dd68a6a"
      unitRef="usd">500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i2b533bda471c43de8c9462b34a0d9a43_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyODM5OQ_1143e1f0-5794-4701-99f1-40debec3e4fc"
      unitRef="usd">1200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i8da58c43207b48f6a1b9e434f1ac7154_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfMTA5OTUxMTY0MTg3NQ_6ef1ae7e-36c2-4ad8-b7ac-ef524f263296"
      unitRef="usd">8800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9500da6417d34000ac404737b417d8bd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfMTA5OTUxMTYzOTUyNA_76115c54-fa08-478a-98f6-2d435e455ded">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ifb1830bc344d452b941276a1a72aeebc_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyODQ0Ng_fab484b4-ba32-4402-92be-5130adc7a4e3"
      unitRef="usd">11000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icd9ad4c02af44a4c8285da667d06c96c_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyODQzOQ_93cd8ab1-3a88-47b6-8132-97873fc7f6b6"
      unitRef="shares">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="icd9ad4c02af44a4c8285da667d06c96c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80My9mcmFnOjBkNGJlOWQwMjNjMTQ4NDJhNzE4YWRkNGFhNGYyYzNiL3RleHRyZWdpb246MGQ0YmU5ZDAyM2MxNDg0MmE3MThhZGQ0YWE0ZjJjM2JfODc5NjA5MzAyODQ1MA_fee45fcc-2ed9-4693-94ea-96d1867fd562">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfMTQyOQ_74f77f9b-7522-4f59-9374-4b78f0a638de">LEASES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for office and warehouse space and certain equipment. In certain of the Company&#x2019;s lease agreements, the rental payments are adjusted periodically based on defined terms within the lease. The Company did not have any finance leases as of March&#160;31, 2022 and 2021, respectively, or for the three-month periods then ended, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our leases relating to office and warehouse space have lease terms of 18 months to 126 months. Our leases relating to equipment have lease terms of 24 months to 203 months, with certain of them having automatic renewal clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s warehouse agreements also contain non-lease components, in the form of payments towards variable logistics services and labor charges, which the Company is obligated to pay based on the services consumed by it. Such amounts are not included in the measurement of the lease liability but are recognized as expenses when they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating lease expense was $1.8 million and $1.0 million for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to the Company&#x2019;s operating leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cash paid for amounts included in the measurements of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Operating cash flow used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the weighted average remaining lease term was 5.3 years and the weighted average discount rate was  2.1%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the maturity of the Company&#x2019;s operating lease liabilities as of March&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:FinanceLeaseLiability
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfMjY4_2c65b672-49d5-43a4-bbb1-506d9c7b8008"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i7a9e8a7828aa4da5bce1881ad3c595da_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfMjY4_c0d86698-a044-4e4d-a647-58eb0dbbf8cf"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="id40d4dcdbd49490291af588086ec5521_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzY2Mw_286e4f09-3927-4f3e-a917-2787098f5702">P18M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i0c29fd8c68674ff7803a9bee93d6d42a_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzY2OQ_8c14af2f-d454-41d9-8337-11d70b52dafd">P126M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia1c011b39e09482b9d155a886f684109_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzY3NA_3de5fba5-1c60-4ca9-b028-dfda7e0e319b">P24M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie77f1726dab04431a3971d0a6973047b_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzY3OA_61a74316-6c3c-4fa0-8a92-d8c2cd9e99da">P203M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseExpense
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzc5Nw_d2952dda-a314-4eda-b826-705c66d1bbbd"
      unitRef="usd">1800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzc5Mw_25abffea-8989-4371-947f-ef2909ce9bb3"
      unitRef="usd">1000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfMTQzMA_85641d7e-b3ed-47e8-bf66-2070de5dea25">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to the Company&#x2019;s operating leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cash paid for amounts included in the measurements of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Operating cash flow used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOjJlMWFjNjA3YzlhMDRhZTc4YzQwNWNmNjU4MjU5ZWFjL3RhYmxlcmFuZ2U6MmUxYWM2MDdjOWEwNGFlNzhjNDA1Y2Y2NTgyNTllYWNfNC0xLTEtMS00ODg_313b6ed1-a96b-4b9b-979d-613e560a7400"
      unitRef="usd">1756000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOjJlMWFjNjA3YzlhMDRhZTc4YzQwNWNmNjU4MjU5ZWFjL3RhYmxlcmFuZ2U6MmUxYWM2MDdjOWEwNGFlNzhjNDA1Y2Y2NTgyNTllYWNfNC0zLTEtMS00ODg_0d1da9d4-2bc3-4d5e-9bda-874f2d7ade41"
      unitRef="usd">1002000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOjJlMWFjNjA3YzlhMDRhZTc4YzQwNWNmNjU4MjU5ZWFjL3RhYmxlcmFuZ2U6MmUxYWM2MDdjOWEwNGFlNzhjNDA1Y2Y2NTgyNTllYWNfNy0xLTEtMS00ODg_eed18d68-df4c-4ea0-bcbe-59ab4b5ee25c"
      unitRef="usd">103000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOjJlMWFjNjA3YzlhMDRhZTc4YzQwNWNmNjU4MjU5ZWFjL3RhYmxlcmFuZ2U6MmUxYWM2MDdjOWEwNGFlNzhjNDA1Y2Y2NTgyNTllYWNfNy0zLTEtMS00ODg_23610e0a-7fa1-4116-a6dd-5b700b9d931c"
      unitRef="usd">11000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzg2NA_60b4fa59-db35-492b-a48f-ee492c9f2019">P5Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfODc5NjA5MzAyMzg2OA_4b3110b0-dd00-4f84-8a62-b2938abb2393"
      unitRef="number">0.021</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RleHRyZWdpb246MTg3Y2E5OTg1Zjg1NDQ5NDk5N2QwMTRmZmYwMTVlYjJfMTQzMQ_afd93b53-7d4b-4fda-b818-ce1c3d75e835">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the maturity of the Company&#x2019;s operating lease liabilities as of March&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2022 (excluding the three months ended March&#160;31, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfMC0xLTEtMS00ODg_da8967c4-4cb6-4e08-be04-680e27b48bf2"
      unitRef="usd">5443000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfMS0xLTEtMS00ODg_8875e7dc-8602-47ce-ae36-59b1e8770027"
      unitRef="usd">6242000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfMi0xLTEtMS00ODg_5c38963c-ac52-4a25-b97f-a2dfc6136355"
      unitRef="usd">5693000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfMy0xLTEtMS00ODg_76d32d4a-a485-4c13-a536-bf723d9600e2"
      unitRef="usd">5825000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfNC0xLTEtMS00ODg_4cf44fc4-f4f0-42b5-ac8e-7902c642441f"
      unitRef="usd">4160000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <med:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfNS0xLTEtMS00ODg_52f8817f-e01f-493a-b28a-c9ca67462796"
      unitRef="usd">5412000</med:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfNi0xLTEtMS00ODg_2c4ed829-743e-42ae-ba33-6ef09026a750"
      unitRef="usd">32775000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfNy0xLTEtMS00ODg_289507b5-a5fc-4658-a2a6-e1e0538c08c7"
      unitRef="usd">1733000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80Ni9mcmFnOjE4N2NhOTk4NWY4NTQ0OTQ5OTdkMDE0ZmZmMDE1ZWIyL3RhYmxlOmUyOWM2Nzg3MzI5NDQ1MjU4ZjY4MTM5MzgzNzJhMTk2L3RhYmxlcmFuZ2U6ZTI5YzY3ODczMjk0NDUyNThmNjgxMzkzODM3MmExOTZfOC0xLTEtMS00ODg_cee62b9e-52c1-489f-8904-55995396bf6d"
      unitRef="usd">31042000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RleHRyZWdpb246OThkMzI1ZmUyZGJjNDA2ZmIxMTMwNzZmNjE2NjI0YTlfMTgw_ed218144-b820-4ba9-a36d-8b556ca269b0">ACCUMULATED OTHER COMPREHENSIVE INCOME&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Unrealized gains on investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RleHRyZWdpb246OThkMzI1ZmUyZGJjNDA2ZmIxMTMwNzZmNjE2NjI0YTlfMTgx_3f415d87-f4b3-4194-ae1f-1198ec70d3a0">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Unrealized gains on investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accumulated other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfMi0xLTEtMS00ODg_f2c10cf4-e800-4977-b383-b40a47f88818"
      unitRef="usd">120000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfMi0zLTEtMS00ODg_fb82ba1a-b00f-4ee4-b9b7-df80eca4cd18"
      unitRef="usd">90000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfMy0xLTEtMS00ODg_4a84a308-c8e9-483b-adb2-22afd91aff0a"
      unitRef="usd">7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfMy0zLTEtMS00ODg_bc99205f-6f7c-4866-b4e5-a3871f111756"
      unitRef="usd">21000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfNC0xLTEtMS00ODg_0f65660e-5bd0-4c1a-b5e3-2c6866f22377"
      unitRef="usd">127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF80OS9mcmFnOjk4ZDMyNWZlMmRiYzQwNmZiMTEzMDc2ZjYxNjYyNGE5L3RhYmxlOmVjMmFiMzgzZGIyODRmNmU4ZDk4ZTRiMzA2ZDczNTM1L3RhYmxlcmFuZ2U6ZWMyYWIzODNkYjI4NGY2ZThkOThlNGIzMDZkNzM1MzVfNC0zLTEtMS00ODg_f66949e4-5117-48c4-9015-f4c316c45bf0"
      unitRef="usd">111000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RleHRyZWdpb246YzU4MmRkNzYwZTNjNDg3ZjhmNzE2MzM2NmEzMWZhODZfMTYyMA_2d975109-9370-472e-a101-bc1877d1414a">FINANCIAL INSTRUMENTS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2013; Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2013; Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2013; Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management&#x2019;s best estimate of fair value from the perspective of a market participant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the Company&#x2019;s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Accrued Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Cash &amp;amp; Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Investment&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Accrued Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Cash &amp;amp; Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Investment&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no realized losses or gains for the three months ended March 31, 2022 and 2021, respectively. As of March&#160;31, 2022, the maturities of the Company&#x2019;s investment securities were less than one year for all the municipal bonds, and government and agency securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RleHRyZWdpb246YzU4MmRkNzYwZTNjNDg3ZjhmNzE2MzM2NmEzMWZhODZfMTYyMQ_f8c96eff-3577-4e74-8ca4-755f62801270">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the Company&#x2019;s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Accrued Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Cash &amp;amp; Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Investment&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Accrued Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Estimated Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Cash &amp;amp; Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"&gt;Investment&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecurities
      contextRef="i6f1737eb3fa34225b424226bad5f803d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMy0xLTEtMS00ODg_27bd4461-8f5d-4d55-a654-ebdc0df6b5f8"
      unitRef="usd">107342000</us-gaap:MarketableSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6f1737eb3fa34225b424226bad5f803d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMy03LTEtMS00ODg_d9a0aaf9-86dd-4a29-b71d-56748844df70"
      unitRef="usd">107342000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6f1737eb3fa34225b424226bad5f803d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMy05LTEtMS00ODg_9448046d-3373-4f36-a433-4923eaa6deb7"
      unitRef="usd">107342000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="ibe8f508f43e54111833213da6455af89_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNi0xLTEtMS00ODg_80e8a548-76bc-414f-8d5b-df658927d137"
      unitRef="usd">10661000</us-gaap:MarketableSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibe8f508f43e54111833213da6455af89_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNi03LTEtMS00ODg_4e23279d-ec8d-4b3f-adec-05af25626a3d"
      unitRef="usd">10661000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibe8f508f43e54111833213da6455af89_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNi05LTEtMS00ODg_6d14955a-699f-4cbf-93e6-2b52019f480c"
      unitRef="usd">10661000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i6407fc628f864d3fa3ae6e4aac9245af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNy0xLTEtMS00ODg_6a1cbd25-97bb-4442-8257-f430d755eef2"
      unitRef="usd">1401000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="icaa9fb09240445bf98fca5702ebfec16_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNy0zLTEtMS00ODg_d175e125-c379-4c7e-989e-d634f3d06d5c"
      unitRef="usd">5000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:InterestReceivable
      contextRef="i6407fc628f864d3fa3ae6e4aac9245af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNy01LTEtMS00ODg_8fb47092-4cda-4b92-bd45-2d7b0db35c47"
      unitRef="usd">8000</us-gaap:InterestReceivable>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6407fc628f864d3fa3ae6e4aac9245af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNy03LTEtMS00ODg_5fe15efc-78c8-4f80-92fe-74fefb2e0745"
      unitRef="usd">1414000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="i6407fc628f864d3fa3ae6e4aac9245af_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfNy0xMS0xLTEtNDg4_543bc8eb-621f-44fa-b71e-c62e6df1c522"
      unitRef="usd">1414000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:MarketableSecurities
      contextRef="i8513597370b84626bfb13b09cf0983ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC0xLTEtMS00ODg_a5279ff8-8984-40c3-89ec-21427b727884"
      unitRef="usd">12062000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i653038e869054618added697946df31b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC0zLTEtMS00ODg_3ae1acf4-7293-4fce-9dec-fe683f33b7e4"
      unitRef="usd">5000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:InterestReceivable
      contextRef="i8513597370b84626bfb13b09cf0983ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC01LTEtMS00ODg_07ac477a-ff9a-491f-ba46-ed7fc5219b96"
      unitRef="usd">8000</us-gaap:InterestReceivable>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8513597370b84626bfb13b09cf0983ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC03LTEtMS00ODg_6a3b76f6-123e-4321-bbe5-2be81160c83c"
      unitRef="usd">12075000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8513597370b84626bfb13b09cf0983ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC05LTEtMS00ODg_876c6893-913f-4d02-84ff-426a89e9160a"
      unitRef="usd">10661000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="i8513597370b84626bfb13b09cf0983ee_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfOC0xMS0xLTEtNDg4_180a9342-187e-4b09-a3dd-02479be78bda"
      unitRef="usd">1414000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:MarketableSecurities
      contextRef="i64a5e80f0c594a478bfaeab9d9c75376_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTEtMS0xLTEtNDg4_c4a77644-5bb3-4e95-8251-763a0624503d"
      unitRef="usd">2625000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ief468fba41754dcfb701ff282f1d7886_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTEtMy0xLTEtNDg4_bb9898d8-fdd4-4073-98c2-093b9f28ce70"
      unitRef="usd">2000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:InterestReceivable
      contextRef="i64a5e80f0c594a478bfaeab9d9c75376_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTEtNS0xLTEtNDg4_c81511c7-2bd8-43fe-8bfb-c12635f40ce1"
      unitRef="usd">16000</us-gaap:InterestReceivable>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i64a5e80f0c594a478bfaeab9d9c75376_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTEtNy0xLTEtNDg4_dc17f5de-1a46-4ddc-a060-3871a29ce601"
      unitRef="usd">2643000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="i64a5e80f0c594a478bfaeab9d9c75376_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTEtMTEtMS0xLTQ4OA_1607eee0-c687-4c7e-8036-84bc090cc6ac"
      unitRef="usd">2643000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:MarketableSecurities
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtMS0xLTEtNDg4_b940d6a2-c9eb-4e45-9217-2530e91079ef"
      unitRef="usd">122029000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtMy0xLTEtNDg4_78977b39-978e-406b-96e0-f1380308b62a"
      unitRef="usd">7000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:InterestReceivable
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtNS0xLTEtNDg4_955bcf8e-e40c-49e8-bf1e-33e37b193328"
      unitRef="usd">24000</us-gaap:InterestReceivable>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtNy0xLTEtNDg4_dde9d688-26ae-4973-a0c6-a741063aae36"
      unitRef="usd">122060000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtOS0xLTEtNDg4_2f7b5a15-48c8-4d53-890c-2b667f2a1796"
      unitRef="usd">118003000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="i82c8748a0dca4006b1fc0390e3411793_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjJiOGE5MzliYTk1NjQ4ZWU4NmYzN2JlNThjNzc2MjBhL3RhYmxlcmFuZ2U6MmI4YTkzOWJhOTU2NDhlZTg2ZjM3YmU1OGM3NzYyMGFfMTMtMTEtMS0xLTQ4OA_bc4d6035-c61a-4656-9741-c3775e526feb"
      unitRef="usd">4057000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:MarketableSecurities
      contextRef="i974db996e18c46f18311cfb1651cd09d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMy0xLTEtMS00ODg_da81e825-f505-43be-90af-d732a03fc3b4"
      unitRef="usd">94824000</us-gaap:MarketableSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i974db996e18c46f18311cfb1651cd09d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMy03LTEtMS00ODg_130dd6da-a10f-4b07-84bf-3fc0ab670bb0"
      unitRef="usd">94824000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i974db996e18c46f18311cfb1651cd09d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMy05LTEtMS00ODg_8f049386-d4ef-4ef3-9648-90bfb0f03098"
      unitRef="usd">94824000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i235c14ce303349c8b5bd8fb87f69b715_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNi0xLTEtMS00ODg_cc3b4c65-8221-44d7-ab9f-738e68f434c0"
      unitRef="usd">9359000</us-gaap:MarketableSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i235c14ce303349c8b5bd8fb87f69b715_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNi03LTEtMS00ODg_e1ba2c37-b749-47bb-bb8b-0366d4e723a1"
      unitRef="usd">9359000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i235c14ce303349c8b5bd8fb87f69b715_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNi05LTEtMS00ODg_bea56705-0ae3-40df-a624-88fa1752cc93"
      unitRef="usd">9359000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="ife377ae99f2f433eb0a7cf0a05c6b0dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNy0xLTEtMS00ODg_509b7d50-48e0-4433-beb6-69dcc439b6af"
      unitRef="usd">1401000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ia79de0bb84114512b113cea98756e693_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNy0zLTEtMS00ODg_8f950135-ae2d-4c7d-92c7-bd21b0ef451f"
      unitRef="usd">12000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ife377ae99f2f433eb0a7cf0a05c6b0dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNy03LTEtMS00ODg_b9e3adef-f0b4-4a8d-b57e-141e255e21dc"
      unitRef="usd">1413000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="ife377ae99f2f433eb0a7cf0a05c6b0dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfNy0xMS0xLTEtNDg4_ae0cb53d-8c6b-4149-8a0d-d916d6cc1d1b"
      unitRef="usd">1413000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:MarketableSecurities
      contextRef="icc62a0c317534ee789386d9dc17785ad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfOC0xLTEtMS00ODg_ed79de0f-594c-400a-b85d-632a0747a75c"
      unitRef="usd">10760000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i1ce626a32c3a44f081b4594e23a21964_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfOC0zLTEtMS00ODg_e29c6725-7e69-4b2f-a1c5-feb86454871e"
      unitRef="usd">12000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="icc62a0c317534ee789386d9dc17785ad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfOC03LTEtMS00ODg_2e087011-10c8-421a-acd0-d4880c887229"
      unitRef="usd">10772000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icc62a0c317534ee789386d9dc17785ad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfOC05LTEtMS00ODg_af10ef71-90c6-4b9f-b224-e82749c329d4"
      unitRef="usd">9359000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="icc62a0c317534ee789386d9dc17785ad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfOC0xMS0xLTEtNDg4_8f377939-7811-46e1-a45f-7ffc88bfa51b"
      unitRef="usd">1413000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:MarketableSecurities
      contextRef="i7de4c2e8202f4fccbc696b8231685861_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTEtMS0xLTEtNDg4_561c6a73-7aa3-4556-bb5f-a43d3aa092eb"
      unitRef="usd">3880000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ib61ff22c30ce4b0caf4653ce9e1255e2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTEtMy0xLTEtNDg4_2f67ba07-ee76-4099-ae26-8a80026364f4"
      unitRef="usd">9000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:InterestReceivable
      contextRef="i7de4c2e8202f4fccbc696b8231685861_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTEtNS0xLTEtNDg4_138dd1bb-501e-4c77-8991-a87a000aabb6"
      unitRef="usd">59000</us-gaap:InterestReceivable>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7de4c2e8202f4fccbc696b8231685861_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTEtNy0xLTEtNDg4_b508ee02-d6ee-4a83-a50a-0fbe22eb1bb1"
      unitRef="usd">3948000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="i7de4c2e8202f4fccbc696b8231685861_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTEtMTEtMS0xLTQ4OA_b68ff0d2-8882-4d9c-bee1-ec2d52d335e5"
      unitRef="usd">3948000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:MarketableSecurities
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtMS0xLTEtNDg4_8a1899e0-f06d-49c4-b702-53485742c0a4"
      unitRef="usd">109464000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ia68ebc6c33294b0189b4af137724ab7b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtMy0xLTEtNDg4_236a8df3-9395-4f2c-81e8-e0ae2c105494"
      unitRef="usd">21000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:InterestReceivable
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtNS0xLTEtNDg4_fabb1610-c72e-4148-aceb-077295206709"
      unitRef="usd">59000</us-gaap:InterestReceivable>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtNy0xLTEtNDg4_db21ad1f-9146-4912-be7a-cbdd57b393e8"
      unitRef="usd">109544000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtOS0xLTEtNDg4_efb547bd-5b90-434c-aed0-0c231950d25f"
      unitRef="usd">104183000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="i50029b51a6fc4239b1bdc483c08fbdc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RhYmxlOjNlNDY5NDViNDkzMTRkMGU4OWIxMmM4ZDY3YWI1NDMzL3RhYmxlcmFuZ2U6M2U0Njk0NWI0OTMxNGQwZTg5YjEyYzhkNjdhYjU0MzNfMTMtMTEtMS0xLTQ4OA_b4b5a052-f45a-438d-8def-f28caa9b214b"
      unitRef="usd">5361000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:DebtAndEquitySecuritiesRealizedGainLoss
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RleHRyZWdpb246YzU4MmRkNzYwZTNjNDg3ZjhmNzE2MzM2NmEzMWZhODZfMTQwMw_04eca04f-cace-4e39-b759-0b9e550f750f"
      unitRef="usd">0</us-gaap:DebtAndEquitySecuritiesRealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesRealizedGainLoss
      contextRef="i3de035571620420bb741ec985a844201_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81Mi9mcmFnOmM1ODJkZDc2MGUzYzQ4N2Y4ZjcxNjMzNjZhMzFmYTg2L3RleHRyZWdpb246YzU4MmRkNzYwZTNjNDg3ZjhmNzE2MzM2NmEzMWZhODZfMTQwMw_3b648237-2e6b-48b7-8758-8035a7cf6d33"
      unitRef="usd">0</us-gaap:DebtAndEquitySecuritiesRealizedGainLoss>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfMzE1OA_31e49db6-99a7-4397-a59b-3f47536e283a">DEBT&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;13, 2021, the Company and certain of its subsidiaries (collectively, the &#x201c;Guarantors&#x201d;) entered into a credit agreement (the &#x201c;Credit Agreement&#x201d;) among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;administrative agent. The Credit Agreement provides for a $125.0 million senior secured revolving credit facility with a $20.0 million letter of credit sub-limit. The Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $100.0 million. The Credit Agreement matures on April&#160;13, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the Credit Agreement are guaranteed by the Guarantors. The obligations of the Company and the Guarantors are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Credit Agreement, the Company will pay to the administrative agent for the account of each revolving lender a commitment fee on a quarterly basis based on amounts committed but unused under the revolving facility from 0.20% to 0.40% per annum depending on the Company&#x2019;s Total Net Leverage Ratio (as defined in the Credit Agreement). The Company is also obligated to pay the administrative agent customary fees for credit facilities of this size and type.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revolving borrowings under the Credit Agreement bear interest at a rate per annum equal to (i) the Adjusted LIBOR Rate for the interest period plus the Applicable Rate (as defined in the Credit Agreement) based on the Company&#x2019;s Total Net Leverage Ratio (with customary provisions under the Credit Agreement providing for the replacement of LIBOR with a successor rate) or (ii) the Alternate Base Rate (as defined in the Credit Agreement) as in effect from time to time plus the Applicable Rate based on the Company&#x2019;s Total Net Leverage Ratio. As of March&#160;31, 2022, the Applicable Rate for Eurodollar Loans is 1.25% per annum and the Applicable Rate for ABR Loans is 0.25% per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Company and its subsidiaries, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments and change the nature of their businesses. The Credit Agreement also contains customary events of default, subject to thresholds and grace periods, including, among others, payment default, covenant default, cross default to other material indebtedness and judgment default. In addition, the Credit Agreement requires the Company to maintain a Total Net Leverage Ratio of no more than 3.00 to 1.00 and an Interest Coverage Ratio of at least 3.50 to 1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no borrowings under the Credit Agreement as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic11da4d8ef7f495db6691f1262fb8e0c_I20210413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQwMQ_7c015781-da7a-4073-b00a-9c64ecb44cfd"
      unitRef="usd">125000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if64b680e548d49b194bcae4857dedc09_I20210413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQwNQ_597dd149-4038-44ff-8c91-3d99c022a948"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icef01955e8974f7697be299053de3a2f_I20210413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQwOQ_a0b9c67e-f824-4049-8f15-5f626cedf872"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i3fb986de689d4becaae458587ee9b2fd_D20210413-20210413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQxMw_2802239e-5e51-4fb7-b574-1cf3502eae74"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i450c071fc9504d04b9fc30de60ec4480_D20210413-20210413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQxNw_74a42841-d6e5-45cd-b06e-2eb707c25a60"
      unitRef="number">0.0040</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9c2bfdfda3ad4daa9fd8c347153a8690_D20210413-20210413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQyNQ_ef9e67e2-6c8e-4312-af32-357402250aa0"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i45f88c0342b14d22baf0e44c2b6dbf25_D20210413-20210413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQyMQ_ee185dba-ae74-422a-b51f-bfb4e6d6f55e"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <med:MaximumTotalNetLeverageRatio
      contextRef="if5ac0c800edb46e5a7552707f96539fb_I20210413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQyOQ_260f0177-2868-474d-8bea-521616b982e1"
      unitRef="number">3.00</med:MaximumTotalNetLeverageRatio>
    <med:MinimumInterestCoverageRatio
      contextRef="if5ac0c800edb46e5a7552707f96539fb_I20210413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQzNw_485b0307-dcb7-49be-a178-b0b4316e035f"
      unitRef="number">3.50</med:MinimumInterestCoverageRatio>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i57d6fd02196e4a488975ef3607163df9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM1ZTM2ZmZkNzEzZDRjNDE5MmRjNTc3ZmE0OTQ1NzJkL3NlYzozNWUzNmZmZDcxM2Q0YzQxOTJkYzU3N2ZhNDk0NTcyZF81NS9mcmFnOjkzNDg4MWJiZjg5NTRiZTQ5ZDVmM2Y4ZGJkZTNjNGEyL3RleHRyZWdpb246OTM0ODgxYmJmODk1NGJlNDlkNWYzZjhkYmRlM2M0YTJfODc5NjA5MzAyNTQ0NQ_3b89bdb7-90d5-406b-8cf3-dbb21e089b2d"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#^#]6DI=WI@?J,Y3Q_\!4$L#!!0    ( $:%HE2#KP#(H@0  ,H0   8
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULG9A9;^,V$(#_"F'L0P)D(Y&Z%XZ!
MV,ZV 9H#<;;[4/2!MFA;6$ET2=I._WU'1R1'HIBD+[&.F>$WH^$,)^,C%[_D
MEC&%7K(TEU>CK5*[;Y8E5UN647G)=RR'-VLN,JK@5FPLN1.,QJ52EEK$MGTK
MHTD^FHS+9X]B,N9[E28Y>Q1([K.,BG^G+.7'JQ$>O3YX2C9;53RP)N,=W; %
M4S]VCP+NK,9*G&0LEPG/D6#KJ]$U_C8C3J%02OR9L*,\N4:%*TO.?Q4WM_'5
MR"Z(6,I6JC!!X>? 9BQ-"TO \4]M=-2L62B>7K]:_UXZ#\XLJ60SGOY,8K6]
M&H4C%+,UW:?JB1]_9[5#7F%OQ5-9_D7'6M8>H=5>*I[5RD"0)7GU2U_J0)PH
M@!V] JD52%?!'5!P:H4R<E9%5KHUIXI.QH(?D2BDP5IQ4<:FU 9ODKSXC LE
MX&T">FHR>[B?W]PO;N8(KA8/?]S.KY_A9O$,/W<W]\\+]/ =W=[/'NYNT%?T
M8S%'9U_.D=Q2P21*<O2\Y7M)\UA>H"]O[L>6 KQB$6M5HTPK%#* XJ [GJNM
M1#=YS.*W^A:XU?A&7GV;$J/!.RHND8,O$+$)T?#,/JZ.#3A.$VJGM.<,V+O-
M5SQC:*&H8K 1%/KK>BF5@$3^VV#=;:R[I75WP/H3.[!\SW1AKQ3]4K'8UH>)
MBP/?ML?6X30:?3''M7T_:L3><'D-EV?DFG&I$%\C25.F38I*W3M9%F//P6Z'
MKB\6$5Q\5AV<W\#Y1KC?!)<2[01?)TK'YO<6=2"50K_#UA<C;NBY@1XN:. "
M(]P":EN2;R[0AN5,T/0"P;Y"-(8JD!1Y4]0_'72@H0EP%'6@^V(X\@(WU$.'
M#71HA*Z3?"UXAJ#7%)0\UW[WL+>^Y]EAT*'42)$@&LC)J(&,C#OQ06V90&?L
M!9JA9.=0MPIHPR;$=EM.[7?\5PQ*HWK'>ET/[9YW7R.O$P&-$''T_N.3JH^-
MF!^)0,V(^XRXNP$T0GC@&V'2,A(CXS-7-$7\XZ1$0XIQ%[4OY0Y4$=Q6=NS\
MCZQ'2P;G+%8C(T5?]!6P-OXFR=THZ 59(T9"%P_ MXT#FSO'H^"'I#R6 >W[
ML&[_4SNXG[4:,1P$ ]4%M]T$F]O)/9QL#2G@Z5I=V,L!G9CM#^VJMIM@WUA7
MIE0F*\2HR*%N0U^!Q"U/2J;*TG8#;&X'-SVS<"!;EBN>P<$KYFE*Q<G;<VV
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M?3W<9S ;5E9V4<)3&8D497Q_/9B1CW/J:H5"XJ^(/\N3,=*N;(7XIB>KW?4
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MZEH WN^%4&\3_:FG^K0W_0]02P,$%     @ 1H6B5*A#*CR7 @  R@8  !@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6R5E5UOFS 4AO^*A7;12EWX"EE;
M)4AIDJJ5^A&5;KN8=N& $ZP:F]DFZ?;K=VP(2C/2K#=@F_.^?L[!'(8;(5]4
M3HA&KP7C:N3D6I>7KJO2G!18]41).#Q9"EE@#5.Y<E4I"<ZLJ&!NX'D#M\"4
M._'0KLUE/!259I23N42J*@HL?U\1)C8CQW>V"T]TE6NSX,;#$J](0O37<BYA
MYK8N&2T(5U1P),ERY(S]R\G Q-N ;Y1LU,X8F4P60KR8R6TV<CP#1!A)M7'
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M]MDMEV:!&9X>Y_09Y$+-1Q,7Y?J6T7Q%XDR4XH;E_-.8Q['I?'VY6%YNE@O
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MO<-=/A<.+U'"^!6VE>WE30!)::S*=\[$(.>RVMGKK@X'#M?1)P[QSB'VO*M
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MB)8%:']NZ.9O)ZR@>V)>_ 502P,$%     @ 1H6B5 YILG1X!@  U1   !D
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MV?);OUQXDX?OZZGQ^%H/CPFXFRP?P/[,@'FK!2MH?G"Y_ =02P,$%     @
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MP\OAP /=;G6K6+5M-FFM+.UE(Y;T$*)V >2G0=F#XA)T3^OL#U!+ P04
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MK3:@W6Y"<QT?JK<F<ERZI"RMIE5.=G;Q\>YZ>;>$\T>V$F@N9K$E4+<4%UN
MFP"0'0'(X5Y)6QNXDR66K^UC(M,SREX8W60G >^9OH0\'4"69-D)O+R/,/=X
M^;$(D9)FX//UREA-(OAR G/88PX]YO (YC)(&%0%RZYM!9),+1-PRTP-[TCH
M\$&&@B'E'3K3D_"N$*>F907.(ZHT@_H;1HM7C@KGJ'*.^,X1%8E@%DNP"FR-
M<*N:ELGG7W^YRM+)'P:HDC5ME&L0X4PVS !]E1*$9."<2[)3G6&R-!=3>*PU
M(C0AO>C2"Y2<HNZSXYHT!-TR7A*0!M:H3EI#O K1.1,/2C#DLM.>OW'GYBF
MX&S%!;><V/S9T]M%UYF \ /U,T@'D]'8_Y,D W^;O%'5&[*@F PZ+RM+MU(
MP*>B9G*-GF/PK5:"K_W![?O>X2>Y:U,XH9=1KY?1_]7+/;.=YM;W]Y+TVSX'
M+UGXN#N;0Q(ZZ?&PA!YKW";;>;&NY,&ONISX)!TF=TQ!K]+'3 COE4"^EU28
MI&20-CP'<F)_)K,+RL-H,!SF;I3#>) -O?2&-#O^W<^.J'M%+77',!RDXX34
MB_1*51:U,TXS>%2N<@+QECT')9Y!G@TFDQ&=N3%3X$W;6:\8LD-CX9QDEN<7
M6^,SQRDA[X<T$>_=P@WJM7]K#!2N'L*%W,_VS]EUN,5WV\-;2/&O.<E28$6F
MR>6$DJW#^Q(&5K7^3E\I2R^$[];T)*-V&VB]4LJ^#)R#_I%?_ =02P,$%
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ME TP^SLI\638!,,[E_X&4$L#!!0    ( $:%HE28Z^7(E04  )07   9
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;,U8WV_;. S^5XA@#QO0UK&<I&F1
M!DC3'E;@V@7->GLXW(-J*XDQV_))2M+>7W^4[-A.;2O9[@>ZA]562.HC3?*C
M--IR\5VN&%/P$D>)O.JLE$HO'4?Z*Q93><93EN O"RYBJO!5+!V9"D8#HQ1'
M#NEV!TY,PZ0S'IFUF1B/^%I%8<)F N0ZCJEXO681WUYUW,YNX3%<KI1><,:C
ME"[9G*FG=";PS2FL!&',$AGR! 1;7'4F[N74(UK!2/P6LJVL/(-VY9GS[_KE
M+KCJ=#4B%C%?:1,4_VS8E$61MH0X_LR-=HH]M6+U>6?]%^,\.O-,)9ORZ%L8
MJ-559]B!@"WH.E*/?/N9Y0[UM3V?1]+\#]M<MML!?RT5CW-E1!"'2?:7ON2!
MJ"B008L"R17(&P6WUZ+@Y0J><31#9MRZH8J.1X)O06AIM*8?3&R,-GH3)OHS
MSI7 7T/44^/YY\GC[>GU9'Y[ ],O][/;A_GDZ]V7!SB%!RH$U4&&CS=,T3"2
MGW#U:7X#'S]\@@_@@%Q1P22$"3PEH9(GN(C/7U=\+6D2R)&C$*'>Q_%S--<9
M&M*"QH-[GJB5A-LD8,&^OH.>%>Z1G7O7Q&KPGHHS\-P3(%U"&O!,CU=W+7"\
M(MJ>L>>U15L'[%2G70!3'F,M2FJR>8*A3I8,ZT/!\RM4Y6;TU2Q/ME0$\/NO
M:!+N%(OE'Q9 O0)0SP#J'0'(KP*B^X!D12[- 5$-Z 1XJA7PXR]10YEL2)D(
M>:!7N&S,@@Q4WX#2C68S[HZ<3?6[V"3V/.T7GO:MGLX$]QD+)"P$CP'KRO^^
M@P[LA0D_E&\S+L.:F1U8L-8E>D.W&>V@0#LX_%TD]@*U6K$H .S7P.(TXJ^,
M@:(OK#&L@UK0AMWN6[1UH?.JT![<\P+NN17N(Y-*A+["[)CKR%HR<UB8'+Z/
M4KDH %U8?<R,;M#3,%GF*=[T$>Q6^O#*J) 6/&ZW;-U=JZV]L/A<*N15GR^Q
M%>N%K6$PC K=,(&,;(%\8!^2888>Q%EW)CT(Z*O5B0K_N/^X YW @H8"-C1:
M,^"+K/-(\RV::S;?LUJ2'JE50I/415LIN*3TB!Q3NZ8=HE-%/VP$2FK52"[>
MPJS+N.<M($LB<CTKR*]<T0BQ8<A-0X%GEK!%6*307XA<L(AJ#Q3'QZ+ L]:9
M?8)&E[Q:5/OUT->%7-(:^I+-7#N=/245^/[;\FB&VZLA&0Y;D91LX]KIQK1!
M^)(1C*U02D9P!^^C(;IEUW?M;?_8EGC C'>X)Y:LX0Z/@,1>TE!DT;&@LEMR
MNX=AE=SAVMM^6Y<[V<W0=*U67)B\7>/L*_8F%$@CJB>LW9P"*=8B _/93P!/
M8BAO7B *XU U.IOA.Z\VFL%9GS3G.2DYB-BYX;]T;)VFAQW+\54=&PS.!GKP
MV?UKF<5(R5'$SE'?<BH]W5&I8/J$K)/>1T84>!9=8S>-PH6AI]U8B:=FJ? @
MA'*-R.V;YI,"N!GKPN 0YY*2H8B=H2;+I6!+[.U( -C6\4SNE^1Z+'I2)\_6
MODE*7B)V7OK)4.<)1)\CU@C6OFEO%^KN\1,.*4F)V$GIJ&@?<J#.4I[7&NV2
MI8B=I6YW1PK)Q$97GBE::)C&$IYDX]9N^%)F@*AQ+ HJC&9UCFCTIWYF<EO=
M*2F2V$]-_]I ?&"?'\J3DDV)G0;O#F9'8RRGN=EJ+$E[;I1,2NS\-V/"W!(F
MF!;92&OSLF1"<O$^QABOY##O?SI''=B'_&A']TJ&\HXX11UYYLA-]?<8L_4*
MP"M9Q;.SRD\,WUZ=1%RW#L6IW&_&3"S-M:]$L^M$97>!Q6IQM3PQ%ZIOUJ_=
MRVEV05R:R>ZK[ZE88O%!Q!9HLGMVCN$1V15P]J)X:FY1G[E2/#:/*T9QH-$"
M^/N"<[5[T1L4%_'COP%02P,$%     @ 1H6B5"G=UE-- P  )0L  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&ULK59=;]HP%/TK5K2'32KDDZ\)D )E
M:J6U165;'Z8]F.1"K"8VLTUI__UL)TU3$BCK]I+8SKG7YQS;\1WN&+\7"8!$
MCUE*Q<A*I-Q\MFT1)9!AT68;H.K+BO$,2]7E:UML..#8!&6I[3E.U\XPH=9X
M:,;F?#QD6YD2"G..Q#;+,'^:0,IV(\NUG@=NR3J1>L >#S=X#0N0WS=SKGIV
MF24F&5!!&$4<5B,K=#]/71-@$#\([$2EC;24)6/WNG,9CRQ',X(4(JE38/5Z
M@"FDJ<ZD>/PNDEKEG#JPVG[._L6(5V*66,"4I7<DELG(ZELHAA7>IO*6[2Z@
M$-31^2*6"O-$NP+K6"C:"LFR(E@QR C-W_BQ,*(2H/(T!WA%@+<?$!P(\(L
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M $FBE13'[US4*M;4COO/._4[$[P*9HH%#%CR2F*Y[%@M"\4PQ^M$CMGV'O*
M0JTW8XDPOVB;V[H6FJV%9&GNK A20K-__)XG8L]!Z50[^+F#7W:HGW (<H?
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M_3;4IF/ [I9Q!,V<KIR:0@]'YT$S9,HXZB[C_X=FN>F#4E;METTR+;T'F9:
MX,EHEILN,Z@WJ!:S)J%1OP6V:1NHNVW\.\_@J"NIIM:C,]GL(U/*T>FV^ZB^
MEZ_6A081Z+7DRW0%=+K]/JKOY6N8ZR(>A!70=ND GA"VT?<2'/ATEXKL,%K,
M%G<?,WWBK\S/X>TBN\$P9K(+%7G4W$0R-3%92Y/.C2=QL>R.(AL(NM7'_!<J
M!$WT8TAP0)@2D._7E(K/@5J@N"F:_@-02P,$%     @ 1H6B5-,Z,@8- P
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M83 32%:48O%Q#07?3!S?V2T\D76NS((['9=X#7-0+^5,Z)G;>,D(!28)9TC
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MT4!'90WH_4)*\[JQ,Z/ZBXC_ 5!+ P04    " !&A:)4H&&7N4L"   B!0
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M#YS8G.)L;A1?%N<:#UPIGA:7"TIF5.0&^O='SM7K3=Y =99V_#]02P,$%
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M"*HJAJ$1U \MC9T _RZ;Y=ZE';V(UZO9O=2?6[,=T<VA6^BUH@5;=?-5,0C
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M!)Y&',$4@ 8,B:+N'#PXCX+-.15L?R.9_0902P,$%     @ 1H6B5)>*NQS
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M2P$"% ,4    " !&A:)4!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $:%HE05_*<&[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M $:%HE297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ 1H6B5 5UOEXH!0  6Q4  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M $:%HE2#KP#(H@0  ,H0   8              " @6L-  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " !&A:)4SS3 .P<#  !("   &
M            @(%#$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ 1H6B5#"]+!&:!0  YA,  !@              ("!@!4  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $:%HE2H0RH\EP(  ,H&
M   8              " @5 ;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " !&A:)4J'9&3$,&  #C%P  &               @($='@
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 1H6B5!MX7Q3
M!0  8AH  !@              ("!EB0  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( $:%HE1-'JFT0 8  'T/   8              "
M@8PJ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !&A:)4
M#=?_!H<#  !Q!P  &               @($",0  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ 1H6B5*7''=%' P  OP<  !D
M     ("!OS0  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $:%HE0.:;)T> 8  -40   9              "
M@0Q0  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 1H6B
M5%:(^;V(!@  ?!$  !D              ("!NU8  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " !&A:)4A@0HQIL"  !F!0  &0
M        @(%Z70  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( $:%HE0<'5TP^0(  &T&   9              " @4Q@  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 1H6B5%"X=O<Z!   D0L
M !D              ("!?&,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " !&A:)4 MO\&FD#  #P!P  &0              @('M9P
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $:%HE3.@6<W
MS0(  .$%   9              " @8UK  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ 1H6B5+V/.I#F P  # D  !D
M ("!D6X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !&
MA:)4N.*Z&Z\"  !W!P  &0              @(&N<@  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( $:%HE17^AB$30,  "<*   9
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M970R."YX;6Q02P$"% ,4    " !&A:)4G/THE/@#   U$@  &0
M    @($NB   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M $:%HE33.C(&#0,  &,+   9              " @5V,  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ 1H6B5&S+95WW @  FP<  !D
M             ("!H8\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " !&A:)4FHH8=-0"  "Z!P  &0              @('/D@  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $:%HE0!P.1SE@(
M "X&   9              " @=J5  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ 1H6B5*!AE[E+ @  (@4  !D              ("!
MIY@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !&A:)4
MNF+_#)T%  !7&P  &0              @($IFP  >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( $:%HE2L5Y#%BP,  $T.   9
M      " @?V@  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ 1H6B5,+L35X/ P  ,!$   T              ( !OZ0  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !&A:)4EXJ[',     3 @  "P
M@ 'YIP  7W)E;',O+G)E;'-02P$"% ,4    " !&A:)4JX_2D6\#  !/&
M#P              @ 'BJ   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M1H6B5-;Z^;%X 0   Q8  !H              ( !?JP  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 1H6B5.N(NN65 0  @A8  !,
M             ( !+JX  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "P
,+ #K"P  ]*\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>96</ContextCount>
  <ElementCount>196</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/EARNINGSPERSHARE</Role>
      <ShortName>EARNINGS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medifast1.com/role/INVENTORIES</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - EARNINGS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/EARNINGSPERSHARETables</Role>
      <ShortName>EARNINGS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medifast1.com/role/EARNINGSPERSHARE</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medifast1.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medifast1.com/role/LEASES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2325306 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.medifast1.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/INVENTORIESDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.medifast1.com/role/INVENTORIESTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails</Role>
      <ShortName>EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - EARNINGS PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails</Role>
      <ShortName>EARNINGS PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - SHARE-BASED COMPENSATION - Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails</Role>
      <ShortName>LEASES - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - LEASES - Future Minimum Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>LEASES - Future Minimum Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE INCOME - Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/FINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - FINANCIAL INSTRUMENTS - Cash and Financial Assets That are Measured at Fair Value on a Recurring Basis for Each of the Hierarchy Levels (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Cash and Financial Assets That are Measured at Fair Value on a Recurring Basis for Each of the Hierarchy Levels (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="med-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="med-20220331.htm">med-20220331.htm</File>
    <File>ex-101medifastformpsuagree.htm</File>
    <File>ex-102medifastformrestrict.htm</File>
    <File>ex-103medifastformrestrict.htm</File>
    <File>ex-104medifastformrestrict.htm</File>
    <File>med-20220331.xsd</File>
    <File>med-20220331_cal.xml</File>
    <File>med-20220331_def.xml</File>
    <File>med-20220331_lab.xml</File>
    <File>med-20220331_pre.xml</File>
    <File>med-20220331xexx311.htm</File>
    <File>med-20220331xexx312.htm</File>
    <File>med-20220331xexx321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="423">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "med-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 96,
   "dts": {
    "calculationLink": {
     "local": [
      "med-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "med-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "med-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "med-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "med-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "med-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 296,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 6,
   "keyStandard": 190,
   "memberCustom": 10,
   "memberStandard": 19,
   "nsprefix": "med",
   "nsuri": "http://www.medifast1.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.medifast1.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - EARNINGS PER SHARE",
     "role": "http://www.medifast1.com/role/EARNINGSPERSHARE",
     "shortName": "EARNINGS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - LEASES",
     "role": "http://www.medifast1.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME",
     "role": "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - FINANCIAL INSTRUMENTS",
     "role": "http://www.medifast1.com/role/FINANCIALINSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - DEBT",
     "role": "http://www.medifast1.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.medifast1.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - EARNINGS PER SHARE (Tables)",
     "role": "http://www.medifast1.com/role/EARNINGSPERSHARETables",
     "shortName": "EARNINGS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - LEASES (Tables)",
     "role": "http://www.medifast1.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)",
     "role": "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325306 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.medifast1.com/role/FINANCIALINSTRUMENTSTables",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - INVENTORIES (Details)",
     "role": "http://www.medifast1.com/role/INVENTORIESDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details)",
     "role": "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails",
     "shortName": "EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i4a53f9a4936845ba8bdfa229ddc8998c_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - EARNINGS PER SHARE - Narrative (Details)",
     "role": "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails",
     "shortName": "EARNINGS PER SHARE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i4a53f9a4936845ba8bdfa229ddc8998c_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "ie2bb291e995d4d86b1e75f18f4e74ee5_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - SHARE-BASED COMPENSATION - Stock Options Activity (Details)",
     "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "ie2bb291e995d4d86b1e75f18f4e74ee5_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i9a78198c05df4b5a8deb5385b586ffe7_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)",
     "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails",
     "shortName": "SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i9a78198c05df4b5a8deb5385b586ffe7_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details)",
     "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://www.medifast1.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)",
     "role": "http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails",
     "shortName": "LEASES - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - LEASES - Future Minimum Lease Commitments (Details)",
     "role": "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails",
     "shortName": "LEASES - Future Minimum Lease Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME - Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME - Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndEquitySecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)",
     "role": "http://www.medifast1.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndEquitySecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - FINANCIAL INSTRUMENTS - Cash and Financial Assets That are Measured at Fair Value on a Recurring Basis for Each of the Hierarchy Levels (Details)",
     "role": "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails",
     "shortName": "FINANCIAL INSTRUMENTS - Cash and Financial Assets That are Measured at Fair Value on a Recurring Basis for Each of the Hierarchy Levels (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "if5ac0c800edb46e5a7552707f96539fb_I20210413",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "med:MaximumTotalNetLeverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - DEBT - Narrative (Details)",
     "role": "http://www.medifast1.com/role/DEBTNarrativeDetails",
     "shortName": "DEBT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "if5ac0c800edb46e5a7552707f96539fb_I20210413",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "med:MaximumTotalNetLeverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i82c8748a0dca4006b1fc0390e3411793_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i5f1f4b37e28c44289b679e4cf804f107_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i5f1f4b37e28c44289b679e4cf804f107_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - INVENTORIES",
     "role": "http://www.medifast1.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "med-20220331.htm",
      "contextRef": "i11f1ad2b7de748f0a1ba5a2ad9dd93c7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 31,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "med_AmortizationOfPremiumOnInvestmentSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against amortization of premium on investment securities.",
        "label": "Amortization of Premium on Investment Securities",
        "terseLabel": "Amortization of premium on investment securities"
       }
      }
     },
     "localname": "AmortizationOfPremiumOnInvestmentSecurities",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Cash And Cash Equivalents And Marketable securities [Line Items]",
        "terseLabel": "Cash And Cash Equivalents And Marketable securities [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndMarketableSecuritiesLineItems",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "med_CashAndCashEquivalentsAndMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Cash And Cash Equivalents And Marketable securities [Table]",
        "terseLabel": "Cash And Cash Equivalents And Marketable securities [Table]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndMarketableSecuritiesTable",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "med_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "med_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator [Abstract]",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "med_GovernmentAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Agency Securities [Member]",
        "label": "Government Agency Securities [Member]",
        "terseLabel": "Government &amp; agency securities"
       }
      }
     },
     "localname": "GovernmentAgencySecuritiesMember",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "med_GrantedIn2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Granted In 2019",
        "label": "Granted In 2019 [Member]",
        "terseLabel": "Granted In 2019"
       }
      }
     },
     "localname": "GrantedIn2019Member",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "med_GrantedIn2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Granted In 2020",
        "label": "Granted In 2020 [Member]",
        "terseLabel": "Granted In 2020"
       }
      }
     },
     "localname": "GrantedIn2020Member",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "med_GrantedIn2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Granted In 2021",
        "label": "Granted In 2021 [Member]",
        "terseLabel": "Granted In 2021"
       }
      }
     },
     "localname": "GrantedIn2021Member",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "med_GrantedIn2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Granted In 2022",
        "label": "Granted In 2022 [Member]",
        "terseLabel": "Granted In 2022"
       }
      }
     },
     "localname": "GrantedIn2022Member",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "med_InventoryNonFoodFinishedGoods": {
     "auth_ref": [],
     "calculation": {
      "http://www.medifast1.com/role/INVENTORIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before last-in first-out (LIFO) and valuation reserves of (Non-food) merchandise or goods held by the entity that are readily available for sale.",
        "label": "Inventory Non Food Finished Goods",
        "verboseLabel": "Non-food finished goods"
       }
      }
     },
     "localname": "InventoryNonFoodFinishedGoods",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "med_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Payments Due Year Five And After Year Five",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "med_MaximumTotalNetLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum ratio as of any date, of (a) Total Net Funded Indebtedness on such date to (b) Consolidated EBITDA for the Reference Period ended on such date under credit facility.",
        "label": "Maximum Total Net Leverage Ratio",
        "terseLabel": "Maximum Total Net Leverage Ratio"
       }
      }
     },
     "localname": "MaximumTotalNetLeverageRatio",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "med_MinimumInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Interest Coverage Ratio",
        "label": "Minimum Interest Coverage Ratio",
        "terseLabel": "Minimum Interest Coverage Ratio"
       }
      }
     },
     "localname": "MinimumInterestCoverageRatio",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "med_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator [Abstract]",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "med_OperatingLeaseArrangementForEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the operating lease arrangement for equipment.",
        "label": "Operating Lease Arrangement For Equipment [Member]",
        "terseLabel": "Operating Lease Arrangement for Equipment"
       }
      }
     },
     "localname": "OperatingLeaseArrangementForEquipmentMember",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "med_OperatingLeaseArrangementForRealEstateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the operating lease arrangement for real estate.",
        "label": "Operating Lease Arrangement For Real Estate [Member]",
        "terseLabel": "Operating Lease Arrangement for Real Estate"
       }
      }
     },
     "localname": "OperatingLeaseArrangementForRealEstateMember",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "med_OperatingLeaseExpenseNonCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Expense, Non-Cash",
        "label": "Operating Lease, Expense, Non-Cash",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpenseNonCash",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "med_OptionsAndRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options And Restricted Stock",
        "label": "Options And Restricted Stock [Member]",
        "terseLabel": "Options And Restricted Stock"
       }
      }
     },
     "localname": "OptionsAndRestrictedStockMember",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "med_UncommittedIncrementalFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncommitted Incremental Facility [Member]",
        "label": "Uncommitted Incremental Facility [Member]",
        "terseLabel": "Uncommitted Incremental Facility"
       }
      }
     },
     "localname": "UncommittedIncrementalFacilityMember",
     "nsuri": "http://www.medifast1.com/20220331",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r171",
      "r203",
      "r221",
      "r222",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r346",
      "r347",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails",
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r171",
      "r203",
      "r221",
      "r222",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r346",
      "r347",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails",
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r171",
      "r203",
      "r212",
      "r221",
      "r222",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r346",
      "r347",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails",
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r171",
      "r203",
      "r212",
      "r221",
      "r222",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r346",
      "r347",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails",
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized gains on investment securities"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r44",
      "r48",
      "r49",
      "r50",
      "r274"
     ],
     "calculation": {
      "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r48",
      "r49",
      "r50",
      "r336",
      "r352",
      "r353"
     ],
     "calculation": {
      "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "totalLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r57",
      "r58",
      "r59",
      "r93",
      "r94",
      "r95",
      "r263",
      "r348",
      "r349",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r250",
      "r304"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r247",
      "r248",
      "r249",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Net shares repurchased for taxes"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Recognition and Exercise",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to cash provided by operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r224",
      "r243",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based payment arrangement, expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive awards"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r133",
      "r136",
      "r142",
      "r149",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r261",
      "r264",
      "r275",
      "r302",
      "r304",
      "r317",
      "r335"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r43",
      "r89",
      "r149",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r261",
      "r264",
      "r275",
      "r302",
      "r304"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r148",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r225",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r225",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r30",
      "r83"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash &amp; Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r83",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents - end of period",
        "periodStartLabel": "Cash and cash equivalents - beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r276"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "verboseLabel": "Cash dividends declared per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r304"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $.001 per share: 20,000 shares authorized; 11,594 and 11,594 issued and 11,593 and 11,593 outstanding at March\u00a031, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r65",
      "r327",
      "r342"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r64",
      "r73",
      "r326",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r69",
      "r89",
      "r149",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r275"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt and equity securities.",
        "label": "Debt and Equity Securities, Realized Gain (Loss)",
        "terseLabel": "Realized loss or gains"
       }
      }
     },
     "localname": "DebtAndEquitySecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r185",
      "r192",
      "r193",
      "r195",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r88",
      "r91",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r197",
      "r198",
      "r199",
      "r200",
      "r286",
      "r318",
      "r319",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Applicable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r196",
      "r319",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36",
      "r88",
      "r91",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r197",
      "r198",
      "r199",
      "r200",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r36",
      "r88",
      "r91",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r205",
      "r206",
      "r207",
      "r208",
      "r284",
      "r285",
      "r286",
      "r287",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r131"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r225",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCash": {
     "auth_ref": [
      "r209",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Cash",
        "verboseLabel": "Dividends declared included in accounts payable"
       }
      }
     },
     "localname": "DividendsCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Cash dividends declared to stockholders"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r107",
      "r109",
      "r111",
      "r112",
      "r113",
      "r117",
      "r118",
      "r271",
      "r272",
      "r328",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "verboseLabel": "Basic earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r109",
      "r111",
      "r112",
      "r113",
      "r117",
      "r118",
      "r271",
      "r272",
      "r328",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "verboseLabel": "Diluted earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/EARNINGSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Foreign currency impact"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Employee service share based compensation nonvested awards total compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation cost recognition weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Total income tax benefit recognized related to restricted stock awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r57",
      "r58",
      "r59",
      "r93",
      "r94",
      "r95",
      "r97",
      "r103",
      "r105",
      "r120",
      "r150",
      "r204",
      "r209",
      "r247",
      "r248",
      "r249",
      "r256",
      "r257",
      "r270",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r348",
      "r349",
      "r350",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r183",
      "r197",
      "r198",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r273",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r183",
      "r213",
      "r214",
      "r219",
      "r220",
      "r273",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1:"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r183",
      "r197",
      "r198",
      "r213",
      "r214",
      "r219",
      "r220",
      "r273",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2:"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r183",
      "r197",
      "r198",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r289",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "verboseLabel": "FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r68",
      "r89",
      "r133",
      "r135",
      "r138",
      "r141",
      "r143",
      "r149",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r275"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r133",
      "r135",
      "r138",
      "r141",
      "r143",
      "r316",
      "r324",
      "r329",
      "r344"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r104",
      "r105",
      "r132",
      "r255",
      "r258",
      "r259",
      "r345"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidTaxes": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Taxes",
        "negatedTerseLabel": "Income taxes, prepaid"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "verboseLabel": "Interest (expense) income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Accrued Interest"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.medifast1.com/role/INVENTORIESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r41",
      "r304"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.medifast1.com/role/INVENTORIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.medifast1.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.medifast1.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r41",
      "r152"
     ],
     "calculation": {
      "http://www.medifast1.com/role/INVENTORIESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Reserve for obsolete inventory"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "auth_ref": [
      "r354",
      "r361",
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.",
        "label": "Investment Owned, at Fair Value",
        "terseLabel": "Investment Securities"
       }
      }
     },
     "localname": "InvestmentOwnedAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturity of the Company's Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the three months ended March\u00a031, 2022)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r89",
      "r137",
      "r149",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r262",
      "r264",
      "r265",
      "r275",
      "r302",
      "r303"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r89",
      "r149",
      "r275",
      "r304",
      "r320",
      "r338"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r89",
      "r149",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r262",
      "r264",
      "r265",
      "r275",
      "r302",
      "r303",
      "r304"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market accounts"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flow used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flow used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flow provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r51",
      "r54",
      "r59",
      "r63",
      "r82",
      "r89",
      "r96",
      "r98",
      "r99",
      "r100",
      "r101",
      "r104",
      "r105",
      "r110",
      "r133",
      "r135",
      "r138",
      "r141",
      "r143",
      "r149",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r272",
      "r275",
      "r325",
      "r340"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r133",
      "r135",
      "r138",
      "r141",
      "r143"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "verboseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease obligations, net of current lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r291",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurements of lease liabilities - Operating cash flow used in operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r297",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r296",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r202",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r92",
      "r106",
      "r128",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "verboseLabel": "Presentation of Financial Statements"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r45",
      "r46",
      "r48"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized losses on investment securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r52",
      "r55",
      "r57",
      "r58",
      "r60",
      "r64",
      "r204",
      "r277",
      "r282",
      "r283",
      "r326",
      "r341"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income",
        "totalLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "verboseLabel": "Other comprehensive income, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Stock repurchases"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfOtherEquity": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to reacquire equity classified as other.",
        "label": "Payments for Repurchase of Other Equity",
        "negatedLabel": "Net shares repurchased for taxes"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Cash dividends paid to stockholders"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r5",
      "r7",
      "r154",
      "r155"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Income taxes, prepaid"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "verboseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "terseLabel": "Sale and maturities of investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r246"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised",
        "verboseLabel": "Options exercised by executives and directors"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r156",
      "r304",
      "r330",
      "r339"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment - net of accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSCashandFinancialAssetsThatareMeasuredatFairValueonaRecurringBasisforEachoftheHierarchyLevelsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.medifast1.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of items used in storage, presentation or transportation of physical goods that are targeted for sale to end users.",
        "label": "Retail Related Inventory, Packaging and Other Supplies",
        "terseLabel": "Packaging"
       }
      }
     },
     "localname": "RetailRelatedInventoryPackagingAndOtherSupplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r209",
      "r250",
      "r304",
      "r337",
      "r351",
      "r353"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r93",
      "r94",
      "r95",
      "r97",
      "r103",
      "r105",
      "r150",
      "r247",
      "r248",
      "r249",
      "r256",
      "r257",
      "r270",
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r61",
      "r89",
      "r129",
      "r130",
      "r134",
      "r139",
      "r140",
      "r144",
      "r145",
      "r146",
      "r149",
      "r157",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r275",
      "r329"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Senior Secured Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r295",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets obtained in exchange for lease obligations - Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r50",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Cash and Financial Assets That are Measured at Fair Value on a Recurring Basis for Each of the Hierarchy Levels"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of the Table Sets Forth the Computation of Basic and Diluted EPS"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/EARNINGSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r225",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r229",
      "r238",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Shares granted in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Share-based compensation arrangement, fair value of awards vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Shares, Exercisable at end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-Average Exercise Price, Exercisable at end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, grants in period, gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r231",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding at end of the period (in shares)",
        "periodStartLabel": "Shares, Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Outstanding at end of the period (in dollars per share)",
        "periodStartLabel": "Weighted-Average Exercise Price, Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r223",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "verboseLabel": "Share-based compensation, shares authorized under stock option plans, exercise price range, lower range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "verboseLabel": "Share-based compensation, shares authorized under stock option plans, exercise price range, upper range limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life of options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedLabel": "Net shares repurchased for employee taxes (in shares)",
        "terseLabel": "Shares withheld for employee taxes"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r321",
      "r322",
      "r334"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Investment securities"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r86",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r57",
      "r58",
      "r59",
      "r93",
      "r94",
      "r95",
      "r97",
      "r103",
      "r105",
      "r120",
      "r150",
      "r204",
      "r209",
      "r247",
      "r248",
      "r249",
      "r256",
      "r257",
      "r270",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r348",
      "r349",
      "r350",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r120",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r204",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Options and restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r204",
      "r209",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised (in shares)",
        "verboseLabel": "Options exercised by executives and directors (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r204",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Options exercised by executives and directors"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r89",
      "r147",
      "r149",
      "r275",
      "r304"
     ],
     "calculation": {
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r37",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r18",
      "r204",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Treasury stock retired from stock repurchases"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r18",
      "r204",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Treasury stock retire from stock repurchases (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r204",
      "r209",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Treasury stock from stock repurchases"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/DEBTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive common stock equivalents (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r108",
      "r113"
     ],
     "calculation": {
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted average shares of common stock outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted average shares outstanding -"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r107",
      "r113"
     ],
     "calculation": {
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average shares of common stock outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r374": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r375": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r376": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r377": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r378": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r379": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001628280-22-011751-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-011751-xbrl.zip
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ME\I:0J66LJ&!]A"5RCS^2%Q"HAPP@;XL<-[6T&&8'AC)XA2LYLB!!X;9L[>
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M.[51_D^4S4\7T\(B>G/JV,A=AK'.+5MRR6*""1!SK;/E,ZX&*6;!P+6[(V(
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M-/+@N"Z8N^[8Y NONF$GR$[!7\/Y*;;25^3O F]VA9H5\F)D.F,TNNMAT.H
M'Z3KJZ#4+VC*X7.%0?2>#<[N)6HNI#TU\UZ?KD=4Q]V<P+ .-[R@V._T<-9B
MQ"F?]G7 @ZQE30PZWVG!$*0BG_@VZ?XH8)\O;M%I^Q3Y\#'K=YJ?[4CO(<QU
MJ]$15\GS19/DV<B1G314ELY-5X+6PG3*^#N&*XQ<0DM>Z,%3/'.&8JPU\U82
M6NKUY>@DMM+ WKHIDY@ F<%"P^XF<1M,E1JR7*9VH(5:#AI^ 9"/P.CVZA@R
M-F?<[]96(MESW<)D/W1S:-,-,;PYA$=G(S;.,5WG0> ]5T)3E+TR%[XU;G6
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MWU:;*9MEKS5C&\\/;C&$'J4PS>6KSTL*;X^+= G_-ZUGV>O_!U!+ P04
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M+#7Q^(.O^>G.L/(9!QZH],]#.9>K4H \7WJZ5045\ 52=I9AD1'7;&';<_K
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M@\Q_ROOBWX!]E,[Z'B>S#_2PLYVY+N\\\PANMM%7&_5(7?PVM^NPD\AAFT%
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MYUSN[6_C5T-Z7RYZNI]XO\O?1AT\_;;4P<Y09W/X9UQ/BI?_#U!+ P04
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ME<145RX)K('@(7+#&E]D2I#;N+/GR'HVG:I%BGABTHP21E-TQHSB0KL$O9O
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MLC9+=+ \.1DNK8:*7I&/PB+L,0'VXLM*@&U/=+&"?V;-O/SN_P!02P,$%
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MJ():+ZK)4)K$3F6J1LH/M9?,QBH=)W8L\CRYA&[P>9&FVF0".DAFJAS3^W_
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MT?FG2"QS"&\5=!\6^'^.[B=(?Z0-_&RL^-4C;XX3)1 M)! 1YR%A3"">-H>
MQ@B*O%62:4GC=Y0#$1H#$2J!Z%6 Z'("B'1P4#@3,<A%(/(" QFP!(3&_PFG
M/4G9O(3"9<Y5X8%H <AFR/^[LX\076&%A<&<=VYT^X-\#YN4/W&O'X<?]_IW
M#@#S#)-3YVNIV^MA!)8E5DX+*VL;DZ1-.Z^(U 1PE+:[]X8"8Z4%!DH!'>*(
MF'PC'K9,$'TN5OX$!V9%VFX\\E[G_JW;[]1I3FF_L[+?":X3!))$* 0XIY'K
M&(. 8M@ ;1PB2*$(P6QI3>%EE.*V!3??!: Z18ZKW3V_\K'7[><;[H;FX$GT
M9O3*#PJN%A$[[X[:OR;WR47R5RZ1$CFGAIR[D\S'0Q\X0A(XPA2@1%D@K22
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ME.['VW0_7+-U-O"N=$#>% &8O0-2&>I520$>10%NK/CFF"H?,(Z.AQ1I[BF
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M8'?/X@U=__ZV/V1HRH>U'QB<#_LV/>6T[U?''SZ,A\5F)V]9?M&'T>U'P)V
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M40(Q$,Q%A'(: 6FE!-AQ))E22,-4.:](57G+J$%!649IMS.UVPEFP04ARI
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M,P_6_)S$&I>TD,E*E(+,!3XE0XY$BK0+2F@9D\]IXJ0<3"DXLQHXPZ+'/&%
M$J)ST?.<04N9U\%JJXWS=\&90G@6!D)D$H2\H)Z8E)!E0B*N6.Y/D122G&)L
M5#" 31F$UO$5K8P*$!4@6D8@<I32F/N=*T&YMMS%1)V)5D@%RRR6A? \%-:P
M*>>*<6()T8@JGITK&Y$6X%QA1R1QGCD:<C]Z<N>R(05H"M \"- D+!5AWAGA
M##>6&\E)<(E8*S2+ZDZ>56$\"T,A,8E"+&I)HP<4PDXCCIU!UHF$F*2"!^RU
M4RH?^<+KC"U32<Z"1 6)KD>B*%+ TFCF)>$N8:L9Y\IA:8F"158L"HE2^T<,
MZ&?L]PH(S1EGGCIX:GUTGGJ,C(P<<6(DLL8*)(ET5 1CM;2Y7X&FA/Y94*B@
MT$J@T*+:%A0^=,]0-'DV- CF=30,*18QXC9WN@]1(Z6#D<9%'+'(%1WI.E?+
MM.FUTK4$;[;EWHK#7)KD5YEW*]:DZF:0,UKW2BNQ(J4BI2*E(J4BI:60TAQ4
MV%K,!#<V8&NYP<QB':F)2L< _%?*N4M" 1>HD_#_TQNL2('S5:##K9?3X4$'
MA%=YZ1"/F0T3<-%US&7\J/&$&F85EFN;G*PKO:CRYL5\"\@6*2U%W;T"LO<%
MLM,Q!Y^PIR*78K8V(JZ<0E9:B@A.7FG%G8QJ"5'V&63Y5WGFR-FZS-+Q2>P.
MJN(S)<?_^AQ_)X)4V-G$(N>11:><)@0+K115/+FY8:@2PHLL@Y<3(MCJ]W.'
MZUS@ZL79Q25O[%G^T]9WVP^3IP1VNW7+[()4\R#5_LR! .HE_)]'SA&"N"8*
M.4P"R-'[Q*RFUN8&CD\P-^YI&_CMJ&"1TI+ \!4;X-+0D%Q@T4<>K=<Q:A^B
MU9@ZBGF<&X.WPI?3P;"J)GC0NZ@^D(L/['9'50<JN'67<+H;=G[$OF\/XEZJ
MMK+V3O+?"Z%<)$Q/I3&SP WEX*L'K<%K]UHBS05&0AD;21+>2[VV2=>I$@6I
M5PL#"E(7*14I%2D]'RD]9@"LL)[E9CW3833&I<(^&!25=H@#V4%.*(P\2<Q$
MCPW6?/EHSS-)W*E#18U^/#GM^Z,JH :&4'>(?%[I//]8AG!:U=OL5:]_8']\
M: ^/<G8AS"+\X>I@6P&F>8"I/1TUXYPS[;5!S!*+N -/S"2G$.->4FPIP<JN
M;5X.FOVS;,HMJ0F7K=-5D-+U0/NP ;-WL2HG>="[,=@6BK@P)";3Z2Q8>"4D
MLA3((0\D(9T415(8J;U(E I 8K+.A2EHO#)V7M"X2*E(J4CI^4AI'F9SGT&Q
MPFP>T\><[FF(2=#$2B2(DX@GKY$V."#CM?8J:.E-7"IJ\PRRQ\Z+<@]R +B1
M^KWCT8\78;#;!;]6-II?]ER*E(J4BI2*E(J4BI2*E.[/[V'18L>T$#@E;F5P
M/"I/$\<T!)5(F-OO&;.Y:C?_;]LYC5O^OZ?M?G9Q!L-F'![U2BWZQ3DXLS6"
MP(UQDE",HJ,,<:DT<@;\'2V5<99$D'<"!P>O@P;>P<,I)KV\)KWP4$8QZ0<W
MZ<F8A;+"\.AS?XE< C5*CG24!E%/K=:"ZJ#<<IGT,TC6F0E:].,PV\,B@Q=/
M,.SZ,)D[4W!5I_&\J\53<&@.'-I[.9V?DY31B6J"F%41<>,X,L$X1*2R4;J(
M*6-KF^+RT=NR);RLEEJVL8J4BI2*E)Z/E.;QHQ9>C6F*F(PHR84'M74,,SPL
M?M0"^<M4D2;K@L;$ ']1B2)NN41:N0"_*B:<TYP&N0 WJECTTAY\6D"L<P"O
M"S\5RWYLSV0JZ.E2,DD(@B)E-!=&3\CP*)%(6"M"7,+Q^J!G6;&?BGW?;^#S
M1F9=6AW<WJ*G#BD&8BT1&&$< N).&N0,TRCZH(,PR@)X+ZS504G7FB?RN3<\
MBOVJS%<_'L7NH/TMWJ7>^,INR92]\"*E(J4BI><CI3FH&#<J<1T3-M1S8.%6
M44.Y%HH$I;VC<U.Q:M5Y.;GH7-1<;<7A7CJP/PKEFH=R[<\TVK26,BP,BD+&
MG!FOD*5*H(2QDX0H95)N<2>7J"9$,=H"K45*14K+N  N/!91%L#%+X#3,8=(
MO:4D$*0%M8AKFI#V22#!HPQ*"H:K#8)E6@&?0:+52SLX:H3VMW:(W3#()M*Q
M.=-JV*OSK$8=_YY7BE79;"Y2*E(J4BI2*E):)BD]:GK-]I@D $L^[G6K3;O,
M'LK&^\+: !]L#?<F-]ZET#0:1I&2S"&>F$2:YIP:&7!0WCBC,F4VZUBRDE.S
M,F9<P'85I/2H9\(*V#X$V#8/FL,ZT^DMW]OZ+ *C7E&'O%$!<2$<LIHJ^"=&
M)E,THBK,MT1P.PI0C)\UUE]:F>FB8X[E'N4>Y1[W?X]G$'5\83NVZ^-ZHVG[
M_JC!R'HCKXMWB3*Z7C_$/JK?Z@\&@!IZIZX3&^.7&5TP[)W\D>%VT.NTP_F'
MJT=/YCL%*FC"2AA!*8^<.:N)UU++A)/5EC#[>7>>LNUU,\/"11;'17:'TV4F
MG%*2:(6(IAAQDSRR(F 4F,>&81$#9\!$R+H0EYG([?R*Q=G/(WLECPP42P2U
M%4[\[^,IPAP*L$P >MF]6QAZ3NRH[?SWM#T\*S Y+TQ.;BESQU)4,2%B"3AL
MW&GD<K/!?"3%8T=R"!1@DA:(+!!9(/)^,U(E-1: T=+D.3;.2!=D]#)8[HRF
M]"X066CFXO"S-4DSJ0B)2!Y04#HB[H)#UO&$N%:"@*)+()X9/]<UXP5#"X86
M#+U7#'4QV60=H9%;KIEV*5B/<:1>R&A%*C3SX6!RDF:FI!4G*:!(1&Z=YBQR
M 7Z50CC'L60@H@R3JF!DP<B"D?=;9,)H+8-.T@;.B>).Y!:K5!(A*%-,%YZY
M'  ZE<>"P1V(Q"J$95"(1T*1Y=0@0XG2F7':W'L2I+:.KRAP5T"T@&@!T46"
M:*36.&J)MLKQ**1UBBCO1"0!:V?"HD"TE.NX?9RS/CLZ3DUQ5AJC/4&4<(HX
MHQH9$AV24NC$8E2!V447["@(6A"T(.C5"*JI!Y]06QR\A9M)1Y+'S.#(."'*
ML$)#EP5&IS+\HL0F"@U$U-N N%<!.<D%BE@(*['%5A@@HD2N8_IT(IZ_22@*
M[<%)QY[E5XV_1MYR9;FR*%6YLBA5N7)UKBQ*5:XL2E6N7/XKBU*5*XM2E2N7
M_\JB5.7*HE3ERN6_LBA5N;(H5;ER^:\L2E6N+$I5KES^*XM2E2N+4I4KE__*
MHE3ERJ)4Y<KEO[(H5;FR*%6Y<OFO+$I5KBQ*5:Y<_BN+4I4K[T>I_C6TKA/A
MOZ'];?/?\,_X&\>V?]CNUH=Y1F6X\Y7CCT=G?>!1'7LRB'^,?_AS_*1VMSJ7
M5GWIS]'-1D>'Q,FE<S[5.:#ZXS^_M\/P*)]DV\#U:;:1XH^>//IXH_IH_,I3
MGU&SP86X]F.\0:[][%>WU1O2W.ZNO_Z,:;[PL<H-PZ__=+G&JC>HD"LR5D(V
M)#$K,EBU(=5MQ_/P8]5$K\Q8*:<WNNMOUNW?5UXWEZZ]XERVC]UA[#_. 61U
M95GT@Z-^C(UCN.YHT(C=$,-T@70R=?;TSK-T?NG$"52\H<3O#J$N]R2V3H]=
M[#=ZJ?%OU__79EVQO%&7++^VP/S\<_'<IK5N1-.H#JR7:;SU-&[!6/-A<MMI
MO+'M@':[M9J^M"?MH>V4F;W]S'I_>GS:L4- S:J;<SVODRV=&W5/YS+)MY[D
M=W%HX8^A5MH=V^_"T*_O#EPF]+=+?C_:P6G_K #K72>R-PN?MVB.=;O)FZ[:
M,8\$RO/*\Y;C>7,WG9KI8+7<=:^FFTYM1Q\K'V'D5N%;]9VZ8@*>9.>H1!)W
M3$6J/>=4&R>5B=PGC7DB6%65KC"AI7/4=(VK5W"OOX\^'OB?GUZ__?[QX.V/
M3U\^\M;!WU];K]_33P>M]J=\OR]OQ:4:5Q]V<.L#?/]GZ^LG>&YK^]5QZ\LA
M:7UXBS\=?.HTZ5^=YH?6<6N[D\;M4)K[&.]M'WYF- 1!N$1$*(>X%!Y9XA)B
MPA E?,3)F*IQE*9W[HIR-0+<:Z&_W[3>N[.M+A%DS5FJ[ZHW7$T4NJ+]TJ(@
MZ*G6Q7\PK/DYB35$R* ](4A'E[LO)8T,PQPYQGA,1%MKR"*Z+Q6<*3CS(#BC
MK#.,8$,DQ=P*[$ARE,K @XF!.'L7G"F$9V$@1*9 "&OB$^5(^0B$1T6#'&8.
MB823\U$130&$U+KF!8<*#JT&#E%%N>0R1I,45]8XDUCP4C!,M.#1%[[S4%##
M)J'&@%2",!(E:BSBVDJD*;9(&NLTIBH8G-8V^9T;6!2<*3CS(#B3M*:@O(%A
MQ;FW7$<JDY7,<^I(E*SPG:4 (3$%0HQ%IL#+$B+D $\@X&\1C;B)6@1)N)<*
MG"[!U]G=6^D4)"I(=/M7^\<<4!0(IY)Q8QEC7!'G> PZLH2CI4K&=#T4#> U
MX:>"20\;=&Y.]O>R.!D6' 4JI#@X81A R7B'HG:$@B=-(S9KFV(=U.T2)/VS
MH-'RF.P31J,YP,@;FJ+T0EF!>:3!.>!(&K. 7010(H47+0D&339IU8Q[KSA#
MT>2=K^@$,A%^-51R39CDU(A,C-0ZN'%+1(SFWGB?:7:UW*A29^3&8:/]Z\R[
M7VVT7_'"J['1/FK'=KNV04O4/ZU(J4BI2*E(J4CI:4AI'K_<21P$Y4FJ -ZY
MLMAK$CTQ0("C9_KS=CZ6A.'_4?7#;QL> A>HD_#_TQL,"AU>&!V>;;E-M;;:
M@5A(\ QQJ2VR5#"D0S0\81>B#7FS8AU+MJ!&A\5^"\H6*=T&95F(F FAJL03
MBIU3'$#6:&$UA]])0=GE0=F9CK(V:4E9""A2SNJP@[.,(68PX8)KR11?0IQ]
M!NG^5<(Y"&,0\RL>G\3NP.99+\G^UR?[NZ2<UYP2X@CG2ME$J3.$1F<3TU'.
M#425$%YD&;R<$,%6OV^[A_$X=H<OSBXN>6//\I^VOMM^F#PNL-M] ^_>"P6K
MYL*J,4Z-&*$GU!H>'*A98#E]Q2#G1$(&9&M]X$Q2O;9)[HQ2R[=-\[0M_'9L
ML$AI27#X,AN,1BJM9,#<$$Y] E^-<).BYEX:I>;WN;?"E]/!,$/KX*!W48 @
MUQ_8[8X*#U1XZRX!=3?L_(A]WQ[$O51M9^V=Y+\73KE0G&Y-XG3D@5$A)0K)
M)\05E\@E"8PRVB0<]]%;M;9)UXG1!:I7"P0*5!<I%2D5*3T?*3UF$*S0GB6G
M/3.A-!-Q8(%IY+Q4B"=AD:%<(\VL)20*ZX5>/N+S#/)W1LK?B".;" UWEG_Q
MI\/V-WB*[89&:/>C'_;ZU]>">EY!_@<*KV5LJH-DVZ=]F+HZ4%8'SR:!:PQG
M)88V'TB]G8ZA,:ZLD-JA*)Q'W%@+8*49BH[;X+P-'.<C[W<^>%'VZE:!3!8I
M+0G8/D ,[1JD_=MV3F,!VD4 [500S.H@M#<"!1$ :+5CR#!5E1HQ#E;-X'0^
M:ZL+TJZ8#1>D+5(J4BI2>CY2>LP06&$M]^X>3L>PN-:!<T:0](DBSC%'X!0R
MQ$-TR@1&"./+QEN>02Y8/H%61V0:_7ARVO='55I8ZO4;0_LCWBYHM;)!^>L/
MYC]@4M@@Q^%?]?H']L>']O H'Y.%680_7)TR5H!I+F!Z/QVWDH8SQK%&4>0#
M^H[G4HV1(&6(-T1&;0G DGI2A_.?M@V7[<]5D-(\)5#N,^WK7:SZHAST;HRV
M99]S<5 \%=GRU@:3A$*$^(!X5!19[#D*,@:C+#>*RK5-LJYQ@>/5,?0"QT5*
M14I%2L]'2O-0F_M,[2K4YE&]S)D4+FE5TOFL.?,8<6\I I7/^1$1&*U.*0:W
M5.3F&61OG7>8&^2 ;R/U>\>C'R]"8<\L:ZMLG!0I%2D5*14I%2D5*14IW9_G
MDZA(7G 6A>/<26YP#(0XE8*E%OXWM^<S9G/5[GVUC[_E_WO:[F<G9S!LQN%1
MK[177*"+\Q%<G)WQ9AIK;6_]^"PU-MP&@HAR*B>!.V0(#B@EYZ*4R>F8<LLA
M<:=JU\6JE]>J%Q[/*%;]\%;=G+;JY(W$26#$4N2(8TN03B8@S(PF7B6,95@J
MJWX&:3M[PZ/8KXHW]>-1[ [:W^)="DFO;*RU1,2+E(J4BI2>CY3F*5$<-;;"
M!T.)YQIC)URRCEHN J:,LKG)6+7JO)Q<="YJ:;;B<"\=V!^%;\W)MUJ3O3H,
M=E:!<) /U" N7$ V,(>2H-&J: FU>&U3/L&.K4_;:@NV%BD5*:W^L:&R MYK
MQ*%*E7 A)LF"08%KB3AC!FD'O_(8L4B1VQ3"DJV!SR!9XJ4='#5"^QNPRFX8
M9"/IV'X,C6&OSID8=7,KZ1(E@%VD5*14I%2D5*2T"EMV"V]DM3TF"<"3CWO=
M:N<NLX>R3;<XTGPXW=-*8(&KLU),FYQ=G!S2B7@D/<>&2N.TQVN;1*YK<9DV
MEYWW937C K:K(*5'S8\H8/L08#L3H1#.BH231M9&AKA3#EDC"2))<ZE,4B[R
MY8+;48!B_*QSS[XRTT5''<L]RCW*/>[_'L\@ZOC"=FS7Q_5&T_;]48.1]49>
M%^\2972]?HA]5+_5'PP -?1.72<VQB\SNF#8._DCP^V@UVF'\P]7CY[,5]+(
M)Z*P]<023+G%0AOJ"9.88>\]"^SS[CR5C.H":X6++(R+?-F:+E]$7*!1!8N,
M(P3Q2 G25"6DF7:2**T2C[GL]KIF9D&%U19G/X_LE3PR4"P1U%8X\;^/IPAS
M*, R >AE]VYAZ#FQH[;SW]/V\*S Y+PP.9E6Q0@+'MPRQ&5*B'N,D3.*(DFH
MXIH8 S@*,'GG+>4"D04B"T3^$B(M5\ES:VAPD@>*-<-<ZB29<"Y$K.\"D85F
M+@X_ITJS&2J5PRP@&5FNDHDI<DE[I%CBC#LJ+==KFWI=$5X@M$!H@=![A5 =
M,57*$$V3X8IR)PR1+A@N78J*XL(R'PXE)UDFQL$)$L /YWE;(%F.G X)*0>X
M2)1@2AI@F?C.C>0+1A:,+!CYFXU6RK!,40NO.2/)^"1M4(H*K"+VJM#,Y0#0
MJ326:*+PUC)$@N0Y\YLA+4D^<VXD4=QS$BD J-+KXN[IWP5$"X@^1Q"=)UU%
M@4%B3PT7SG"N<&[I*6E($H/[%V6X'D4'\)KP4X'3!XYZGI?DJ1)5"(Z"N2B0
MM X8*18:V0RH5% "<F02,#;'/1=3NZ- :8'29P6E\R"I-5%;I:FVE@<KG(]$
M:V(#\\*(8 L?718 G<KTBTF%1)5$D5&)N%01.0?.?5!1N60Q5S0G5BN^KLVB
M.I<]/HQ6B47_&EIX*/PWM+]M_AO^&0_\V/8/V]WZ\70:N7P$E>\OVA@)_ITU
MTFR-!T>Q87VNB62[9S %C6YO"'>W??ASM]&&D1WV;:=Q8OO#1B\UAD=Q$+.1
MAMC-+<_@IVHF<\WT1FIW;=>WX?+!$/Y0U5/?.!?D[(R,AL$%C/.D-VAGX?_1
MS^77V]_BG]_;87@T1HR);XT$C"^^8AV,X'1X_5>68*J)@#')Z:F8_#>/MD(:
M)B*3*05%6,BNFZ'!"Z62Y4 G%0V? >K&7SHZSTP]L8=@8OUHOR*;X 7_L)WO
M]FRP]J]I%03]FYSTZ^9K0E4IV9#5(G_-?*5T;_-56P@@<J]?%=K_ VP^]O-5
M,!R[-&-I'/7S4O4_OY>< F/+X)#-Z&5>Y< Z_OTONWF55CRJ]JHK@:*YL[W[
M:FO_8+VQVWJYT=AJ;3?VW[_8W]W>W7JWN[-_K9DOR_A;>P<[^XV#O<;+/5BB
M6_L[V_FG_;W_[&YO'< OKW9;6ZV7NUO_:>P?P!^:.ZV#_<8_WK>VWF_OPN?_
MO/R"-S18OC;?<I!;4;33V2--$]EHC A:Z_08;N&G&1DA">@7=2I$Q77"EC@K
M<NU9$X)A7E5',>CX* :MJ=D,&8.7;"=81KO#+5AX3KM#6';>P"+BVW%P $]Z
MT0&V]KC,ZV=KS+R^'!VU/NR<?3S89:V#MPSN"3__==2DP'X.0KMY\/7'IP^[
M^./QW\? HCKQ_]Z=??H03ASE<N_U#JFN_>)):]N+UC;\?+SS\R/]2%IT%Y[]
MJO/QR[OVIP^?4FO[\'MF3E9&A[5'DA&==T0DLB((1**()DCO>" U1VYW3V/8
MROQ5."H]<4830[@/V&%//%4DDA DM7:M$8'.GF13[)\">.Z_;S:WWGUL[+UJ
M[.^^;NV^VGVYU3IH;+U\N?>^=;#;>MUX T;QLK+I*4V802KX;#20"A-K>?U^
M,-.#UR)Y1A5GQC&P&&ZQQXD(*8FCACI[[B[<ES:^L(/V8"_-:.)9_>^SUL:W
MGS4H(==6(IH8:&,^K&-8;D%L&<9">26CF-6NE0"Y2NAY'7[3!SK;'=8*C,;Z
M_1@\O'&)B)]V[6EH#VN2?5.ZG5^J&4,[V<$05NJNWP :'QIM^.0[.,"=,]3[
MWH7O#D[=H!W:M@^8V_A'/C))\9_G7ZQ^)W]FMM\8??:R'MCY1Z,_?X^S?SD=
MG/^EUQ__L7?:'_WQG[GB:N<TP!B.8C^VNXTC^RTV7(S=QDD_GE3E4>"O>2KZ
M(1]C:'QO#X\:A[$;P1'IG.5/XDE^?WMNL_!-N&O[I ,O ]_-PW[?K:9N/\],
M-2M;%7[8\Y=]O;7UYGQ,N7-S]G7Z[>/<QJ;7K^Z:9^[DM#\XA:4JEVS)]^V?
MYH?D3_KQ\+13:<Y@Y!DU]J,_[8-7,KIBYX<_LMW#V,C'#-N#05:R?TS,Z?[.
MR_$(@%!5+PR/[9RM-SPXFK:=_:\Z3)&_F>]8.V?#(SNL/+1N_C#/23_6Y9T;
M[JR17VQB4B^4!]ZQ=]P>PK1L-/ZO]SV"-[L^GJ[>2;N;'P(O JH,[D36IO4&
MW+QA+YIC5?K7'E23 U?6CU^'I\-K]ZL9F[T6:#(\N1M]' QL_ZR::-M(MMW/
MTKZPO=$$7JCTV+T;3?7@M%,K=^\D]D>3?O&.YRJ5+[X8/WS8:<-K#JI[A_;
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MOECRPAA3L>3'L>0I=B1$P#H7(J9&YU.)6B+'HT*!2D^)]SHY!^P(FZ4WY2=
MC4J(Z8:1[^LSO9XJUCY4_.DZN"W^Z<(0>*8HGC"8I6 3,IPGQ!7CR$I+$8W*
M\:0#%RI5_JEDEVOBW<X_O;$EK5!XZEFCPT/%K@HZ/  Z3.<@8(UY!'1@+&#$
MA<3($6N1Y4)HE4+@EE7HH._N;3TN.BPM?[M;@L("]UOO,4%A&4>YM IQWX3^
M,4M[[%P^I(WJTYE/N87EG,F*5[WA:K*)TT$8']!>K,.QVWKUNZ(5HWVO$3G
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M[S['6YSMJ,L$9XQW]NX52X-2VQ\D.G@V1A+#;\%RS,:L)0-U#<3X__Q81RG
MYD.C%3G[!6H O='P'[^9YZL.>*7X> +BX%*$-!XHM#T<#1(W)WUQM),E.WD)
MGK+C0?];VX=*:S;9_[E.1TK&O!&^#+&(0DO0%)0&%8PK'FT9J*L<L52P?,&D
MDLM*UU^P_OU8K>P/P+(.H-F>^=[NCKO_[ \&_9-V[_!%C7)7<\VJGTQAVW_I
M9.O+KMP[VSUMH:'UYG/A*)-%R8@WA2&"%CFQ.%Y$.P4VMA7"18^@*'?.]X#)
M@"0[>/C#T&L#621# ^3?('SK=[[!:4Q$8*Q/*SMICXZN23U1":M*&B0PH-"6
M:6&="9C-#(::H[JAGH>BGM:;SU(7WN.\*4'SD@@1(RF=9B3W6CNPG8P6Y=9S
M3B\CGDX8@0!%C*ZI!10PTFEWVQ=!$1QP?PF/D()<OPO7C)+^!7?"KX)U/"4]
M,*4!Q<*@B\K0@GH%S_L"*EX&^M-$%00*]$EO06VK7]W0#$.Z[LK$;D^S\3%>
M?BVP#)$R+64H=2%BH71A ]>:RMR'W/#8D/M#D?O^F\^&6AS)$D@LN0":QT%K
MD4DBH^+*!1_+@F.@_#)ZOX"HDZ\('46KC!:U\X3,LH,5?K"^A14GQ6N8)4VO
MXM!SG#\(V6%E" 5@/7NZ9!I5>SM_LT6_6[*/%B])]YSP,MPPM@?#$8$3Z ^0
MASOMT$N'@E;A""YIFT[G-'GAZEN;X3",KO"@E3@3OKMPG%;ZE$[X_84GN&A\
MGP!'@ %[BCN2MG*%.CKUTAKGX)5&N-'!N*,YW*U,832XDP1(E!)#P%,SV7_A
M $"\P)E9,VP/\?]PT/A1%V\WS&9BPXY'0'QC_'Q&@[/'3'$]#OK=BX-' )\6
MC->E\$*TNE0^J%)[88,SH,'(4I9%"-KRZ.OP J Z607OKUM_7 7?7TS?_X\0
M_@X#M*-A$Z<(3OC/#>'?]TX^\Q+4DEP'(H-D1$1;X%!B09B+N:0\F%"(K>=T
MAY]'\/]%.KW>N0M)'2U8=%I2X2E.<W Y!3J@P0E1TN;<[^7<6R>?"V$$+P7#
M#CZ2".D\V#DJ$!YL00O'I5$4SUVL.O=CA)<>G#"<S3&@#<(!G/VJB$ZJD08@
M'678'7H QY"]15F4_6*&<'6$XT,%=24Z_EKK!C4\ EHE5;>69W =T%^"RXNP
MTH$\ /@>G"+^5:KQHE(Z#47!O1'1*SEU>AR>DOAY.X5L.]%T+]4J+,;6VG51
M3@96@LE@5\/<J0>0(AW<_5_:OZ9[['I\=SB1OU[_<_\MGG"8"JKIG>#Z=M]G
MQYUQ97#L'A]WVBXYI-(%5Z&(F;RZ'K$E0WM&#LE:&OY(O:ILJB3K^A/I=]PQ
MKOH4Z*9ZV]J('XZ="\,A?!-WZU>,J_[2GNQ/!_:@AR_Y3S2;KOZZ!F.B68@1
M%:4D:$= &DE!P'\OW,L;;=,/ [C+3\%M>34>]'V_TP&:^:L/5(IL>CVAH!VW
MT4=O<N.%-T9'7[I<%$SFIE3Z!D(!PY&O>P &8]S%?Z*B\^X8+%:_W_N/&;3Q
M!7#]K)$(M40X;;WY'*(.8,MQHEP9B,@9)R;FG.2@#@ %2&H,2 2VP^6E$F&B
MZ:^BE=U_OKTID0@9R]+17'#+A.?<FDB#$$ ZRMO(94,D=T\D>T D@9726T-0
M+R2"<P/J(HO$1BN"\BI*&9*Z>"F1/"7INM)[@:2;<FI,! .Z6^LDP!F]<%C]
MXOK?0L\D@ZN62FVTHV=, Q"_Y%D[I[I@+--UQDE"S>Z'CKWM.FS:QT HJC<@
M\K>SY$1$N83B>-!&TQLU)UN9<2LL]N7P[X+-#J_2!_,?I?[,;)^X!\=PTKYR
M&8*H:8.,M?#%'N;PI$R<V6=3CP(\O#VHW0?;6>@=HEP"X=<-@T.,[*)?T_UW
MW*X"J.EWWQX>]X<IGC6Y#O5!H*>V![4T?:=KOH9Z'SSJAVTP:ZN5@E8$%F^U
M\<#X>&7UO?GE;E=1["J&#=IE;UB1\[ 6^W"^G6H3@+J'Z;[IB;-,INJ-W9'I
M'58.TUYR;=7[#:]LQ\,V/BH,+W/P3DEJIL6 \.Y5KA;0(\RX,UHX'TSC&A[U
M.[Y:P"'P8:AUL'G*62"5:@/30Z>WG%#6W%\&_>%P\BL^JMHV('.X^ZKC_C+V
MA_,WW<E>]Z8TL+U:^1J DME&#^ \4<*SNK )R5=D+E;W8$=Z\,W^(%098]<3
M-5$:1UU):?!6@'5D"BDY&$51*YGK:%>[G.<D3#?X9[5O.2T15CA98%K?QB0S
M/K1 V7_SF2L:*2L*PDM5$E$(3THP0(CD3#%E=<D#=I+=H2L\R$ -##ZH$*67
M3?H( +4L4P,8,9U@X*.'H 2P2X$2)JN;+*ZAA#E*.&N=?!:EM#2G!?'.%D1H
M&XAA14DLM:",*LQ'CD@)\F)*>')ZQ30[_Q)U>46E5P&*F ?*U"H((\I2%S+$
M7-&"J=S'*D1\+BG_ARKRI/QT-WF*-SY3^X%)FH))E=M26P_4K*F71%!E2>EB
M3KRUG 4*'W*_,FO[BIX:<Y&YOL[$YG)S$YM?CT(WXSO9WFYK]\]7>Z]:![6/
MXUWV\O6[%^_?O7N]W\IV6R_AO]V_/KY[_2[;_R/[XW5KM_7B]>Y?V8O]ULO7
M!Y/OO'WU[OU?!^DK^W^_>KN+'[P[CRA7VS;%-G?;6GVPQ]^")3)(IL,?_<$)
M_$C^ZO>_XN_O1J#(=:ODL'7!Z7VAYHLZD-CN5>B44M=ZE8,75/S^8,XVVXKU
MBW?J%Q].7WPK:?>U5ZX;3"]YN"L#Z>]!^QLZ-&9%+-E?\$\5885MQ0=GNRXY
M")G6<AN_F3[CQ>[D)G,73[^:Y]O(T8# 6'-153!,+V6O5ESZZGMM5LSN(>;O
MD>R)8?*]7/"BV6'H@3J",5P'IV7!< '+"0ZP785_QY5U=7PT,'6MR A31GIP
MG(>GZ/(\PL=MH8^WY[>W)MF\&!C&:HQ1V*X3>2>?A.]8+S+)$<8;5L;#$&Q3
M]"&>] >5W98LI8FU#$M(SYI[^$[VKKH$\Y!]&+I!^W@:X]X#H(R@[_U_&$K_
M4N4KH_6*X8%PF"S9XXY!8^VP#\(O/0](.J3X9R(/>'W,(48[ ZR(B04&EG#*
M:+YX0R=;/K?%>(,%?ZRK^LMDU5[,(O/],1I1/5 .9R4K&(U?$2=/EM]V-F@/
MO\(_XU[]0:(*O*[:U CB9)(& &M*WTX?+UY0V8)A.T5\\8F]_JAR%J08"QIH
M:&57FVPK=S6N%95?1(]NQBCY?[7G;_&;YUW6];5QG(S@BB>'&5C1\.UD4B<:
M?_5B!YWF1_WQX='T-($\.VUX]<K'D;XXOX7;"YN.FS<<CKLU40Q"Q+SUJ:_]
M<JXP:6D&['GTQ8"U#+!AQI,[F91ICNGE*<EY2ACS:1"XUY/]KPV4B7NAOA-:
M\'./=/#,.$9&3.=K.BBJ854IN'_A4I? #3=MNH1+WN\<D0^/@_D*]-DYK94*
MO(%'F)N$Q^H'/#Z1<)"VHM-)ZA3Z@-QX.$Q9FD!='8^8AT>:56EN7X U$N).
M:7'<,V.?6 &SX$)O6/V4.F$GQT]L]TS/H>-CB?Y260!\ =@)V?(8]GB0CK0S
M#">X\?7NK]C4*RH98G.5C'TP<[^UX5Z/CV*F>-.NO$^'G;Z%TW6U-68#: 8^
ME2%.. V^#*8].:QT=CA6TT'G('SK)'0ZR0^&>35HLR7A,]F3!SF8OP]V[^?Y
MJW?W/Z_OYO$J]8K_T?-7%.T@ 9(\7;W<RP*D=E7O >95(7Y_R&W;SDZ.VB *
M^C&B]/FK'4,'_;8'Z).>*KO;V3Z0Y;\2_9UF_S*V74?P<2W-ME]_VW=0HT\5
M;W456AWFG^AK1R & *L<PON@C[(:]((5_ _'!W!O4N0'M(4A%M^ L$7$Z&%2
M7>B- 4Z^U9;^,:)/1,T7"YU!@=N/==)%NXMB&.1-2'>L])^T$L LH Q4WI/0
MZ?9]2#D:DXI._!G^U,9GX&-A@;6! ]0#^E!(8:=*+[M8S/]\]6]Y4__V$]:_
M/08]91^X_B?7)#([2.9N)11-=@0?HR\#5+4P:D_#[E4"%?[6 ;F9EIDE_$%-
MWTWJE.%G#TC<Z1\CV/=@D4>U(#U"08K*X" 9I,,N6'IAL W("71HZDAVY8M!
M2ZZ#QFRW[09]4EU9!79!0!P.3!?52CMN=]#6QNOQ+H/L:ZB6#6HED.6S*VO-
M=8<B@DWWGN5J)7U6?\*P;&_TC+#R'HR"U2>6W#[JG@3Z*J)=W"XF=E(GLM>]
M*H\5#>H-(.J'Y&D 1E!BPO#9/2'+ZDWXNZIFPTP"S.48UQUKAN/CY,)-^0QC
M,+]!#4HJ3DJ)2$DBO5I_&B5%K'\\PNC6LD)FP>@^O%C':5CJ]BS5L%%E[I\^
MY"8\>] M>,@WWYT= &I[G?97_ *6/F&B5O^X$^:RNY.+M?+-)J\?=L@BR5D-
MME.OCL @=M3XTR#'72(':DK_JO0M.+G*E7%/GHO5B]QXS\4%_+?H&0(I^.YT
M. K=>P*%U327[2+?'0_:893B'VE%BYZM8(88& G'58@%F&Z(L0HPW$ZG^OA4
MB]^YV+W<\.+M>1'T,#]VP(G_UW2/?\_^QICIPVJ&+^!/R'"=JH@G]*I ;@7/
MKEW%KJO/:UL.$;]^C>V);58'H_\8([<>#J=!:LSZJ@+?OIWLQQ0CKN\[K,,Z
MQT>GP[;#CQYA-.P#!ITZQW,J,P@_#*K6R<BUIER%Q2?VK@%C>'32'WQ-N93H
MZ/S>QFQ?V&25;VM*4\KOQ(+ZV5T2M06UG1G;'X\R3?\7M^WDJ-^M.EG.MCX5
MUU>)'LDUW.X>&U<Y;R>IRWS6%Z2=(M_]%);=:7:YVF5,S$_</;^OE=P(*2=F
MT863VK]U^T.,YV-""XB607+M3\.]Z7OS%X84AZ].*8DH+'?HC(?H39H"2"W"
M4O+$>#1 O" I5KR=H<8(YT?0#S_ [GE^N_I.)953P'\4!I7W*+DG$Y8!+515
M(.-A2.ZCTW1WE.?C*JR<EHP.+X*1 =1T82F8(CA+@*@NJ--YTO>!=VV[CP$+
M-^ZD%AO;V;?V"$ZI!E'X 1."ABF/"(WEE!"0E./)FX&,'@Y3H*&3RKH.^WU?
M;]=.AD[)"=Y.#?91Y?V:!$[PA0\'57[#DHLMU5F@/VQRFM.J16]. 4\)_%.Q
MPB,$7U1M?W:^=<BW>/!5@*H]G)XT04<L=J=%,K1]4\G;#!/4#I/[Y[*P^NE.
M]CI5['93LL4T++?JFB3$^Y,ZH@D!5BM/V7, #B/3 =T4^0]8"@M;YCS'M:.W
MP> )!M?-I^H2J"5GW8)_+B$,P$_*H 14Z**N-3RJ\F(J#>385.DYB"PS?3_5
MK^/5LV,8+=@W.QFH-G6"6)6Q-%G-C.3:%4'-P"OE9Z7,GWJ%T_#N-&$OME-_
M@V&5R@:D42N@L-]C#TKHV *E'55Y9?LV#!&'WZ'"Z"H@_SOE=+N4^,8I*R>B
MXIN9Y ^E/+9)@*)70R30M6WW)D'GGYW0ND '2=&OA%@ Z6*6O3)S@?6)-#?P
MDYF29]+K?_:=K%GVD0I/%!#A> !<,DZ5AL/C]J#2UOI-+'2F$B/,52H;1A5K
MA:I&MJ37C5"==$FPI3Y1*4.D/P9Q>NJJ^'B5(0)?=@FL)P'1*9)CF6OO=&K8
M'/93Z*4/" S(U0#6A,U0*-5& ^QROPL:2;N'>DXRYCR(B\->U<AF@F+)&=UL
MG\&2IEKSQSPW@JG_,QJN9.C)3.*#<#A-TGV2(#7*P-@*=8H3J!6S+-U92M8L
M!(!"MI\.H(H98!5[-SF8%B['811'[8D*.+FPUC%!'\$\_?X@L47:FY3L.9?Y
M644N4\G%8I>[QY.2QS99<FPX18>JLF#>69:\ E69P':JNPA@]_=/0TA$/H.%
M)17:#+Z&*NUO:FLG50ASKEW2R-MU2XF)#P\+:Y NN_TQXGKHFG:GNJ:?N*(;
M?-LDNNZ%SG!:VO,'C@[O][]N9U@(:C!_93L[.&FG'K5X.6I6*<DP)1\ZY G@
MQ1'JY</44&A>9C>ISU-"6'6$@#H1/2S8H*%:P%PQ#S:_2+T/$(;N!CBN&EG:
MA'V<T3V62!VUC]'1[]L#0.!.PN^?G=!FB($X@KN$'ORIKQ/;8OSD.Y18L?'B
M3!#)]Y,  @G@T0883+/%NY5WVK>'B]E6Z)9&6V,P0']8U6=V@(T6&V-LMJO)
M;71DDO\JM:_I57V-L((35<7DI\?JM&'E#UMH<8/5I]TAZ83>8:5@3MH/@<"N
MM#90(@'[:JTT]AWV$IIXTLP(G2'H)DD-FV>Y<R"GX8CJ.M-'Z H HPKQ['P%
M5O:#"BQ8:U7PFBYZWTME?:G>?9C]LO5^Y]W.UJ_;DX:.':P(KGLG57>=R.R9
MH;#@=4QA"SQV4GD/IQYN[(@QC>SX0;+];'_:D7+.[3AY&D92/BR4=TP'<\T/
MR6NCFW2(;9?0.PH6CQUC:&N:^E0G&#?\.$D4-\UNS-!I%H5)G<<7"H4&*75^
M+ODFX+#'XV#2V-MIS[)L<'0Z.NI6R%,YS%,5>[ORX:-C#KT?$TL9-)".OU'M
MVB-$*8R$]H\GIGY"+*P@'KO*Z5^99;A;H)]A&+B/X]27^NW]&VO0L[^/0 R
M(39.)OD0;3&W\].;4MO97W^]F&S1*XRA@]4[#-/MJ?=N@&=0E=VF[T^K>_\
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M3:!0UDB!0GQ1Y1%4>5@DHR$E7'(*)X@S^D_J<33!L=Y%SK1*9WY<6WZ:8MI
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MP"--.??R%[A- :,%^XFN3@DS8%* E5<9;;?BS#$OA8*F$1U"[%_^33G_@$6
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M[]V>>EI*U-T"?4"6W0L_PC\9 PIU[,=P#''1C>8CF-V#GBJI1."4Y)0LD1@
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M1 B@'#*BU/)+$3+Q6J.S5EIR5(GEK$TOG[6A]FEIMW^,6]N83\*Y5]-%-T2
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M;,3=.BA&\T 3& E=KQ?UY*D@4QF\M(5\%RRI48^N79!^=^K1@T);?+' LZ$
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M?XG>M\YSH-[E82=@@$[E@00>05_RL-"[=2$//&;GL..V^K89RH79>B,@D48
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MX)2'\ZH?)S\XW-.QD)D0B^>YK0=<EI.Q?0?6_CA.,$FUQH!DR%"&9!I0#!-
M\ES2%$JB,K^:9B>'&INW<RMIM!:UL[NS!6 W]@@#6\_<T1$Q_U)H9\$(6Q7M
M]'##%D@[J_91K;3S=W2U,D1A*X>_5=5_;^=E>Y--6?$J)'HB*844*F;( Q*
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MTW7>V( 67SA$P]IU 73'M=["@3BQT2)>[:>5?'39!]M*9KK_-O=) <Z:**
M0DGLC[D2< B=;6&0E)8+1)6.T4.=5*:G>9QVD4N?^?W5'"15^E-2^^=6SN3A
M2W]XN2(O0;MG($P-W8QK<L63&M)HM701LD$543>E457/16&/E<WEAWN&5:S7
M9K-N2EKMO/$ZQY@8PH!EF#DSAS$@N#  (84(LPI9'E5<H)/*Y-1+4TZM9C8R
M4*(3QC =<3,XB75$S=_=KMQ<BE3RBQ@,&_O026G<@(=+PIY$.5Q\N*=WQULI
M56TJ6X=.WR]T1_7YW7=,&,9440V4SJE3!T@#24@)"O>C(M!J][^H6B-Q]*>F
M*';L>T=Y9WN&V/O0OA,3Z!%)!W=JI\D02,>[5/KA-:S7)9*'<1TS_0 Z\=WT
M'"9!X;S??:IFU0#7Z)^_*?=HG0TZLUQC5OHRZ[QTEA"6%,@2N1DK.9(B)UI
M$Q?JU8N/H#4Y:A28%^/?LOG3EV?OI)@[AMWHFP&KX9V=DC"EEP[FZ=3 :XN1
MU7)DM2 C5;Z[AN-X1>_.<C*=>G?7P(HJ=7=UL+Y!K_4ZKC5OTPCO_7*QW'+Q
MWFQFAD-4X$*!7!L$B"X,D% 1P%EN"L&E-J2,Z]$;0C9F;8Y3G&++M:\<6G'\
M8Z\6:$&8ARF]H7%,K.-V &Z[FC4<_UA5.-LQ7;4Y&S).-ARD@2-F PB/'#L;
M#L5I%&W$NWU--M\U>'?:P04WE.80H!QBGZHH@%0, @YY7@@F%#)!0;7=PT_M
ME+GM:=WS*'F$7:C1U!>1Y-90*!@]#)PNF0>V7 Y(C&R2=(EW:FMT/M73I^RK
MX/GJ>-5%"86$F)SZGB:Y<B<HMV!9:=V/G/$<E5J4-.JJZF#TJ2W:BKFZ^&:?
MJZ9#Y +=QWWQ2.TV#H8BWEO<)?*P7N(#"N-ZA[N$._$*=S[4MQO1O=9NYM<?
ME^N->/S/^9=72VUFRF@AC+/M$=,&$$8,X)(QP!')+12(<!K9BZB+S-06<,UI
MUK!ZE]7,9H[;S+,;VXFH$]G+ZWHXO!(O\+Y0]>A"= F)&WL0=0X]<@>B2^*=
M]A^Z^'3?"Z&E^GL=1/?Z>>5L]X]UD&T57%?]XV&O-*-GC,-"6*V!M-X8MZ5U
MZH%2@*C*3<FH@5#&.0'BF9B>2^##89M-4]7[<S^H*DMY7455Z/G**/?%KV\(
MBXV?+UCB$FF*0 E]Q%!!.>",24 H)B41V!2<QCFR$\W7J%[L;53NCL51YR3T
M^B[ENDA]@S=\>U*WC'RMJLL)2CTN_?JB//"]7S0;(U_]]87I]/:O]TC]-KFF
M?E;CJ;I?Z"JD[2"^8J:5MI+*'"C)B-.-H@2,2P(,5<+DN*!*EC&'U0":4[.
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M971[.;IBH!K<TQ5$?'175PPD7;ZNJ/?[::B?G[X\+E^,:=E 36M8*VQ1&E4
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M,M57?HH5F$$,A.3.>.72.,7$,2BP*<L"8ENBJ"N_4Q)34T(UA]F6Q5XW>AU
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MXI-=:/U_7[DI/G'T[3Q]GDSG ^O0!NH8(3.T@L*B[70!K:BW7B2.IM2(U!D
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M=ZHCT#Q!PD9P,:W#I0OY-@&4HQA1!;/5?]X-QXD.F/(R>"XAR121B<# )Q]
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M(,\.)=PCDW4[0KN]2W NTYB$!:TR>ABXF, *)B%SG[)4!F.\.O>KV]\E5',
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M/_SE^/CB0U>'6O<?6O$(ZQGJNS^P>CL<NW$8NM'[R7+Z]0WLC-(141> (MI
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M;8EZ2*6BL@K<]!NB'AC-O<.A 9/Z)N&;T<$N*L;O1VG5&O_H<C*=#_^Y^/E
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MH2C8'#@N&\.YTYSX2C=PAW!PSMWOOV*H.!VZT6S 76::4P+X-6&X:'"KSBZ
MM#9Q)95CK$ZGA+7DM&M<MD'$DR[-SI)OX.A]T=9LM"K_N.'HO0O_<!_+@,CQ
MLGG>HLM_&1-)*5K*K#D8I4.I^TCXG0^0 KJ 7 MT ^ML9%L2VN_Q>"W(U=16
MCV#$W>)69*>3\=O))+X=CH<SW+U_P>]G RUYT,8:C#6\!1%E!IL(?E'2*L8T
MLJ*^L[%]]R7]GDEW#9EN9=K$D>(-._?Y**6ZTE,%*FET$)-VX"(&J$K0+ )#
MUZZ2;[V>GGY/HZMO=KO+OH'=[H:+4G"VT,DYJF?Z!4VE1=%0&AR*1/+22=V
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M4,8J:?$7_.!\=K+:=W^9EL:YR0G"LW7E%F(QM@:U8] +%3IPJP6G0=1)_J_
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MGSB$G(.C(2ONZD!J+3DMGO_MJ/!)U])O $+KKL\NTO2RM%$9+P_1#='6,")
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M)-R:_HYN!X]"N+J\6@S=7$PZ+MU#I^E3&L_05SL9(WWIW60V.TWSLWSAOMX
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MDCH21>O$\8<Q77=.YIYT.<]3F."J&0W=31>VVZ5B)?-6<P9,>5^F#5(PQCA
MS],&[J1)OHY-VY?R%V'LMD'?,X>N]57;[*GK.JO2P="<C1Y;SRX>9*#.AAA%
M9(;HLX7,$"M",@F>$@LQ(U1%)"152@D[C(5\D_S\:!Q+']+YM[LKQXV&_TSQ
M%S<<EQ!G(*,V7*&3X(70('+YCD4!D;%,N)!>ZCI92!L2^"+LW398>FCO:BCJ
M19FUTB+,C>.-D[OH>C.[^.3FJ*)?DRL^;G3SMVXX_:L;7:7)V)T7,95IU*_<
M;#C+D^FQ"Y\F&=7SEV&:(M^?OKU+7])HC_X(?5%:S_@>7,Z'M>?*J.1-0G>#
M^@3"J0"." &2VQ BH8**.BW\Z]KS4FQ0-(<FHORGF(DOZ LM6UO_ZJ;_0,G[
MN[[1LMUPU"2XR @H:04(K1DXRP(0S?+B*(OP31K*;__F%V&OM\'*W:J/RHIH
MX.KG9O6_^G;S[?VUOICYD 1Q@9  41D#PN10FK@J8#EHXBPUTM6I\MB,OGY
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M*L_!YW)4G&0$@]SA:F2&6>FB?Y@[L/]M^;NM9A9WWEKV@%O?@133@O5:P\S
M.X<B(@*"T:[DHRIP&K^36J640X[:5;)>:ZAY(3?C.R+@H37;5QV-0NJW\?1A
M=F#P*;IBF;DL:2TEF<5Y*H +FM!8.YI)G82,S>A[(6?Y]6"WI\H: .+)&)^%
MOL=Y"@G%6#8##'FE8$Q"C@27$K$<;"01E,#8VB4;;*P#NL>TO)#XL1N [:F*
M!L#T=&E'28>^_=>RO4(9Q!2$3:5U#J?H@D9?YG1X"Z0P+;P(NE*6^I:$OA!?
MKAL8UE1B QA]0J+SUVXZ_38<?UPD!0R\#(PEFTHJ:<1HBSL4(,HS^V#05394
MF3HV<"/R^AD*T!,>NU=8 RB\#?C/?A^G>'2;GS\@E%EA;(247)&5SF T4Z C
MH3%&I56H7<'TD*9^.O_WM@UWHIIFBW7>'+^ZV*%R9O%GW92Q/*:@HYJ2LD'=
M5M#?MEN5P413"@&(RU!JJL XJT$KED1,221?I^'#>GJZJ %<UR<@>Y-=9!IB
M=+[T(D!G43DT@5J$J)7!WQV"S49JFCO PKJ:OGT%W[19Z* 4>>UCNC,;!RDU
M?@HZ1<\Z4XAEH* P&:V_0T<WQ<RIBR114J?Y0CTS<MMY9'D.;+EDI7LT4&T(
M"&<L&!8I;J-&,IH<";J.V[N&F#;-QQ886&<^]A%XCV[K;#H?G+OQQ^7=)E$D
M\I0Y,!Y*WT-TN$TDJHA#NL"=RWJCTAQ\ZAV$X+\>HN/>:_O'PU[*F^PKR1;4
MO[HZ5$XS2Y,'K7'7PRU3@4\9XWZI65(H"+69F=@< 'U>TNZALH=*WT%^/:O]
MU^%X>'EU>4VXSRKC!X!2$4L'& &.4@?6*G0"O*%FL]Z'&RG^WJM[5OTNBIMT
M(<6^U>^^WB'<A*")%!*8+,-T@A9@8W*0)#?H__*4V$;GM9NI_^ZK^[EIZDS]
M.TNQ@:.J^SO?P@8ZJ9PW"D,G'00(%1&[M$S@%#DS'325E3)W'M/2;PYT5UY!
M1[)N#BVG[C*MBO7\XN[3F%(!P$'$PI'Q!+A1W$G+>*S8D6@=12WYD]MK^EG@
M["CVOK.\\'7#^='':5K4?5[7^R;MN<X"<BJ)WL75\AG#KJ2B,2E;SDR\CYOU
M25SK'MX2!';5V:1+ 39@0)9,O'5A,;]OF4L;='2QC#$5/N,7W#I-*IT,%*56
M)%F"[SJ7<8]HZ;=BHNOM9D]9-X>6U?KA)ML4HP3DODQ $Q:<8,@(45)PRZU3
M==R3==3T7$JZIX:?!<P.XFX ,N?IRV3T93C^>)^9Z]I_Z2G-*D F)*&U#!Y,
MR8F-.D4C;)GC70<[SY+5$HAVT?JC2N2N5-  GMZE.3[L+"]YN:EWE=0+[H"2
ML#@GMF"-,H41W,(C=2JX*C!:1TW?Y<>=*?O1I.D])=^SP_M;&4EQ.40FXLDX
M++N=N-$# 3'NE!48!KC$BS,H/=B0)$2E(LF.&",V\7\W>5??]<1=XZ2*C!NP
M.']UTV'Q_<[=?'DFS3RCD6#0R*T,I;J>HP]H#7@3A#?:!5EI7O%#2OI)E*SE
M'N\EY\9PLMJUJ19H#(T LBSZXKAK2T: :.N#]$)3G:HCI07'>#_=/@.4'03=
M %2.KZ:3.!F-W/3ZU, 2:KPVD$5BI9Y&@/$B  K"ET8>TOE8!2@/*6D')KMH
M=M*AF!N R2LW6XAB1;TF+L12CDI$N0\A7(*W,0"SVA+KB>6BSL',?3KZ]5LZ
MAL@>(FX (/>WX'<W";E9HVDEC(,2$;WR)!2Z;UR!)L2GG$T*E9HP/4%0/QGT
MA[DVVDWJ#8"G$'X=S=UXZ,NKTU>3Z73R>PD.W&?\S?S;(!G&**&X53MD2R@4
ME0N:  _,1TD=U[Q.,XIMJ&SI@F%'6#R,N6OIJ%'\O5Y$CT5^;U-ZGZ:A*/!C
M&E I-+&:@Q1.EDM\7*Y4!S#&,8?1J0X/._%7A-\31+9T-UX/?5UHJ 'PW1?7
M8C+'!Z3%Q;/Q70^##KPCBJG P;M4LH=*I7M0!#3*31IAO&=UCA8WI;"E.[)N
M8%=%-ST?/JZ,]D493WN:YJ4!\A27S7E1U"!GJAE!%D(0I<FV2Z6_=D8G5'!F
M>3)1/]A<UQXZ/O>.EHZ*]D-)I]+L&Q7+1,7K4O37DWM\8"0C;8Z@"L1%0K/J
M@T,^9 B4:XVQJMH$%<^\HR6_O -4="7-YO:GZ^+;H\O)5:D!]TE0Q1)P*1'A
M'%T^+TP&]/(40[N'V_ APKO[5/53M7JX?6@/'=2O0EO]HGSQ;I;^ZS_^?U!+
M P04    " !&A:)4=R3+OK('  !-)@  %P   &UE9"TR,#(R,#,S,7AE>'@S
M,3$N:'1M[5IK;QNW$OW>7\$J:.H >C]B1W8,I+:+&LBC-5P$_71!+;E:PMSE
MEN1*5G]]SY K2[+L1D'Z4(P;(&OM<C@<SAR>&7+WY-OS#V?7O_U\P3*?:_;S
MKS^\O3QCC5:G\W%PUNF<7Y^SGZ[?O67#=K?'KBTOG/+*%%QW.A?O&ZR1>5^.
M.YWY?-Z>#]K&3CO75QU2->QH8YQL"R\:IR?T!%?)Q>DW)]^V6NS<)%4N"\\2
M*[F7@E5.%5/V44AWPUJM6NK,E NKIIEG_6Z_SSX:>Z-F/+9[Y;4\7>HYZ<3[
MDTX8Y&1BQ.+T1*@94^)U0R5'@_0E[PYE=Y0,19?SM)^,>#^9O!H=3L1D^+\>
MC.Q //9Q?J'EZT:NBE8F:?SQ<%3ZX[D2/AOWNMWO&D'N]"0UA<=@%IWCSZAC
M6Q.W4RCSIASW^M#DY:UO<:VFQ3C,KQ%5+<43HXT=/^N&?\?4TDIYKO1B_/VU
MRJ5C[^6<79F<%]\W'6+2<M*J- HZ]8>$C1@DW,ZC_8?0HU4AE_/I]6D2%[>9
MFBC__%GO9?=XT&OW-J>QVP02N%_:_V@&5[^^O6"] 6_UA@?\!3N[N+J^_/'R
M[,WUY8?WNT[F'S=]^*#IETUVS@LE-;MJL[.,6]%DB;1>I0OF,XZHC(Z.=PY(
MR87 "FIIF6* HV6(5"$0GG&+GOQ'\^RUEY/X]T>_YY9N>T1NN&09GTEFY4S)
M.;C'9\KAKC36,U.P'XW-6:_;^H69E+V30J7<^2:[+)(V8O+J*<2DOW<Q^8$[
M1 +>SQ?LIC!S+<54-C="(PQ,* QR!D;@JF"\6+"J\+:2F &R2$@HB!EG.>ZL
MXIJE/,$CRTRN//,FRFT)%#*1SG&[()&<WTB,NZ;3X9F ,1A2AVR$,4@@41;9
M!V(%NL,2(2V;9RK)F*OHLNH_EU;62F@"N7(::8HRWESY#!-TI4R"@:2WA&E&
M8)HS=!-LLEAWPU.!X.#K@:!DJ2H09,++*JA-X _B:+9K[:I(01^<BB3\3G0E
MH!/ 68M@$Z!35B]8B;@39 G*6J\P6</!W1L:L!>A^FJ21*4A " :H"4,YX(]
M"7<92[69NR5*K9PJYU&Z><;I8;0;5C;7P.:6QFQ9^U3P-MP[O%UO!.?YLZ-^
M[_#8U8BJ*P&B").F"K<A;)>,6QD @H"KB9842":!RHE6+B-Q$LM!CT21="^4
M2[1Q%?H1<5JC(U)*:Q(I\-BQ P!#2" M1O_B-LEX,97L#3CIJM*0""76Z$"^
M"%U[(Q'OXJVB K"(""7]C(AK#;@12&3+S@.E&P.E&(CF>1_.D*!,_@65TN#E
M'D$4%>R^8/1E^U6/_' N'6I\1"MDM$]#J4G)-N&5V[T+9;V)!"SJD6(>-96%
M I#33+E >9"21=!#Q?&*+-<)UTK- \[J1+K"2K,F8VI4($[8XHQ6(NP]735Q
M2BAN%4U Q70?4D!!FBI'*3@L2Q?R=2!(;&YA$':=H5/) ?"DTIQX'=,*1JQ2
M.7K$PF"]GL&OB21!4"_Z2_$%5+M?.)[L$8X'PVT<[TQ86W#>G>IV1C56PDP)
M BMWIN#$Z=P!Z%15$H*Q,5RB"?A6?**T\@O*[@\-2VLK "]@*BZ+#=&UJC2D
MCMMZ0F5E2V#:A6HD28P5P8!0GTYE@2)# ]IHD26M&1)![1WAB[6E2K#WDP%P
MLD< CD1\,>.Z"FQ%T95IB@)1S1 7]T"A=U=+[,"^\?;AVB_@%1W!G"Y6F!-3
M^<<MV"4_\#MI2>5S^ND=#YLL"_.P!&7T!.P)<*,!G@+DQ!Y!KN;,&,UM5-"^
MNR[<0LN#T/L,IJ1\;I*DLA3[M>3Y@-;<.(_G=.8(72Z!HM\KY%ZH/GBD2PH0
M@\/N2=>&8[LDPY$!G284U9U=+Z)5&7=WE0:Q7P"]%"$M!'_4E+U@6MU(79\?
MW)-O?K&+OA#H>[4/&SV1?5@X0A3+)=)<D52^V$#IBJX(9Y]1>6S5L'>6<=2Q
MWEAWE^S# ZC,<^6]E'^1$"8&Y02U"P7[@I(#8!G\ZXC?\9>JZ>4"E+]7"N:'
MQ58523AE>/'_W=8_EN3?:-1GJ!<5@$8;7-HJ)TH"&G6BOMOUS"6_H<P;Z[60
M>T.E&<XZER="GP6X>H,2CQ<>H#4NT-').U9[%)QU?8HN0)BAMQHA_3OD?E?E
MP ><%"939Y,'S\Z>5&K?O^W0&V3PU((VF@B[#$0'X(2CZ1IAS9@ 53$S>B8I
M"Q9\6I^PVYH;95YJLY!HG6<F$B+?P"_P]K>4".W/>)7GPPZJ;IX ?]*VX&K-
M2R?'RQ_'(.Y2\\58%<%AH=-QK6QBO#?YF-[XSHC]43;4KSH#HF+SZF5PNQM?
M"'N+_V(Y<MW<#DT=+[;;ANW#X>&CK=UV[]&VO]0Z:'='_;]?[5'[5??QKNMJ
M.\$1T1GPMRMY\;HQ:"P[U'@<]\M;UMM\DTP0W7*Y*?_]91L">HZ5L)GKZIE_
MS9-ZQQ>LWPR?4SRE:3U_-@2AA&O\F&'[>N]=^\;L=X1LEX4LO8O'=A"MN2E0
M5PF/T7$D(U<=?S5NWSN??C6>.\N43-G%K4PJ.D1A'^+>8MN#G9":'LA\ZQ\F
ME29^EC6.!^ SN?6IT@IT(;=U5UWX!,BK_':73WS=5%_CAU;ADZ_3/P%02P,$
M%     @ 1H6B5!0BI;.I!P  \"4  !<   !M960M,C R,C S,S%X97AX,S$R
M+FAT;>U:;6_;.!+^?K^"Z^*Z*>!W.TWBI &Z28K-H6\79%'LIP4E4C8OE*@E
M*3N^7W_/D'+LQ$[KHOOB!E>@BB4.A\.9A\\,*9W\</[A[/K7CQ=LXG/-/O[R
MT]O+,]9H=3J?!F>=SOGU.?OY^MU;-FQW>^S:\L(IKTS!=:=S\;[!&A/ORU&G
M,YO-VK-!V]AQY_JJ0ZJ&'6V,DVWA1>/TA)[@*KDX_<?)#ZT6.S=IE<O"L]1*
M[J5@E5/%F'T2TMVP5JN6.C/EW*KQQ+-^M]]GGXR]45,>V[WR6IXN])QTXOU)
M)PQRDA@Q/ST1:LJ4>-50"4\.DV%VT$\'Z7!P>'38SV3ZLB_Z8GB4'O2&O_5@
M9 ?BL8_S<RU?-7)5M":2QA\-]TM_/%/"3T:];O>?C2!W>I*9PF,PB\[Q9]2Q
MKHG;,91Y4XYZ?6CR\M:WN%;C8A3FUXBJ%N*IT<:.GG7#OV-J:64\5WH^^O%:
MY=*Q]W+&KDS.BQ^;#C%I.6E5%@6=^J^$C1@DW,ZB_0?0HU4A%_/I]6D2%[<3
ME2C__%GO9?=XT&OW[T]CNPFD<+^T?],,KGYY>\%Z ][J#??X"W9V<75]^>;R
M[/7UY8?WVT[F3S=]N-'TRR;[%R=]']OL'=>FD/,F2Z7U*ILS/^$(R_[A\=81
M*;D06$(M+3.,<+B(D2H$XC-JT9._::*]]F(2?_WH#]S2;>^3&R[9A$\ELW*J
MY SDXR?*X:XTUC-3L#?&YJS7;?V;F8R]DT)EW/DFNRS2-F)R]!1BTM^YF/S$
M'2(![^=S=E.8F99B+)OW0B,,3"@,D@9&X*I@O)BSJO"VDI@!TDC(*(@99SGN
MK.*:93S%(\M,KCSS)LJM"10RE<YQ.R>1G-](C+NBT^&9@#$84H=TA#%((%46
MZ0=B!;K#$B$MFTU4.F&NHLNR_TQ:62NA">3*:>0I2GDSY2>8H"ME&@PDO25,
M,P+3G**;8,E\U0U/!8*#[P>"DF6J0) )+\N@-H$_B*/9KK2K(@-]<*J2\#O5
ME8!. &<E@DV 3ED]9R7B3I E*&N]Q&0-!_=@:,!>A/*K21*5A@" :("6,)P+
M]J3<35BFS<PM4&KE6#F/VLTS3@^CW;"RN0(VMS!FS=JG@K?ASN'MDO$\Q!JQ
M4XF6%!,F ;!$*S<A<J! Y6 Z8CNZ%\JEVK@*9$(<:(V.02^M2:7 8\?V$&,A
M 9H8R(O;=,*+L62O02]7E89$*)?V]^2+T+6W+^)=O%54S!41;*2?$0>M8#!B
M@FS9>J#LWD 9!J)Y/D0F)"@I?T/1,WBY0VA#-;HK<'O9/NJ1'\ZE0[V.:(7D
M]&4H-2EOIKQRVW>A!)9(P*(>*:9$4UDH ,],E0OL!2E9!#U4YRYY;Y4[K=0\
MX*S.B4NL-&M>I48%#H0MSF@EPC[258E30G&K: (J9N[ Y@5IJAQET\#9+J3>
MP'78J,(@["!#IY(#X&FE.5$TIA6,6&9E](@Y?K4TP:]$DB!8%/VE^ ;6W"T<
M)SN$X\%P'<=;$]8:G+>GNJU1C94P58+ RITI.'$Z=P Z%8B$8&[% DW M^*)
MTLK/*5%O&I;65@!>P%1<%O=$5PK,D#INZPF5E2V!:1<*BS0U5@0#0JDYE@7J
M!0UHHT66M&9(!&5TA"_6EBK!WD\&P.D. 3@2\<64ZRJP%4579AEJ/35%7-R&
MFNWYL\-^[^#8;<.^\79S&1?PBHY@3A>+Q<14_G$+MLD/_$Y:4B6<?7GSPI)%
MC1V6H(R>@#T!;C3 4X"<V"'(U9P9H[F."MI"UX5;:-D(O:]@2LKG)DTK2[%?
M29X;M.;&>3RG\T/H<BD4_5XA]T+UWB-=,H 8'/9 NC8<.Q\9=O]T,%!4=W:]
MB%9-N+NK-(C] NBE"&DA^*.F[#GV^#=2UT<!#^2;W^RB;P3Z3FVI]G=P2Q5.
M]L0"[LTEX6!3OXJX)?409KZBBEBK1^\PP%&3>F/=7>(.#Z RSY7W4GZ&W!.#
MTH#:A8)]0<D>< DN=<35^$N5\6(QR=\K!?/#PJF*-&S^7_Q_Y_2G)>S7&K46
M:C^5J90VJ[3M394$-.JD>[>#F4E^0UDTUEXACX:J,1Q!+@YJO@IP]68#>XK-
M%,4%.CIYQU"/@K.N-=$%"$-)V(RIW"&/NRH'/N"D,)DZ,VP\TGI2:7KWMC:O
MD8TS"]IH(NPRG"P"..'$N$98,R8S54R-GDK*: 4?UP??MCZ,E'FIS5RB=38Q
MD1#Y/?P";W](NF]_Q2LV'W9#=7,"_$G;@JLU+YT<+7X<@[A+S><C502'A4['
MM;+$>&_R$;V)G=)K,I0 ]2O(@*C8O'Q)V^[&%[7>XK]8C%PWMT-3QXOUMF'[
M8'CP:&NWW7NT[;-:!^WN?O^/5WO8/NH^WG55;2<X(CH#_G8E+UXU!HU%AQJ/
MHWYYRWKWW_#^IW+T4G+-ZZ;\ZU=NB.DY%L/]=%=/_CN?USL^9_UF^-CAB<WL
M^;,AF"5<X]<&Z]>'+\/O>6!+\'99R-?;>&T+T9JE HF5<!D=,C+RU?%G7$]\
MOCM^WSVG?C>N.YLHF;$W=UGO0X;L*>VZ!SLA2VU(@JO?#I4F?CDUBN?:4[GV
M-=$2=2'-=9==> +H57Z]RQ<^0*JO\5NH\%76Z?\ 4$L#!!0    ( $:%HE0E
M<Q13* 4  -\:   7    ;65D+3(P,C(P,S,Q>&5X>#,R,2YH=&WM66UOVD@0
M_GZ_8DIT;2+A5Z 00R-1<!2J!%)PU>NGT^)=PZJVU[67$.[7W^P:DZ1I[M)>
MKTFJ1I'!GI>=>69F9Q;WG@TG@^##N0]+F<1P_N[UZ6@ -<.RWC<&EC4,AG 2
MG)U"T[0="'*2%EQRD9+8LOQQ#6I+*3//LM;KM;ENF")?6,'44JJ:5BQ$P4PJ
M:>VHIY[@E1%Z]%OOF6' 4(2KA*42PIP1R2BL"IXNX#UEQ4<PC"W70&2;G"^6
M$ES;=>&]R#_R"U+2)9<Q.ZKT]*SROF?I17IS03='/<HO@--7-4[M0SIO1 VW
M13O-IAV1>:/3;AQ&\VC>:;$6^]-!(RUD+V4*N8G9JUK"4V/)U/I>LY7)[II3
MN?0<V_Z]IOF.>I%()2Z6HW#YM=1Q6Q/)%ZA,BLQS7-0DV:4T2,P7J:?]JY6J
M*O90Q"+W]FS]UU44(R()CS?>BX GK( Q6\-4)"1]42\P)D;!<AZ5C 7_BZ&-
MN(B^79?VMU%/S%-6^>.XR@G_<LGG7#[?<U[:W89K.C?=N)\#(<+/\@?RX,P?
MCH[[LZ .H_' ?'+F#_QI,#H>#?K!:#+&ZIO.WO7' 023.SUY+)8['7AGSLR!
M"3-_H*UW&BV[_NCM[L^@/YR<!_[P2<%=@7QHOX3),00G/LSZT]?]L3\S)G^<
M^A^@/P@4Q;5M][YE\+_[TORB+Z,40I&F+%2=!-9<+D$N&;Q=D1P!CC<P99G(
M)2#Q6.0).+;Q%O85R_.]CNO:W9*N;YSN 40BUPH^E0J I10;RAG)PR4TG'K9
M.T0$9XSRB!02]XHT-&]H'(@D(^FF4ED'4D#$8U2S,V_&PE6.S0]Q("D%_S)<
MDG3!L$<E"2\*Y0K^*TZ*#0V6+&>XYMUFHQ5U&)*4LQBF)@R6)*=U_. L0N6X
MF.07#"91Q$/T22V)_&^(BL.YB=[%(F6;2N"8IR0-.8DK@3K@1?((.;)57JP(
MAED*N%:U6_AUU2IW"169:L37V2LFE77HC(:!Y'.2LL*87,9L _U0*HK*NKJ2
M4"QS5NB'R08^IF*-*"X8$I<$?6]UNO?>I#-"*0X%1LPB3)U.M6US#&\J/4,]
M>: ,WG<.*B]^_/(W<7EI-IH*AP"!W]9-M(JQB$),Z5AEZRZ#<_9IQ7.FQJ5"
MQ><J!?;) 6 1.:U]>K +]%6^[W)]&VWGL-$L<R;1M89A/>RJ%/T90NL^RM#R
M%'>YA.AXX>8I"4I2?*I#5<6=<+5[9CDK5(CKBDSB&% ,C<&] 0D9QKRH:ZEH
MMV>@0JK'>KW-(-<J+C-$L8F,Y7K=W9/M9GGO:0LC*<D\9A5Y+G+*<@,AC4E6
M,*_ZTJ6\R&*R\7BJ@=%"W:VRN9!2))X:PR_4SA:2>-N7=>:4Y*L)W;3+*5WB
M:"YIM?*6;&J2)>EMFFMVFNT[J;;IW$G[)ZU-/#ZU6]]?[:'9;G?NI=;20)1@
M(-X%!O!5K5&K!+9YY[G9)3@WYV.5BK<@%]F/+T\=T->;FSUDZ_=3=NGY7K/=
M+?05AOWQR#_5\\!)?SK\"C=MY>171ON&S)=9M[6J2SE#:$3,*2A,NI_A"^JS
M8[J/&>G/IJV'1_<)8GC'@/H+RV_ \HQLP"W/)_\1OXIG-TN47?=[8?JMK$_"
MNN^?>X\WXZ[WFC?],W^FSY+]T\G8__#P)?Q3-9O/C^H/#^\3!/&.7S=^8?F
MW<;2Y[(O'/NNORK)1/FBR,M93-2@<.OER571ZX.=?25"YECY*WE;Y%_>MVRO
MY:L?_1+JZ&]02P$"% ,4    " !&A:)4RX8;1RTE  ""TP  '@
M    @ $     97@M,3 Q;65D:69A<W1F;W)M<'-U86=R964N:'1M4$L! A0#
M%     @ 1H6B5&?=!E=/&@  _9<  !X              ( !:24  &5X+3$P
M,FUE9&EF87-T9F]R;7)E<W1R:6-T+FAT;5!+ 0(4 Q0    ( $:%HE3]8-VR
MSB,  #+,   >              "  ?0_  !E>"TQ,#-M961I9F%S=&9O<FUR
M97-T<FEC="YH=&U02P$"% ,4    " !&A:)4_ZD/S=H:   WI0  '@
M        @ '^8P  97@M,3 T;65D:69A<W1F;W)M<F5S=')I8W0N:'1M4$L!
M A0#%     @ 1H6B5)6(K5PV$P$ $^@, !               ( !%'\  &UE
M9"TR,#(R,#,S,2YH=&U02P$"% ,4    " !&A:)4N (IOD@*   P6@  $
M            @ %XD@$ ;65D+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0    ( $:%
MHE2TYI5Z_!0  %6^   4              "  >Z< 0!M960M,C R,C S,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( $:%HE3]J82W9R0  (V7 0 4
M  "  1RR 0!M960M,C R,C S,S%?9&5F+GAM;%!+ 0(4 Q0    ( $:%HE3.
M"S"GNH<  *2L!0 4              "  ;76 0!M960M,C R,C S,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( $:%HE3#_9:" TX  !:) P 4              "
M :%> @!M960M,C R,C S,S%?<')E+GAM;%!+ 0(4 Q0    ( $:%HE1W),N^
ML@<  $TF   7              "  =:L @!M960M,C R,C S,S%X97AX,S$Q
M+FAT;5!+ 0(4 Q0    ( $:%HE04(J6SJ0<  / E   7              "
M ;VT @!M960M,C R,C S,S%X97AX,S$R+FAT;5!+ 0(4 Q0    ( $:%HE0E
M<Q13* 4  -\:   7              "  9N\ @!M960M,C R,C S,S%X97AX
=,S(Q+FAT;5!+!08     #0 - (,#  #XP0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
